1	AAPS	NN	O	aap	dep	170	SENT_1	0/4
2	JAAPS	NN	O	jaap	dep	170	SENT_1	5/10
3	JThe	NN	O	jthe	dep	170	SENT_1	11/15
4	AAPS	NN	O	aap	dep	170	SENT_1	16/20
5	Journal1550-7416Springer	NN	O	journal1550-7416springer	dep	170	SENT_1	21/45
6	USBoston216301273144367928510	NN	O	usboston216301273144367928510	dep	170	SENT_1	46/75
7	.1208	CD	NUMBER	.1208	dep	170	SENT_1	75/80
8	/	:	O	/	dep	170	SENT_1	80/81
9	s12248-011-9285-6Meeting	NN	O	s12248-011-9285-6meeting	dep	170	SENT_1	81/105
10	ReportAAPS	NN	O	reportaap	dep	170	SENT_1	106/116
11	Workshop	NNP	O	Workshop	dep	170	SENT_1	117/125
12	Report	NNP	O	Report	dep	170	SENT_1	126/132
13	:	:	O	:		-1	SENT_1	132/133
14	Strategies	NNS	O	strategy	dep	170	SENT_1	134/144
15	to	TO	O	to	dep	170	SENT_1	145/147
16	Address	NNP	O	Address	dep	170	SENT_1	148/155
17	Therapeutic	JJ	O	therapeutic	dep	170	SENT_1	156/167
18	Protein-Drug	NNP	O	Protein-Drug	dep	170	SENT_1	168/180
19	Interactions	NNS	O	interaction	dep	170	SENT_1	181/193
20	during	IN	O	during	dep	170	SENT_1	194/200
21	Clinical	JJ	O	clinical	dep	170	SENT_1	201/209
22	DevelopmentGirishSandhya+1-650-4678508+1-650-7425234sandhyag@g	JJ	O	developmentgirishsandhya+1-650-4678508+1-650-7425234sandhyag@g	dep	170	SENT_1	210/272
23	ene.com	NN	O	ene.com	dep	170	SENT_1	273/280
24	MartinSteven	NNP	O	MartinSteven	dep	170	SENT_1	280/292
25	WPetersonMark	NNP	O	WPetersonMark	dep	170	SENT_1	293/306
26	CZhangLei	NNP	O	CZhangLei	dep	170	SENT_1	307/316
27	K.	NNP	O	K.	dep	170	SENT_1	317/319
28	ZhaoHongBalthasarJosephEversRaym	NNP	O	ZhaoHongBalthasarJosephEversRaym	dep	170	SENT_1	319/351
29	ondZhouHonghuiZhuMinKlunkLewisHanChaoBerglundEva	NNP	O	ondZhouHonghuiZhuMinKlunkLewisHanChaoBerglundEva	dep	170	SENT_1	352/400
30	GilHuangShiew	NNP	O	GilHuangShiew	dep	170	SENT_1	401/414
31	-	:	O	-		-1	SENT_1	414/415
32	MeiJoshiAmitaClinical	NNP	O	MeiJoshiAmitaClinical	dep	170	SENT_1	416/437
33	Pharmacology	NNP	O	Pharmacology	dep	170	SENT_1	438/450
34	,	,	O	,		-1	SENT_1	450/451
35	Department	NNP	ORGANIZATION	Department	dep	170	SENT_1	452/462
36	of	IN	ORGANIZATION	of	dep	170	SENT_1	463/465
37	Pharmacokinetics	NNPS	ORGANIZATION	Pharmacokinetics	dep	170	SENT_1	466/482
38	and	CC	O	and	dep	170	SENT_1	483/486
39	Pharmacodynamics	NNPS	PERSON	Pharmacodynamics	dep	170	SENT_1	487/503
40	,	,	O	,		-1	SENT_1	503/504
41	gRED	NNP	O	gRED	dep	170	SENT_1	505/509
42	,	,	O	,		-1	SENT_1	509/510
43	Genentech	NNP	ORGANIZATION	Genentech	dep	170	SENT_1	511/520
44	,	,	O	,		-1	SENT_1	520/521
45	South	NNP	LOCATION	South	dep	170	SENT_1	522/527
46	San	NNP	LOCATION	San	dep	170	SENT_1	528/531
47	Francisco	NNP	LOCATION	Francisco	dep	170	SENT_1	532/541
48	,	,	O	,		-1	SENT_1	541/542
49	California	NNP	LOCATION	California	dep	170	SENT_1	543/553
50	USA	NNP	O	USA	dep	170	SENT_1	554/557
51	Pfizer	NNP	ORGANIZATION	Pfizer	dep	170	SENT_1	558/564
52	Global	NNP	ORGANIZATION	Global	dep	170	SENT_1	565/571
53	Research	NNP	ORGANIZATION	Research	dep	170	SENT_1	572/580
54	and	CC	ORGANIZATION	and	dep	170	SENT_1	581/584
55	Development	NNP	ORGANIZATION	Development	dep	170	SENT_1	585/596
56	,	,	O	,		-1	SENT_1	596/597
57	New	NNP	LOCATION	New	dep	170	SENT_1	598/601
58	London	NNP	LOCATION	London	dep	170	SENT_1	602/608
59	,	,	O	,		-1	SENT_1	608/609
60	Connecticut	NNP	ORGANIZATION	Connecticut	dep	170	SENT_1	610/621
61	USA	NNP	ORGANIZATION	USA	dep	170	SENT_1	622/625
62	Pfizer	NNP	ORGANIZATION	Pfizer	dep	170	SENT_1	626/632
63	Global	NNP	ORGANIZATION	Global	dep	170	SENT_1	633/639
64	Research	NNP	ORGANIZATION	Research	dep	170	SENT_1	640/648
65	and	CC	ORGANIZATION	and	dep	170	SENT_1	649/652
66	Development	NNP	ORGANIZATION	Development	dep	170	SENT_1	653/664
67	,	,	O	,		-1	SENT_1	664/665
68	San	NNP	LOCATION	San	dep	170	SENT_1	666/669
69	Diego	NNP	LOCATION	Diego	dep	170	SENT_1	670/675
70	,	,	O	,		-1	SENT_1	675/676
71	California	NNP	ORGANIZATION	California	dep	170	SENT_1	677/687
72	USA	NNP	ORGANIZATION	USA	dep	170	SENT_1	688/691
73	Office	NNP	ORGANIZATION	Office	dep	170	SENT_1	692/698
74	of	IN	ORGANIZATION	of	dep	170	SENT_1	699/701
75	Clinical	JJ	ORGANIZATION	clinical	dep	170	SENT_1	702/710
76	Pharmacology	NN	ORGANIZATION	pharmacology	dep	170	SENT_1	711/723
77	,	,	O	,		-1	SENT_1	723/724
78	Office	NNP	ORGANIZATION	Office	dep	170	SENT_1	725/731
79	of	IN	ORGANIZATION	of	dep	170	SENT_1	732/734
80	Translational	JJ	ORGANIZATION	translational	dep	170	SENT_1	735/748
81	Sciences	NNPS	ORGANIZATION	Sciences	dep	170	SENT_1	749/757
82	,	,	O	,		-1	SENT_1	757/758
83	Center	NNP	ORGANIZATION	Center	dep	170	SENT_1	759/765
84	for	IN	ORGANIZATION	for	dep	170	SENT_1	766/769
85	Drug	NNP	ORGANIZATION	Drug	dep	170	SENT_1	770/774
86	Evaluation	NN	ORGANIZATION	evaluation	dep	170	SENT_1	775/785
87	and	CC	ORGANIZATION	and	dep	170	SENT_1	786/789
88	Research	NN	ORGANIZATION	research	dep	170	SENT_1	790/798
89	,	,	ORGANIZATION	,		-1	SENT_1	798/799
90	Food	NNP	ORGANIZATION	Food	dep	170	SENT_1	800/804
91	and	CC	ORGANIZATION	and	dep	170	SENT_1	805/808
92	Drug	NNP	ORGANIZATION	Drug	dep	170	SENT_1	809/813
93	Administration	NNP	ORGANIZATION	Administration	dep	170	SENT_1	814/828
94	,	,	O	,		-1	SENT_1	828/829
95	Silver	NNP	O	Silver	dep	170	SENT_1	830/836
96	Spring	NNP	DATE	Spring	dep	170	SENT_1	837/843
97	,	,	O	,		-1	SENT_1	843/844
98	Maryland	NNP	LOCATION	Maryland	dep	170	SENT_1	845/853
99	USA	NNP	LOCATION	USA	dep	170	SENT_1	854/857
100	The	NNP	O	The	dep	170	SENT_1	858/861
101	State	NNP	ORGANIZATION	State	dep	170	SENT_1	862/867
102	University	NNP	ORGANIZATION	University	dep	170	SENT_1	868/878
103	of	IN	ORGANIZATION	of	dep	170	SENT_1	879/881
104	New	NNP	ORGANIZATION	New	dep	170	SENT_1	882/885
105	York	NNP	ORGANIZATION	York	dep	170	SENT_1	886/890
106	at	IN	O	at	dep	170	SENT_1	891/893
107	Buffalo	NNP	LOCATION	Buffalo	dep	170	SENT_1	894/901
108	,	,	O	,		-1	SENT_1	901/902
109	Buffalo	NNP	LOCATION	Buffalo	dep	170	SENT_1	903/910
110	,	,	O	,		-1	SENT_1	910/911
111	New	NNP	ORGANIZATION	New	dep	170	SENT_1	912/915
112	York	NNP	ORGANIZATION	York	dep	170	SENT_1	916/920
113	USA	NNP	ORGANIZATION	USA	dep	170	SENT_1	921/924
114	Merck	NNP	ORGANIZATION	Merck	dep	170	SENT_1	925/930
115	&	CC	ORGANIZATION	&	dep	170	SENT_1	931/932
116	Co.	NNP	ORGANIZATION	Co.	dep	170	SENT_1	933/936
117	,	,	O	,		-1	SENT_1	936/937
118	Inc.	NNP	ORGANIZATION	Inc.	dep	170	SENT_1	938/942
119	,	,	O	,		-1	SENT_1	942/943
120	Whitehouse	NNP	ORGANIZATION	Whitehouse	dep	170	SENT_1	944/954
121	Station	NNP	ORGANIZATION	Station	dep	170	SENT_1	955/962
122	,	,	O	,		-1	SENT_1	962/963
123	New	NNP	LOCATION	New	dep	170	SENT_1	964/967
124	Jersey	NNP	LOCATION	Jersey	dep	170	SENT_1	968/974
125	USA	NNP	LOCATION	USA	dep	170	SENT_1	975/978
126	Centocor	NNP	ORGANIZATION	Centocor	dep	170	SENT_1	979/987
127	R&D	NNP	ORGANIZATION	R&D	dep	170	SENT_1	988/991
128	,	,	O	,		-1	SENT_1	991/992
129	Johnson	NNP	ORGANIZATION	Johnson	dep	170	SENT_1	993/1000
130	&	CC	ORGANIZATION	&	dep	170	SENT_1	1001/1002
131	Johnson	NNP	ORGANIZATION	Johnson	dep	170	SENT_1	1003/1010
132	,	,	O	,		-1	SENT_1	1010/1011
133	New	NNP	LOCATION	New	dep	170	SENT_1	1012/1015
134	Brunswick	NNP	LOCATION	Brunswick	dep	170	SENT_1	1016/1025
135	,	,	O	,		-1	SENT_1	1025/1026
136	New	NNP	ORGANIZATION	New	dep	170	SENT_1	1027/1030
137	Jersey	NNP	ORGANIZATION	Jersey	dep	170	SENT_1	1031/1037
138	USA	NNP	ORGANIZATION	USA	dep	170	SENT_1	1038/1041
139	Amgen	NNP	ORGANIZATION	Amgen	dep	170	SENT_1	1042/1047
140	Inc.	NNP	ORGANIZATION	Inc.	dep	170	SENT_1	1048/1052
141	,	,	O	,		-1	SENT_1	1052/1053
142	Thousand	NNP	LOCATION	Thousand	dep	170	SENT_1	1054/1062
143	Oaks	NNP	LOCATION	Oaks	dep	170	SENT_1	1063/1067
144	,	,	O	,		-1	SENT_1	1067/1068
145	California	NNP	LOCATION	California	dep	170	SENT_1	1069/1079
146	USA	NNP	O	USA	dep	170	SENT_1	1080/1083
147	Biogen	NNP	ORGANIZATION	Biogen	dep	170	SENT_1	1084/1090
148	Idec	NNP	ORGANIZATION	Idec	dep	170	SENT_1	1091/1095
149	,	,	O	,		-1	SENT_1	1095/1096
150	Weston	NNP	PERSON	Weston	dep	170	SENT_1	1097/1103
151	,	,	O	,		-1	SENT_1	1103/1104
152	Massachussets	NNP	ORGANIZATION	Massachussets	dep	170	SENT_1	1105/1118
153	USA	NNP	ORGANIZATION	USA	dep	170	SENT_1	1119/1122
154	Medical	NNP	ORGANIZATION	Medical	dep	170	SENT_1	1123/1130
155	Products	NNP	ORGANIZATION	Products	dep	170	SENT_1	1131/1139
156	Agency	NNP	ORGANIZATION	Agency	dep	170	SENT_1	1140/1146
157	,	,	O	,		-1	SENT_1	1146/1147
158	Uppsala	NNP	LOCATION	Uppsala	dep	170	SENT_1	1148/1155
159	,	,	O	,		-1	SENT_1	1155/1156
160	Sweden	NNP	LOCATION	Sweden	dep	170	SENT_1	1157/1163
161	1620119201113340541616220112742011	CD	NUMBER	1620119201113340541616220112742011	dep	170	SENT_1	1164/1198
162	(	CD	NUMBER	(	dep	170	SENT_1	1198/1199
163	C	NN	O	c	dep	170	SENT_1	1199/1200
164	)	CD	NUMBER	)	dep	170	SENT_1	1200/1201
165	American	NNP	O	American	dep	170	SENT_1	1202/1210
166	Association	NNP	O	Association	dep	170	SENT_1	1211/1222
167	of	IN	O	of	dep	170	SENT_1	1223/1225
168	Pharmaceutical	NNP	O	Pharmaceutical	dep	170	SENT_1	1226/1240
169	Scientists	NNS	O	scientist	dep	170	SENT_1	1241/1251
170	2011	CD	DATE	2011		-1	SENT_1	1252/1256

1	Therapeutic	JJ	O	therapeutic	amod	2	SENT_2	1273/1284
2	proteins	NNS	O	protein	nsubj	3	SENT_2	1285/1293
3	(	VBP	O	(		-1	SENT_2	1294/1295
4	TPs	NNS	O	tp	nsubj	12	SENT_2	1295/1298
5	)	CD	NUMBER	)	nsubjpass	8	SENT_2	1298/1299
6	are	VBP	O	be	auxpass	8	SENT_2	1300/1303
7	increasingly	RB	O	increasingly	advmod	8	SENT_2	1304/1316
8	combined	VBN	O	combine	rcmod	4	SENT_2	1317/1325
9	with	IN	O	with		-1	SENT_2	1326/1330
10	small	JJ	O	small	amod	11	SENT_2	1331/1336
11	molecules	NNS	O	molecule	prep_with	8	SENT_2	1337/1346
12	and/or	VBP	O	and/or	ccomp	3	SENT_2	1347/1353
13	with	IN	O	with		-1	SENT_2	1354/1358
14	other	JJ	O	other	amod	15	SENT_2	1359/1364
15	TPs	NNS	O	tp	prep_with	12	SENT_2	1365/1368
16	.	.	O	.		-1	SENT_2	1368/1369

1	However	RB	O	however	advmod	26	SENT_3	1370/1377
2	preclinical	JJ	O	preclinical	amod	3	SENT_3	1378/1389
3	tools	NNS	O	tool	nn	8	SENT_3	1390/1395
4	and	CC	O	and	cc	3	SENT_3	1396/1399
5	in	FW	O	in	nn	6	SENT_3	1400/1402
6	vitro	FW	O	vitro	advmod	3	SENT_3	1403/1408
7	test	NN	O	test	nn	8	SENT_3	1409/1413
8	systems	NNS	O	system	nsubjpass	26	SENT_3	1414/1421
9	for	IN	O	for		-1	SENT_3	1422/1425
10	assessing	VBG	O	assess	prepc_for	8	SENT_3	1426/1435
11	drug	NN	O	drug	nn	13	SENT_3	1436/1440
12	interaction	NN	O	interaction	nn	13	SENT_3	1441/1452
13	potential	NN	O	potential	dobj	10	SENT_3	1453/1462
14	of	IN	O	of		-1	SENT_3	1463/1465
15	TPs	NNS	O	tp	prep_of	13	SENT_3	1466/1469
16	such	JJ	O	such		-1	SENT_3	1470/1474
17	as	IN	O	as		-1	SENT_3	1475/1477
18	monoclonal	JJ	O	monoclonal	amod	19	SENT_3	1478/1488
19	antibodies	NNS	O	antibody	prep_such_as	15	SENT_3	1489/1499
20	,	,	O	,		-1	SENT_3	1499/1500
21	cytokines	NNS	O	cytokine	conj_and	19	SENT_3	1501/1510
22	and	CC	O	and		-1	SENT_3	1511/1514
23	cytokine	NN	O	cytokine	nn	24	SENT_3	1515/1523
24	modulators	NNS	O	modulator	conj_and	19	SENT_3	1524/1534
25	are	VBP	O	be	auxpass	26	SENT_3	1535/1538
26	limited	VBN	O	limit		-1	SENT_3	1539/1546
27	.	.	O	.		-1	SENT_3	1546/1547

1	Published	VBN	O	publish	amod	2	SENT_4	1548/1557
2	data	NN	O	datum	nsubj	3	SENT_4	1558/1562
3	suggests	VBZ	O	suggest		-1	SENT_4	1563/1571
4	that	IN	O	that	mark	9	SENT_4	1572/1576
5	clinically	RB	O	clinically	advmod	6	SENT_4	1577/1587
6	relevant	JJ	O	relevant	amod	8	SENT_4	1588/1596
7	TP-drug	NN	O	tp-drug	nn	8	SENT_4	1597/1604
8	interactions	NNS	O	interaction	nsubj	9	SENT_4	1605/1617
9	(	VBP	O	(	ccomp	3	SENT_4	1618/1619
10	TP-DI	NN	O	tp-di	nn	11	SENT_4	1619/1624
11	)	NN	O	)	nsubj	13	SENT_4	1624/1625
12	are	VBP	O	be	cop	13	SENT_4	1626/1629
13	likely	JJ	O	likely	ccomp	9	SENT_4	1630/1636
14	from	IN	O	from		-1	SENT_4	1637/1641
15	overlap	VBP	O	overlap	prepc_from	13	SENT_4	1642/1649
16	in	IN	O	in		-1	SENT_4	1650/1652
17	mechanisms	NNS	O	mechanism	prep_in	15	SENT_4	1653/1663
18	of	IN	O	of		-1	SENT_4	1664/1666
19	action	NN	O	action	prep_of	17	SENT_4	1667/1673
20	,	,	O	,		-1	SENT_4	1673/1674
21	alteration	NN	O	alteration	appos	19	SENT_4	1675/1685
22	in	IN	O	in		-1	SENT_4	1686/1688
23	target	NN	O	target	nn	26	SENT_4	1689/1695
24	and/or	NN	O	and/or	nn	26	SENT_4	1696/1702
25	drug-disease	NN	O	drug-disease	nn	26	SENT_4	1703/1715
26	interaction	NN	O	interaction	prep_in	21	SENT_4	1716/1727
27	.	.	O	.		-1	SENT_4	1727/1728

1	Clinical	JJ	O	clinical	amod	4	SENT_5	1729/1737
2	drug	NN	O	drug	nn	4	SENT_5	1738/1742
3	interaction	NN	O	interaction	nn	4	SENT_5	1743/1754
4	studies	NNS	O	study	nsubjpass	8	SENT_5	1755/1762
5	are	VBP	O	be	auxpass	8	SENT_5	1763/1766
6	not	RB	O	not	neg	8	SENT_5	1767/1770
7	routinely	RB	O	routinely	advmod	8	SENT_5	1771/1780
8	conducted	VBN	O	conduct		-1	SENT_5	1781/1790
9	for	IN	O	for		-1	SENT_5	1791/1794
10	TPs	NNS	O	tp	prep_for	8	SENT_5	1795/1798
11	because	IN	O	because		-1	SENT_5	1799/1806
12	of	IN	O	of		-1	SENT_5	1807/1809
13	the	DT	O	the	det	15	SENT_5	1810/1813
14	logistical	JJ	O	logistical	amod	15	SENT_5	1814/1824
15	constraints	NNS	O	constraint	prep_because_of	8	SENT_5	1825/1836
16	in	IN	O	in		-1	SENT_5	1837/1839
17	study	NN	O	study	nn	18	SENT_5	1840/1845
18	design	NN	O	design	prep_in	15	SENT_5	1846/1852
19	to	TO	O	to	aux	20	SENT_5	1853/1855
20	address	VB	O	address	xcomp	8	SENT_5	1856/1863
21	pharmacokinetic	JJ	O	pharmacokinetic	amod	23	SENT_5	1864/1879
22	(	NN	O	(	nn	23	SENT_5	1880/1881
23	PK	NN	O	pk	dobj	20	SENT_5	1881/1883
24	)	SYM	O	)	dep	23	SENT_5	1883/1884
25	-	:	O	-		-1	SENT_5	1884/1885
26	and	CC	O	and		-1	SENT_5	1886/1889
27	pharmacodynamic	JJ	O	pharmacodynamic	amod	29	SENT_5	1890/1905
28	(	NN	O	(	nn	29	SENT_5	1906/1907
29	PD	NN	O	pd	nsubj	32	SENT_5	1907/1909
30	)	SYM	O	)	dep	32	SENT_5	1909/1910
31	-	:	O	-		-1	SENT_5	1910/1911
32	based	VBN	O	base	conj_and	8	SENT_5	1911/1916
33	interactions	NNS	O	interaction	dobj	32	SENT_5	1917/1929
34	.	.	O	.		-1	SENT_5	1929/1930

1	Different	JJ	O	different	amod	3	SENT_6	1931/1940
2	pharmaceutical	JJ	O	pharmaceutical	amod	3	SENT_6	1941/1955
3	companies	NNS	O	company	nsubj	5	SENT_6	1956/1965
4	have	VBP	O	have	aux	5	SENT_6	1966/1970
5	developed	VBN	O	develop		-1	SENT_6	1971/1980
6	their	PRP$	O	they	poss	8	SENT_6	1981/1986
7	respective	JJ	O	respective	amod	8	SENT_6	1987/1997
8	question	NN	O	question	dobj	5	SENT_6	1998/2006
9	-	:	O	-		-1	SENT_6	2006/2007
10	and/or	NN	O	and/or	nn	12	SENT_6	2008/2014
11	risk-based	JJ	O	risk-based	amod	12	SENT_6	2015/2025
12	approaches	NNS	O	approach	dep	8	SENT_6	2026/2036
13	for	IN	O	for		-1	SENT_6	2037/2040
14	TP-DI	NN	O	tp-di	prep_for	12	SENT_6	2041/2046
15	based	VBN	O	base		-1	SENT_6	2047/2052
16	on	IN	O	on	prepc_based_on	5	SENT_6	2053/2055
17	the	DT	O	the	det	19	SENT_6	2056/2059
18	TP	NN	O	tp	nn	19	SENT_6	2060/2062
19	mechanism	NN	O	mechanism	pobj	5	SENT_6	2063/2072
20	of	IN	O	of		-1	SENT_6	2073/2075
21	action	NN	O	action	prep_of	19	SENT_6	2076/2082
22	as	RB	O	as		-1	SENT_6	2083/2085
23	well	RB	O	well		-1	SENT_6	2086/2090
24	as	IN	O	as		-1	SENT_6	2091/2093
25	patient	NN	O	patient	nn	26	SENT_6	2094/2101
26	population	NN	O	population	conj_and	19	SENT_6	2102/2112
27	.	.	O	.		-1	SENT_6	2112/2113

1	During	IN	O	during		-1	SENT_7	2114/2120
2	the	DT	O	the	det	3	SENT_7	2121/2124
3	workshop	NN	O	workshop	prep_during	11	SENT_7	2125/2133
4	both	DT	O	both	preconj	6	SENT_7	2134/2138
5	company	NN	O	company	nn	6	SENT_7	2139/2146
6	strategies	NNS	O	strategy	nsubjpass	11	SENT_7	2147/2157
7	and	CC	O	and		-1	SENT_7	2158/2161
8	regulatory	JJ	O	regulatory	amod	9	SENT_7	2162/2172
9	perspectives	NNS	O	perspective	conj_and	6	SENT_7	2173/2185
10	were	VBD	O	be	auxpass	11	SENT_7	2186/2190
11	discussed	VBN	O	discuss		-1	SENT_7	2191/2200
12	in	IN	O	in		-1	SENT_7	2201/2203
13	depth	NN	O	depth	prep_in	11	SENT_7	2204/2209
14	using	VBG	O	use	xcomp	11	SENT_7	2210/2215
15	case	NN	O	case	nn	16	SENT_7	2216/2220
16	studies	NNS	O	study	dobj	14	SENT_7	2221/2228
17	;	:	O	;		-1	SENT_7	2228/2229
18	knowledge	NN	O	knowledge	nn	19	SENT_7	2230/2239
19	gaps	NNS	O	gap	nsubjpass	25	SENT_7	2240/2244
20	and	CC	O	and		-1	SENT_7	2245/2248
21	best	JJS	O	best	amod	22	SENT_7	2249/2253
22	practices	NNS	O	practice	conj_and	19	SENT_7	2254/2263
23	were	VBD	O	be	auxpass	25	SENT_7	2264/2268
24	subsequently	RB	O	subsequently	advmod	25	SENT_7	2269/2281
25	identified	VBN	O	identify	parataxis	11	SENT_7	2282/2292
26	and	CC	O	and		-1	SENT_7	2293/2296
27	discussed	VBN	O	discuss	conj_and	25	SENT_7	2297/2306
28	.	.	O	.		-1	SENT_7	2306/2307

1	Understanding	VBG	O	understand	partmod	15	SENT_8	2308/2321
2	the	DT	O	the	det	4	SENT_8	2322/2325
3	functional	JJ	O	functional	amod	4	SENT_8	2326/2336
4	role	NN	O	role	dobj	1	SENT_8	2337/2341
5	of	IN	O	of		-1	SENT_8	2342/2344
6	target	NN	O	target	prep_of	4	SENT_8	2345/2351
7	,	,	O	,		-1	SENT_8	2351/2352
8	target	NN	O	target	nn	9	SENT_8	2353/2359
9	expression	NN	O	expression	nsubjpass	15	SENT_8	2360/2370
10	and	CC	O	and		-1	SENT_8	2371/2374
11	their	PRP$	O	they	poss	13	SENT_8	2375/2380
12	downstream	JJ	O	downstream	amod	13	SENT_8	2381/2391
13	consequences	NNS	O	consequence	conj_and	9	SENT_8	2392/2404
14	were	VBD	O	be	auxpass	15	SENT_8	2405/2409
15	identified	VBN	O	identify		-1	SENT_8	2410/2420
16	as	RB	O	as	advmod	17	SENT_8	2421/2423
17	important	JJ	O	important	acomp	15	SENT_8	2424/2433
18	for	IN	O	for		-1	SENT_8	2434/2437
19	assessing	VBG	O	assess	prepc_for	15	SENT_8	2438/2447
20	the	DT	O	the	det	21	SENT_8	2448/2451
21	potential	NN	O	potential	dobj	19	SENT_8	2452/2461
22	for	IN	O	for		-1	SENT_8	2462/2465
23	a	DT	O	a	det	24	SENT_8	2466/2467
24	TP-DI	NN	O	tp-di	prep_for	21	SENT_8	2468/2473
25	.	.	O	.		-1	SENT_8	2473/2474

1	Therefore	RB	O	therefore	advmod	17	SENT_9	2475/2484
2	,	,	O	,		-1	SENT_9	2484/2485
3	a	DT	O	a	det	6	SENT_9	2486/2487
4	question-and/or	JJ	O	question-and/or	amod	6	SENT_9	2488/2503
5	risk-based	JJ	O	risk-based	amod	6	SENT_9	2504/2514
6	approach	NN	O	approach	nsubjpass	17	SENT_9	2515/2523
7	based	VBN	O	base	prep	6	SENT_9	2524/2529
8	upon	IN	O	upon	pcomp	7	SENT_9	2530/2534
9	the	DT	O	the	det	10	SENT_9	2535/2538
10	mechanism	NN	O	mechanism	pobj	8	SENT_9	2539/2548
11	of	IN	O	of		-1	SENT_9	2549/2551
12	action	NN	O	action	nn	15	SENT_9	2552/2558
13	and	CC	O	and		-1	SENT_9	2559/2562
14	patient	NN	O	patient	conj_and	12	SENT_9	2563/2570
15	population	NN	O	population	prep_of	10	SENT_9	2571/2581
16	was	VBD	O	be	auxpass	17	SENT_9	2582/2585
17	proposed	VBN	O	propose		-1	SENT_9	2586/2594
18	as	IN	O	as		-1	SENT_9	2595/2597
19	a	DT	O	a	det	22	SENT_9	2598/2599
20	reasonable	JJ	O	reasonable	amod	22	SENT_9	2600/2610
21	TP-DI	NN	O	tp-di	nn	22	SENT_9	2611/2616
22	strategy	NN	O	strategy	prep_as	17	SENT_9	2617/2625
23	.	.	O	.		-1	SENT_9	2625/2626

1	This	DT	O	this	det	2	SENT_10	2627/2631
2	field	NN	O	field	nsubj	3	SENT_10	2632/2637
3	continues	VBZ	O	continue		-1	SENT_10	2638/2647
4	to	TO	O	to	aux	5	SENT_10	2648/2650
5	evolve	VB	O	evolve	xcomp	3	SENT_10	2651/2657
6	as	IN	O	as	mark	8	SENT_10	2658/2660
7	companies	NNS	O	company	nsubj	8	SENT_10	2661/2670
8	generate	VBP	O	generate	advcl	5	SENT_10	2671/2679
9	additional	JJ	O	additional	amod	10	SENT_10	2680/2690
10	preclinical	JJ	O	preclinical	dobj	8	SENT_10	2691/2702
11	and	CC	O	and		-1	SENT_10	2703/2706
12	clinical	JJ	O	clinical	amod	13	SENT_10	2707/2715
13	data	NNS	O	datum	conj_and	10	SENT_10	2716/2720
14	to	TO	O	to	aux	15	SENT_10	2721/2723
15	improve	VB	O	improve	xcomp	8	SENT_10	2724/2731
16	their	PRP$	O	they	poss	17	SENT_10	2732/2737
17	understanding	NN	O	understanding	dobj	15	SENT_10	2738/2751
18	of	IN	O	of		-1	SENT_10	2752/2754
19	possible	JJ	O	possible	amod	20	SENT_10	2755/2763
20	mechanisms	NNS	O	mechanism	prep_of	17	SENT_10	2764/2774
21	for	IN	O	for		-1	SENT_10	2775/2778
22	drug	NN	O	drug	nn	23	SENT_10	2779/2783
23	interactions	NNS	O	interaction	prep_for	15	SENT_10	2784/2796
24	.	.	O	.		-1	SENT_10	2796/2797

1	Regulatory	JJ	O	regulatory	amod	2	SENT_11	2798/2808
2	agencies	NNS	O	agency	nsubj	3	SENT_11	2809/2817
3	are	VBP	O	be		-1	SENT_11	2818/2821
4	in	IN	O	in		-1	SENT_11	2822/2824
5	the	DT	O	the	det	6	SENT_11	2825/2828
6	process	NN	O	process	prep_in	3	SENT_11	2829/2836
7	of	IN	O	of		-1	SENT_11	2837/2839
8	updating	VBG	O	update	prepc_of	6	SENT_11	2840/2848
9	their	PRP$	O	they	poss	10	SENT_11	2849/2854
10	recommendations	NNS	O	recommendation	dobj	8	SENT_11	2855/2870
11	to	TO	O	to		-1	SENT_11	2871/2873
12	sponsors	NNS	O	sponsor	prep_to	8	SENT_11	2874/2882
13	regarding	VBG	O	regard		-1	SENT_11	2883/2892
14	the	DT	O	the	det	15	SENT_11	2893/2896
15	conduct	NN	O	conduct	prep_regarding	12	SENT_11	2897/2904
16	of	IN	O	of		-1	SENT_11	2905/2907
17	in	FW	O	in	nn	18	SENT_11	2908/2910
18	vitro	FW	O	vitro	dep	23	SENT_11	2911/2916
19	and	CC	O	and		-1	SENT_11	2917/2920
20	in	FW	O	in	conj_and	18	SENT_11	2921/2923
21	vivo	FW	O	vivo	pobj	20	SENT_11	2924/2928
22	interaction	NN	O	interaction	nn	23	SENT_11	2929/2940
23	studies	NNS	O	study	prep_of	15	SENT_11	2941/2948
24	for	IN	O	for		-1	SENT_11	2949/2952
25	new	JJ	O	new	amod	27	SENT_11	2953/2956
26	drug	NN	O	drug	nn	27	SENT_11	2957/2961
27	applications	NNS	O	application	prep_for	23	SENT_11	2962/2974
28	(	JJ	O	(	amod	30	SENT_11	2975/2976
29	NDAs	NNS	O	nda	nn	30	SENT_11	2976/2980
30	)	NN	O	)	dep	27	SENT_11	2980/2981
31	and	CC	O	and		-1	SENT_11	2982/2985
32	biologics	NNS	O	biologic	nn	34	SENT_11	2986/2995
33	license	NN	O	license	nn	34	SENT_11	2996/3003
34	applications	NNS	O	application	conj_and	27	SENT_11	3004/3016
35	(	JJ	O	(	amod	37	SENT_11	3017/3018
36	BLAs	NNS	O	bla	nn	37	SENT_11	3018/3022
37	)	NN	O	)	dep	34	SENT_11	3022/3023
38	.	.	O	.		-1	SENT_11	3023/3024

1	Key	NN	O	key	nn	2	SENT_12	3060/3063
2	words	NNS	O	word		-1	SENT_12	3064/3069

1	drug	NN	O	drug	nn	3	SENT_13	3086/3090
2	interactionsquestion	NN	O	interactionsquestion	nn	3	SENT_13	3091/3111
3	basedregulatoryrisk	NN	O	basedregulatoryrisk	dep	12	SENT_13	3112/3131
4	basedtherapeutic	JJ	O	basedtherapeutic	amod	5	SENT_13	3132/3148
5	proteinsissue	NN	O	proteinsissue	dep	3	SENT_13	3149/3162
6	-	:	O	-		-1	SENT_13	3162/3163
7	copyright-statement	NN	O	copyright-statement	nn	8	SENT_13	3164/3183
8	(	NN	O	(	dep	5	SENT_13	3183/3184
9	C	NN	O	c	dep	12	SENT_13	3184/3185
10	)	CD	NUMBER	)	num	9	SENT_13	3185/3186
11	American	NNP	O	American	nn	12	SENT_13	3187/3195
12	Association	NNP	O	Association	dep	16	SENT_13	3196/3207
13	of	IN	O	of		-1	SENT_13	3208/3210
14	Pharmaceutical	NNP	O	Pharmaceutical	nn	15	SENT_13	3211/3225
15	Scientists	NNS	O	scientist	prep_of	12	SENT_13	3226/3236
16	2011	CD	DATE	2011		-1	SENT_13	3237/3241

1	Introduction	NN	O	introduction		-1	SENT_14	3258/3270

1	Therapeutic	JJ	O	therapeutic	amod	2	SENT_15	3306/3317
2	proteins	NNS	O	protein	nsubj	3	SENT_15	3318/3326
3	(	VBP	O	(		-1	SENT_15	3327/3328
4	TPs	NNS	O	tp	nsubj	10	SENT_15	3328/3331
5	)	CD	NUMBER	)	num	4	SENT_15	3331/3332
6	such	JJ	O	such		-1	SENT_15	3333/3337
7	as	IN	O	as		-1	SENT_15	3338/3340
8	monoclonal	JJ	O	monoclonal	amod	9	SENT_15	3341/3351
9	antibodies	NNS	O	antibody	prep_such_as	4	SENT_15	3352/3362
10	(	VBP	O	(	ccomp	3	SENT_15	3363/3364
11	mAbs	NNS	O	mab	dobj	10	SENT_15	3364/3368
12	)	CD	NUMBER	)	nsubjpass	16	SENT_15	3368/3369
13	are	VBP	O	be	aux	16	SENT_15	3370/3373
14	increasingly	RB	O	increasingly	advmod	16	SENT_15	3374/3386
15	being	VBG	O	be	auxpass	16	SENT_15	3387/3392
16	combined	VBN	O	combine	rcmod	11	SENT_15	3393/3401
17	with	IN	O	with		-1	SENT_15	3402/3406
18	small	JJ	O	small	amod	20	SENT_15	3407/3412
19	molecule	NN	O	molecule	nn	20	SENT_15	3413/3421
20	drugs	NNS	O	drug	prep_with	16	SENT_15	3422/3427
21	(	CD	NUMBER	(	num	22	SENT_15	3428/3429
22	SMDs	NNS	O	smd	dep	20	SENT_15	3429/3433
23	)	CD	NUMBER	)	tmod	16	SENT_15	3433/3434
24	and	CC	O	and		-1	SENT_15	3435/3438
25	other	JJ	O	other	amod	26	SENT_15	3439/3444
26	TPs	NNS	O	tp	conj_and	23	SENT_15	3445/3448
27	to	TO	O	to	aux	28	SENT_15	3449/3451
28	treat	VB	O	treat	xcomp	16	SENT_15	3452/3457
29	various	JJ	O	various	amod	30	SENT_15	3458/3465
30	diseases	NNS	O	disease	dobj	28	SENT_15	3466/3474
31	including	VBG	O	include		-1	SENT_15	3475/3484
32	immune-mediated	JJ	O	immune-mediated	amod	33	SENT_15	3485/3500
33	diseases	NNS	O	disease	prep_including	30	SENT_15	3501/3509
34	and	CC	O	and		-1	SENT_15	3510/3513
35	cancer	NN	O	cancer	conj_and	33	SENT_15	3514/3520
36	.	.	O	.		-1	SENT_15	3520/3521

1	The	DT	ORGANIZATION	the	det	2	SENT_16	3522/3525
2	Food	NNP	ORGANIZATION	Food	nsubj	10	SENT_16	3526/3530
3	and	CC	ORGANIZATION	and		-1	SENT_16	3531/3534
4	Drug	NNP	ORGANIZATION	Drug	nn	7	SENT_16	3535/3539
5	Administration	NNP	ORGANIZATION	Administration	nn	7	SENT_16	3540/3554
6	(	CD	NUMBER	(	num	7	SENT_16	3555/3556
7	FDA	NNP	ORGANIZATION	FDA	conj_and	2	SENT_16	3556/3559
8	)	CD	NUMBER	)	npadvmod	9	SENT_16	3559/3560
9	recently	RB	DATE	recently	advmod	10	SENT_16	3561/3569
10	highlighted	VBD	O	highlight		-1	SENT_16	3570/3581
11	the	DT	O	the	det	12	SENT_16	3582/3585
12	potential	JJ	O	potential	nsubj	19	SENT_16	3586/3595
13	and	CC	O	and		-1	SENT_16	3596/3599
14	importance	NN	O	importance	conj_and	12	SENT_16	3600/3610
15	of	IN	O	of		-1	SENT_16	3611/3613
16	therapeutic	JJ	O	therapeutic	amod	18	SENT_16	3614/3625
17	protein-drug	JJ	O	protein-drug	amod	18	SENT_16	3626/3638
18	interactions	NNS	O	interaction	prep_of	12	SENT_16	3639/3651
19	(	VBP	O	(	ccomp	10	SENT_16	3652/3653
20	TP-DI	NN	O	tp-di	dobj	19	SENT_16	3653/3658
21	;	:	O	;		-1	SENT_16	3658/3659
22	1,2	CD	NUMBER	1,2	num	23	SENT_16	3660/3663
23	)	NN	O	)	dep	20	SENT_16	3663/3664
24	.	.	O	.		-1	SENT_16	3664/3665

1	Other	JJ	O	other	amod	3	SENT_17	3666/3671
2	review	NN	O	review	nn	3	SENT_17	3672/3678
3	papers	NNS	O	papers	nsubjpass	8	SENT_17	3679/3685
4	have	VBP	O	have	aux	8	SENT_17	3686/3690
5	also	RB	O	also	advmod	8	SENT_17	3691/3695
6	recently	RB	DATE	recently	advmod	8	SENT_17	3696/3704
7	been	VBN	O	be	auxpass	8	SENT_17	3705/3709
8	published	VBN	O	publish		-1	SENT_17	3710/3719
9	on	IN	O	on		-1	SENT_17	3720/3722
10	TP-DI	NN	O	tp-di	prep_on	8	SENT_17	3723/3728
11	(	CD	NUMBER	(	num	10	SENT_17	3729/3730
12	3-5	CD	NUMBER	3-5	num	13	SENT_17	3730/3733
13	)	NN	O	)	dep	10	SENT_17	3733/3734
14	.	.	O	.		-1	SENT_17	3734/3735

1	As	IN	O	as	mark	5	SENT_18	3736/3738
2	TPs	NNS	O	tp	nsubjpass	5	SENT_18	3739/3742
3	are	VBP	O	be	auxpass	5	SENT_18	3743/3746
4	not	RB	O	not	neg	5	SENT_18	3747/3750
5	metabolized	VBN	O	metabolize	advcl	28	SENT_18	3751/3762
6	by	IN	O	by		-1	SENT_18	3763/3765
7	cytochrome	NN	O	cytochrome	nn	8	SENT_18	3766/3776
8	P450	NN	O	p450	agent	5	SENT_18	3777/3781
9	(	CD	NUMBER	(	num	12	SENT_18	3782/3783
10	CYP	NN	O	cyp	nn	12	SENT_18	3783/3786
11	)	NN	O	)	nn	12	SENT_18	3786/3787
12	enzymes	NNS	O	enzyme	dep	8	SENT_18	3788/3795
13	or	CC	O	or		-1	SENT_18	3796/3798
14	transported	VBN	O	transport	conj_or	5	SENT_18	3799/3810
15	by	IN	O	by		-1	SENT_18	3811/3813
16	transporters	NNS	O	transporter	prep_by	14	SENT_18	3814/3826
17	and	CC	O	and		-1	SENT_18	3827/3830
18	biotransformation	NN	O	biotransformation	nn	19	SENT_18	3831/3848
19	studies	NNS	O	study	nsubjpass	24	SENT_18	3849/3856
20	have	VBP	O	have	aux	24	SENT_18	3857/3861
21	not	RB	O	not	neg	24	SENT_18	3862/3865
22	been	VBN	O	be	auxpass	24	SENT_18	3866/3870
23	routinely	RB	O	routinely	advmod	24	SENT_18	3871/3880
24	conducted	VBN	O	conduct	conj_and	5	SENT_18	3881/3890
25	,	,	O	,		-1	SENT_18	3890/3891
26	it	PRP	O	it	nsubjpass	28	SENT_18	3892/3894
27	was	VBD	O	be	auxpass	28	SENT_18	3895/3898
28	assumed	VBN	O	assume		-1	SENT_18	3899/3906
29	that	IN	O	that	mark	33	SENT_18	3907/3911
30	TPs	NNS	O	tp	nsubj	33	SENT_18	3912/3915
31	do	VBP	O	do	aux	33	SENT_18	3916/3918
32	not	RB	O	not	neg	33	SENT_18	3919/3922
33	cause	VB	O	cause	ccomp	28	SENT_18	3923/3928
34	metabolism-based	JJ	O	metabolism-based	amod	36	SENT_18	3929/3945
35	drug	NN	O	drug	nn	36	SENT_18	3946/3950
36	interactions	NNS	O	interaction	dobj	33	SENT_18	3951/3963
37	(	CD	NUMBER	(	num	38	SENT_18	3964/3965
38	DI	NNP	O	DI	dep	36	SENT_18	3965/3967
39	)	CD	NUMBER	)	num	38	SENT_18	3967/3968
40	.	.	O	.		-1	SENT_18	3968/3969

1	However	RB	O	however	advmod	5	SENT_19	3970/3977
2	,	,	O	,		-1	SENT_19	3977/3978
3	recent	JJ	O	recent	amod	4	SENT_19	3979/3985
4	reports	NNS	O	report	nsubj	5	SENT_19	3986/3993
5	suggest	VBP	O	suggest		-1	SENT_19	3994/4001
6	that	IN	O	that	mark	29	SENT_19	4002/4006
7	the	DT	O	the	det	8	SENT_19	4007/4010
8	use	NN	O	use	nsubj	29	SENT_19	4011/4014
9	of	IN	O	of		-1	SENT_19	4015/4017
10	cytokines	NNS	O	cytokine	prep_of	8	SENT_19	4018/4027
11	,	,	O	,		-1	SENT_19	4027/4028
12	cytokine	NN	O	cytokine	nn	13	SENT_19	4029/4037
13	modulators	NNS	O	modulator	appos	10	SENT_19	4038/4048
14	such	JJ	O	such		-1	SENT_19	4049/4053
15	as	IN	O	as		-1	SENT_19	4054/4056
16	anti-cytokine	JJ	O	anti-cytokine	amod	17	SENT_19	4057/4070
17	mAb	NN	O	mab	prep_such_as	13	SENT_19	4071/4074
18	or	CC	O	or		-1	SENT_19	4075/4077
19	immunosuppressant	JJ	O	immunosuppressant	conj_or	17	SENT_19	4078/4095
20	containing	VBG	O	contain	partmod	13	SENT_19	4096/4106
21	drug	NN	O	drug	nn	22	SENT_19	4107/4111
22	combinations	NNS	O	combination	dobj	20	SENT_19	4112/4124
23	,	,	O	,		-1	SENT_19	4124/4125
24	in	IN	O	in		-1	SENT_19	4126/4128
25	inflammatory	JJ	O	inflammatory	amod	26	SENT_19	4129/4141
26	indications	NNS	O	indication	prep_in	20	SENT_19	4142/4153
27	,	,	O	,		-1	SENT_19	4153/4154
28	can	MD	O	can	aux	29	SENT_19	4155/4158
29	lead	VB	O	lead	ccomp	5	SENT_19	4159/4163
30	to	TO	O	to		-1	SENT_19	4164/4166
31	CYP-mediated	JJ	O	cyp-mediated	amod	32	SENT_19	4167/4179
32	DI	NNP	O	DI	prep_to	29	SENT_19	4180/4182
33	,	,	O	,		-1	SENT_19	4182/4183
34	with	IN	O	with		-1	SENT_19	4184/4188
35	the	DT	O	the	det	36	SENT_19	4189/4192
36	SMD	NNP	O	SMD	prep_with	29	SENT_19	4193/4196
37	as	IN	O	as		-1	SENT_19	4197/4199
38	the	DT	O	the	det	42	SENT_19	4200/4203
39	victim	NN	O	victim	nn	42	SENT_19	4204/4210
40	(	NN	O	(	nn	42	SENT_19	4211/4212
41	5,6	CD	NUMBER	5,6	num	42	SENT_19	4212/4215
42	)	NN	O	)	prep_as	36	SENT_19	4215/4216
43	.	.	O	.		-1	SENT_19	4216/4217

1	Many	JJ	O	many	amod	2	SENT_20	4218/4222
2	TPs	NNS	O	tp	nsubjpass	14	SENT_20	4223/4226
3	,	,	O	,		-1	SENT_20	4226/4227
4	cytokines	NNS	O	cytokine	conj_or	2	SENT_20	4228/4237
5	,	,	O	,		-1	SENT_20	4237/4238
6	or	CC	O	or		-1	SENT_20	4239/4241
7	cytokine	NN	O	cytokine	nn	8	SENT_20	4242/4250
8	modulators	NNS	O	modulator	conj_or	2	SENT_20	4251/4261
9	(	CD	NUMBER	(	num	10	SENT_20	4262/4263
10	antagonists	NNS	O	antagonist	dep	8	SENT_20	4263/4274
11	)	CD	NUMBER	)	dep	8	SENT_20	4274/4275
12	have	VBP	O	have	aux	14	SENT_20	4276/4280
13	been	VBN	O	be	auxpass	14	SENT_20	4281/4285
14	shown	VBN	O	show		-1	SENT_20	4286/4291
15	to	TO	O	to	aux	16	SENT_20	4292/4294
16	alter	VB	O	alter	xcomp	14	SENT_20	4295/4300
17	CYP	NN	O	cyp	nn	20	SENT_20	4301/4304
18	or	CC	O	or		-1	SENT_20	4305/4307
19	transporter	NN	O	transporter	conj_or	17	SENT_20	4308/4319
20	activities	NNS	O	activity	dobj	16	SENT_20	4320/4330
21	through	IN	O	through		-1	SENT_20	4331/4338
22	direct	JJ	O	direct	amod	25	SENT_20	4339/4345
23	or	CC	O	or		-1	SENT_20	4346/4348
24	indirect	JJ	O	indirect	conj_or	22	SENT_20	4349/4357
25	effects	NNS	O	effect	prep_through	16	SENT_20	4358/4365
26	.	.	O	.		-1	SENT_20	4365/4366

1	In	FW	O	in	nn	3	SENT_21	4402/4404
2	vitro	FW	O	vitro	nn	3	SENT_21	4405/4410
3	strategies	NNS	O	strategy	nsubjpass	11	SENT_21	4411/4421
4	for	IN	O	for		-1	SENT_21	4422/4425
5	assessing	VBG	O	assess	prepc_for	3	SENT_21	4426/4435
6	TP-DI	NN	O	tp-di	dobj	5	SENT_21	4436/4441
7	during	IN	O	during		-1	SENT_21	4442/4448
8	drug	NN	O	drug	nn	9	SENT_21	4449/4453
9	development	NN	O	development	prep_during	5	SENT_21	4454/4465
10	are	VBP	O	be	auxpass	11	SENT_21	4466/4469
11	limited	VBN	O	limit		-1	SENT_21	4470/4477
12	.	.	O	.		-1	SENT_21	4477/4478

1	Because	IN	O	because		-1	SENT_22	4479/4486
2	of	IN	O	of	prepc_because_of	29	SENT_22	4487/4489
3	inherent	JJ	O	inherent	amod	4	SENT_22	4490/4498
4	differences	NNS	O	difference	pobj	29	SENT_22	4499/4510
5	in	IN	O	in		-1	SENT_22	4511/4513
6	metabolic	JJ	O	metabolic	amod	7	SENT_22	4514/4523
7	pathways	NNS	O	pathway	prep_in	4	SENT_22	4524/4532
8	between	IN	O	between		-1	SENT_22	4533/4540
9	TPs	NNS	O	tp	prep_between	7	SENT_22	4541/4544
10	and	CC	O	and		-1	SENT_22	4545/4548
11	SMDs	NNS	O	smd	conj_and	9	SENT_22	4549/4553
12	,	,	O	,		-1	SENT_22	4553/4554
13	few	JJ	O	few	amod	18	SENT_22	4555/4558
14	preclinical	JJ	O	preclinical	nn	18	SENT_22	4559/4570
15	or	CC	O	or	cc	14	SENT_22	4571/4573
16	in	FW	O	in	nn	17	SENT_22	4574/4576
17	vitro	FW	O	vitro	advmod	14	SENT_22	4577/4582
18	tools	NNS	O	tool	nsubjpass	29	SENT_22	4583/4588
19	commonly	RB	O	commonly	advmod	20	SENT_22	4589/4597
20	used	VBN	O	use	partmod	18	SENT_22	4598/4602
21	for	IN	O	for		-1	SENT_22	4603/4606
22	DI	NNP	O	DI	nn	23	SENT_22	4607/4609
23	assessment	NN	O	assessment	prep_for	20	SENT_22	4610/4620
24	for	IN	O	for		-1	SENT_22	4621/4624
25	SMDs	NNS	O	smd	prep_for	23	SENT_22	4625/4629
26	can	MD	O	can	aux	29	SENT_22	4630/4633
27	be	VB	O	be	auxpass	29	SENT_22	4634/4636
28	readily	RB	O	readily	advmod	29	SENT_22	4637/4644
29	adopted	VBN	O	adopt		-1	SENT_22	4645/4652
30	to	TO	O	to	aux	31	SENT_22	4653/4655
31	predict	VB	O	predict	xcomp	29	SENT_22	4656/4663
32	DI	NNP	O	DI	dobj	31	SENT_22	4664/4666
33	for	IN	O	for		-1	SENT_22	4667/4670
34	TPs	NNS	O	tp	prep_for	32	SENT_22	4671/4674
35	.	.	O	.		-1	SENT_22	4674/4675

1	There	EX	O	there	expl	2	SENT_23	4676/4681
2	are	VBP	O	be		-1	SENT_23	4682/4685
3	also	RB	O	also	advmod	2	SENT_23	4686/4690
4	constraints	NNS	O	constraint	nsubj	2	SENT_23	4691/4702
5	in	IN	O	in		-1	SENT_23	4703/4705
6	designing	VBG	O	design	prepc_in	4	SENT_23	4706/4715
7	appropriate	JJ	O	appropriate	amod	10	SENT_23	4716/4727
8	clinical	JJ	O	clinical	amod	10	SENT_23	4728/4736
9	DI	NN	O	di	nn	10	SENT_23	4737/4739
10	studies	NNS	O	study	nsubj	11	SENT_23	4740/4747
11	due	JJ	O	due	xcomp	6	SENT_23	4748/4751
12	to	TO	O	to		-1	SENT_23	4752/4754
13	pharmacokinetic	JJ	O	pharmacokinetic	amod	17	SENT_23	4755/4770
14	(	NN	O	(	nn	17	SENT_23	4771/4772
15	PK	NN	O	pk	nn	17	SENT_23	4772/4774
16	)	NN	O	)	nn	17	SENT_23	4774/4775
17	properties	NNS	O	property	prep_to	11	SENT_23	4776/4786
18	of	IN	O	of		-1	SENT_23	4787/4789
19	TPs	NNS	O	tp	prep_of	17	SENT_23	4790/4793
20	.	.	O	.		-1	SENT_23	4793/4794

1	The	DT	O	the	det	2	SENT_24	4830/4833
2	FDA	NNP	ORGANIZATION	FDA	poss	7	SENT_24	4834/4837
3	's	POS	O	's		-1	SENT_24	4837/4839
4	Draft	NNP	ORGANIZATION	Draft	nn	7	SENT_24	4840/4845
5	Drug	NNP	ORGANIZATION	Drug	nn	7	SENT_24	4846/4850
6	Interaction	NN	ORGANIZATION	interaction	nn	7	SENT_24	4851/4862
7	Guidance	NN	ORGANIZATION	guidance	nsubj	8	SENT_24	4863/4871
8	published	VBN	O	publish		-1	SENT_24	4872/4881
9	in	IN	O	in		-1	SENT_24	4882/4884
10	2006	CD	DATE	2006	prep_in	8	SENT_24	4885/4889
11	,	,	O	,		-1	SENT_24	4889/4890
12	titled	VBN	O	title	dep	8	SENT_24	4891/4897
13	"	``	O	"	punct	16	SENT_24	4898/4899
14	Drug	NN	O	drug	nn	16	SENT_24	4899/4903
15	Interaction	NN	O	interaction	nn	16	SENT_24	4904/4915
16	Studies	NNS	O	study	dobj	12	SENT_24	4916/4923
17	--	:	O	--		-1	SENT_24	4923/4925
18	Study	NNP	O	Study	nn	19	SENT_24	4925/4930
19	Design	NNP	O	Design	dep	16	SENT_24	4931/4937
20	,	,	O	,		-1	SENT_24	4937/4938
21	Data	NNP	O	Data	nn	22	SENT_24	4939/4943
22	Analysis	NN	O	analysis	dobj	8	SENT_24	4944/4952
23	and	CC	O	and		-1	SENT_24	4953/4956
24	Implications	NNS	O	implication	conj_and	22	SENT_24	4957/4969
25	for	IN	O	for		-1	SENT_24	4970/4973
26	Dosing	NN	O	dosing	prep_for	22	SENT_24	4974/4980
27	and	CC	O	and		-1	SENT_24	4981/4984
28	Labeling	VBG	O	label	conj_and	8	SENT_24	4985/4993
29	"	``	O	"	punct	28	SENT_24	4993/4994
30	states	NNS	O	state	dobj	28	SENT_24	4995/5001
31	that	WDT	O	that	dobj	38	SENT_24	5002/5006
32	classical	JJ	O	classical	amod	34	SENT_24	5007/5016
33	biotransformation	NN	O	biotransformation	nn	34	SENT_24	5017/5034
34	studies	NNS	O	study	nsubjpass	38	SENT_24	5035/5042
35	are	VBP	O	be	auxpass	38	SENT_24	5043/5046
36	not	RB	O	not	neg	38	SENT_24	5047/5050
37	generally	RB	O	generally	advmod	38	SENT_24	5051/5060
38	required	VBN	O	require	rcmod	30	SENT_24	5061/5069
39	for	IN	O	for		-1	SENT_24	5070/5073
40	biologics	NNS	O	biologic	prep_for	38	SENT_24	5074/5083
41	because	IN	O	because	mark	45	SENT_24	5084/5091
42	they	PRP	O	they	nsubjpass	45	SENT_24	5092/5096
43	are	VBP	O	be	auxpass	45	SENT_24	5097/5100
44	not	RB	O	not	neg	45	SENT_24	5101/5104
45	metabolized	VBN	O	metabolize	advcl	28	SENT_24	5105/5116
46	by	IN	O	by		-1	SENT_24	5117/5119
47	metabolizing	VBG	O	metabolize	agent	45	SENT_24	5120/5132
48	enzymes	NNS	O	enzyme	nsubj	51	SENT_24	5133/5140
49	(	CD	NUMBER	(	number	50	SENT_24	5141/5142
50	7	CD	NUMBER	7	num	51	SENT_24	5142/5143
51	)	NN	O	)	xcomp	47	SENT_24	5143/5144
52	.	.	O	.		-1	SENT_24	5144/5145

1	The	DT	O	the	det	2	SENT_25	5146/5149
2	guidance	NN	O	guidance	nsubj	4	SENT_25	5150/5158
3	however	RB	O	however	advmod	4	SENT_25	5159/5166
4	raises	VBZ	O	raise		-1	SENT_25	5167/5173
5	concerns	NNS	O	concern	dobj	4	SENT_25	5174/5182
6	regarding	VBG	O	regard		-1	SENT_25	5183/5192
7	potential	JJ	O	potential	amod	8	SENT_25	5193/5202
8	interactions	NNS	O	interaction	prep_regarding	5	SENT_25	5203/5215
9	between	IN	O	between		-1	SENT_25	5216/5223
10	TPs	NNS	O	tp	prep_between	8	SENT_25	5224/5227
11	and	CC	O	and		-1	SENT_25	5228/5231
12	SMDs	NNS	O	smd	conj_and	10	SENT_25	5232/5236
13	such	JJ	O	such		-1	SENT_25	5237/5241
14	as	IN	O	as		-1	SENT_25	5242/5244
15	interferons	NNS	O	interferon	prep_such_as	10	SENT_25	5245/5256
16	and	CC	O	and		-1	SENT_25	5257/5260
17	SMDs	NNS	O	smd	conj_and	15	SENT_25	5261/5265
18	or	CC	O	or		-1	SENT_25	5266/5268
19	between	IN	O	between		-1	SENT_25	5269/5276
20	two	CD	NUMBER	two	num	22	SENT_25	5277/5280
21	different	JJ	O	different	amod	22	SENT_25	5281/5290
22	TPs	NNS	O	tp	conj_or	10	SENT_25	5291/5294
23	.	.	O	.		-1	SENT_25	5294/5295

1	The	DT	O	the	det	2	SENT_26	5296/5299
2	guidance	NN	O	guidance	nsubj	4	SENT_26	5300/5308
3	also	RB	O	also	advmod	4	SENT_26	5309/5313
4	states	VBZ	O	state		-1	SENT_26	5314/5320
5	that	IN	O	that	mark	8	SENT_26	5321/5325
6	in	FW	O	in	nn	7	SENT_26	5326/5328
7	vitro	FW	O	vitro	dep	8	SENT_26	5329/5334
8	methods	NNS	O	method	dep	4	SENT_26	5335/5342
9	may	MD	O	may	aux	12	SENT_26	5343/5346
10	not	RB	O	not	neg	12	SENT_26	5347/5350
11	be	VB	O	be	cop	12	SENT_26	5351/5353
12	suitable	JJ	O	suitable	rcmod	8	SENT_26	5354/5362
13	.	.	O	.		-1	SENT_26	5362/5363

1	Two	CD	NUMBER	two	num	3	SENT_27	5364/5367
2	recent	JJ	O	recent	amod	3	SENT_27	5368/5374
3	publications	NNS	O	publication	nsubj	7	SENT_27	5375/5387
4	from	IN	O	from		-1	SENT_27	5388/5392
5	the	DT	O	the	det	6	SENT_27	5393/5396
6	FDA	NNP	ORGANIZATION	FDA	prep_from	3	SENT_27	5397/5400
7	highlight	NN	O	highlight		-1	SENT_27	5401/5410
8	the	DT	O	the	det	10	SENT_27	5411/5414
9	current	JJ	DATE	current	amod	10	SENT_27	5415/5422
10	perspectives	NNS	O	perspective	dobj	7	SENT_27	5423/5435
11	on	IN	O	on		-1	SENT_27	5436/5438
12	TP-DI	NN	O	tp-di	prep_on	10	SENT_27	5439/5444
13	,	,	O	,		-1	SENT_27	5444/5445
14	particularly	RB	O	particularly	advmod	12	SENT_27	5446/5458
15	those	DT	O	those	dep	12	SENT_27	5459/5464
16	involving	VBG	O	involve	xcomp	7	SENT_27	5465/5474
17	effect	NN	O	effect	dobj	16	SENT_27	5475/5481
18	of	IN	O	of		-1	SENT_27	5482/5484
19	cytokine	NN	O	cytokine	nn	20	SENT_27	5485/5493
20	modulators	NNS	O	modulator	prep_of	17	SENT_27	5494/5504
21	on	IN	O	on		-1	SENT_27	5505/5507
22	CYPs	NNS	O	cyp	prep_on	16	SENT_27	5508/5512
23	(	CD	NUMBER	(	number	24	SENT_27	5513/5514
24	1,2	CD	NUMBER	1,2	num	25	SENT_27	5514/5517
25	)	NN	O	)	dep	16	SENT_27	5517/5518
26	.	.	O	.		-1	SENT_27	5518/5519

1	The	DT	O	the	det	5	SENT_28	5520/5523
2	European	JJ	ORGANIZATION	european	amod	5	SENT_28	5524/5532
3	Medicines	NNP	ORGANIZATION	Medicines	nn	5	SENT_28	5533/5542
4	Agency	NNP	ORGANIZATION	Agency	nn	5	SENT_28	5543/5549
5	guidance	NN	O	guidance	nsubj	54	SENT_28	5550/5558
6	published	VBN	O	publish	partmod	5	SENT_28	5559/5568
7	in	IN	O	in		-1	SENT_28	5569/5571
8	July	NNP	DATE	July	prep_in	6	SENT_28	5572/5576
9	2007	CD	DATE	2007	num	8	SENT_28	5577/5581
10	titled	VBN	O	title	partmod	8	SENT_28	5582/5588
11	"	``	O	"	punct	24	SENT_28	5589/5590
12	Guideline	NN	O	guideline	nsubj	24	SENT_28	5590/5599
13	on	IN	O	on		-1	SENT_28	5600/5602
14	the	DT	O	the	det	16	SENT_28	5603/5606
15	Clinical	JJ	O	clinical	amod	16	SENT_28	5607/5615
16	Investigation	NN	O	investigation	prep_on	12	SENT_28	5616/5629
17	of	IN	O	of		-1	SENT_28	5630/5632
18	the	DT	O	the	det	19	SENT_28	5633/5636
19	Pharmacokinetics	NNS	O	pharmacokinetic	prep_of	16	SENT_28	5637/5653
20	of	IN	O	of		-1	SENT_28	5654/5656
21	Therapeutic	JJ	O	therapeutic	amod	22	SENT_28	5657/5668
22	Proteins	NNS	O	protein	prep_of	19	SENT_28	5669/5677
23	"	``	O	"	punct	24	SENT_28	5677/5678
24	supports	VBZ	O	support	ccomp	10	SENT_28	5679/5687
25	concerns	NNS	O	concern	dobj	24	SENT_28	5688/5696
26	about	IN	O	about		-1	SENT_28	5697/5702
27	immunomodulators	NNS	O	immunomodulator	prep_about	24	SENT_28	5703/5719
28	such	JJ	O	such		-1	SENT_28	5720/5724
29	as	IN	O	as		-1	SENT_28	5725/5727
30	cytokines	NNS	O	cytokine	prep_such_as	27	SENT_28	5728/5737
31	that	WDT	O	that	nsubj	33	SENT_28	5738/5742
32	have	VBP	O	have	aux	33	SENT_28	5743/5747
33	shown	VBN	O	show	rcmod	30	SENT_28	5748/5753
34	a	DT	O	a	det	35	SENT_28	5754/5755
35	potential	NN	O	potential	dobj	33	SENT_28	5756/5765
36	for	IN	O	for		-1	SENT_28	5766/5769
37	the	DT	O	the	det	38	SENT_28	5770/5773
38	inhibition	NN	O	inhibition	nsubj	45	SENT_28	5774/5784
39	or	CC	O	or		-1	SENT_28	5785/5787
40	induction	NN	O	induction	conj_or	38	SENT_28	5788/5797
41	of	IN	O	of		-1	SENT_28	5798/5800
42	CYP	NN	O	cyp	nn	43	SENT_28	5801/5804
43	enzymes	NNS	O	enzyme	prep_of	38	SENT_28	5805/5812
44	thereby	RB	O	thereby	advmod	45	SENT_28	5813/5820
45	altering	VBG	O	alter	prepc_for	33	SENT_28	5821/5829
46	the	DT	O	the	det	47	SENT_28	5830/5833
47	metabolism	NN	O	metabolism	dobj	45	SENT_28	5834/5844
48	of	IN	O	of		-1	SENT_28	5845/5847
49	SMDs	NNS	O	smd	prep_of	47	SENT_28	5848/5852
50	metabolized	VBN	O	metabolize	partmod	49	SENT_28	5853/5864
51	by	IN	O	by		-1	SENT_28	5865/5867
52	these	DT	O	these	det	53	SENT_28	5868/5873
53	enzymes	NNS	O	enzyme	agent	50	SENT_28	5874/5881
54	(	VBP	O	(		-1	SENT_28	5882/5883
55	8	CD	NUMBER	8	number	56	SENT_28	5883/5884
56	)	CD	NUMBER	)	dobj	54	SENT_28	5884/5885
57	.	.	O	.		-1	SENT_28	5885/5886

1	It	PRP	O	it	nsubj	3	SENT_29	5922/5924
2	is	VBZ	O	be	cop	3	SENT_29	5925/5927
3	critical	JJ	O	critical		-1	SENT_29	5928/5936
4	to	TO	O	to	aux	5	SENT_29	5937/5939
5	understand	VB	O	understand	xcomp	3	SENT_29	5940/5950
6	the	DT	O	the	det	9	SENT_29	5951/5954
7	possible	JJ	O	possible	amod	9	SENT_29	5955/5963
8	DI	NN	O	di	nn	9	SENT_29	5964/5966
9	mechanisms	NNS	O	mechanism	dobj	5	SENT_29	5967/5977
10	for	IN	O	for		-1	SENT_29	5978/5981
11	TPs	NNS	O	tp	prep_for	5	SENT_29	5982/5985
12	and	CC	O	and		-1	SENT_29	5986/5989
13	build	VB	O	build	conj_and	5	SENT_29	5990/5995
14	a	DT	O	a	det	15	SENT_29	5996/5997
15	strategy	NN	O	strategy	dobj	13	SENT_29	5998/6006
16	during	IN	O	during		-1	SENT_29	6007/6013
17	drug	NN	O	drug	nn	18	SENT_29	6014/6018
18	development	NN	O	development	prep_during	13	SENT_29	6019/6030
19	to	TO	O	to	aux	20	SENT_29	6031/6033
20	ensure	VB	O	ensure	xcomp	13	SENT_29	6034/6040
21	safe	JJ	O	safe	amod	24	SENT_29	6041/6045
22	and	CC	O	and		-1	SENT_29	6046/6049
23	effective	JJ	O	effective	conj_and	21	SENT_29	6050/6059
24	use	NN	O	use	dobj	20	SENT_29	6060/6063
25	of	IN	O	of		-1	SENT_29	6064/6066
26	therapeutics	NNS	O	therapeutics	prep_of	24	SENT_29	6067/6079
27	.	.	O	.		-1	SENT_29	6079/6080

1	An	DT	O	a	det	3	SENT_30	6081/6083
2	American	NNP	ORGANIZATION	American	nn	3	SENT_30	6084/6092
3	Association	NNP	ORGANIZATION	Association	nsubj	10	SENT_30	6093/6104
4	of	IN	ORGANIZATION	of		-1	SENT_30	6105/6107
5	Pharmaceutical	NNP	ORGANIZATION	Pharmaceutical	nn	7	SENT_30	6108/6122
6	Scientists-sponsored	JJ	O	scientists-sponsored	amod	7	SENT_30	6123/6143
7	workshop	NN	O	workshop	prep_of	3	SENT_30	6144/6152
8	was	VBD	O	be	aux	10	SENT_30	6153/6156
9	organized1	CD	NUMBER	organized1	num	10	SENT_30	6157/6167
10	,2	CD	NUMBER	,2		-1	SENT_30	6167/6169
11	to	TO	O	to	aux	12	SENT_30	6170/6172
12	address	VB	O	address	dep	10	SENT_30	6173/6180
13	limitations	NNS	O	limitation	dobj	12	SENT_30	6181/6192
14	and	CC	O	and		-1	SENT_30	6193/6196
15	knowledge	NN	O	knowledge	nn	16	SENT_30	6197/6206
16	gaps	NNS	O	gap	conj_and	13	SENT_30	6207/6211
17	in	IN	O	in		-1	SENT_30	6212/6214
18	assessing	VBG	O	assess	prepc_in	12	SENT_30	6215/6224
19	the	DT	O	the	det	20	SENT_30	6225/6228
20	potential	NN	O	potential	dobj	18	SENT_30	6229/6238
21	for	IN	O	for		-1	SENT_30	6239/6242
22	TP-DI	NN	O	tp-di	prep_for	20	SENT_30	6243/6248
23	,	,	O	,		-1	SENT_30	6248/6249
24	to	TO	O	to	aux	25	SENT_30	6250/6252
25	share	VB	O	share	conj_and	12	SENT_30	6253/6258
26	drug	NN	O	drug	nn	27	SENT_30	6259/6263
27	development	NN	O	development	dobj	25	SENT_30	6264/6275
28	,	,	O	,		-1	SENT_30	6275/6276
29	research	NN	O	research	conj_and	27	SENT_30	6277/6285
30	and	CC	O	and		-1	SENT_30	6286/6289
31	regulatory	JJ	O	regulatory	amod	32	SENT_30	6290/6300
32	experience	NN	O	experience	conj_and	27	SENT_30	6301/6311
33	in	IN	O	in		-1	SENT_30	6312/6314
34	TP-DI	NN	O	tp-di	nn	35	SENT_30	6315/6320
35	assessment	NN	O	assessment	prep_in	25	SENT_30	6321/6331
36	,	,	O	,		-1	SENT_30	6331/6332
37	and	CC	O	and		-1	SENT_30	6333/6336
38	to	TO	O	to	aux	39	SENT_30	6337/6339
39	develop	VB	O	develop	conj_and	12	SENT_30	6340/6347
40	strategies	NNS	O	strategy	dobj	39	SENT_30	6348/6358
41	for	IN	O	for		-1	SENT_30	6359/6362
42	assessing	VBG	O	assess	prepc_for	39	SENT_30	6363/6372
43	TP-DI	NN	O	tp-di	dobj	42	SENT_30	6373/6378
44	during	IN	O	during		-1	SENT_30	6379/6385
45	drug	NN	O	drug	nn	46	SENT_30	6386/6390
46	development	NN	O	development	prep_during	42	SENT_30	6391/6402
47	.	.	O	.		-1	SENT_30	6402/6403

1	Participants	NNS	O	participant	nsubj	2	SENT_31	6404/6416
2	included	VBD	O	include		-1	SENT_31	6417/6425
3	industry	NN	O	industry	dobj	2	SENT_31	6426/6434
4	,	,	O	,		-1	SENT_31	6434/6435
5	academic	JJ	O	academic	conj_and	3	SENT_31	6436/6444
6	,	,	O	,		-1	SENT_31	6444/6445
7	and	CC	O	and		-1	SENT_31	6446/6449
8	regulatory	JJ	O	regulatory	amod	9	SENT_31	6450/6460
9	representatives	NNS	O	representative	conj_and	3	SENT_31	6461/6476
10	.	.	O	.		-1	SENT_31	6476/6477

1	Goals	NNS	O	goal		-1	SENT_32	6513/6518
2	and	CC	O	and		-1	SENT_32	6519/6522
3	Objectives	NNS	O	objective	conj_and	1	SENT_32	6523/6533

1	This	DT	O	this	det	2	SENT_33	6569/6573
2	workshop	NN	O	workshop		-1	SENT_33	6574/6582
3	aimed	VBN	O	aim	partmod	2	SENT_33	6583/6588
4	to	TO	O	to	aux	5	SENT_33	6589/6591
5	provide	VB	O	provide	xcomp	3	SENT_33	6592/6599
6	participants	NNS	O	participant	dobj	5	SENT_33	6600/6612
7	with	IN	O	with		-1	SENT_33	6613/6617
8	a	DT	O	a	det	10	SENT_33	6618/6619
9	clear	JJ	O	clear	amod	10	SENT_33	6620/6625
10	understanding	NN	O	understanding	prep_with	5	SENT_33	6626/6639
11	on	IN	O	on		-1	SENT_33	6640/6642
12	how	WRB	O	how	advmod	14	SENT_33	6643/6646
13	to	TO	O	to	aux	14	SENT_33	6647/6649
14	develop	VB	O	develop	prepc_on	10	SENT_33	6650/6657
15	strategies	NNS	O	strategy	dobj	14	SENT_33	6658/6668
16	for	IN	O	for		-1	SENT_33	6669/6672
17	assessing	VBG	O	assess	prepc_for	14	SENT_33	6673/6682
18	TP-DI	NN	O	tp-di	dobj	17	SENT_33	6683/6688
19	during	IN	O	during		-1	SENT_33	6689/6695
20	drug	NN	O	drug	nn	21	SENT_33	6696/6700
21	development	NN	O	development	prep_during	17	SENT_33	6701/6712
22	by	IN	O	by	prep	17	SENT_33	6713/6715
23	:	:	O	:		-1	SENT_33	6715/6716

1	reviewing	VBG	O	review		-1	SENT_34	6733/6742
2	preclinical	JJ	O	preclinical	amod	8	SENT_34	6743/6754
3	tools	NNS	O	tool	nn	8	SENT_34	6755/6760
4	and	CC	O	and	cc	3	SENT_34	6761/6764
5	in	FW	O	in	nn	6	SENT_34	6765/6767
6	vitro	FW	O	vitro	advmod	3	SENT_34	6768/6773
7	test	NN	O	test	nn	8	SENT_34	6774/6778
8	systems	NNS	O	system	dobj	1	SENT_34	6779/6786
9	for	IN	O	for		-1	SENT_34	6787/6790
10	assessing	VBG	O	assess	prepc_for	1	SENT_34	6791/6800
11	the	DT	O	the	det	13	SENT_34	6801/6804
12	DI	NNP	O	DI	nn	13	SENT_34	6805/6807
13	potential	NN	O	potential	dobj	10	SENT_34	6808/6817
14	of	IN	O	of		-1	SENT_34	6818/6820
15	TPs	NNS	O	tp	prep_of	13	SENT_34	6821/6824
16	such	JJ	O	such		-1	SENT_34	6825/6829
17	as	IN	O	as		-1	SENT_34	6830/6832
18	cytokines	NNS	O	cytokine	prep_such_as	15	SENT_34	6833/6842
19	and	CC	O	and		-1	SENT_34	6843/6846
20	cytokine	NN	O	cytokine	nn	21	SENT_34	6847/6855
21	modulators	NNS	O	modulator	conj_and	18	SENT_34	6856/6866
22	,	,	O	,		-1	SENT_34	6866/6867

1	reviewing	VBG	O	review		-1	SENT_35	6903/6912
2	literature	NN	O	literature	dobj	1	SENT_35	6913/6923
3	on	IN	O	on		-1	SENT_35	6924/6926
4	clinically	RB	O	clinically	advmod	5	SENT_35	6927/6937
5	relevant	JJ	O	relevant	amod	6	SENT_35	6938/6946
6	TP-DI	NN	O	tp-di	prep_on	2	SENT_35	6947/6952
7	,	,	O	,		-1	SENT_35	6952/6953

1	discussing	VBG	O	discuss		-1	SENT_36	6989/6999
2	study	NN	O	study	nn	3	SENT_36	7000/7005
3	designs	NNS	O	design	dobj	1	SENT_36	7006/7013
4	and	CC	O	and		-1	SENT_36	7014/7017
5	acceptance	NN	O	acceptance	nn	6	SENT_36	7018/7028
6	criteria	NNS	O	criterion	conj_and	3	SENT_36	7029/7037
7	for	IN	O	for		-1	SENT_36	7038/7041
8	assessing	VBG	O	assess	prepc_for	1	SENT_36	7042/7051
9	PK	NN	O	pk	dobj	8	SENT_36	7052/7054
10	-	:	O	-		-1	SENT_36	7054/7055
11	and	CC	O	and		-1	SENT_36	7056/7059
12	pharmacodynamic	JJ	O	pharmacodynamic	amod	14	SENT_36	7060/7075
13	(	NN	O	(	nn	14	SENT_36	7076/7077
14	PD	NN	O	pd	conj_and	9	SENT_36	7077/7079
15	)	SYM	O	)	dep	17	SENT_36	7079/7080
16	-	:	O	-		-1	SENT_36	7080/7081
17	based	VBN	O	base	rcmod	14	SENT_36	7081/7086
18	TP-DI	NN	O	tp-di	dobj	17	SENT_36	7087/7092
19	in	IN	O	in		-1	SENT_36	7093/7095
20	clinical	JJ	O	clinical	amod	21	SENT_36	7096/7104
21	studies	NNS	O	study	prep_in	17	SENT_36	7105/7112
22	,	,	O	,		-1	SENT_36	7112/7113
23	and	CC	O	and	advmod	17	SENT_36	7114/7117

1	providing	VBG	O	provide	csubj	12	SENT_37	7153/7162
2	participants	NNS	O	participant	dobj	1	SENT_37	7163/7175
3	with	IN	O	with		-1	SENT_37	7176/7180
4	the	DT	O	the	det	5	SENT_37	7181/7184
5	knowledge	NN	O	knowledge	prep_with	1	SENT_37	7185/7194
6	and	CC	O	and		-1	SENT_37	7195/7198
7	skills	NNS	O	skill	conj_and	5	SENT_37	7199/7205
8	to	TO	O	to	aux	9	SENT_37	7206/7208
9	develop	VB	O	develop	xcomp	1	SENT_37	7209/7216
10	a	DT	O	a	det	11	SENT_37	7217/7218
11	science	NN	O	science	dobj	9	SENT_37	7219/7226
12	driven	VBN	O	drive		-1	SENT_37	7227/7233
13	approach	NN	O	approach	dobj	12	SENT_37	7234/7242
14	for	IN	O	for		-1	SENT_37	7243/7246
15	assessing	VBG	O	assess	prepc_for	12	SENT_37	7247/7256
16	the	DT	O	the	det	17	SENT_37	7257/7260
17	risk	NN	O	risk	dobj	15	SENT_37	7261/7265
18	and	CC	O	and		-1	SENT_37	7266/7269
19	potential	NN	O	potential	conj_and	17	SENT_37	7270/7279
20	of	IN	O	of		-1	SENT_37	7280/7282
21	TP-DI	NN	O	tp-di	prep_of	17	SENT_37	7283/7288
22	.	.	O	.		-1	SENT_37	7288/7289

1	This	DT	O	this	det	2	SENT_38	7344/7348
2	paper	NN	O	paper	nsubj	3	SENT_38	7349/7354
3	condenses	VBZ	O	condense		-1	SENT_38	7355/7364
4	the	DT	O	the	det	6	SENT_38	7365/7368
5	salient	JJ	O	salient	amod	6	SENT_38	7369/7376
6	points	NNS	O	point	dobj	3	SENT_38	7377/7383
7	,	,	O	,		-1	SENT_38	7383/7384
8	considerations	NNS	O	consideration	conj_and	6	SENT_38	7385/7399
9	,	,	O	,		-1	SENT_38	7399/7400
10	and	CC	O	and		-1	SENT_38	7401/7404
11	positions	NNS	O	position	conj_and	6	SENT_38	7405/7414
12	presented	VBN	O	present	partmod	11	SENT_38	7415/7424
13	and	CC	O	and		-1	SENT_38	7425/7428
14	discussed	VBN	O	discuss	conj_and	12	SENT_38	7429/7438
15	during	IN	O	during		-1	SENT_38	7439/7445
16	the	DT	O	the	det	17	SENT_38	7446/7449
17	workshop	NN	O	workshop	prep_during	12	SENT_38	7450/7458
18	providing	VBG	O	provide	partmod	17	SENT_38	7459/7468
19	a	DT	O	a	det	20	SENT_38	7469/7470
20	sense	NN	O	sense	dobj	18	SENT_38	7471/7476
21	of	IN	O	of		-1	SENT_38	7477/7479
22	the	DT	O	the	det	30	SENT_38	7480/7483
23	state-of	JJ	O	state-of	amod	30	SENT_38	7484/7492
24	-	:	O	-		-1	SENT_38	7492/7493
25	the-art	NN	O	the-art	dep	23	SENT_38	7494/7501
26	with	IN	O	with		-1	SENT_38	7502/7506
27	respect	NN	O	respect		-1	SENT_38	7507/7514
28	to	TO	O	to		-1	SENT_38	7515/7517
29	TP-DI	NN	O	tp-di	prep_with_respect_to	25	SENT_38	7518/7523
30	exploration	NN	O	exploration	prep_of	20	SENT_38	7524/7535
31	.	.	O	.		-1	SENT_38	7535/7536

1	Session	NN	O	session	nn	2	SENT_39	7572/7579
2	I	NN	O	i		-1	SENT_39	7580/7581
3	:	:	O	:		-1	SENT_39	7581/7582
4	Prolog	NNP	O	Prolog	dep	2	SENT_39	7583/7589
5	--	:	O	--		-1	SENT_39	7589/7591
6	In	IN	O	in	dep	4	SENT_39	7591/7593
7	Vitro	NNP	O	Vitro	pobj	6	SENT_39	7594/7599
8	and	CC	O	and		-1	SENT_39	7600/7603
9	Preclinical	JJ	O	preclinical	amod	10	SENT_39	7604/7615
10	Models	NNS	O	model	conj_and	4	SENT_39	7616/7622
11	and	CC	O	and		-1	SENT_39	7623/7626
12	Current	JJ	DATE	current	amod	13	SENT_39	7627/7634
13	Status	NN	O	status	conj_and	10	SENT_39	7635/7641

1	Preclinical	JJ	O	preclinical	amod	2	SENT_40	7677/7688
2	Tools	NNS	O	tool		-1	SENT_40	7689/7694
3	and	CC	O	and		-1	SENT_40	7695/7698
4	In	IN	O	in	conj_and	2	SENT_40	7699/7701
5	Vitro	NNP	O	Vitro	nn	7	SENT_40	7702/7707
6	Test	NNP	O	Test	nn	7	SENT_40	7708/7712
7	Systems	NNPS	O	Systems	pobj	4	SENT_40	7713/7720
8	to	TO	O	to	aux	9	SENT_40	7721/7723
9	Assess	VB	O	assess	infmod	7	SENT_40	7724/7730
10	TP-DI	NN	O	tp-di	dobj	9	SENT_40	7731/7736
11	Potential	JJ	O	potential	amod	10	SENT_40	7737/7746
12	during	IN	O	during		-1	SENT_40	7747/7753
13	Drug	NNP	O	Drug	nn	14	SENT_40	7754/7758
14	Development	NNP	O	Development	prep_during	9	SENT_40	7759/7770

1	In	FW	O	in	nn	3	SENT_41	7806/7808
2	vitro	FW	O	vitro	nn	3	SENT_41	7809/7814
3	studies	NNS	O	study	nsubj	12	SENT_41	7815/7822
4	with	IN	O	with		-1	SENT_41	7823/7827
5	isolated	VBN	O	isolate	amod	7	SENT_41	7828/7836
6	human	JJ	O	human	amod	7	SENT_41	7837/7842
7	hepatocytes	NNS	O	hepatocyte	prep_with	3	SENT_41	7843/7854
8	or	CC	O	or		-1	SENT_41	7855/7857
9	liver	NN	O	liver	nn	10	SENT_41	7858/7863
10	microsomes	NNS	O	microsome	conj_or	7	SENT_41	7864/7874
11	generally	RB	O	generally	advmod	12	SENT_41	7875/7884
12	provide	VBP	O	provide		-1	SENT_41	7885/7892
13	insight	NN	O	insight	dobj	12	SENT_41	7893/7900
14	into	IN	O	into		-1	SENT_41	7901/7905
15	the	DT	O	the	det	18	SENT_41	7906/7909
16	PK	NNP	O	PK	nn	18	SENT_41	7910/7912
17	DI	NNP	O	DI	nn	18	SENT_41	7913/7915
18	potential	NN	O	potential	prep_into	12	SENT_41	7916/7925
19	for	IN	O	for		-1	SENT_41	7926/7929
20	co-administered	JJ	O	co-administered	amod	21	SENT_41	7930/7945
21	SMDs	NNS	O	smd	prep_for	18	SENT_41	7946/7950
22	.	.	O	.		-1	SENT_41	7950/7951

1	In	IN	O	in		-1	SENT_42	7952/7954
2	contrast	NN	O	contrast	prep_in	8	SENT_42	7955/7963
3	,	,	O	,		-1	SENT_42	7963/7964
4	it	PRP	O	it	nsubj	8	SENT_42	7965/7967
5	is	VBZ	O	be	cop	8	SENT_42	7968/7970
6	currently	RB	DATE	currently	advmod	8	SENT_42	7971/7980
7	not	RB	O	not	neg	8	SENT_42	7981/7984
8	feasible	JJ	O	feasible		-1	SENT_42	7985/7993
9	to	TO	O	to	aux	10	SENT_42	7994/7996
10	predict	VB	O	predict	xcomp	8	SENT_42	7997/8004
11	the	DT	O	the	det	12	SENT_42	8005/8008
12	propensity	NN	O	propensity	dobj	10	SENT_42	8009/8019
13	for	IN	O	for		-1	SENT_42	8020/8023
14	DI	NN	O	di	prep_for	10	SENT_42	8024/8026
15	between	IN	O	between		-1	SENT_42	8027/8034
16	TPs	NNS	O	tp	prep_between	14	SENT_42	8035/8038
17	and	CC	O	and		-1	SENT_42	8039/8042
18	SMDs	NNS	O	smd	conj_and	16	SENT_42	8043/8047
19	.	.	O	.		-1	SENT_42	8047/8048

1	Although	IN	O	although	mark	8	SENT_43	8049/8057
2	the	DT	O	the	det	3	SENT_43	8058/8061
3	effects	NNS	O	effect	nsubj	8	SENT_43	8062/8069
4	in	IN	O	in		-1	SENT_43	8070/8072
5	general	JJ	O	general	prep_in	3	SENT_43	8073/8080
6	have	VBP	O	have	aux	8	SENT_43	8081/8085
7	been	VBN	O	be	cop	8	SENT_43	8086/8090
8	weak	JJ	O	weak	advcl	21	SENT_43	8091/8095
9	to	TO	O	to		-1	SENT_43	8096/8098
10	moderate	JJ	O	moderate	prep_to	8	SENT_43	8099/8107
11	,	,	O	,		-1	SENT_43	8107/8108
12	examples	NNS	O	example	nsubjpass	21	SENT_43	8109/8117
13	of	IN	O	of		-1	SENT_43	8118/8120
14	DI	NN	O	di	prep_of	12	SENT_43	8121/8123
15	between	IN	O	between		-1	SENT_43	8124/8131
16	TPs	NNS	O	tp	prep_between	14	SENT_43	8132/8135
17	and	CC	O	and		-1	SENT_43	8136/8139
18	SMDs	NNS	O	smd	conj_and	16	SENT_43	8140/8144
19	have	VBP	O	have	aux	21	SENT_43	8145/8149
20	been	VBN	O	be	auxpass	21	SENT_43	8150/8154
21	observed	VBN	O	observe		-1	SENT_43	8155/8163
22	,	,	O	,		-1	SENT_43	8163/8164
23	particularly	RB	O	particularly	advmod	21	SENT_43	8165/8177
24	for	IN	O	for		-1	SENT_43	8178/8181
25	cytokines	NNS	O	cytokine	prep_for	21	SENT_43	8182/8191
26	.	.	O	.		-1	SENT_43	8191/8192

1	Based	VBN	O	base		-1	SENT_44	8193/8198
2	on	IN	O	on	prepc_based_on	18	SENT_44	8199/8201
3	clinical	JJ	O	clinical	amod	4	SENT_44	8202/8210
4	data	NNS	O	datum	pobj	18	SENT_44	8211/8215
5	with	IN	O	with		-1	SENT_44	8216/8220
6	interferons	NNS	O	interferon	prep_with	4	SENT_44	8221/8232
7	and	CC	O	and		-1	SENT_44	8233/8236
8	interleukins	NNS	O	interleukin	conj_and	6	SENT_44	8237/8249
9	(	CD	NUMBER	(	num	11	SENT_44	8250/8251
10	9-13	CD	NUMBER	9-13	num	11	SENT_44	8251/8255
11	)	NN	O	)	dep	6	SENT_44	8255/8256
12	,	,	O	,		-1	SENT_44	8256/8257
13	two	CD	NUMBER	two	num	15	SENT_44	8258/8261
14	important	JJ	O	important	amod	15	SENT_44	8262/8271
15	conclusions	NNS	O	conclusion	nsubjpass	18	SENT_44	8272/8283
16	can	MD	O	can	aux	18	SENT_44	8284/8287
17	be	VB	O	be	auxpass	18	SENT_44	8288/8290
18	drawn	VBN	O	draw		-1	SENT_44	8291/8296
19	:	:	O	:		-1	SENT_44	8296/8297
20	(	CD	NUMBER	(	number	21	SENT_44	8298/8299
21	1	CD	NUMBER	1	num	23	SENT_44	8299/8300
22	)	NN	O	)	nn	23	SENT_44	8300/8301
23	cytokines	NNS	O	cytokine	nsubj	25	SENT_44	8302/8311
24	can	MD	O	can	aux	25	SENT_44	8312/8315
25	cause	VB	O	cause	parataxis	18	SENT_44	8316/8321
26	the	DT	O	the	det	27	SENT_44	8322/8325
27	downregulation	NN	O	downregulation	dobj	25	SENT_44	8326/8340
28	of	IN	O	of		-1	SENT_44	8341/8343
29	a	DT	O	a	det	31	SENT_44	8344/8345
30	wide	JJ	O	wide	amod	31	SENT_44	8346/8350
31	range	NN	O	range	prep_of	27	SENT_44	8351/8356
32	of	IN	O	of		-1	SENT_44	8357/8359
33	CYP	NN	O	cyp	nn	38	SENT_44	8360/8363
34	or	CC	O	or		-1	SENT_44	8364/8366
35	isoform	NN	O	isoform	conj_or	33	SENT_44	8367/8374
36	specific	JJ	O	specific	amod	38	SENT_44	8375/8383
37	CYP	NN	O	cyp	nn	38	SENT_44	8384/8387
38	enzymes	NNS	O	enzyme	prep_of	31	SENT_44	8388/8395
39	,	,	O	,		-1	SENT_44	8395/8396
40	(	NN	O	(	appos	31	SENT_44	8397/8398
41	2	CD	NUMBER	2	number	42	SENT_44	8398/8399
42	)	CD	NUMBER	)	dep	40	SENT_44	8399/8400
43	a	DT	O	a	det	46	SENT_44	8401/8402
44	high	JJ	O	high	amod	46	SENT_44	8403/8407
45	inter-individual	JJ	O	inter-individual	amod	46	SENT_44	8408/8424
46	variability	NN	O	variability	nsubjpass	53	SENT_44	8425/8436
47	in	IN	O	in		-1	SENT_44	8437/8439
48	effects	NNS	O	effect	prep_in	46	SENT_44	8440/8447
49	on	IN	O	on		-1	SENT_44	8448/8450
50	CYP	NN	O	cyp	nn	51	SENT_44	8451/8454
51	levels	NNS	O	level	prep_on	48	SENT_44	8455/8461
52	is	VBZ	O	be	auxpass	53	SENT_44	8462/8464
53	observed	VBN	O	observe	rcmod	27	SENT_44	8465/8473
54	.	.	O	.		-1	SENT_44	8473/8474

1	Complicating	VBG	O	complicate	amod	2	SENT_45	8475/8487
2	factors	NNS	O	factor	nsubj	10	SENT_45	8488/8495
3	in	IN	O	in		-1	SENT_45	8496/8498
4	interpreting	VBG	O	interpret	prepc_in	2	SENT_45	8499/8511
5	clinical	JJ	O	clinical	amod	7	SENT_45	8512/8520
6	DI	NNP	O	DI	nn	7	SENT_45	8521/8523
7	data	NNS	O	datum	dobj	4	SENT_45	8524/8528
8	with	IN	O	with		-1	SENT_45	8529/8533
9	cytokines	NNS	O	cytokine	prep_with	4	SENT_45	8534/8543
10	include	VBP	O	include		-1	SENT_45	8544/8551
11	:	:	O	:		-1	SENT_45	8551/8552
12	(	CD	NUMBER	(	number	13	SENT_45	8553/8554
13	1	CD	NUMBER	1	num	15	SENT_45	8554/8555
14	)	NN	O	)	nn	15	SENT_45	8555/8556
15	variability	NN	O	variability	dobj	10	SENT_45	8557/8568
16	in	IN	O	in		-1	SENT_45	8569/8571
17	the	DT	O	the	det	18	SENT_45	8572/8575
18	dose	NN	O	dose	prep_in	15	SENT_45	8576/8580
19	and	CC	O	and		-1	SENT_45	8581/8584
20	duration	NN	O	duration	conj_and	18	SENT_45	8585/8593
21	of	IN	O	of		-1	SENT_45	8594/8596
22	treatment	NN	O	treatment	prep_of	18	SENT_45	8597/8606
23	,	,	O	,		-1	SENT_45	8606/8607
24	(	NN	O	(	appos	22	SENT_45	8608/8609
25	2	CD	NUMBER	2	number	26	SENT_45	8609/8610
26	)	CD	NUMBER	)	dep	24	SENT_45	8610/8611
27	whether	IN	O	whether	mark	31	SENT_45	8612/8619
28	the	DT	O	the	det	29	SENT_45	8620/8623
29	study	NN	O	study	nsubjpass	31	SENT_45	8624/8629
30	was	VBD	O	be	auxpass	31	SENT_45	8630/8633
31	conducted	VBN	O	conduct	dep	18	SENT_45	8634/8643
32	in	IN	O	in		-1	SENT_45	8644/8646
33	healthy	JJ	O	healthy	amod	34	SENT_45	8647/8654
34	volunteers	NNS	O	volunteer	prep_in	31	SENT_45	8655/8665
35	or	CC	O	or		-1	SENT_45	8666/8668
36	in	IN	O	in	conj_or	31	SENT_45	8669/8671
37	patients	NNS	O	patient	pobj	36	SENT_45	8672/8680
38	,	,	O	,		-1	SENT_45	8680/8681
39	and	CC	O	and		-1	SENT_45	8682/8685
40	(	NN	O	(	nn	43	SENT_45	8686/8687
41	3	CD	NUMBER	3	num	43	SENT_45	8687/8688
42	)	NN	O	)	nn	43	SENT_45	8688/8689
43	use	NN	O	use	conj_and	18	SENT_45	8690/8693
44	of	IN	O	of		-1	SENT_45	8694/8696
45	non	JJ	O	non	prep_of	43	SENT_45	8697/8700
46	-	:	O	-		-1	SENT_45	8700/8701
47	standardized	JJ	O	standardized	amod	49	SENT_45	8702/8714
48	probe	NN	O	probe	nn	49	SENT_45	8715/8720
49	substrates	NNS	O	substrate	dep	43	SENT_45	8721/8731
50	to	TO	O	to	aux	51	SENT_45	8732/8734
51	monitor	VB	O	monitor	infmod	49	SENT_45	8735/8742
52	CYP	NN	O	cyp	nn	53	SENT_45	8743/8746
53	activities	NNS	O	activity	dobj	51	SENT_45	8747/8757
54	.	.	O	.		-1	SENT_45	8757/8758

1	In	IN	O	in		-1	SENT_46	8794/8796
2	contrast	NN	O	contrast	prep_in	22	SENT_46	8797/8805
3	to	TO	O	to		-1	SENT_46	8806/8808
4	the	DT	O	the	det	6	SENT_46	8809/8812
5	straightforward	JJ	O	straightforward	amod	6	SENT_46	8813/8828
6	evaluation	NN	O	evaluation	prep_to	2	SENT_46	8829/8839
7	of	IN	O	of	prep	6	SENT_46	8840/8842
8	in	FW	O	in	nn	9	SENT_46	8843/8845
9	vitro	FW	O	vitro	advmod	11	SENT_46	8846/8851
10	hepatocyte	NN	O	hepatocyte	nn	11	SENT_46	8852/8862
11	data	NNS	O	datum	dep	7	SENT_46	8863/8867
12	for	IN	O	for		-1	SENT_46	8868/8871
13	SMD	NNP	O	SMD	nn	14	SENT_46	8872/8875
14	DI	NNP	O	DI	prep_for	11	SENT_46	8876/8878
15	,	,	O	,		-1	SENT_46	8878/8879
16	in	FW	O	in	nn	17	SENT_46	8880/8882
17	vitro	FW	O	vitro	dep	18	SENT_46	8883/8888
18	TP	NN	O	tp	dep	22	SENT_46	8889/8891
19	DI	NNP	O	DI	nn	20	SENT_46	8892/8894
20	data	NNS	O	datum	nsubj	22	SENT_46	8895/8899
21	have	VBP	O	have	aux	22	SENT_46	8900/8904
22	proven	VBN	O	prove		-1	SENT_46	8905/8911
23	to	TO	O	to	aux	26	SENT_46	8912/8914
24	be	VB	O	be	cop	26	SENT_46	8915/8917
25	more	RBR	O	more	advmod	26	SENT_46	8918/8922
26	difficult	JJ	O	difficult	xcomp	22	SENT_46	8923/8932
27	to	TO	O	to	aux	28	SENT_46	8933/8935
28	interpret	VB	O	interpret	xcomp	26	SENT_46	8936/8945
29	(	NN	O	(	nn	31	SENT_46	8946/8947
30	2	CD	NUMBER	2	num	31	SENT_46	8947/8948
31	)	NN	O	)	dobj	28	SENT_46	8948/8949
32	.	.	O	.		-1	SENT_46	8949/8950

1	For	IN	O	for		-1	SENT_47	8951/8954
2	example	NN	O	example	prep_for	34	SENT_47	8955/8962
3	,	,	O	,		-1	SENT_47	8962/8963
4	although	IN	O	although	mark	15	SENT_47	8964/8972
5	a	DT	O	a	det	7	SENT_47	8973/8974
6	high	JJ	O	high	amod	7	SENT_47	8975/8979
7	dose	NN	O	dose	nsubj	15	SENT_47	8980/8984
8	of	IN	O	of		-1	SENT_47	8985/8987
9	interleukin	NN	O	interleukin	nn	11	SENT_47	8988/8999
10	(	CD	NUMBER	(	num	11	SENT_47	9000/9001
11	IL	NN	O	il	prep_of	7	SENT_47	9001/9003
12	)	CD	NUMBER	)	num	13	SENT_47	9003/9004
13	-2	CD	NUMBER	-2	dep	11	SENT_47	9004/9006
14	has	VBZ	O	have	aux	15	SENT_47	9007/9010
15	shown	VBN	O	show	advcl	34	SENT_47	9011/9016
16	decreased	VBN	O	decrease	amod	17	SENT_47	9017/9026
17	CYP3A4	NN	O	cyp3a4	dobj	15	SENT_47	9027/9033
18	and	CC	O	and		-1	SENT_47	9034/9037
19	other	JJ	O	other	amod	21	SENT_47	9038/9043
20	CYP	NN	O	cyp	nn	21	SENT_47	9044/9047
21	activities	NNS	O	activity	conj_and	17	SENT_47	9048/9058
22	in	IN	O	in		-1	SENT_47	9059/9061
23	human	JJ	O	human	amod	27	SENT_47	9062/9067
24	liver	NN	O	liver	nn	27	SENT_47	9068/9073
25	(	NN	O	(	nn	27	SENT_47	9074/9075
26	12	CD	NUMBER	12	num	27	SENT_47	9075/9077
27	)	NN	O	)	prep_in	21	SENT_47	9077/9078
28	,	,	O	,		-1	SENT_47	9078/9079
29	this	DT	O	this	det	30	SENT_47	9080/9084
30	finding	NN	O	finding	nsubjpass	34	SENT_47	9085/9092
31	could	MD	O	could	aux	34	SENT_47	9093/9098
32	not	RB	O	not	neg	34	SENT_47	9099/9102
33	be	VB	O	be	auxpass	34	SENT_47	9103/9105
34	reproduced	VBN	O	reproduce		-1	SENT_47	9106/9116
35	in	FW	O	in	nn	36	SENT_47	9117/9119
36	vitro	FW	O	vitro	advmod	34	SENT_47	9120/9125
37	using	VBG	O	use	xcomp	34	SENT_47	9126/9131
38	hepatocytes	NNS	O	hepatocyte	dobj	37	SENT_47	9132/9143
39	.	.	O	.		-1	SENT_47	9143/9144

1	However	RB	O	however	advmod	7	SENT_48	9145/9152
2	,	,	O	,		-1	SENT_48	9152/9153
3	a	DT	O	a	det	5	SENT_48	9154/9155
4	sustained	JJ	O	sustained	amod	5	SENT_48	9156/9165
5	downregulation	NN	O	downregulation	nsubjpass	7	SENT_48	9166/9180
6	was	VBD	O	be	auxpass	7	SENT_48	9181/9184
7	observed	VBN	O	observe		-1	SENT_48	9185/9193
8	in	IN	O	in		-1	SENT_48	9194/9196
9	hepatocytes	NNS	O	hepatocyte	prep_in	7	SENT_48	9197/9208
10	co-cultured	VBN	O	co-culture	partmod	9	SENT_48	9209/9220
11	with	IN	O	with		-1	SENT_48	9221/9225
12	Kupffer	NN	O	kupffer	nn	13	SENT_48	9226/9233
13	cells	NNS	O	cell	prep_with	10	SENT_48	9234/9239
14	(	VBP	O	(	dep	9	SENT_48	9240/9241
15	14	CD	NUMBER	14	num	16	SENT_48	9241/9243
16	)	CD	NUMBER	)	dobj	14	SENT_48	9243/9244
17	,	,	O	,		-1	SENT_48	9244/9245
18	suggesting	VBG	O	suggest	partmod	14	SENT_48	9246/9256
19	that	IN	O	that	mark	21	SENT_48	9257/9261
20	IL-2	NN	O	il-2	nsubj	21	SENT_48	9262/9266
21	causes	VBZ	O	cause	ccomp	18	SENT_48	9267/9273
22	Kupffer	NN	PERSON	kupffer	nn	23	SENT_48	9274/9281
23	cells	NNS	O	cell	nsubj	25	SENT_48	9282/9287
24	to	TO	O	to	aux	25	SENT_48	9288/9290
25	secrete	VB	O	secrete	xcomp	21	SENT_48	9291/9298
26	a	DT	O	a	det	27	SENT_48	9299/9300
27	cytokine	NN	O	cytokine	dobj	25	SENT_48	9301/9309
28	,	,	O	,		-1	SENT_48	9309/9310
29	which	WDT	O	which	nsubj	31	SENT_48	9311/9316
30	indirectly	RB	O	indirectly	advmod	31	SENT_48	9317/9327
31	downregulates	VBZ	O	downregulate	rcmod	9	SENT_48	9328/9341
32	CYP3A4	NN	O	cyp3a4	dobj	31	SENT_48	9342/9348
33	in	IN	O	in		-1	SENT_48	9349/9351
34	hepatocytes	NNS	O	hepatocyte	prep_in	32	SENT_48	9352/9363
35	.	.	O	.		-1	SENT_48	9363/9364

1	Complex	NN	O	complex	nn	2	SENT_49	9365/9372
2	signaling	NN	O	signaling	nsubjpass	6	SENT_49	9373/9382
3	may	MD	O	may	aux	6	SENT_49	9383/9386
4	be	VB	O	be	auxpass	6	SENT_49	9387/9389
5	often	RB	O	often	advmod	6	SENT_49	9390/9395
6	involved	VBN	O	involve		-1	SENT_49	9396/9404
7	in	IN	O	in		-1	SENT_49	9405/9407
8	TP-DI	NN	O	tp-di	prep_in	6	SENT_49	9408/9413
9	and	CC	O	and		-1	SENT_49	9414/9417
10	it	PRP	O	it	nsubj	14	SENT_49	9418/9420
11	is	VBZ	O	be	cop	14	SENT_49	9421/9423
12	not	RB	O	not	neg	14	SENT_49	9424/9427
13	currently	RB	DATE	currently	advmod	14	SENT_49	9428/9437
14	possible	JJ	O	possible	conj_and	6	SENT_49	9438/9446
15	to	TO	O	to	aux	16	SENT_49	9447/9449
16	assure	VB	O	assure	xcomp	14	SENT_49	9450/9456
17	that	DT	O	that	det	18	SENT_49	9457/9461
18	cell	NN	O	cell	dobj	16	SENT_49	9462/9466
19	culture	NN	O	culture	nn	20	SENT_49	9467/9474
20	systems	NNS	O	system	nsubj	21	SENT_49	9475/9482
21	provide	VBP	O	provide	rcmod	18	SENT_49	9483/9490
22	the	DT	O	the	det	24	SENT_49	9491/9494
23	appropriate	JJ	O	appropriate	amod	24	SENT_49	9495/9506
24	mix	NN	O	mix	dobj	21	SENT_49	9507/9510
25	of	IN	O	of		-1	SENT_49	9511/9513
26	cell	NN	O	cell	nn	27	SENT_49	9514/9518
27	types	NNS	O	type	prep_of	24	SENT_49	9519/9524
28	required	VBN	O	require	partmod	27	SENT_49	9525/9533
29	for	IN	O	for		-1	SENT_49	9534/9537
30	meaningful	JJ	O	meaningful	amod	31	SENT_49	9538/9548
31	evaluation	NN	O	evaluation	prep_for	28	SENT_49	9549/9559
32	in	FW	O	in	nn	33	SENT_49	9560/9562
33	vitro	FW	O	vitro	advmod	28	SENT_49	9563/9568
34	.	.	O	.		-1	SENT_49	9568/9569

1	As	IN	O	as		-1	SENT_50	9570/9572
2	such	JJ	O	such	prep_such_as	7	SENT_50	9573/9577
3	,	,	O	,		-1	SENT_50	9577/9578
4	relatively	RB	O	relatively	advmod	5	SENT_50	9579/9589
5	little	JJ	O	little	dep	7	SENT_50	9590/9596
6	is	VBZ	O	be	auxpass	7	SENT_50	9597/9599
7	known	VBN	O	know		-1	SENT_50	9600/9605
8	about	IN	O	about		-1	SENT_50	9606/9611
9	the	DT	O	the	det	10	SENT_50	9612/9615
10	effects	NNS	O	effect	prep_about	7	SENT_50	9616/9623
11	of	IN	O	of		-1	SENT_50	9624/9626
12	TPs	NNS	O	tp	prep_of	10	SENT_50	9627/9630
13	on	IN	O	on		-1	SENT_50	9631/9633
14	CYPs	NNS	O	cyp	prep_on	12	SENT_50	9634/9638
15	,	,	O	,		-1	SENT_50	9638/9639
16	and	CC	O	and		-1	SENT_50	9640/9643
17	little	JJ	O	little	nsubjpass	19	SENT_50	9644/9650
18	is	VBZ	O	be	auxpass	19	SENT_50	9651/9653
19	known	VBN	O	know	conj_and	7	SENT_50	9654/9659
20	about	IN	O	about		-1	SENT_50	9660/9665
21	the	DT	O	the	det	22	SENT_50	9666/9669
22	effects	NNS	O	effect	prep_about	19	SENT_50	9670/9677
23	of	IN	O	of		-1	SENT_50	9678/9680
24	TPs	NNS	O	tp	prep_of	22	SENT_50	9681/9684
25	on	IN	O	on		-1	SENT_50	9685/9687
26	other	JJ	O	other	amod	27	SENT_50	9688/9693
27	drug	NN	O	drug	prep_on	24	SENT_50	9694/9698
28	metabolizing	VBG	O	metabolize	xcomp	19	SENT_50	9699/9711
29	enzymes	NNS	O	enzyme	dobj	28	SENT_50	9712/9719
30	or	CC	O	or		-1	SENT_50	9720/9722
31	drug	NN	O	drug	nn	32	SENT_50	9723/9727
32	transporters	NNS	O	transporter	conj_or	29	SENT_50	9728/9740
33	.	.	O	.		-1	SENT_50	9740/9741

1	Recent	JJ	O	recent	amod	2	SENT_51	9742/9748
2	work	NN	O	work	nsubj	4	SENT_51	9749/9753
3	has	VBZ	O	have	aux	4	SENT_51	9754/9757
4	demonstrated	VBN	O	demonstrate		-1	SENT_51	9758/9770
5	that	IN	O	that	mark	10	SENT_51	9771/9775
6	TNF	NN	O	tnf	nsubj	10	SENT_51	9776/9779
7	-	:	O	-		-1	SENT_51	9779/9780
8	and	CC	O	and		-1	SENT_51	9783/9786
9	IL-6	NN	O	il-6	conj_and	6	SENT_51	9787/9791
10	reduce	VB	O	reduce	ccomp	4	SENT_51	9792/9798
11	the	DT	O	the	det	13	SENT_51	9799/9802
12	protein	NN	O	protein	nn	13	SENT_51	9803/9810
13	levels	NNS	O	level	dobj	10	SENT_51	9811/9817
14	and	CC	O	and		-1	SENT_51	9818/9821
15	activity	NN	O	activity	conj_and	13	SENT_51	9822/9830
16	of	IN	O	of		-1	SENT_51	9831/9833
17	several	JJ	O	several	amod	19	SENT_51	9834/9841
18	drug	NN	O	drug	nn	19	SENT_51	9842/9846
19	transporters	NNS	O	transporter	prep_of	13	SENT_51	9847/9859
20	,	,	O	,		-1	SENT_51	9859/9860
21	supporting	VBG	O	support	dep	13	SENT_51	9861/9871
22	the	DT	O	the	det	23	SENT_51	9872/9875
23	contention	NN	O	contention	dobj	21	SENT_51	9876/9886
24	that	IN	O	that	mark	26	SENT_51	9887/9891
25	there	EX	O	there	expl	26	SENT_51	9892/9897
26	is	VBZ	O	be	ccomp	21	SENT_51	9898/9900
27	a	DT	O	a	det	29	SENT_51	9901/9902
28	clear	JJ	O	clear	amod	29	SENT_51	9903/9908
29	need	NN	O	need	nsubj	26	SENT_51	9909/9913
30	for	IN	O	for		-1	SENT_51	9914/9917
31	additional	JJ	O	additional	amod	32	SENT_51	9918/9928
32	investigation	NN	O	investigation	prep_for	29	SENT_51	9929/9942
33	(	CD	NUMBER	(	number	34	SENT_51	9943/9944
34	15	CD	NUMBER	15	num	35	SENT_51	9944/9946
35	)	NN	O	)	dep	13	SENT_51	9946/9947
36	.	.	O	.		-1	SENT_51	9947/9948

1	The	DT	O	the	det	2	SENT_52	9984/9987
2	observation	NN	O	observation	nsubj	15	SENT_52	9988/9999
3	that	IN	O	that	mark	7	SENT_52	10000/10004
4	different	JJ	O	different	amod	5	SENT_52	10005/10014
5	cytokines	NNS	O	cytokine	nsubj	7	SENT_52	10015/10024
6	can	MD	O	can	aux	7	SENT_52	10025/10028
7	have	VB	O	have	dep	2	SENT_52	10029/10033
8	differential	JJ	O	differential	amod	9	SENT_52	10034/10046
9	effects	NNS	O	effect	dobj	7	SENT_52	10047/10054
10	on	IN	O	on		-1	SENT_52	10055/10057
11	the	DT	O	the	det	14	SENT_52	10058/10061
12	various	JJ	O	various	amod	14	SENT_52	10062/10069
13	CYP	NN	O	cyp	nn	14	SENT_52	10070/10073
14	enzymes	NNS	O	enzyme	prep_on	9	SENT_52	10074/10081
15	suggests	VBZ	O	suggest		-1	SENT_52	10082/10090
16	that	IN	O	that	mark	18	SENT_52	10091/10095
17	there	EX	O	there	expl	18	SENT_52	10096/10101
18	are	VBP	O	be	ccomp	15	SENT_52	10102/10105
19	multiple	JJ	O	multiple	amod	20	SENT_52	10106/10114
20	mechanisms	NNS	O	mechanism	nsubj	18	SENT_52	10115/10125
21	which	WDT	O	which	nsubj	23	SENT_52	10126/10131
22	could	MD	O	could	aux	23	SENT_52	10132/10137
23	result	VB	O	result	rcmod	20	SENT_52	10138/10144
24	in	IN	O	in		-1	SENT_52	10145/10147
25	reducing	VBG	O	reduce	prepc_in	23	SENT_52	10148/10156
26	enzyme	NN	O	enzyme	nn	27	SENT_52	10157/10163
27	activities	NNS	O	activity	nsubj	28	SENT_52	10164/10174
28	(	VBP	O	(	ccomp	25	SENT_52	10175/10176
29	16	CD	NUMBER	16	num	30	SENT_52	10176/10178
30	)	CD	NUMBER	)	dobj	28	SENT_52	10178/10179
31	.	.	O	.		-1	SENT_52	10179/10180

1	With	IN	O	with		-1	SENT_53	10216/10220
2	current	JJ	DATE	current	amod	3	SENT_53	10221/10228
3	knowledge	NN	O	knowledge	prep_with	10	SENT_53	10229/10238
4	and	CC	O	and		-1	SENT_53	10239/10242
5	technology	NN	O	technology	conj_and	3	SENT_53	10243/10253
6	,	,	O	,		-1	SENT_53	10253/10254
7	it	PRP	O	it	nsubj	10	SENT_53	10255/10257
8	is	VBZ	O	be	cop	10	SENT_53	10258/10260
9	not	RB	O	not	neg	10	SENT_53	10261/10264
10	feasible	JJ	O	feasible		-1	SENT_53	10265/10273
11	to	TO	O	to	aux	12	SENT_53	10274/10276
12	make	VB	O	make	xcomp	10	SENT_53	10277/10281
13	prospective	JJ	O	prospective	amod	14	SENT_53	10282/10293
14	predictions	NNS	O	prediction	dobj	12	SENT_53	10294/10305
15	based	VBN	O	base		-1	SENT_53	10306/10311
16	on	IN	O	on	prepc_based_on	12	SENT_53	10312/10314
17	in	FW	O	in	nn	18	SENT_53	10315/10317
18	vitro	FW	O	vitro	advmod	20	SENT_53	10318/10323
19	hepatocyte	NN	O	hepatocyte	nn	20	SENT_53	10324/10334
20	data	NNS	O	datum	dep	12	SENT_53	10335/10339
21	whether	IN	O	whether	mark	23	SENT_53	10340/10347
22	cytokines	NNS	O	cytokine	nsubj	23	SENT_53	10348/10357
23	have	VBP	O	have	ccomp	20	SENT_53	10358/10362
24	the	DT	O	the	det	25	SENT_53	10363/10366
25	propensity	NN	O	propensity	dobj	23	SENT_53	10367/10377
26	to	TO	O	to	aux	27	SENT_53	10378/10380
27	cause	VB	O	cause	infmod	25	SENT_53	10381/10386
28	DI	NN	O	di	dobj	27	SENT_53	10387/10389
29	with	IN	O	with		-1	SENT_53	10390/10394
30	SMDs	NNS	O	smd	prep_with	27	SENT_53	10395/10399
31	.	.	O	.		-1	SENT_53	10399/10400

1	An	DT	O	a	det	3	SENT_54	10401/10403
2	important	JJ	O	important	amod	3	SENT_54	10404/10413
3	step	NN	O	step	nsubj	15	SENT_54	10414/10418
4	towards	IN	O	towards		-1	SENT_54	10419/10426
5	establishing	VBG	O	establish	prepc_towards	3	SENT_54	10427/10439
6	whether	IN	O	whether	mark	10	SENT_54	10440/10447
7	this	DT	O	this	nsubj	10	SENT_54	10448/10452
8	might	MD	O	might	aux	10	SENT_54	10453/10458
9	be	VB	O	be	cop	10	SENT_54	10459/10461
10	possible	JJ	O	possible	ccomp	5	SENT_54	10462/10470
11	in	IN	O	in		-1	SENT_54	10471/10473
12	the	DT	DATE	the	det	13	SENT_54	10474/10477
13	future	NN	DATE	future	prep_in	10	SENT_54	10478/10484
14	would	MD	O	would	aux	15	SENT_54	10485/10490
15	require	VB	O	require		-1	SENT_54	10491/10498
16	systematic	JJ	O	systematic	amod	17	SENT_54	10499/10509
17	retrospective	JJ	O	retrospective	amod	18	SENT_54	10510/10523
18	analysis	NN	O	analysis	dobj	15	SENT_54	10524/10532
19	using	VBG	O	use	xcomp	15	SENT_54	10533/10538
20	standardized	JJ	O	standardized	amod	22	SENT_54	10539/10551
21	assay	NN	O	assay	nn	22	SENT_54	10552/10557
22	conditions	NNS	O	condition	dobj	19	SENT_54	10558/10568
23	,	,	O	,		-1	SENT_54	10568/10569
24	and	CC	O	and		-1	SENT_54	10570/10573
25	the	DT	O	the	det	26	SENT_54	10574/10577
26	identification	NN	O	identification	nsubj	32	SENT_54	10578/10592
27	of	IN	O	of		-1	SENT_54	10593/10595
28	suitable	JJ	O	suitable	amod	30	SENT_54	10596/10604
29	positive	JJ	O	positive	amod	30	SENT_54	10605/10613
30	controls	NNS	O	control	prep_of	26	SENT_54	10614/10622
31	to	TO	O	to	aux	32	SENT_54	10623/10625
32	monitor	VB	O	monitor	conj_and	15	SENT_54	10626/10633
33	assay	NN	O	assay	nn	34	SENT_54	10634/10639
34	performance	NN	O	performance	dobj	32	SENT_54	10640/10651
35	.	.	O	.		-1	SENT_54	10651/10652

1	A	DT	O	a	det	7	SENT_55	10688/10689
2	Recent	JJ	O	recent	amod	7	SENT_55	10690/10696
3	Biotechnology	NNP	O	Biotechnology	nn	7	SENT_55	10697/10710
4	Industry	NNP	O	Industry	nn	7	SENT_55	10711/10719
5	Organization	NNP	O	Organization	nn	7	SENT_55	10720/10732
6	(	NN	O	(	nn	7	SENT_55	10733/10734
7	BIO	NN	O	bio		-1	SENT_55	10734/10737
8	)	CD	NUMBER	)	num	9	SENT_55	10737/10738
9	Survey	NN	O	survey	dep	7	SENT_55	10739/10745
10	on	IN	O	on		-1	SENT_55	10746/10748
11	TP-DI	NN	O	tp-di	nn	12	SENT_55	10749/10754
12	Evaluation	NN	O	evaluation	prep_on	9	SENT_55	10755/10765
13	during	IN	O	during		-1	SENT_55	10766/10772
14	Development	NN	O	development	prep_during	12	SENT_55	10773/10784
15	of	IN	O	of		-1	SENT_55	10785/10787
16	TPs	NNS	O	tp	prep_of	14	SENT_55	10788/10791

1	Because	IN	O	because		-1	SENT_56	10827/10834
2	of	IN	O	of		-1	SENT_56	10835/10837
3	emerging	VBG	O	emerge	amod	4	SENT_56	10838/10846
4	science	NN	O	science	prep_because_of	13	SENT_56	10847/10854
5	and	CC	O	and		-1	SENT_56	10855/10858
6	lack	NN	O	lack	conj_and	4	SENT_56	10859/10863
7	of	IN	O	of		-1	SENT_56	10864/10866
8	clear	JJ	O	clear	amod	10	SENT_56	10867/10872
9	regulatory	JJ	O	regulatory	amod	10	SENT_56	10873/10883
10	guidance	NN	O	guidance	prep_of	6	SENT_56	10884/10892
11	,	,	O	,		-1	SENT_56	10892/10893
12	there	EX	O	there	expl	13	SENT_56	10894/10899
13	is	VBZ	O	be		-1	SENT_56	10900/10902
14	a	DT	O	a	det	15	SENT_56	10903/10904
15	perception	NN	O	perception	nsubj	13	SENT_56	10905/10915
16	that	IN	O	that	mark	19	SENT_56	10916/10920
17	substantial	JJ	O	substantial	amod	18	SENT_56	10921/10932
18	inconsistencies	NNS	O	inconsistency	nsubj	19	SENT_56	10933/10948
19	exist	VBP	O	exist	ccomp	13	SENT_56	10949/10954
20	in	IN	O	in		-1	SENT_56	10955/10957
21	DI	NNP	O	DI	nn	23	SENT_56	10958/10960
22	assessment	NN	O	assessment	nn	23	SENT_56	10961/10971
23	strategies	NNS	O	strategy	prep_in	19	SENT_56	10972/10982
24	for	IN	O	for		-1	SENT_56	10983/10986
25	TPs	NNS	O	tp	prep_for	19	SENT_56	10987/10990
26	across	IN	O	across		-1	SENT_56	10991/10997
27	pharmaceutical/biotechnology	NN	O	pharmaceutical/biotechnology	nn	28	SENT_56	10998/11026
28	companies	NNS	O	company	prep_across	25	SENT_56	11027/11036
29	.	.	O	.		-1	SENT_56	11036/11037

1	Recently	RB	DATE	recently	advmod	11	SENT_57	11038/11046
2	,	,	O	,		-1	SENT_57	11046/11047
3	the	DT	O	the	det	5	SENT_57	11048/11051
4	BioSafe	NNP	ORGANIZATION	BioSafe	nn	5	SENT_57	11052/11059
5	Pharmacokinetics	NNPS	ORGANIZATION	Pharmacokinetics	nsubj	11	SENT_57	11060/11076
6	and	CC	O	and		-1	SENT_57	11077/11080
7	Disposition	NNP	O	Disposition	nn	10	SENT_57	11081/11092
8	Expert	NNP	O	Expert	nn	10	SENT_57	11093/11099
9	Working	NNP	O	Working	nn	10	SENT_57	11100/11107
10	Group	NNP	O	Group	conj_and	5	SENT_57	11108/11113
11	completed	VBD	O	complete		-1	SENT_57	11114/11123
12	a	DT	O	a	det	13	SENT_57	11124/11125
13	survey	NN	O	survey	dobj	11	SENT_57	11126/11132
14	to	TO	O	to	aux	16	SENT_57	11133/11135
15	better	RBR	O	better	advmod	16	SENT_57	11136/11142
16	understand	VB	O	understand	infmod	13	SENT_57	11143/11153
17	"	''	O	"	punct	16	SENT_57	11154/11155
18	current	JJ	DATE	current	amod	19	SENT_57	11155/11162
19	practices	NNS	O	practice	dobj	16	SENT_57	11163/11172
20	"	``	O	"	punct	19	SENT_57	11172/11173
21	as	IN	O	as		-1	SENT_57	11174/11176
22	to	TO	O	to		-1	SENT_57	11177/11179
23	when	WRB	O	when	advmod	30	SENT_57	11180/11184
24	a	DT	O	a	det	27	SENT_57	11185/11186
25	DI	NNP	O	DI	nn	27	SENT_57	11187/11189
26	assessment	NN	O	assessment	nn	27	SENT_57	11190/11200
27	strategy	NN	O	strategy	nsubjpass	30	SENT_57	11201/11209
28	should	MD	O	should	aux	30	SENT_57	11210/11216
29	be	VB	O	be	auxpass	30	SENT_57	11217/11219
30	incorporated	VBN	O	incorporate	prepc_as_to	19	SENT_57	11220/11232
31	into	IN	O	into		-1	SENT_57	11233/11237
32	TP	NN	O	tp	nn	35	SENT_57	11238/11240
33	drug	NN	O	drug	nn	35	SENT_57	11241/11245
34	development	NN	O	development	nn	35	SENT_57	11246/11257
35	programs	NNS	O	program	prep_into	30	SENT_57	11258/11266
36	.	.	O	.		-1	SENT_57	11266/11267

1	Twenty-one	CD	NUMBER	twenty-one	num	2	SENT_58	11268/11278
2	companies	NNS	O	company	nsubj	11	SENT_58	11279/11288
3	representing	VBG	O	represent	partmod	2	SENT_58	11289/11301
4	a	DT	O	a	det	6	SENT_58	11302/11303
5	comprehensive	JJ	O	comprehensive	amod	6	SENT_58	11304/11317
6	cross-section	NN	O	cross-section	dobj	3	SENT_58	11318/11331
7	of	IN	O	of		-1	SENT_58	11332/11334
8	the	DT	O	the	det	10	SENT_58	11335/11338
9	BIO	NNP	O	BIO	nn	10	SENT_58	11339/11342
10	organization	NN	O	organization	prep_of	6	SENT_58	11343/11355
11	participated	VBD	O	participate		-1	SENT_58	11356/11368
12	in	IN	O	in		-1	SENT_58	11369/11371
13	the	DT	O	the	det	14	SENT_58	11372/11375
14	survey	NN	O	survey	prep_in	11	SENT_58	11376/11382
15	.	.	O	.		-1	SENT_58	11382/11383

1	Unlike	IN	O	unlike		-1	SENT_59	11384/11390
2	SMD-DI	NN	O	smd-di	nn	3	SENT_59	11391/11397
3	studies	NNS	O	study	prep_unlike	13	SENT_59	11398/11405
4	,	,	O	,		-1	SENT_59	11405/11406
5	in	FW	O	in	nn	6	SENT_59	11407/11409
6	vitro	FW	O	vitro	dep	9	SENT_59	11410/11415
7	and	CC	O	and		-1	SENT_59	11416/11419
8	preclinical	JJ	O	preclinical	conj_and	6	SENT_59	11420/11431
9	methods	NNS	O	method	nsubjpass	13	SENT_59	11432/11439
10	are	VBP	O	be	auxpass	13	SENT_59	11440/11443
11	not	RB	O	not	neg	13	SENT_59	11444/11447
12	widely	RB	O	widely	advmod	13	SENT_59	11448/11454
13	used	VBN	O	use		-1	SENT_59	11455/11459
14	for	IN	O	for		-1	SENT_59	11460/11463
15	DI	NNP	O	DI	nn	16	SENT_59	11464/11466
16	assessments	NNS	O	assessment	prep_for	13	SENT_59	11467/11478
17	of	IN	O	of		-1	SENT_59	11479/11481
18	TPs	NNS	O	tp	prep_of	16	SENT_59	11482/11485
19	.	.	O	.		-1	SENT_59	11485/11486

1	As	IN	O	as		-1	SENT_60	11487/11489
2	a	DT	O	a	det	3	SENT_60	11490/11491
3	result	NN	O	result	prep_as	10	SENT_60	11492/11498
4	,	,	O	,		-1	SENT_60	11498/11499
5	clinical	JJ	O	clinical	amod	6	SENT_60	11500/11508
6	methods	NNS	O	method	nsubjpass	10	SENT_60	11509/11516
7	are	VBP	O	be	auxpass	10	SENT_60	11517/11520
8	still	RB	O	still	advmod	10	SENT_60	11521/11526
9	primarily	RB	O	primarily	advmod	10	SENT_60	11527/11536
10	used	VBN	O	use		-1	SENT_60	11537/11541
11	for	IN	O	for		-1	SENT_60	11542/11545
12	these	DT	O	these	det	13	SENT_60	11546/11551
13	assessments	NNS	O	assessment	prep_for	10	SENT_60	11552/11563
14	.	.	O	.		-1	SENT_60	11563/11564

1	Three	CD	NUMBER	three	num	2	SENT_61	11565/11570
2	methods	NNS	O	method	nsubjpass	5	SENT_61	11571/11578
3	are	VBP	O	be	auxpass	5	SENT_61	11579/11582
4	commonly	RB	O	commonly	advmod	5	SENT_61	11583/11591
5	employed	VBN	O	employ		-1	SENT_61	11592/11600
6	:	:	O	:		-1	SENT_61	11600/11601
7	(	CD	NUMBER	(	number	8	SENT_61	11602/11603
8	1	CD	NUMBER	1	num	9	SENT_61	11603/11604
9	)	NN	O	)	dobj	5	SENT_61	11604/11605
10	dedicated	VBN	O	dedicate	dep	9	SENT_61	11606/11615
11	DI	NNP	O	DI	nn	12	SENT_61	11616/11618
12	studies	NNS	O	study	dobj	10	SENT_61	11619/11626
13	,	,	O	,		-1	SENT_61	11626/11627
14	(	NN	O	(	appos	12	SENT_61	11628/11629
15	2	CD	NUMBER	2	number	16	SENT_61	11629/11630
16	)	CD	NUMBER	)	num	18	SENT_61	11630/11631
17	population	NN	O	population	nn	18	SENT_61	11632/11642
18	pharmacokinetics	NNS	O	pharmacokinetic	dep	14	SENT_61	11643/11659
19	-	:	O	-		-1	SENT_61	11659/11660
20	based	VBN	O	base	dep	10	SENT_61	11661/11666
21	assessments	NNS	O	assessment	dobj	20	SENT_61	11667/11678
22	,	,	O	,		-1	SENT_61	11678/11679
23	and	CC	O	and		-1	SENT_61	11680/11683
24	(	NN	O	(	nn	26	SENT_61	11684/11685
25	3	CD	NUMBER	3	num	26	SENT_61	11685/11686
26	)	NN	O	)	conj_and	21	SENT_61	11686/11687
27	clinical	JJ	O	clinical	amod	29	SENT_61	11688/11696
28	cocktail	NN	O	cocktail	nn	29	SENT_61	11697/11705
29	studies	NNS	O	study	dobj	10	SENT_61	11706/11713
30	.	.	O	.		-1	SENT_61	11713/11714

1	Survey	NN	O	survey	nsubj	2	SENT_62	11715/11721
2	results	VBZ	O	result		-1	SENT_62	11722/11729
3	indicated	VBD	O	indicate	dobj	2	SENT_62	11730/11739
4	that	IN	O	that	mark	15	SENT_62	11740/11744
5	most	JJS	O	most	nsubj	15	SENT_62	11745/11749
6	of	IN	O	of		-1	SENT_62	11750/11752
7	the	DT	O	the	det	9	SENT_62	11753/11756
8	observed	VBN	O	observe	amod	9	SENT_62	11757/11765
9	DI	NNP	O	DI	prep_of	5	SENT_62	11766/11768
10	involving	VBG	O	involve	partmod	9	SENT_62	11769/11778
11	TPs	NNS	O	tp	dobj	10	SENT_62	11779/11782
12	was	VBD	O	be	cop	15	SENT_62	11783/11786
13	not	RB	O	not	neg	15	SENT_62	11787/11790
14	clinically	RB	O	clinically	advmod	15	SENT_62	11791/11801
15	relevant	JJ	O	relevant	ccomp	3	SENT_62	11802/11810
16	,	,	O	,		-1	SENT_62	11810/11811
17	i.e.	FW	O	i.e.	dep	3	SENT_62	11812/11816
18	,	,	O	,		-1	SENT_62	11816/11817
19	did	VBD	O	do	aux	21	SENT_62	11818/11821
20	not	RB	O	not	neg	21	SENT_62	11822/11825
21	result	VB	O	result	parataxis	3	SENT_62	11826/11832
22	in	IN	O	in		-1	SENT_62	11833/11835
23	dose	NN	O	dose	nn	24	SENT_62	11836/11840
24	adjustment	NN	O	adjustment	prep_in	21	SENT_62	11841/11851
25	.	.	O	.		-1	SENT_62	11851/11852

1	In	IN	O	in		-1	SENT_63	11853/11855
2	several	JJ	O	several	amod	3	SENT_63	11856/11863
3	companies	NNS	O	company	prep_in	13	SENT_63	11864/11873
4	,	,	O	,		-1	SENT_63	11873/11874
5	science-driven	JJ	O	science-driven	nsubjpass	13	SENT_63	11875/11889
6	,	,	O	,		-1	SENT_63	11889/11890
7	risk	NN	O	risk	appos	5	SENT_63	11891/11895
8	-	:	O	-		-1	SENT_63	11895/11896
9	based	VBN	O	base	dep	5	SENT_63	11897/11902
10	strategies	NNS	O	strategy	dep	9	SENT_63	11903/11913
11	are	VBP	O	be	aux	13	SENT_63	11914/11917
12	being	VBG	O	be	auxpass	13	SENT_63	11918/11923
13	applied	VBN	O	apply		-1	SENT_63	11924/11931
14	to	TO	O	to	aux	15	SENT_63	11932/11934
15	incorporate	VB	O	incorporate	xcomp	13	SENT_63	11935/11946
16	DI	NNP	O	DI	nn	17	SENT_63	11947/11949
17	assessments	NNS	O	assessment	dobj	15	SENT_63	11950/11961
18	for	IN	O	for		-1	SENT_63	11962/11965
19	TP	NN	O	tp	nn	21	SENT_63	11966/11968
20	drug	NN	O	drug	nn	21	SENT_63	11969/11973
21	development	NN	O	development	prep_for	15	SENT_63	11974/11985
22	.	.	O	.		-1	SENT_63	11985/11986

1	However	RB	O	however	advmod	5	SENT_64	11987/11994
2	,	,	O	,		-1	SENT_64	11994/11995
3	it	PRP	O	it	nsubj	5	SENT_64	11996/11998
4	is	VBZ	O	be	cop	5	SENT_64	11999/12001
5	unclear	JJ	O	unclear		-1	SENT_64	12002/12009
6	from	IN	O	from		-1	SENT_64	12010/12014
7	the	DT	O	the	det	8	SENT_64	12015/12018
8	survey	NN	O	survey	prep_from	5	SENT_64	12019/12025
9	whether	IN	O	whether	mark	14	SENT_64	12026/12033
10	other	JJ	O	other	amod	11	SENT_64	12034/12039
11	companies	NNS	O	company	nsubj	14	SENT_64	12040/12049
12	are	VBP	O	be	aux	14	SENT_64	12050/12053
13	currently	RB	DATE	currently	advmod	14	SENT_64	12054/12063
14	developing	VBG	O	develop	ccomp	5	SENT_64	12064/12074
15	similar	JJ	O	similar	amod	16	SENT_64	12075/12082
16	strategies	NNS	O	strategy	dobj	14	SENT_64	12083/12093
17	or	CC	O	or		-1	SENT_64	12094/12096
18	intend	VBP	O	intend	conj_or	14	SENT_64	12097/12103
19	to	TO	O	to	aux	20	SENT_64	12104/12106
20	do	VB	O	do	xcomp	18	SENT_64	12107/12109
21	so	RB	O	so	advmod	20	SENT_64	12110/12112
22	in	IN	O	in		-1	SENT_64	12113/12115
23	the	DT	DATE	the	det	24	SENT_64	12116/12119
24	future	NN	DATE	future	prep_in	20	SENT_64	12120/12126
25	.	.	O	.		-1	SENT_64	12126/12127

1	A	DT	O	a	det	4	SENT_65	12128/12129
2	future	JJ	DATE	future	amod	4	SENT_65	12130/12136
3	follow-up	NN	O	follow-up	nn	4	SENT_65	12137/12146
4	survey	NN	O	survey	nsubj	6	SENT_65	12147/12153
5	will	MD	O	will	aux	6	SENT_65	12154/12158
6	attempt	VB	O	attempt		-1	SENT_65	12159/12166
7	to	TO	O	to	aux	8	SENT_65	12167/12169
8	address	VB	O	address	xcomp	6	SENT_65	12170/12177
9	these	DT	O	these	det	10	SENT_65	12178/12183
10	topics	NNS	O	topic	dobj	8	SENT_65	12184/12190
11	,	,	O	,		-1	SENT_65	12190/12191
12	among	IN	O	among		-1	SENT_65	12192/12197
13	others	NNS	O	other	prep_among	8	SENT_65	12198/12204
14	.	.	O	.		-1	SENT_65	12204/12205

1	Session	NN	O	session		-1	SENT_66	12241/12248
2	II	CD	NUMBER	ii	num	1	SENT_66	12249/12251
3	:	:	O	:		-1	SENT_66	12251/12252
4	Industry	NN	O	industry	nn	5	SENT_66	12253/12261
5	Perspectives	NNS	O	perspective	dep	1	SENT_66	12262/12274
6	on	IN	O	on		-1	SENT_66	12275/12277
7	TP-DI	NN	O	tp-di	nn	8	SENT_66	12278/12283
8	Evaluation	NN	O	evaluation	prep_on	5	SENT_66	12284/12294
9	:	:	O	:		-1	SENT_66	12294/12295
10	Case	NNP	O	Case	nn	11	SENT_66	12296/12300
11	Studies	NNPS	O	Studies	dep	5	SENT_66	12301/12308
12	and	CC	O	and		-1	SENT_66	12309/12312
13	Strategies	NNS	O	strategy	conj_and	11	SENT_66	12313/12323

1	To	TO	O	to	aux	2	SENT_67	12359/12361
2	evaluate	VB	O	evaluate	csubj	18	SENT_67	12362/12370
3	current	JJ	DATE	current	amod	4	SENT_67	12371/12378
4	practices	NNS	O	practice	dobj	2	SENT_67	12379/12388
5	in	IN	O	in		-1	SENT_67	12389/12391
6	industry	NN	O	industry	prep_in	2	SENT_67	12392/12400
7	,	,	O	,		-1	SENT_67	12400/12401
8	speakers	NNS	O	speaker	appos	6	SENT_67	12402/12410
9	from	IN	O	from		-1	SENT_67	12411/12415
10	four	CD	NUMBER	four	num	11	SENT_67	12416/12420
11	companies	NNS	O	company	prep_from	2	SENT_67	12421/12430
12	with	IN	O	with		-1	SENT_67	12431/12435
13	diverse	JJ	O	diverse	amod	14	SENT_67	12436/12443
14	experience	NN	O	experience	prep_with	11	SENT_67	12444/12454
15	in	IN	O	in		-1	SENT_67	12455/12457
16	developing	VBG	O	develop	amod	17	SENT_67	12458/12468
17	TPs	NNS	O	tp	prep_in	14	SENT_67	12469/12472
18	presented	VBN	O	present		-1	SENT_67	12473/12482
19	challenges	NNS	O	challenge	dobj	18	SENT_67	12483/12493
20	and	CC	O	and		-1	SENT_67	12494/12497
21	strategies	NNS	O	strategy	conj_and	19	SENT_67	12498/12508
22	in	IN	O	in		-1	SENT_67	12509/12511
23	assessing	VBG	O	assess	prepc_in	18	SENT_67	12512/12521
24	TP-DI	NN	O	tp-di	dobj	23	SENT_67	12522/12527
25	with	IN	O	with		-1	SENT_67	12528/12532
26	case	NN	O	case	nn	27	SENT_67	12533/12537
27	examples	NNS	O	example	prep_with	23	SENT_67	12538/12546
28	and	CC	O	and		-1	SENT_67	12547/12550
29	insights	NNS	O	insight	conj_and	27	SENT_67	12551/12559
30	on	IN	O	on		-1	SENT_67	12560/12562
31	how	WRB	O	how	advmod	34	SENT_67	12563/12566
32	approaches	NNS	O	approach	nsubjpass	34	SENT_67	12567/12577
33	were	VBD	O	be	auxpass	34	SENT_67	12578/12582
34	developed	VBN	O	develop	prepc_on	23	SENT_67	12583/12592
35	to	TO	O	to	aux	36	SENT_67	12593/12595
36	address	VB	O	address	xcomp	34	SENT_67	12596/12603
37	risk-based	JJ	O	risk-based	amod	38	SENT_67	12604/12614
38	assessment	NN	O	assessment	dobj	36	SENT_67	12615/12625
39	of	IN	O	of		-1	SENT_67	12626/12628
40	TP-DI	NN	O	tp-di	prep_of	38	SENT_67	12629/12634
41	.	.	O	.		-1	SENT_67	12634/12635

1	Examples	NNS	O	example	nsubj	4	SENT_68	12636/12644
2	were	VBD	O	be	cop	4	SENT_68	12645/12649
3	largely	RB	O	largely	advmod	4	SENT_68	12650/12657
4	restricted	JJ	O	restricted		-1	SENT_68	12658/12668
5	to	TO	O	to		-1	SENT_68	12669/12671
6	mAbs	NNS	O	mab	prep_to	4	SENT_68	12672/12676
7	due	JJ	O	due		-1	SENT_68	12677/12680
8	to	TO	O	to		-1	SENT_68	12681/12683
9	limited	JJ	O	limited	amod	10	SENT_68	12684/12691
10	information	NN	O	information	prep_due_to	6	SENT_68	12692/12703
11	available	JJ	O	available	amod	10	SENT_68	12704/12713
12	on	IN	O	on		-1	SENT_68	12714/12716
13	other	JJ	O	other	amod	14	SENT_68	12717/12722
14	classes	NNS	O	class	prep_on	11	SENT_68	12723/12730
15	of	IN	O	of		-1	SENT_68	12731/12733
16	TPs	NNS	O	tp	prep_of	14	SENT_68	12734/12737
17	.	.	O	.		-1	SENT_68	12737/12738

1	Amgen	NNP	ORGANIZATION	Amgen	poss	4	SENT_69	12774/12779
2	's	POS	O	's		-1	SENT_69	12779/12781
3	Integrated	NNP	O	Integrated	nn	4	SENT_69	12782/12792
4	Approach	NNP	O	Approach		-1	SENT_69	12793/12801
5	to	TO	O	to	aux	6	SENT_69	12802/12804
6	Assess	VB	O	assess	infmod	4	SENT_69	12805/12811
7	TP-DI	NN	O	tp-di	dobj	6	SENT_69	12812/12817
8	in	IN	O	in		-1	SENT_69	12818/12820
9	Cancer	NNP	O	Cancer	nn	10	SENT_69	12821/12827
10	Treatment	NN	O	treatment	prep_in	4	SENT_69	12828/12837

1	The	DT	O	the	det	3	SENT_70	12873/12876
2	safety	NN	O	safety	nn	3	SENT_70	12877/12883
3	profile	NN	O	profile	nsubj	8	SENT_70	12884/12891
4	of	IN	O	of		-1	SENT_70	12892/12894
5	drug	NN	O	drug	nn	6	SENT_70	12895/12899
6	combinations	NNS	O	combination	prep_of	3	SENT_70	12900/12912
7	is	VBZ	O	be	cop	8	SENT_70	12913/12915
8	critical	JJ	O	critical		-1	SENT_70	12916/12924
9	for	IN	O	for		-1	SENT_70	12925/12928
10	balancing	VBG	O	balance	prepc_for	8	SENT_70	12929/12938
11	treatment	NN	O	treatment	nn	12	SENT_70	12939/12948
12	benefit	NN	O	benefit	dobj	10	SENT_70	12949/12956
13	and	CC	O	and		-1	SENT_70	12957/12960
14	risk	NN	O	risk	conj_and	12	SENT_70	12961/12965
15	in	IN	O	in		-1	SENT_70	12966/12968
16	cancer	NN	O	cancer	nn	17	SENT_70	12969/12975
17	patients	NNS	O	patient	prep_in	12	SENT_70	12976/12984
18	.	.	O	.		-1	SENT_70	12984/12985

1	Four	CD	NUMBER	four	num	3	SENT_71	12986/12990
2	selected	VBN	O	select	amod	3	SENT_71	12991/12999
3	TPs	NNS	O	tp	nsubjpass	19	SENT_71	13000/13003
4	approved	VBD	O	approve	rcmod	3	SENT_71	13004/13012
5	for	IN	O	for		-1	SENT_71	13013/13016
6	cancer	NN	O	cancer	nn	7	SENT_71	13017/13023
7	treatment	NN	O	treatment	prep_for	4	SENT_71	13024/13033
8	,	,	O	,		-1	SENT_71	13033/13034
9	namely	RB	O	namely	advmod	7	SENT_71	13035/13041
10	bevacizumab	NN	O	bevacizumab	dep	7	SENT_71	13042/13053
11	,	,	O	,		-1	SENT_71	13053/13054
12	trastuzumab	NN	O	trastuzumab	conj_and	10	SENT_71	13055/13066
13	,	,	O	,		-1	SENT_71	13066/13067
14	panitumumab	NN	LOCATION	panitumumab	conj_and	10	SENT_71	13068/13079
15	,	,	O	,		-1	SENT_71	13079/13080
16	and	CC	O	and		-1	SENT_71	13081/13084
17	cetuximab	NN	O	cetuximab	conj_and	10	SENT_71	13085/13094
18	were	VBD	O	be	auxpass	19	SENT_71	13095/13099
19	used	VBN	O	use		-1	SENT_71	13100/13104
20	as	IN	O	as		-1	SENT_71	13105/13107
21	examples	NNS	O	example	prep_as	19	SENT_71	13108/13116
22	.	.	O	.		-1	SENT_71	13116/13117

1	A	DT	O	a	det	3	SENT_72	13118/13119
2	literature	NN	O	literature	nn	3	SENT_72	13120/13130
3	review	NN	O	review	nsubj	11	SENT_72	13131/13137
4	of	IN	O	of		-1	SENT_72	13138/13140
5	80	CD	NUMBER	80	num	7	SENT_72	13141/13143
6	journal	NN	O	journal	nn	7	SENT_72	13144/13151
7	articles	NNS	O	article	prep_of	3	SENT_72	13152/13160
8	and	CC	O	and		-1	SENT_72	13161/13164
9	conference	NN	O	conference	nn	10	SENT_72	13165/13175
10	abstracts	NNS	O	abstract	conj_and	7	SENT_72	13176/13185
11	revealed	VBD	O	reveal		-1	SENT_72	13186/13194
12	that	IN	O	that	mark	16	SENT_72	13195/13199
13	TP-DI	NN	O	tp-di	nn	14	SENT_72	13200/13205
14	potential	NN	O	potential	nsubjpass	16	SENT_72	13206/13215
15	was	VBD	O	be	auxpass	16	SENT_72	13216/13219
16	evaluated	VBN	O	evaluate	ccomp	11	SENT_72	13220/13229
17	in	IN	O	in		-1	SENT_72	13230/13232
18	only	RB	O	only	quantmod	20	SENT_72	13233/13237
19	one	CD	NUMBER	one	number	20	SENT_72	13238/13241
20	third	NN	ORDINAL	third	prep_in	16	SENT_72	13242/13247
21	of	IN	O	of		-1	SENT_72	13248/13250
22	the	DT	O	the	det	24	SENT_72	13251/13254
23	clinical	JJ	O	clinical	amod	24	SENT_72	13255/13263
24	trials	NNS	O	trial	prep_of	20	SENT_72	13264/13270
25	.	.	O	.		-1	SENT_72	13270/13271

1	Most	JJS	O	most	amod	2	SENT_73	13272/13276
2	results	NNS	O	result	nsubj	5	SENT_73	13277/13284
3	were	VBD	O	be	cop	5	SENT_73	13285/13289
4	either	RB	O	either	advmod	5	SENT_73	13290/13296
5	negative	JJ	O	negative		-1	SENT_73	13297/13305
6	for	IN	O	for		-1	SENT_73	13306/13309
7	DI	NNP	O	DI	prep_for	5	SENT_73	13310/13312
8	or	CC	O	or		-1	SENT_73	13313/13315
9	showed	VBD	O	show	conj_or	5	SENT_73	13316/13322
10	less	JJR	O	less	mwe	11	SENT_73	13323/13327
11	than	IN	O	than	quantmod	12	SENT_73	13328/13332
12	30	CD	PERCENT	30	dep	13	SENT_73	13333/13335
13	%	NN	PERCENT	%	dep	14	SENT_73	13335/13336
14	change	NN	O	change	dobj	9	SENT_73	13337/13343
15	in	IN	O	in		-1	SENT_73	13344/13346
16	mean	JJ	O	mean	amod	18	SENT_73	13347/13351
17	drug	NN	O	drug	nn	18	SENT_73	13352/13356
18	exposure	NN	O	exposure	prep_in	9	SENT_73	13357/13365
19	with	IN	O	with		-1	SENT_73	13366/13370
20	large	JJ	O	large	amod	22	SENT_73	13371/13376
21	intersubject	NN	O	intersubject	nn	22	SENT_73	13377/13389
22	variability	NN	O	variability	prep_with	9	SENT_73	13390/13401
23	.	.	O	.		-1	SENT_73	13401/13402

1	In	IN	O	in		-1	SENT_74	13403/13405
2	general	JJ	O	general	prep_in	8	SENT_74	13406/13413
3	,	,	O	,		-1	SENT_74	13413/13414
4	TP	NN	O	tp	nn	5	SENT_74	13415/13417
5	exposure	NN	O	exposure	nsubjpass	8	SENT_74	13418/13426
6	was	VBD	O	be	auxpass	8	SENT_74	13427/13430
7	not	RB	O	not	neg	8	SENT_74	13431/13434
8	affected	VBN	O	affect		-1	SENT_74	13435/13443
9	in	IN	O	in		-1	SENT_74	13444/13446
10	the	DT	O	the	det	11	SENT_74	13447/13450
11	presence	NN	O	presence	prep_in	8	SENT_74	13451/13459
12	of	IN	O	of		-1	SENT_74	13460/13462
13	SMDs	NNS	O	smd	prep_of	11	SENT_74	13463/13467
14	.	.	O	.		-1	SENT_74	13467/13468

1	Based	VBN	O	base		-1	SENT_75	13469/13474
2	on	IN	O	on	prepc_based_on	16	SENT_75	13475/13477
3	the	DT	O	the	det	5	SENT_75	13478/13481
4	literature	NN	O	literature	nn	5	SENT_75	13482/13492
5	data	NNS	O	datum	pobj	16	SENT_75	13493/13497
6	on	IN	O	on		-1	SENT_75	13498/13500
7	these	DT	O	these	det	10	SENT_75	13501/13506
8	four	CD	NUMBER	four	num	10	SENT_75	13507/13511
9	cancer	NN	O	cancer	nn	10	SENT_75	13512/13518
10	TPs	NNS	O	tp	prep_on	5	SENT_75	13519/13522
11	,	,	O	,		-1	SENT_75	13522/13523
12	no	DT	O	no	det	13	SENT_75	13524/13526
13	interaction	NN	O	interaction	nsubjpass	16	SENT_75	13527/13538
14	has	VBZ	O	have	aux	16	SENT_75	13539/13542
15	been	VBN	O	be	auxpass	16	SENT_75	13543/13547
16	reported	VBN	O	report		-1	SENT_75	13548/13556
17	between	IN	O	between		-1	SENT_75	13557/13564
18	TPs	NNS	O	tp	prep_between	16	SENT_75	13565/13568
19	and	CC	O	and		-1	SENT_75	13569/13572
20	no	DT	O	no	det	23	SENT_75	13573/13575
21	TP	NN	O	tp	nn	23	SENT_75	13576/13578
22	dose	NN	O	dose	nn	23	SENT_75	13579/13583
23	adjustments	NNS	O	adjustment	nsubjpass	26	SENT_75	13584/13595
24	have	VBP	O	have	aux	26	SENT_75	13596/13600
25	been	VBN	O	be	auxpass	26	SENT_75	13601/13605
26	warranted	VBN	O	warrant	conj_and	16	SENT_75	13606/13615
27	.	.	O	.		-1	SENT_75	13615/13616

1	TP-DI	NN	O	tp-di	nn	2	SENT_76	13652/13657
2	evaluation	NN	O	evaluation	nsubj	8	SENT_76	13658/13668
3	is	VBZ	O	be	cop	8	SENT_76	13669/13671
4	usually	RB	O	usually	advmod	8	SENT_76	13672/13679
5	not	RB	O	not	neg	8	SENT_76	13680/13683
6	a	DT	O	a	det	8	SENT_76	13684/13685
7	stand-alone	JJ	O	stand-alone	amod	8	SENT_76	13686/13697
8	study	NN	O	study		-1	SENT_76	13698/13703
9	but	CC	O	but		-1	SENT_76	13704/13707
10	rather	RB	O	rather		-1	SENT_76	13708/13714
11	a	DT	O	a	det	13	SENT_76	13715/13716
12	substudy	JJ	O	substudy	amod	13	SENT_76	13717/13725
13	evaluation	NN	O	evaluation	conj_negcc	8	SENT_76	13726/13736
14	conducted	VBN	O	conduct	partmod	13	SENT_76	13737/13746
15	as	IN	O	as		-1	SENT_76	13747/13749
16	part	NN	O	part	prep_as	14	SENT_76	13750/13754
17	of	IN	O	of		-1	SENT_76	13755/13757
18	ongoing	JJ	O	ongoing	amod	22	SENT_76	13758/13765
19	phase	NN	O	phase	nn	22	SENT_76	13766/13771
20	2/3	CD	NUMBER	2/3	num	22	SENT_76	13772/13775
21	clinical	JJ	O	clinical	amod	22	SENT_76	13776/13784
22	trials	NNS	O	trial	prep_of	16	SENT_76	13785/13791
23	.	.	O	.		-1	SENT_76	13791/13792

1	As	IN	O	as		-1	SENT_77	13793/13795
2	a	DT	O	a	det	3	SENT_77	13796/13797
3	result	NN	O	result	prep_as	34	SENT_77	13798/13804
4	,	,	O	,		-1	SENT_77	13804/13805
5	conventional	JJ	O	conventional	nsubjpass	34	SENT_77	13806/13818
6	"	``	O	"	punct	9	SENT_77	13819/13820
7	well-controlled	JJ	O	well-controlled	amod	9	SENT_77	13820/13835
8	"	''	O	"	punct	9	SENT_77	13835/13836
9	DI	NNP	O	DI	nsubj	12	SENT_77	13837/13839
10	study	NN	O	study	nn	11	SENT_77	13840/13845
11	conditions	NNS	O	condition	dep	9	SENT_77	13846/13856
12	(	VBP	O	(	rcmod	5	SENT_77	13857/13858
13	e.g.	FW	O	e.g.	dobj	12	SENT_77	13858/13862
14	,	,	O	,		-1	SENT_77	13862/13863
15	control	NN	O	control	nn	16	SENT_77	13864/13871
16	diet	NN	O	diet	conj_and	13	SENT_77	13872/13876
17	,	,	O	,		-1	SENT_77	13876/13877
18	co-medications	NNS	O	co-medication	conj_and	13	SENT_77	13878/13892
19	,	,	O	,		-1	SENT_77	13892/13893
20	disease	NN	O	disease	nn	21	SENT_77	13894/13901
21	status	NN	O	status	conj_and	13	SENT_77	13902/13908
22	,	,	O	,		-1	SENT_77	13908/13909
23	treatment	NN	O	treatment	nn	24	SENT_77	13910/13919
24	options	NNS	O	option	conj_and	13	SENT_77	13920/13927
25	,	,	O	,		-1	SENT_77	13927/13928
26	dosing	NN	O	dosing	nn	27	SENT_77	13929/13935
27	time	NN	O	time	conj_and	13	SENT_77	13936/13940
28	,	,	O	,		-1	SENT_77	13940/13941
29	and	CC	O	and		-1	SENT_77	13942/13945
30	schedule	NN	O	schedule	nn	31	SENT_77	13946/13954
31	)	NN	O	)	conj_and	13	SENT_77	13954/13955
32	are	VBP	O	be	auxpass	34	SENT_77	13956/13959
33	hardly	RB	O	hardly	advmod	34	SENT_77	13960/13966
34	preserved	VBN	O	preserve		-1	SENT_77	13967/13976
35	.	.	O	.		-1	SENT_77	13976/13977

1	TP	NN	O	tp	nn	3	SENT_78	13978/13980
2	PK	NN	O	pk	nn	3	SENT_78	13981/13983
3	data	NNS	O	datum	nsubj	7	SENT_78	13984/13988
4	is	VBZ	O	be	cop	7	SENT_78	13989/13991
5	usually	RB	O	usually	advmod	7	SENT_78	13992/13999
6	less	JJR	O	less	dep	7	SENT_78	14000/14004
7	intensive	JJ	O	intensive		-1	SENT_78	14005/14014
8	than	IN	O	than		-1	SENT_78	14015/14019
9	those	DT	O	those	prep_than	7	SENT_78	14020/14025
10	with	IN	O	with		-1	SENT_78	14026/14030
11	traditional	JJ	O	traditional	amod	13	SENT_78	14031/14042
12	study	NN	O	study	nn	13	SENT_78	14043/14048
13	designs	NNS	O	design	prep_with	9	SENT_78	14049/14056
14	for	IN	O	for		-1	SENT_78	14057/14060
15	SMD-DI	NN	O	smd-di	nn	16	SENT_78	14061/14067
16	studies	NNS	O	study	prep_for	13	SENT_78	14068/14075
17	.	.	O	.		-1	SENT_78	14075/14076

1	The	DT	O	the	det	2	SENT_79	14077/14080
2	number	NN	O	number	nsubj	9	SENT_79	14081/14087
3	of	IN	O	of		-1	SENT_79	14088/14090
4	subjects	NNS	O	subject	prep_of	2	SENT_79	14091/14099
5	may	MD	O	may	aux	9	SENT_79	14100/14103
6	not	RB	O	not	neg	9	SENT_79	14104/14107
7	be	VB	O	be	cop	9	SENT_79	14108/14110
8	well	RB	O	well	advmod	9	SENT_79	14111/14115
9	balanced	JJ	O	balanced		-1	SENT_79	14116/14124
10	across	IN	O	across		-1	SENT_79	14125/14131
11	treatment	NN	O	treatment	nn	12	SENT_79	14132/14141
12	cycles	NNS	O	cycle	prep_across	9	SENT_79	14142/14148
13	or	CC	O	or		-1	SENT_79	14149/14151
14	arms	NNS	O	arm	conj_or	12	SENT_79	14152/14156
15	,	,	O	,		-1	SENT_79	14156/14157
16	and	CC	O	and		-1	SENT_79	14158/14161
17	the	DT	O	the	det	18	SENT_79	14162/14165
18	number	NN	O	number	nsubjpass	24	SENT_79	14166/14172
19	of	IN	O	of		-1	SENT_79	14173/14175
20	evaluable	JJ	O	evaluable	amod	21	SENT_79	14176/14185
21	subjects	NNS	O	subject	prep_of	18	SENT_79	14186/14194
22	is	VBZ	O	be	auxpass	24	SENT_79	14195/14197
23	also	RB	O	also	advmod	24	SENT_79	14198/14202
24	affected	VBN	O	affect	conj_and	9	SENT_79	14203/14211
25	by	IN	O	by		-1	SENT_79	14212/14214
26	unscheduled	JJ	O	unscheduled	amod	27	SENT_79	14215/14226
27	dose	NN	O	dose	agent	24	SENT_79	14227/14231
28	and	CC	O	and		-1	SENT_79	14232/14235
29	sampling	NN	O	sampling	nn	30	SENT_79	14236/14244
30	time	NN	O	time	conj_and	27	SENT_79	14245/14249
31	due	JJ	O	due		-1	SENT_79	14250/14253
32	to	TO	O	to		-1	SENT_79	14254/14256
33	dose	NN	O	dose	nn	34	SENT_79	14257/14261
34	interruption/reduction	NN	O	interruption/reduction	prep_due_to	27	SENT_79	14262/14284
35	or	CC	O	or		-1	SENT_79	14285/14287
36	patient	NN	O	patient	nn	37	SENT_79	14288/14295
37	discontinuation	NN	O	discontinuation	conj_or	34	SENT_79	14296/14311
38	.	.	O	.		-1	SENT_79	14311/14312

1	Challenges	NNS	O	challenge	nsubj	3	SENT_80	14313/14323
2	also	RB	O	also	advmod	3	SENT_80	14324/14328
3	exist	VBP	O	exist		-1	SENT_80	14329/14334
4	in	IN	O	in		-1	SENT_80	14335/14337
5	non-compartmental	JJ	O	non-compartmental	amod	7	SENT_80	14338/14355
6	PK	NN	O	pk	nn	7	SENT_80	14356/14358
7	analysis	NN	O	analysis	prep_in	3	SENT_80	14359/14367
8	as	IN	O	as	mark	10	SENT_80	14368/14370
9	there	EX	O	there	expl	10	SENT_80	14371/14376
10	are	VBP	O	be	advcl	3	SENT_80	14377/14380
11	often	RB	O	often	advmod	10	SENT_80	14381/14386
12	a	DT	O	a	det	14	SENT_80	14387/14388
13	significant	JJ	O	significant	amod	14	SENT_80	14389/14400
14	number	NN	O	number	nsubj	10	SENT_80	14401/14407
15	of	IN	O	of		-1	SENT_80	14408/14410
16	data	NNS	O	datum	nn	17	SENT_80	14411/14415
17	exclusions	NNS	O	exclusion	prep_of	14	SENT_80	14416/14426
18	.	.	O	.		-1	SENT_80	14426/14427

1	PK	NN	O	pk	nn	2	SENT_81	14428/14430
2	assessments	NNS	O	assessment	nsubjpass	5	SENT_81	14431/14442
3	are	VBP	O	be	auxpass	5	SENT_81	14443/14446
4	further	RBR	O	further	advmod	5	SENT_81	14447/14454
5	complicated	VBN	O	complicate		-1	SENT_81	14455/14466
6	as	IN	O	as	mark	11	SENT_81	14467/14469
7	many	JJ	O	many	amod	8	SENT_81	14470/14474
8	TPs	NNS	O	tp	nsubj	11	SENT_81	14475/14478
9	in	IN	O	in		-1	SENT_81	14479/14481
10	oncology	NN	O	oncology	prep_in	8	SENT_81	14482/14490
11	have	VBP	O	have	dep	5	SENT_81	14491/14495
12	non-linear	JJ	O	non-linear	amod	13	SENT_81	14496/14506
13	pharmacokinetics	NNS	O	pharmacokinetic	dobj	11	SENT_81	14507/14523
14	.	.	O	.		-1	SENT_81	14523/14524

1	Moreover	RB	O	moreover	advmod	18	SENT_82	14525/14533
2	,	,	O	,		-1	SENT_82	14533/14534
3	since	IN	O	since	mark	8	SENT_82	14535/14540
4	a	DT	O	a	det	6	SENT_82	14541/14542
5	TP-alone	JJ	O	tp-alone	amod	6	SENT_82	14543/14551
6	arm	NN	O	arm	nsubj	8	SENT_82	14552/14555
7	is	VBZ	O	be	cop	8	SENT_82	14556/14558
8	uncommon	JJ	O	uncommon	advcl	18	SENT_82	14559/14567
9	in	IN	O	in		-1	SENT_82	14568/14570
10	an	DT	O	a	det	12	SENT_82	14571/14573
11	oncology	NN	O	oncology	nn	12	SENT_82	14574/14582
12	setting	NN	O	setting	prep_in	8	SENT_82	14583/14590
13	,	,	O	,		-1	SENT_82	14590/14591
14	historical	JJ	O	historical	amod	15	SENT_82	14592/14602
15	data	NNS	O	datum	nsubjpass	18	SENT_82	14603/14607
16	are	VBP	O	be	auxpass	18	SENT_82	14608/14611
17	usually	RB	O	usually	advmod	18	SENT_82	14612/14619
18	referenced	VBN	O	reference		-1	SENT_82	14620/14630
19	in	IN	O	in		-1	SENT_82	14631/14633
20	the	DT	O	the	det	22	SENT_82	14634/14637
21	TP-DI	NN	O	tp-di	nn	22	SENT_82	14638/14643
22	evaluation	NN	O	evaluation	prep_in	18	SENT_82	14644/14654
23	.	.	O	.		-1	SENT_82	14654/14655

1	Therefore	RB	O	therefore	advmod	13	SENT_83	14656/14665
2	,	,	O	,		-1	SENT_83	14665/14666
3	a	DT	O	a	det	5	SENT_83	14667/14668
4	scientifically	RB	O	scientifically	advmod	5	SENT_83	14669/14683
5	sound	JJ	O	sound	nsubj	13	SENT_83	14684/14689
6	and	CC	O	and		-1	SENT_83	14690/14693
7	technically	RB	O	technically	advmod	8	SENT_83	14694/14705
8	feasible	JJ	O	feasible	conj_and	5	SENT_83	14706/14714
9	integrated	VBN	O	integrate	partmod	5	SENT_83	14715/14725
10	TP-DI	NN	O	tp-di	nn	12	SENT_83	14726/14731
11	evaluation	NN	O	evaluation	nn	12	SENT_83	14732/14742
12	strategy	NN	O	strategy	dobj	9	SENT_83	14743/14751
13	needs	VBZ	O	need		-1	SENT_83	14752/14757
14	to	TO	O	to	aux	16	SENT_83	14758/14760
15	be	VB	O	be	auxpass	16	SENT_83	14761/14763
16	developed	VBN	O	develop	xcomp	13	SENT_83	14764/14773
17	to	TO	O	to	aux	18	SENT_83	14774/14776
18	address	VB	O	address	xcomp	16	SENT_83	14777/14784
19	these	DT	O	these	det	20	SENT_83	14785/14790
20	challenges	NNS	O	challenge	dobj	18	SENT_83	14791/14801
21	.	.	O	.		-1	SENT_83	14801/14802

1	It	PRP	O	it	nsubj	3	SENT_84	14838/14840
2	is	VBZ	O	be	cop	3	SENT_84	14841/14843
3	preferable	JJ	O	preferable		-1	SENT_84	14844/14854
4	to	TO	O	to	aux	5	SENT_84	14855/14857
5	include	VB	O	include	xcomp	3	SENT_84	14858/14865
6	TP-DI	NN	O	tp-di	nn	7	SENT_84	14866/14871
7	assessment	NN	O	assessment	dobj	5	SENT_84	14872/14882
8	in	IN	O	in		-1	SENT_84	14883/14885
9	early	JJ	O	early	amod	12	SENT_84	14886/14891
10	phase	NN	O	phase	nn	12	SENT_84	14892/14897
11	1b/2	NN	O	1b/2	nn	12	SENT_84	14898/14902
12	trials	NNS	O	trial	prep_in	5	SENT_84	14903/14909
13	because	IN	O	because	mark	17	SENT_84	14910/14917
14	they	PRP	O	they	nsubj	17	SENT_84	14918/14922
15	are	VBP	O	be	cop	17	SENT_84	14923/14926
16	relatively	RB	O	relatively	advmod	17	SENT_84	14927/14937
17	small	JJ	O	small	advcl	5	SENT_84	14938/14943
18	in	IN	O	in		-1	SENT_84	14944/14946
19	size	NN	O	size	prep_in	17	SENT_84	14947/14951
20	and	CC	O	and		-1	SENT_84	14952/14955
21	operational	JJ	O	operational	amod	22	SENT_84	14956/14967
22	issues	NNS	O	issue	nsubjpass	26	SENT_84	14968/14974
23	are	VBP	O	be	auxpass	26	SENT_84	14975/14978
24	more	RBR	O	more	advmod	25	SENT_84	14979/14983
25	easily	RB	O	easily	advmod	26	SENT_84	14984/14990
26	addressed	VBN	O	address	conj_and	3	SENT_84	14991/15000
27	.	.	O	.		-1	SENT_84	15000/15001

1	Importantly	RB	O	importantly	advmod	8	SENT_85	15002/15013
2	,	,	O	,		-1	SENT_85	15013/15014
3	the	DT	O	the	det	6	SENT_85	15015/15018
4	early	JJ	O	early	amod	6	SENT_85	15019/15024
5	TP-DI	NN	O	tp-di	nn	6	SENT_85	15025/15030
6	data	NNS	O	datum	nsubj	8	SENT_85	15031/15035
7	can	MD	O	can	aux	8	SENT_85	15036/15039
8	help	VB	O	help		-1	SENT_85	15040/15044
9	establish	VB	O	establish	xcomp	8	SENT_85	15045/15054
10	development	NN	O	development	nn	11	SENT_85	15055/15066
11	strategies	NNS	O	strategy	dobj	9	SENT_85	15067/15077
12	and	CC	O	and		-1	SENT_85	15078/15081
13	also	RB	O	also	advmod	11	SENT_85	15082/15086
14	guide	NN	O	guide	conj_and	11	SENT_85	15087/15092
15	later	JJ	O	later	amod	18	SENT_85	15093/15098
16	phase	NN	O	phase	nn	18	SENT_85	15099/15104
17	study	NN	O	study	nn	18	SENT_85	15105/15110
18	designs	NNS	O	design	dep	14	SENT_85	15111/15118
19	.	.	O	.		-1	SENT_85	15118/15119

1	If	IN	O	if	mark	6	SENT_86	15120/15122
2	any	DT	O	any	det	4	SENT_86	15123/15126
3	TP-DI	NN	O	tp-di	nn	4	SENT_86	15127/15132
4	signals	NNS	O	signal	nsubjpass	6	SENT_86	15133/15140
5	are	VBP	O	be	auxpass	6	SENT_86	15141/15144
6	identified	VBN	O	identify	advcl	16	SENT_86	15145/15155
7	in	IN	O	in		-1	SENT_86	15156/15158
8	small	JJ	O	small	amod	10	SENT_86	15159/15164
9	early	JJ	O	early	amod	10	SENT_86	15165/15170
10	trials	NNS	O	trial	prep_in	6	SENT_86	15171/15177
11	,	,	O	,		-1	SENT_86	15177/15178
12	expanded	VBN	O	expand	amod	13	SENT_86	15179/15187
13	assessment	NN	O	assessment	nsubjpass	16	SENT_86	15188/15198
14	can	MD	O	can	aux	16	SENT_86	15199/15202
15	be	VB	O	be	auxpass	16	SENT_86	15203/15205
16	considered	VBN	O	consider		-1	SENT_86	15206/15216
17	.	.	O	.		-1	SENT_86	15216/15217

1	One	CD	NUMBER	one	num	2	SENT_87	15218/15221
2	limitation	NN	O	limitation	nsubj	6	SENT_87	15222/15232
3	of	IN	O	of		-1	SENT_87	15233/15235
4	early	JJ	O	early	amod	5	SENT_87	15236/15241
5	assessment	NN	O	assessment	prep_of	2	SENT_87	15242/15252
6	is	VBZ	O	be		-1	SENT_87	15253/15255
7	that	IN	O	that	mark	14	SENT_87	15256/15260
8	the	DT	O	the	det	11	SENT_87	15261/15264
9	optimal	JJ	O	optimal	amod	11	SENT_87	15265/15272
10	drug	NN	O	drug	nn	11	SENT_87	15273/15277
11	combination	NN	O	combination	nsubjpass	14	SENT_87	15278/15289
12	is	VBZ	O	be	auxpass	14	SENT_87	15290/15292
13	often	RB	O	often	advmod	14	SENT_87	15293/15298
14	modified	VBN	O	modify	ccomp	6	SENT_87	15299/15307
15	in	IN	O	in		-1	SENT_87	15308/15310
16	later	JJR	O	later	amod	17	SENT_87	15311/15316
17	stages	NNS	O	stage	prep_in	14	SENT_87	15317/15323
18	of	IN	O	of		-1	SENT_87	15324/15326
19	development	NN	O	development	prep_of	17	SENT_87	15327/15338
20	.	.	O	.		-1	SENT_87	15338/15339

1	Although	IN	O	although	mark	11	SENT_88	15340/15348
2	testing	NN	O	testing	nn	3	SENT_88	15349/15356
3	TP-DI	NN	O	tp-di	nsubj	11	SENT_88	15357/15362
4	in	IN	O	in		-1	SENT_88	15363/15365
5	late	JJ	O	late	amod	6	SENT_88	15366/15370
6	phase	NN	O	phase	prep_in	3	SENT_88	15371/15376
7	for	IN	O	for		-1	SENT_88	15377/15380
8	product	NN	O	product	nn	9	SENT_88	15381/15388
9	registration	NN	O	registration	prep_for	6	SENT_88	15389/15401
10	is	VBZ	O	be	cop	11	SENT_88	15402/15404
11	possible	JJ	O	possible	advcl	14	SENT_88	15405/15413
12	,	,	O	,		-1	SENT_88	15413/15414
13	it	PRP	O	it	nsubj	14	SENT_88	15415/15417
14	increases	VBZ	O	increase		-1	SENT_88	15418/15427
15	the	DT	O	the	det	16	SENT_88	15428/15431
16	complexity	NN	O	complexity	dobj	14	SENT_88	15432/15442
17	of	IN	O	of		-1	SENT_88	15443/15445
18	pivotal	JJ	O	pivotal	amod	19	SENT_88	15446/15453
19	phase	NN	O	phase	prep_of	16	SENT_88	15454/15459
20	3	CD	NUMBER	3	num	21	SENT_88	15460/15461
21	trials	NNS	O	trial	dep	19	SENT_88	15462/15468
22	and	CC	O	and		-1	SENT_88	15469/15472
23	is	VBZ	O	be	cop	25	SENT_88	15473/15475
24	thus	RB	O	thus	advmod	25	SENT_88	15476/15480
25	likely	JJ	O	likely	conj_and	14	SENT_88	15481/15487
26	to	TO	O	to	aux	27	SENT_88	15488/15490
27	have	VB	O	have	xcomp	25	SENT_88	15491/15495
28	more	RBR	O	more	advmod	29	SENT_88	15496/15500
29	confounding	JJ	O	confounding	amod	30	SENT_88	15501/15512
30	factors	NNS	O	factor	dobj	27	SENT_88	15513/15520
31	that	WDT	O	that	nsubj	33	SENT_88	15521/15525
32	can	MD	O	can	aux	33	SENT_88	15526/15529
33	contribute	VB	O	contribute	rcmod	30	SENT_88	15530/15540
34	to	TO	O	to		-1	SENT_88	15541/15543
35	difficulty	NN	O	difficulty	prep_to	33	SENT_88	15544/15554
36	in	IN	O	in		-1	SENT_88	15555/15557
37	data	NNS	O	datum	nn	38	SENT_88	15558/15562
38	interpretation	NN	O	interpretation	prep_in	35	SENT_88	15563/15577
39	.	.	O	.		-1	SENT_88	15577/15578

1	Selecting	VBG	O	select	amod	3	SENT_89	15614/15623
2	interacting	VBG	O	interact	amod	3	SENT_89	15624/15635
3	drugs	NNS	O	drug	nsubjpass	9	SENT_89	15636/15641
4	for	IN	O	for		-1	SENT_89	15642/15645
5	TP-DI	NN	O	tp-di	nn	6	SENT_89	15646/15651
6	investigation	NN	O	investigation	prep_for	3	SENT_89	15652/15665
7	is	VBZ	O	be	auxpass	9	SENT_89	15666/15668
8	mainly	RB	O	mainly	advmod	9	SENT_89	15669/15675
9	based	VBN	O	base		-1	SENT_89	15676/15681
10	on	IN	O	on		-1	SENT_89	15682/15684
11	potential	JJ	O	potential	amod	18	SENT_89	15685/15694
12	concomitant	JJ	O	concomitant	amod	18	SENT_89	15695/15706
13	usage	NN	O	usage	nn	18	SENT_89	15707/15712
14	,	,	O	,		-1	SENT_89	15712/15713
15	PK	NN	O	pk	conj_and	13	SENT_89	15714/15716
16	and	CC	O	and		-1	SENT_89	15717/15720
17	PD	NN	O	pd	conj_and	13	SENT_89	15721/15723
18	properties	NNS	O	property	prep_on	9	SENT_89	15724/15734
19	and	CC	O	and		-1	SENT_89	15735/15738
20	the	DT	O	the	det	22	SENT_89	15739/15742
21	therapeutic	JJ	O	therapeutic	amod	22	SENT_89	15743/15754
22	window	NN	O	window	conj_and	18	SENT_89	15755/15761
23	of	IN	O	of		-1	SENT_89	15762/15764
24	selected	VBN	O	select	amod	25	SENT_89	15765/15773
25	drugs	NNS	O	drug	prep_of	22	SENT_89	15774/15779
26	.	.	O	.		-1	SENT_89	15779/15780

1	For	IN	O	for	advcl	10	SENT_90	15781/15784
2	evaluating	VBG	O	evaluate	pcomp	1	SENT_90	15785/15795
3	PK	NN	O	pk	nn	4	SENT_90	15796/15798
4	interaction	NN	O	interaction	dobj	2	SENT_90	15799/15810
5	,	,	O	,		-1	SENT_90	15810/15811
6	commonly	RB	O	commonly	advmod	7	SENT_90	15812/15820
7	used	VBN	O	use	amod	4	SENT_90	15821/15825
8	study	NN	O	study	nn	9	SENT_90	15826/15831
9	designs	NNS	O	design	nsubj	10	SENT_90	15832/15839
10	include	VBP	O	include		-1	SENT_90	15840/15847
11	:	:	O	:		-1	SENT_90	15847/15848

1	one-sequence	JJ	O	one-sequence	amod	3	SENT_91	15865/15877
2	crossover	NN	O	crossover	nn	3	SENT_91	15878/15887
3	design	NN	O	design	nsubj	27	SENT_91	15888/15894
4	(	CD	NUMBER	(	dep	3	SENT_91	15895/15896
5	e.g.	FW	O	e.g.	dep	3	SENT_91	15896/15900
6	,	,	O	,		-1	SENT_91	15900/15901
7	chemotherapy	NN	O	chemotherapy	appos	3	SENT_91	15902/15914
8	followed	VBN	O	follow	partmod	7	SENT_91	15915/15923
9	by	IN	O	by		-1	SENT_91	15924/15926
10	chemotherapy	NN	O	chemotherapy	agent	8	SENT_91	15927/15939
11	+	CC	O	+		-1	SENT_91	15942/15943
12	TP	NN	O	tp	conj_+	7	SENT_91	15944/15946
13	to	TO	O	to	aux	14	SENT_91	15947/15949
14	test	VB	O	test	infmod	12	SENT_91	15950/15954
15	TP	NN	O	tp	nn	16	SENT_91	15955/15957
16	effect	NN	O	effect	dobj	14	SENT_91	15958/15964
17	on	IN	O	on		-1	SENT_91	15965/15967
18	chemotherapy	NN	O	chemotherapy	prep_on	14	SENT_91	15968/15980
19	;	:	O	;		-1	SENT_91	15980/15981
20	testing	NN	O	testing	nn	21	SENT_91	15982/15989
21	effect	NN	O	effect	dep	3	SENT_91	15990/15996
22	of	IN	O	of		-1	SENT_91	15997/15999
23	chemotherapy	NN	O	chemotherapy	prep_of	21	SENT_91	16000/16012
24	on	IN	O	on		-1	SENT_91	16013/16015
25	TP	NN	O	tp	prep_on	23	SENT_91	16016/16018
26	may	MD	O	may	aux	27	SENT_91	16019/16022
27	need	VB	O	need		-1	SENT_91	16023/16027
28	cross-study	JJ	O	cross-study	amod	30	SENT_91	16028/16039
29	comparison	NN	O	comparison	nn	30	SENT_91	16040/16050
30	)	NN	O	)	dobj	27	SENT_91	16050/16051
31	;	:	O	;		-1	SENT_91	16051/16052

1	parallel	JJ	O	parallel	amod	2	SENT_92	16088/16096
2	design	NN	O	design	nsubj	28	SENT_92	16097/16103
3	(	CD	NUMBER	(	num	2	SENT_92	16104/16105
4	e.g.	FW	O	e.g.	nsubj	11	SENT_92	16105/16109
5	,	,	O	,		-1	SENT_92	16109/16110
6	TP	NN	O	tp	conj_+	4	SENT_92	16111/16113
7	+	CC	O	+		-1	SENT_92	16116/16117
8	chemotherapy	NN	O	chemotherapy	conj_+	4	SENT_92	16120/16132
9	vs.	CC	O	vs.	prep	4	SENT_92	16133/16136
10	chemotherapy	NN	O	chemotherapy	dep	9	SENT_92	16137/16149
11	alone	RB	O	alone	rcmod	2	SENT_92	16150/16155
12	to	TO	O	to	aux	13	SENT_92	16156/16158
13	test	VB	O	test	xcomp	11	SENT_92	16159/16163
14	the	DT	O	the	det	15	SENT_92	16164/16167
15	effect	NN	O	effect	dobj	13	SENT_92	16168/16174
16	of	IN	O	of		-1	SENT_92	16175/16177
17	TP	NN	O	tp	prep_of	15	SENT_92	16178/16180
18	on	IN	O	on		-1	SENT_92	16181/16183
19	chemotherapy	NN	O	chemotherapy	prep_on	17	SENT_92	16184/16196
20	;	:	O	;		-1	SENT_92	16196/16197
21	testing	NN	O	testing	nn	22	SENT_92	16198/16205
22	effect	NN	O	effect	dep	15	SENT_92	16206/16212
23	of	IN	O	of		-1	SENT_92	16213/16215
24	chemotherapy	NN	O	chemotherapy	prep_of	22	SENT_92	16216/16228
25	on	IN	O	on		-1	SENT_92	16229/16231
26	TP	NN	O	tp	prep_on	13	SENT_92	16232/16234
27	may	MD	O	may	aux	28	SENT_92	16235/16238
28	need	VB	O	need		-1	SENT_92	16239/16243
29	cross-study	JJ	O	cross-study	amod	31	SENT_92	16244/16255
30	comparison	NN	O	comparison	nn	31	SENT_92	16256/16266
31	)	NN	O	)	dobj	28	SENT_92	16266/16267
32	and	CC	O	and	advmod	28	SENT_92	16268/16271

1	a	DT	O	a	det	10	SENT_93	16307/16308
2	one-way	JJ	O	one-way	amod	10	SENT_93	16309/16316
3	sequential	JJ	O	sequential	amod	10	SENT_93	16317/16327
4	phase	NN	O	phase	nn	10	SENT_93	16328/16333
5	1b	NN	O	1b	nn	10	SENT_93	16334/16336
6	study	NN	O	study	nn	10	SENT_93	16337/16342
7	(	CD	NUMBER	(	num	10	SENT_93	16343/16344
8	open	JJ	O	open	amod	10	SENT_93	16344/16348
9	label	NN	O	label	nn	10	SENT_93	16349/16354
10	)	NN	O	)	nsubj	17	SENT_93	16354/16355
11	staggered	VBN	O	stagger	partmod	10	SENT_93	16356/16365
12	with	IN	O	with		-1	SENT_93	16366/16370
13	a	DT	O	a	det	14	SENT_93	16371/16372
14	phase	NN	O	phase	prep_with	11	SENT_93	16373/16378
15	2	CD	NUMBER	2	number	16	SENT_93	16379/16380
16	(	CD	NUMBER	(	num	14	SENT_93	16381/16382
17	double	JJ	O	double		-1	SENT_93	16382/16388
18	blind	JJ	O	blind	amod	20	SENT_93	16389/16394
19	)	NN	O	)	nn	20	SENT_93	16394/16395
20	study	NN	O	study	dobj	17	SENT_93	16396/16401
21	.	.	O	.		-1	SENT_93	16401/16402

1	Design	NN	O	design	nn	2	SENT_94	16457/16463
2	selection	NN	O	selection	nsubjpass	5	SENT_94	16464/16473
3	should	MD	O	should	aux	5	SENT_94	16474/16480
4	be	VB	O	be	auxpass	5	SENT_94	16481/16483
5	based	VBN	O	base		-1	SENT_94	16484/16489
6	on	IN	O	on		-1	SENT_94	16490/16492
7	the	DT	O	the	det	8	SENT_94	16493/16496
8	PK	NN	O	pk	prep_on	5	SENT_94	16497/16499
9	properties	NNS	O	property	dobj	5	SENT_94	16500/16510
10	of	IN	O	of		-1	SENT_94	16511/16513
11	the	DT	O	the	det	13	SENT_94	16514/16517
12	interacting	VBG	O	interact	amod	13	SENT_94	16518/16529
13	drugs	NNS	O	drug	prep_of	9	SENT_94	16530/16535
14	as	RB	O	as		-1	SENT_94	16536/16538
15	well	RB	O	well		-1	SENT_94	16539/16543
16	as	IN	O	as		-1	SENT_94	16544/16546
17	the	DT	O	the	det	18	SENT_94	16547/16550
18	types	NNS	O	type	conj_and	9	SENT_94	16551/16556
19	of	IN	O	of		-1	SENT_94	16557/16559
20	interaction	NN	O	interaction	prep_of	18	SENT_94	16560/16571
21	.	.	O	.		-1	SENT_94	16571/16572

1	TP-DI	NN	O	tp-di	nn	2	SENT_95	16608/16613
2	evaluation	NN	O	evaluation	nsubjpass	5	SENT_95	16614/16624
3	is	VBZ	O	be	auxpass	5	SENT_95	16625/16627
4	usually	RB	O	usually	advmod	5	SENT_95	16628/16635
5	conducted	VBN	O	conduct	conj_or	5	SENT_95	16636/16645
6	as	IN	O	as		-1	SENT_95	16646/16648
7	an	DT	O	a	det	9	SENT_95	16649/16651
8	estimation	NN	O	estimation	nn	9	SENT_95	16652/16662
9	study	NN	O	study	prep_as	5	SENT_95	16663/16668
10	with	IN	O	with		-1	SENT_95	16669/16673
11	10-20	CD	NUMBER	10-20	num	12	SENT_95	16674/16679
12	patients	NNS	O	patient	prep_with	9	SENT_95	16680/16688
13	per	IN	O	per		-1	SENT_95	16689/16692
14	arm	NN	O	arm	prep_per	12	SENT_95	16693/16696
15	in	IN	O	in	prep	9	SENT_95	16697/16699
16	either	CC	O	either	dep	15	SENT_95	16700/16706
17	a	DT	O	a	det	20	SENT_95	16707/16708
18	PK	NN	O	pk	nn	20	SENT_95	16709/16711
19	subgroup	NN	O	subgroup	nn	20	SENT_95	16712/16720
20	study	NN	O	study	conj	15	SENT_95	16721/16726
21	of	IN	O	of		-1	SENT_95	16727/16729
22	phase	NN	O	phase	nn	24	SENT_95	16730/16735
23	2/3	CD	NUMBER	2/3	num	24	SENT_95	16736/16739
24	trial	NN	O	trial	prep_of	9	SENT_95	16740/16745
25	or	CC	O	or		-1	SENT_95	16746/16748
26	in	IN	O	in		-1	SENT_95	16749/16751
27	a	DT	O	a	det	30	SENT_95	16752/16753
28	phase	NN	O	phase	nn	30	SENT_95	16754/16759
29	1b	NN	O	1b	nn	30	SENT_95	16760/16762
30	study	NN	O	study	prep_in	5	SENT_95	16763/16768
31	.	.	O	.		-1	SENT_95	16768/16769

1	Due	JJ	O	due		-1	SENT_96	16770/16773
2	to	TO	O	to		-1	SENT_96	16774/16776
3	large	JJ	O	large	amod	5	SENT_96	16777/16782
4	inter-subject	JJ	O	inter-subject	amod	5	SENT_96	16783/16796
5	variability	NN	O	variability	prep_due_to	21	SENT_96	16797/16808
6	in	IN	O	in		-1	SENT_96	16809/16811
7	exposure	NN	O	exposure	prep_in	5	SENT_96	16812/16820
8	for	IN	O	for		-1	SENT_96	16821/16824
9	TP	NN	O	tp	prep_for	7	SENT_96	16825/16827
10	in	IN	O	in		-1	SENT_96	16828/16830
11	oncology	NN	O	oncology	prep_in	9	SENT_96	16831/16839
12	,	,	O	,		-1	SENT_96	16839/16840
13	fully	RB	O	fully	advmod	14	SENT_96	16841/16846
14	powered	VBN	O	power	partmod	5	SENT_96	16847/16854
15	TP-DI	NN	O	tp-di	nn	16	SENT_96	16855/16860
16	studies	NNS	O	study	nsubj	21	SENT_96	16861/16868
17	for	IN	O	for		-1	SENT_96	16869/16872
18	hypothesis	NN	O	hypothesis	nn	19	SENT_96	16873/16883
19	test	NN	O	test	prep_for	16	SENT_96	16884/16888
20	are	VBP	O	be	cop	21	SENT_96	16889/16892
21	uncommon	JJ	O	uncommon		-1	SENT_96	16893/16901
22	.	.	O	.		-1	SENT_96	16901/16902

1	Depending	VBG	O	depend		-1	SENT_97	16903/16912
2	on	IN	O	on	prepc_depending_on	11	SENT_97	16913/16915
3	the	DT	O	the	det	4	SENT_97	16916/16919
4	pharmacokinetics	NNS	O	pharmacokinetic	pobj	11	SENT_97	16920/16936
5	,	,	O	,		-1	SENT_97	16936/16937
6	intensive	JJ	O	intensive	amod	8	SENT_97	16938/16947
7	PK	NN	O	pk	nn	8	SENT_97	16948/16950
8	sampling	NN	O	sampling	nsubjpass	11	SENT_97	16951/16959
9	has	VBZ	O	have	aux	11	SENT_97	16960/16963
10	been	VBN	O	be	auxpass	11	SENT_97	16964/16968
11	collected	VBN	O	collect		-1	SENT_97	16969/16978
12	for	IN	O	for		-1	SENT_97	16979/16982
13	the	DT	O	the	det	14	SENT_97	16983/16986
14	chemo-agents	NNS	O	chemo-agent	prep_for	11	SENT_97	16987/16999
15	and	CC	O	and		-1	SENT_97	17000/17003
16	relative	JJ	O	relative	amod	19	SENT_97	17004/17012
17	sparse	JJ	O	sparse	amod	19	SENT_97	17013/17019
18	PK	NN	O	pk	nn	19	SENT_97	17020/17022
19	sampling	NN	O	sampling	conj_and	14	SENT_97	17023/17031
20	for	IN	O	for		-1	SENT_97	17032/17035
21	TPs	NNS	O	tp	prep_for	11	SENT_97	17036/17039
22	due	JJ	O	due		-1	SENT_97	17040/17043
23	to	TO	O	to		-1	SENT_97	17044/17046
24	their	PRP$	O	they	poss	27	SENT_97	17047/17052
25	much	JJ	O	much	amod	27	SENT_97	17053/17057
26	longer	JJR	O	longer	dep	25	SENT_97	17058/17064
27	half-lives	NNS	O	half-life	prep_due_to	21	SENT_97	17065/17075
28	.	.	O	.		-1	SENT_97	17075/17076

1	Combined	VBN	O	combine	prep	9	SENT_98	17077/17085
2	intensive	JJ	O	intensive	amod	5	SENT_98	17086/17095
3	and	CC	O	and		-1	SENT_98	17096/17099
4	sparse	JJ	O	sparse	conj_and	2	SENT_98	17100/17106
5	sampling	NN	O	sampling	dep	1	SENT_98	17107/17115
6	schemes	NNS	O	scheme	nsubjpass	9	SENT_98	17116/17123
7	may	MD	O	may	aux	9	SENT_98	17124/17127
8	be	VB	O	be	auxpass	9	SENT_98	17128/17130
9	collected	VBN	O	collect	conj_and	9	SENT_98	17131/17140
10	in	IN	O	in		-1	SENT_98	17141/17143
11	cycle	NN	O	cycle	prep_in	9	SENT_98	17144/17149
12	1	CD	NUMBER	1	num	11	SENT_98	17150/17151
13	and	CC	O	and		-1	SENT_98	17152/17155
14	at	IN	O	at		-1	SENT_98	17156/17158
15	steady	JJ	O	steady	amod	16	SENT_98	17159/17165
16	state	NN	O	state	prep_at	9	SENT_98	17166/17171
17	.	.	O	.		-1	SENT_98	17171/17172

1	To	TO	O	to	aux	2	SENT_99	17173/17175
2	evaluate	VB	O	evaluate	advcl	31	SENT_99	17176/17184
3	the	DT	O	the	det	5	SENT_99	17185/17188
4	clinical	JJ	O	clinical	amod	5	SENT_99	17189/17197
5	relevance	NN	O	relevance	dobj	2	SENT_99	17198/17207
6	of	IN	O	of		-1	SENT_99	17208/17210
7	any	DT	O	any	det	8	SENT_99	17211/17214
8	change	NN	O	change	prep_of	5	SENT_99	17215/17221
9	in	IN	O	in		-1	SENT_99	17222/17224
10	exposure	NN	O	exposure	prep_in	8	SENT_99	17225/17233
11	(	CD	NUMBER	(	num	10	SENT_99	17234/17235
12	e.g.	FW	O	e.g.	dep	2	SENT_99	17235/17239
13	,	,	O	,		-1	SENT_99	17239/17240
14	AUC	NN	O	auc	dep	12	SENT_99	17241/17244
15	,	,	O	,		-1	SENT_99	17244/17245
16	Cmax	NN	O	cmax	conj_or	14	SENT_99	17246/17250
17	,	,	O	,		-1	SENT_99	17250/17251
18	or	CC	O	or		-1	SENT_99	17252/17254
19	Cmin	JJ	O	cmin	amod	20	SENT_99	17255/17259
20	)	NN	O	)	conj_or	14	SENT_99	17259/17260
21	,	,	O	,		-1	SENT_99	17260/17261
22	safety	NN	O	safety	nn	24	SENT_99	17262/17268
23	,	,	O	,		-1	SENT_99	17268/17269
24	PD	NN	O	pd	nsubjpass	31	SENT_99	17270/17272
25	,	,	O	,		-1	SENT_99	17272/17273
26	and	CC	O	and		-1	SENT_99	17274/17277
27	efficacy	NN	O	efficacy	nn	28	SENT_99	17278/17286
28	measures	NNS	O	measure	conj_and	24	SENT_99	17287/17295
29	may	MD	O	may	aux	31	SENT_99	17296/17299
30	be	VB	O	be	auxpass	31	SENT_99	17300/17302
31	collected	VBN	O	collect		-1	SENT_99	17303/17312
32	along	RB	O	along		-1	SENT_99	17313/17318
33	with	IN	O	with		-1	SENT_99	17319/17323
34	the	DT	O	the	det	36	SENT_99	17324/17327
35	PK	NN	O	pk	nn	36	SENT_99	17328/17330
36	samples	NNS	O	sample	prep_along_with	31	SENT_99	17331/17338
37	.	.	O	.		-1	SENT_99	17338/17339

1	If	IN	O	if	mark	5	SENT_100	17340/17342
2	an	DT	O	a	det	3	SENT_100	17343/17345
3	interaction	NN	O	interaction	nsubjpass	5	SENT_100	17346/17357
4	is	VBZ	O	be	auxpass	5	SENT_100	17358/17360
5	observed	VBN	O	observe	advcl	11	SENT_100	17361/17369
6	,	,	O	,		-1	SENT_100	17369/17370
7	clinical	JJ	O	clinical	amod	8	SENT_100	17371/17379
8	relevance	NN	O	relevance	nsubjpass	11	SENT_100	17380/17389
9	should	MD	O	should	aux	11	SENT_100	17390/17396
10	be	VB	O	be	auxpass	11	SENT_100	17397/17399
11	evaluated	VBN	O	evaluate		-1	SENT_100	17400/17409
12	in	IN	O	in		-1	SENT_100	17410/17412
13	conjunction	NN	O	conjunction	prep_in	11	SENT_100	17413/17424
14	with	IN	O	with		-1	SENT_100	17425/17429
15	safety	NN	O	safety	nn	18	SENT_100	17430/17436
16	and	CC	O	and		-1	SENT_100	17437/17440
17	efficacy	NN	O	efficacy	conj_and	15	SENT_100	17441/17449
18	data	NNS	O	datum	prep_with	11	SENT_100	17450/17454
19	and	CC	O	and		-1	SENT_100	17455/17458
20	should	MD	O	should	aux	24	SENT_100	17459/17465
21	be	VB	O	be	cop	24	SENT_100	17466/17468
22	the	DT	O	the	det	24	SENT_100	17469/17472
23	primary	JJ	O	primary	amod	24	SENT_100	17473/17480
24	consideration	NN	O	consideration	conj_and	11	SENT_100	17481/17494
25	in	IN	O	in		-1	SENT_100	17495/17497
26	data	NNS	O	datum	nn	27	SENT_100	17498/17502
27	interpretation	NN	O	interpretation	prep_in	24	SENT_100	17503/17517
28	.	.	O	.		-1	SENT_100	17517/17518

1	Non-compartment	JJ	O	non-compartment	amod	2	SENT_101	17554/17569
2	analysis	NN	O	analysis	nsubj	9	SENT_101	17570/17578
3	and/or	JJ	O	and/or	amod	6	SENT_101	17579/17585
4	population	NN	O	population	nn	6	SENT_101	17586/17596
5	modeling	NN	O	modeling	nn	6	SENT_101	17597/17605
6	approaches	NNS	O	approach	dep	2	SENT_101	17606/17616
7	may	MD	O	may	aux	9	SENT_101	17617/17620
8	be	VB	O	be	cop	9	SENT_101	17621/17623
9	applicable	JJ	O	applicable		-1	SENT_101	17624/17634
10	to	TO	O	to		-1	SENT_101	17635/17637
11	TP-DI	NN	O	tp-di	nn	12	SENT_101	17638/17643
12	evaluation	NN	O	evaluation	prep_to	9	SENT_101	17644/17654
13	.	.	O	.		-1	SENT_101	17654/17655

1	Covariate	JJ	O	covariate	amod	2	SENT_102	17656/17665
2	analysis	NN	O	analysis	nsubjpass	5	SENT_102	17666/17674
3	may	MD	O	may	aux	5	SENT_102	17675/17678
4	be	VB	O	be	auxpass	5	SENT_102	17679/17681
5	used	VBN	O	use		-1	SENT_102	17682/17686
6	to	TO	O	to	aux	7	SENT_102	17687/17689
7	identify	VB	O	identify	xcomp	5	SENT_102	17690/17698
8	potential	JJ	O	potential	amod	10	SENT_102	17699/17708
9	contributing	VBG	O	contribute	amod	10	SENT_102	17709/17721
10	factors	NNS	O	factor	dobj	7	SENT_102	17722/17729
11	to	TO	O	to		-1	SENT_102	17730/17732
12	drug	NN	O	drug	nn	13	SENT_102	17733/17737
13	exposure	NN	O	exposure	prep_to	10	SENT_102	17738/17746
14	,	,	O	,		-1	SENT_102	17746/17747
15	as	RB	O	as		-1	SENT_102	17748/17750
16	well	RB	O	well		-1	SENT_102	17751/17755
17	as	IN	O	as		-1	SENT_102	17756/17758
18	testing	NN	O	testing	conj_and	10	SENT_102	17759/17766
19	for	IN	O	for		-1	SENT_102	17767/17770
20	study	NN	O	study	nn	21	SENT_102	17771/17776
21	effects	NNS	O	effect	prep_for	18	SENT_102	17777/17784
22	in	IN	O	in		-1	SENT_102	17785/17787
23	cross-study	JJ	O	cross-study	amod	24	SENT_102	17788/17799
24	comparisons	NNS	O	comparison	prep_in	21	SENT_102	17800/17811
25	.	.	O	.		-1	SENT_102	17811/17812

1	The	DT	O	the	det	2	SENT_103	17813/17816
2	importance	NN	O	importance	nsubjpass	8	SENT_103	17817/17827
3	of	IN	O	of		-1	SENT_103	17828/17830
4	the	DT	O	the	det	5	SENT_103	17831/17834
5	DI	NNP	O	DI	prep_of	2	SENT_103	17835/17837
6	will	MD	O	will	aux	8	SENT_103	17838/17842
7	be	VB	O	be	auxpass	8	SENT_103	17843/17845
8	determined	VBN	O	determine		-1	SENT_103	17846/17856
9	by	IN	O	by		-1	SENT_103	17857/17859
10	the	DT	O	the	det	12	SENT_103	17860/17863
11	therapeutic	JJ	O	therapeutic	amod	12	SENT_103	17864/17875
12	index	NN	O	index	agent	8	SENT_103	17876/17881
13	of	IN	O	of		-1	SENT_103	17882/17884
14	the	DT	O	the	det	16	SENT_103	17885/17888
15	drug	NN	O	drug	nn	16	SENT_103	17889/17893
16	combination	NN	O	combination	prep_of	12	SENT_103	17894/17905
17	.	.	O	.		-1	SENT_103	17905/17906

1	Amgen	NNP	ORGANIZATION	Amgen	nsubj	2	SENT_104	17907/17912
2	found	VBD	O	find		-1	SENT_104	17913/17918
3	that	IN	O	that	mark	11	SENT_104	17919/17923
4	developing	VBG	O	develop	csubj	11	SENT_104	17924/17934
5	an	DT	O	a	det	8	SENT_104	17935/17937
6	internal	JJ	O	internal	amod	8	SENT_104	17938/17946
7	TP-DI	NN	O	tp-di	nn	8	SENT_104	17947/17952
8	database	NN	O	database	dobj	4	SENT_104	17953/17961
9	is	VBZ	O	be	cop	11	SENT_104	17962/17964
10	extremely	RB	O	extremely	advmod	11	SENT_104	17965/17974
11	useful	JJ	O	useful	ccomp	2	SENT_104	17975/17981
12	to	TO	O	to	aux	13	SENT_104	17982/17984
13	aid	VB	O	aid	xcomp	11	SENT_104	17985/17988
14	systematic	JJ	O	systematic	amod	15	SENT_104	17989/17999
15	planning	NN	O	planning	dobj	13	SENT_104	18000/18008
16	in	IN	O	in		-1	SENT_104	18009/18011
17	design	NN	O	design	prep_in	13	SENT_104	18012/18018
18	of	IN	O	of		-1	SENT_104	18019/18021
19	TP-DI	NN	O	tp-di	nn	20	SENT_104	18022/18027
20	studies	NNS	O	study	prep_of	17	SENT_104	18028/18035
21	across	IN	O	across		-1	SENT_104	18036/18042
22	programs	NNS	O	program	prep_across	13	SENT_104	18043/18051
23	.	.	O	.		-1	SENT_104	18051/18052

1	For	IN	O	for		-1	SENT_105	18053/18056
2	example	NN	O	example	prep_for	30	SENT_105	18057/18064
3	,	,	O	,		-1	SENT_105	18064/18065
4	using	VBG	O	use	csubj	30	SENT_105	18066/18071
5	a	DT	O	a	det	7	SENT_105	18072/18073
6	standardized	JJ	O	standardized	amod	7	SENT_105	18074/18086
7	approach	NN	O	approach	dobj	4	SENT_105	18087/18095
8	to	TO	O	to	aux	9	SENT_105	18096/18098
9	collect	VB	O	collect	xcomp	4	SENT_105	18099/18106
10	PK	NNP	O	PK	nn	11	SENT_105	18107/18109
11	data	NNS	O	datum	dobj	9	SENT_105	18110/18114
12	for	IN	O	for		-1	SENT_105	18115/18118
13	a	DT	O	a	det	16	SENT_105	18119/18120
14	specific	JJ	O	specific	amod	16	SENT_105	18121/18129
15	chemotherapy	NN	O	chemotherapy	nn	16	SENT_105	18130/18142
16	regimen	NN	O	regimen	prep_for	9	SENT_105	18143/18150
17	(	CD	NUMBER	(	num	24	SENT_105	18151/18152
18	e.g.	FW	O	e.g.	amod	24	SENT_105	18152/18156
19	,	,	O	,		-1	SENT_105	18156/18157
20	paclitaxel	NN	O	paclitaxel	dep	18	SENT_105	18158/18168
21	)	CD	NUMBER	)	num	20	SENT_105	18168/18169
22	from	IN	O	from		-1	SENT_105	18170/18174
23	control	NN	O	control	prep_from	20	SENT_105	18175/18182
24	arms	NNS	O	arm	npadvmod	9	SENT_105	18183/18187
25	in	IN	O	in		-1	SENT_105	18188/18190
26	different	JJ	O	different	amod	27	SENT_105	18191/18200
27	studies	NNS	O	study	prep_in	9	SENT_105	18201/18208
28	was	VBD	O	be	cop	30	SENT_105	18209/18212
29	extremely	RB	O	extremely	advmod	30	SENT_105	18213/18222
30	useful	JJ	O	useful		-1	SENT_105	18223/18229
31	in	IN	O	in		-1	SENT_105	18230/18232
32	the	DT	O	the	det	33	SENT_105	18233/18236
33	interpretation	NN	O	interpretation	prep_in	30	SENT_105	18237/18251
34	of	IN	O	of		-1	SENT_105	18252/18254
35	results	NNS	O	result	prep_of	33	SENT_105	18255/18262
36	in	IN	O	in		-1	SENT_105	18263/18265
37	new	JJ	O	new	amod	40	SENT_105	18266/18269
38	TP-drug	JJ	O	tp-drug	amod	40	SENT_105	18270/18277
39	combination	NN	O	combination	nn	40	SENT_105	18278/18289
40	studies	NNS	O	study	prep_in	35	SENT_105	18290/18297
41	.	.	O	.		-1	SENT_105	18297/18298

1	Amgen	NNP	ORGANIZATION	Amgen	nsubj	3	SENT_106	18334/18339
2	thus	RB	O	thus	advmod	3	SENT_106	18340/18344
3	presented	VBD	O	present		-1	SENT_106	18345/18354
4	an	DT	O	a	det	6	SENT_106	18355/18357
5	integrated	JJ	O	integrated	amod	6	SENT_106	18358/18368
6	approach	NN	O	approach	dobj	3	SENT_106	18369/18377
7	as	IN	O	as	mark	8	SENT_106	18378/18380
8	used	VBN	O	use	advcl	3	SENT_106	18381/18385
9	in	IN	O	in		-1	SENT_106	18386/18388
10	an	DT	O	a	det	12	SENT_106	18389/18391
11	oncology	NN	O	oncology	nn	12	SENT_106	18392/18400
12	setting	NN	O	setting	prep_in	8	SENT_106	18401/18408
13	with	IN	O	with		-1	SENT_106	18409/18413
14	specific	JJ	O	specific	amod	15	SENT_106	18414/18422
15	details	NNS	O	detail	prep_with	12	SENT_106	18423/18430
16	around	IN	O	around		-1	SENT_106	18431/18437
17	timing	NN	O	timing	prep_around	8	SENT_106	18438/18444
18	of	IN	O	of		-1	SENT_106	18445/18447
19	such	PDT	O	such	predet	21	SENT_106	18448/18452
20	a	DT	O	a	det	21	SENT_106	18453/18454
21	study	NN	O	study	prep_of	17	SENT_106	18455/18460
22	,	,	O	,		-1	SENT_106	18460/18461
23	type	NN	O	type	appos	21	SENT_106	18462/18466
24	of	IN	O	of		-1	SENT_106	18467/18469
25	DI	NN	O	di	nn	26	SENT_106	18470/18472
26	studies	NNS	O	study	prep_of	23	SENT_106	18473/18480
27	based	VBN	O	base	partmod	26	SENT_106	18481/18486
28	on	IN	O	on		-1	SENT_106	18487/18489
29	stage	NN	O	stage	prep_on	27	SENT_106	18490/18495
30	of	IN	O	of		-1	SENT_106	18496/18498
31	drug	NN	O	drug	nn	32	SENT_106	18499/18503
32	development	NN	O	development	prep_of	29	SENT_106	18504/18515
33	and	CC	O	and		-1	SENT_106	18516/18519
34	DI	NN	O	di	nn	35	SENT_106	18520/18522
35	signal	NN	O	signal	conj_and	32	SENT_106	18523/18529
36	in	IN	O	in		-1	SENT_106	18530/18532
37	early	JJ	O	early	amod	38	SENT_106	18533/18538
38	studies	NNS	O	study	prep_in	32	SENT_106	18539/18546
39	.	.	O	.		-1	SENT_106	18546/18547

1	Modeling	NN	O	modeling	nsubjpass	8	SENT_107	18548/18556
2	-	:	O	-		-1	SENT_107	18556/18557
3	and	CC	O	and		-1	SENT_107	18558/18561
4	simulation-based	JJ	O	simulation-based	amod	6	SENT_107	18562/18578
5	TP-DI	NN	O	tp-di	nn	6	SENT_107	18579/18584
6	evaluation	NN	O	evaluation	conj_and	1	SENT_107	18585/18595
7	was	VBD	O	be	auxpass	8	SENT_107	18596/18599
8	used	VBN	O	use		-1	SENT_107	18600/18604
9	to	TO	O	to	aux	10	SENT_107	18605/18607
10	address	VB	O	address	xcomp	8	SENT_107	18608/18615
11	specific	JJ	O	specific	amod	12	SENT_107	18616/18624
12	challenges	NNS	O	challenge	dobj	10	SENT_107	18625/18635
13	.	.	O	.		-1	SENT_107	18635/18636

1	Genentech	NNP	ORGANIZATION	Genentech		-1	SENT_108	18672/18681
2	's	POS	O	's	possessive	1	SENT_108	18681/18683
3	Question	NN	O	question	dep	1	SENT_108	18684/18692
4	-	:	O	-		-1	SENT_108	18692/18693
5	and	CC	O	and		-1	SENT_108	18694/18697
6	Risk-Based	NNP	O	Risk-Based	nn	7	SENT_108	18698/18708
7	Approach	NNP	O	Approach	conj_and	1	SENT_108	18709/18717
8	to	TO	O	to	aux	9	SENT_108	18718/18720
9	Assess	VB	O	assess	infmod	7	SENT_108	18721/18727
10	TP-DI	NN	O	tp-di	dobj	9	SENT_108	18728/18733

1	The	DT	O	the	det	3	SENT_109	18769/18772
2	Genentech	NNP	O	Genentech	nn	3	SENT_109	18773/18782
3	presentation	NN	O	presentation	nsubj	4	SENT_109	18783/18795
4	provided	VBD	O	provide	ccomp	19	SENT_109	18796/18804
5	an	DT	O	a	det	6	SENT_109	18805/18807
6	overview	NN	O	overview	dobj	4	SENT_109	18808/18816
7	of	IN	O	of		-1	SENT_109	18817/18819
8	potential	JJ	O	potential	amod	9	SENT_109	18820/18829
9	mechanisms	NNS	O	mechanism	prep_of	6	SENT_109	18830/18840
10	for	IN	O	for		-1	SENT_109	18841/18844
11	TP-related	JJ	O	tp-related	amod	12	SENT_109	18845/18855
12	DI	NNP	O	DI	prep_for	4	SENT_109	18856/18858
13	,	,	O	,		-1	SENT_109	18858/18859
14	both	DT	O	both	preconj	18	SENT_109	18860/18864
15	PK	NN	O	pk	nn	18	SENT_109	18865/18867
16	and	CC	O	and		-1	SENT_109	18868/18871
17	PD	NN	O	pd	conj_and	15	SENT_109	18872/18874
18	examples	NNS	O	example	nsubj	19	SENT_109	18875/18883
19	focused	VBD	O	focus		-1	SENT_109	18884/18891
20	on	IN	O	on		-1	SENT_109	18892/18894
21	mAb	NN	O	mab	nn	22	SENT_109	18895/18898
22	therapeutics	NNS	O	therapeutics	prep_on	19	SENT_109	18899/18911
23	,	,	O	,		-1	SENT_109	18911/18912
24	one	CD	NUMBER	one	appos	22	SENT_109	18913/18916
25	of	IN	O	of		-1	SENT_109	18917/18919
26	many	JJ	O	many	amod	28	SENT_109	18920/18924
27	TP	NN	O	tp	nn	28	SENT_109	18925/18927
28	classes	NNS	O	class	prep_of	24	SENT_109	18928/18935
29	.	.	O	.		-1	SENT_109	18935/18936

1	This	DT	O	this	det	2	SENT_110	18937/18941
2	approach	NN	O	approach	nsubjpass	6	SENT_110	18942/18950
3	may	MD	O	may	aux	6	SENT_110	18951/18954
4	also	RB	O	also	advmod	6	SENT_110	18955/18959
5	be	VB	O	be	auxpass	6	SENT_110	18960/18962
6	applied	VBN	O	apply		-1	SENT_110	18963/18970
7	to	TO	O	to		-1	SENT_110	18971/18973
8	other	JJ	O	other	amod	9	SENT_110	18974/18979
9	TPs	NNS	O	tp	prep_to	6	SENT_110	18980/18983
10	.	.	O	.		-1	SENT_110	18983/18984

1	The	DT	O	the	det	3	SENT_111	18985/18988
2	proposed	VBN	O	propose	amod	3	SENT_111	18989/18997
3	question	NN	O	question		-1	SENT_111	18998/19006
4	-	:	O	-		-1	SENT_111	19006/19007
5	and	CC	O	and		-1	SENT_111	19008/19011
6	risk-based	JJ	O	risk-based	amod	7	SENT_111	19012/19022
7	approach	NN	O	approach	nsubj	8	SENT_111	19023/19031
8	assesses	VBZ	O	assess	conj_and	3	SENT_111	19032/19040
9	both	CC	O	both	preconj	10	SENT_111	19041/19045
10	effect	NN	O	effect	dobj	8	SENT_111	19046/19052
11	of	IN	O	of		-1	SENT_111	19053/19055
12	other	JJ	O	other	amod	13	SENT_111	19056/19061
13	therapeutics	NNS	O	therapeutics	prep_of	10	SENT_111	19062/19074
14	on	IN	O	on		-1	SENT_111	19075/19077
15	TPs	NNS	O	tp	prep_on	13	SENT_111	19078/19081
16	and	CC	O	and		-1	SENT_111	19082/19085
17	effect	NN	O	effect	conj_and	10	SENT_111	19086/19092
18	of	IN	O	of		-1	SENT_111	19093/19095
19	TPs	NNS	O	tp	prep_of	17	SENT_111	19096/19099
20	on	IN	O	on		-1	SENT_111	19100/19102
21	other	JJ	O	other	amod	22	SENT_111	19103/19108
22	drugs	NNS	O	drug	prep_on	19	SENT_111	19109/19114
23	.	.	O	.		-1	SENT_111	19114/19115

1	A	DT	O	a	det	3	SENT_112	19151/19152
2	systematic	JJ	O	systematic	amod	3	SENT_112	19153/19163
3	approach	NN	O	approach	nsubj	10	SENT_112	19164/19172
4	to	TO	O	to		-1	SENT_112	19173/19175
5	answering	VBG	O	answer	prepc_to	3	SENT_112	19176/19185
6	the	DT	O	the	det	7	SENT_112	19186/19189
7	question	NN	O	question	dobj	5	SENT_112	19190/19198
8	of	IN	O	of	prep	7	SENT_112	19199/19201
9	"	``	O	"	punct	10	SENT_112	19202/19203
10	Can	MD	O	can		-1	SENT_112	19203/19206
11	a	DT	O	a	det	13	SENT_112	19207/19208
12	therapeutic	JJ	O	therapeutic	amod	13	SENT_112	19209/19220
13	mAb	NN	O	mab	dobj	10	SENT_112	19221/19224
14	be	VB	O	be	cop	17	SENT_112	19225/19227
15	either	CC	O	either	preconj	17	SENT_112	19228/19234
16	a	DT	O	a	det	17	SENT_112	19235/19236
17	victim	NN	O	victim	dep	10	SENT_112	19237/19243
18	or	CC	O	or		-1	SENT_112	19244/19246
19	a	DT	O	a	det	20	SENT_112	19247/19248
20	perpetrator	NN	O	perpetrator	conj_or	17	SENT_112	19249/19260
21	of	IN	O	of		-1	SENT_112	19261/19263
22	a	DT	O	a	det	23	SENT_112	19264/19265
23	TP-DI	NN	O	tp-di	prep_of	17	SENT_112	19266/19271
24	?	.	O	?		-1	SENT_112	19271/19272
25	"	''	O	"	punct	10	SENT_112	19272/19273

1	assesses	VBZ	O	assess		-1	SENT_113	19274/19282
2	the	DT	O	the	det	4	SENT_113	19283/19286
3	clearance	NN	O	clearance	nn	4	SENT_113	19287/19296
4	mechanisms	NNS	O	mechanism	dobj	1	SENT_113	19297/19307
5	of	IN	O	of		-1	SENT_113	19308/19310
6	a	DT	O	a	det	8	SENT_113	19311/19312
7	particular	JJ	O	particular	amod	8	SENT_113	19313/19323
8	mAb	NN	O	mab	prep_of	4	SENT_113	19324/19327
9	and	CC	O	and		-1	SENT_113	19328/19331
10	asks	VBZ	O	ask	conj_and	1	SENT_113	19332/19336
11	whether	IN	O	whether	mark	23	SENT_113	19337/19344
12	extrinsic	JJ	O	extrinsic	amod	13	SENT_113	19345/19354
13	factors	NNS	O	factor	nsubj	23	SENT_113	19355/19362
14	such	JJ	O	such		-1	SENT_113	19363/19367
15	as	IN	O	as		-1	SENT_113	19368/19370
16	co	NN	O	co	prep_such_as	13	SENT_113	19371/19373
17	-	:	O	-		-1	SENT_113	19373/19374
18	administered	VBN	O	administer	partmod	16	SENT_113	19375/19387
19	TPs	NNS	O	tp	dobj	18	SENT_113	19388/19391
20	or	CC	O	or		-1	SENT_113	19392/19394
21	SMDs	NNS	O	smd	conj_or	19	SENT_113	19395/19399
22	can	MD	O	can	aux	23	SENT_113	19400/19403
23	affect	VB	O	affect	ccomp	10	SENT_113	19404/19410
24	these	DT	O	these	det	26	SENT_113	19411/19416
25	clearance	NN	O	clearance	nn	26	SENT_113	19417/19426
26	processes	NNS	O	process	dobj	23	SENT_113	19427/19436
27	.	.	O	.		-1	SENT_113	19436/19437

1	These	DT	O	these	det	3	SENT_114	19438/19443
2	clearance	NN	O	clearance	nn	3	SENT_114	19444/19453
3	mechanisms	NNS	O	mechanism	nsubjpass	6	SENT_114	19454/19464
4	can	MD	O	can	aux	6	SENT_114	19465/19468
5	be	VB	O	be	auxpass	6	SENT_114	19469/19471
6	classified	VBN	O	classify		-1	SENT_114	19472/19482
7	under	IN	O	under		-1	SENT_114	19483/19488
8	the	DT	O	the	det	10	SENT_114	19489/19492
9	following	VBG	O	follow	amod	10	SENT_114	19493/19502
10	categories	NNS	O	category	prep_under	6	SENT_114	19503/19513
11	:	:	O	:		-1	SENT_114	19513/19514

1	Specific	JJ	O	specific	amod	2	SENT_115	19550/19558
2	mechanisms	NNS	O	mechanism	nsubj	3	SENT_115	19559/19569
3	governed	VBN	O	govern		-1	SENT_115	19570/19578
4	by	IN	O	by		-1	SENT_115	19579/19581
5	target	NN	O	target	nn	6	SENT_115	19582/19588
6	biology	NN	O	biology	prep_by	3	SENT_115	19589/19596
7	--	:	O	--		-1	SENT_115	19596/19598
8	these	DT	O	these	nsubj	12	SENT_115	19598/19603
9	are	VBP	O	be	cop	12	SENT_115	19604/19607
10	typically	RB	O	typically	advmod	12	SENT_115	19608/19617
11	high	JJ	O	high	amod	12	SENT_115	19618/19622
12	affinity	NN	O	affinity	parataxis	3	SENT_115	19623/19631
13	,	,	O	,		-1	SENT_115	19631/19632
14	low	JJ	O	low	amod	17	SENT_115	19633/19636
15	capacity	NN	O	capacity	nn	17	SENT_115	19637/19645
16	saturation	NN	O	saturation	nn	17	SENT_115	19646/19656
17	processes	NNS	O	process	conj_and	12	SENT_115	19657/19666
18	like	IN	O	like		-1	SENT_115	19667/19671
19	binding	NN	O	binding	prep_like	17	SENT_115	19672/19679
20	of	IN	O	of		-1	SENT_115	19680/19682
21	mAbs	NNS	O	mab	prep_of	19	SENT_115	19683/19687
22	to	TO	O	to		-1	SENT_115	19688/19690
23	its	PRP$	O	its	poss	24	SENT_115	19691/19694
24	target	NN	O	target	prep_to	21	SENT_115	19695/19701
25	and	CC	O	and		-1	SENT_115	19702/19705
26	subsequent	JJ	O	subsequent	amod	28	SENT_115	19706/19716
27	target-mediated	JJ	O	target-mediated	amod	28	SENT_115	19717/19732
28	clearance	NN	O	clearance	conj_and	12	SENT_115	19733/19742
29	.	.	O	.		-1	SENT_115	19742/19743

1	The	DT	O	the	det	2	SENT_116	19744/19747
2	biology	NN	O	biology	nsubj	28	SENT_116	19748/19755
3	of	IN	O	of		-1	SENT_116	19756/19758
4	the	DT	O	the	det	5	SENT_116	19759/19762
5	target	NN	O	target	prep_of	2	SENT_116	19763/19769
6	,	,	O	,		-1	SENT_116	19769/19770
7	including	VBG	O	include		-1	SENT_116	19771/19780
8	information	NN	O	information	prep_including	5	SENT_116	19781/19792
9	on	IN	O	on		-1	SENT_116	19793/19795
10	the	DT	O	the	det	11	SENT_116	19796/19799
11	site	NN	O	site	prep_on	8	SENT_116	19800/19804
12	of	IN	O	of		-1	SENT_116	19805/19807
13	expression	NN	O	expression	prep_of	11	SENT_116	19808/19818
14	,	,	O	,		-1	SENT_116	19818/19819
15	relative	JJ	O	relative	amod	16	SENT_116	19820/19828
16	abundance	NN	O	abundance	conj_and	11	SENT_116	19829/19838
17	of	IN	O	of		-1	SENT_116	19839/19841
18	expression	NN	O	expression	prep_of	16	SENT_116	19842/19852
19	,	,	O	,		-1	SENT_116	19852/19853
20	and	CC	O	and		-1	SENT_116	19854/19857
21	the	DT	O	the	det	22	SENT_116	19858/19861
22	pharmacology	NN	O	pharmacology	conj_and	11	SENT_116	19862/19874
23	of	IN	O	of		-1	SENT_116	19875/19877
24	the	DT	O	the	det	25	SENT_116	19878/19881
25	target	NN	O	target	prep_of	22	SENT_116	19882/19888
26	are	VBP	O	be	cop	28	SENT_116	19889/19892
27	all	DT	O	all	advmod	28	SENT_116	19893/19896
28	important	JJ	O	important		-1	SENT_116	19897/19906
29	in	IN	O	in		-1	SENT_116	19907/19909
30	assessing	VBG	O	assess	prepc_in	28	SENT_116	19910/19919
31	whether	IN	O	whether	mark	42	SENT_116	19920/19927
32	a	DT	O	a	det	33	SENT_116	19928/19929
33	TP	NN	O	tp	nsubj	42	SENT_116	19930/19932
34	or	CC	O	or		-1	SENT_116	19933/19935
35	SMD	NN	O	smd	conj_or	33	SENT_116	19936/19939
36	in	IN	O	in		-1	SENT_116	19940/19942
37	combination	NN	O	combination	prep_in	33	SENT_116	19943/19954
38	with	IN	O	with		-1	SENT_116	19955/19959
39	a	DT	O	a	det	40	SENT_116	19960/19961
40	mAb	NN	O	mab	prep_with	37	SENT_116	19962/19965
41	can	MD	O	can	aux	42	SENT_116	19966/19969
42	alter	VB	O	alter	ccomp	30	SENT_116	19970/19975
43	mAb	NN	O	mab	nn	44	SENT_116	19976/19979
44	pharmacokinetics	NNS	O	pharmacokinetic	dobj	42	SENT_116	19980/19996
45	.	.	O	.		-1	SENT_116	19996/19997

1	Specific	JJ	O	specific	amod	2	SENT_117	19998/20006
2	examples	NNS	O	example	nsubj	13	SENT_117	20007/20015
3	of	IN	O	of		-1	SENT_117	20016/20018
4	such	JJ	O	such	amod	6	SENT_117	20019/20023
5	PD	NN	O	pd	nn	6	SENT_117	20024/20026
6	interactions	NNS	O	interaction	prep_of	2	SENT_117	20027/20039
7	where	WRB	O	where	advmod	11	SENT_117	20040/20045
8	target	NN	O	target	nn	9	SENT_117	20046/20052
9	biology	NN	O	biology	nsubjpass	11	SENT_117	20053/20060
10	is	VBZ	O	be	auxpass	11	SENT_117	20061/20063
11	altered	VBN	O	alter	rcmod	6	SENT_117	20064/20071
12	are	VBP	O	be	cop	13	SENT_117	20072/20075
13	efalizumab	NN	O	efalizumab		-1	SENT_117	20076/20086
14	in	IN	O	in		-1	SENT_117	20087/20089
15	combination	NN	O	combination	prep_in	13	SENT_117	20090/20101
16	with	IN	O	with		-1	SENT_117	20102/20106
17	triple	JJ	O	triple	amod	20	SENT_117	20107/20113
18	immunosuppressant	JJ	O	immunosuppressant	amod	20	SENT_117	20114/20131
19	therapy	NN	O	therapy	nn	20	SENT_117	20132/20139
20	(	NN	O	(	prep_with	13	SENT_117	20140/20141
21	17	CD	NUMBER	17	num	22	SENT_117	20141/20143
22	)	NN	O	)	dep	20	SENT_117	20143/20144
23	and	CC	O	and		-1	SENT_117	20145/20148
24	anakinra	NN	O	anakinra	conj_and	20	SENT_117	20149/20157
25	in	IN	O	in		-1	SENT_117	20158/20160
26	combination	NN	O	combination	prep_in	24	SENT_117	20161/20172
27	with	IN	O	with		-1	SENT_117	20173/20177
28	etanercept	NN	O	etanercept	prep_with	13	SENT_117	20178/20188
29	(	CD	NUMBER	(	number	30	SENT_117	20189/20190
30	18	CD	NUMBER	18	num	31	SENT_117	20190/20192
31	)	NN	O	)	dep	13	SENT_117	20192/20193
32	.	.	O	.		-1	SENT_117	20193/20194

1	Both	DT	O	both	det	2	SENT_118	20195/20199
2	combinations	NNS	O	combination	nsubj	3	SENT_118	20200/20212
3	resulted	VBD	O	result		-1	SENT_118	20213/20221
4	in	IN	O	in		-1	SENT_118	20222/20224
5	PD-based	JJ	O	pd-based	amod	6	SENT_118	20225/20233
6	interactions	NNS	O	interaction	prep_in	3	SENT_118	20234/20246
7	.	.	O	.		-1	SENT_118	20246/20247

1	In	IN	O	in		-1	SENT_119	20248/20250
2	contrast	NN	O	contrast	prep_in	10	SENT_119	20251/20259
3	,	,	O	,		-1	SENT_119	20259/20260
4	no	DT	O	no	det	5	SENT_119	20261/20263
5	alteration	NN	O	alteration	nsubjpass	10	SENT_119	20264/20274
6	in	IN	O	in		-1	SENT_119	20275/20277
7	target	NN	O	target	nn	8	SENT_119	20278/20284
8	biology	NN	O	biology	prep_in	5	SENT_119	20285/20292
9	was	VBD	O	be	auxpass	10	SENT_119	20293/20296
10	anticipated	VBN	O	anticipate		-1	SENT_119	20297/20308
11	and	CC	O	and		-1	SENT_119	20309/20312
12	no	DT	O	no	det	13	SENT_119	20313/20315
13	interaction	NN	O	interaction	nsubjpass	15	SENT_119	20316/20327
14	was	VBD	O	be	auxpass	15	SENT_119	20328/20331
15	noted	VBN	O	note	conj_and	10	SENT_119	20332/20337
16	for	IN	O	for		-1	SENT_119	20338/20341
17	bevacizumab	NN	O	bevacizumab	prep_for	15	SENT_119	20342/20353
18	in	IN	O	in		-1	SENT_119	20354/20356
19	combination	NN	O	combination	prep_in	17	SENT_119	20357/20368
20	with	IN	O	with		-1	SENT_119	20369/20373
21	erlotinib	NN	O	erlotinib	prep_with	15	SENT_119	20374/20383
22	(	CD	NUMBER	(	number	23	SENT_119	20384/20385
23	19	CD	NUMBER	19	num	24	SENT_119	20385/20387
24	)	NN	O	)	dep	15	SENT_119	20387/20388
25	.	.	O	.		-1	SENT_119	20388/20389

1	Non-specific	JJ	O	non-specific	amod	2	SENT_120	20425/20437
2	mechanisms	NNS	O	mechanism	nsubj	15	SENT_120	20438/20448
3	that	WDT	O	that	nsubjpass	6	SENT_120	20449/20453
4	are	VBP	O	be	auxpass	6	SENT_120	20454/20457
5	typically	RB	O	typically	advmod	6	SENT_120	20458/20467
6	governed	VBN	O	govern	rcmod	2	SENT_120	20468/20476
7	by	IN	O	by		-1	SENT_120	20477/20479
8	immunoglobulin	NN	O	immunoglobulin	nn	9	SENT_120	20480/20494
9	structure	NN	O	structure	agent	6	SENT_120	20495/20504
10	are	VBP	O	be	cop	15	SENT_120	20505/20508
11	high-capacity	JJ	O	high-capacity	amod	15	SENT_120	20509/20522
12	,	,	O	,		-1	SENT_120	20522/20523
13	largely	RB	O	largely	advmod	14	SENT_120	20524/20531
14	nonsaturable	JJ	O	nonsaturable	amod	15	SENT_120	20532/20544
15	processes	NNS	O	process		-1	SENT_120	20545/20554
16	like	IN	O	like		-1	SENT_120	20555/20559
17	neonatal	JJ	O	neonatal	amod	23	SENT_120	20560/20568
18	Fc	NN	O	fc	nn	23	SENT_120	20569/20571
19	receptor	NN	O	receptor	nn	23	SENT_120	20572/20580
20	(	NN	O	(	nn	23	SENT_120	20581/20582
21	FcRn	NN	O	fcrn	nn	23	SENT_120	20582/20586
22	)	CD	NUMBER	)	num	23	SENT_120	20586/20587
23	recycling	NN	O	recycling	prep_like	15	SENT_120	20588/20597
24	,	,	O	,		-1	SENT_120	20597/20598
25	non-specific	JJ	O	non-specific	amod	26	SENT_120	20599/20611
26	uptake	NN	O	uptake	conj_and	15	SENT_120	20612/20618
27	by	IN	O	by		-1	SENT_120	20619/20621
28	tissues	NNS	O	tissue	prep_by	26	SENT_120	20622/20629
29	,	,	O	,		-1	SENT_120	20629/20630
30	binding	VBG	O	bind	appos	28	SENT_120	20631/20638
31	to	TO	O	to		-1	SENT_120	20639/20641
32	Fc	NN	O	fc	nn	33	SENT_120	20642/20644
33	receptors	NNS	O	receptor	prep_to	30	SENT_120	20647/20656
34	,	,	O	,		-1	SENT_120	20656/20657
35	and	CC	O	and		-1	SENT_120	20658/20661
36	proteolytic	JJ	O	proteolytic	amod	37	SENT_120	20662/20673
37	degradation	NN	O	degradation	conj_and	15	SENT_120	20674/20685
38	.	.	O	.		-1	SENT_120	20685/20686

1	There	EX	O	there	expl	2	SENT_121	20687/20692
2	is	VBZ	O	be		-1	SENT_121	20693/20695
3	a	DT	O	a	det	5	SENT_121	20696/20697
4	high	JJ	O	high	amod	5	SENT_121	20698/20702
5	expression	NN	O	expression	nsubj	2	SENT_121	20703/20713
6	of	IN	O	of		-1	SENT_121	20714/20716
7	FcRn	NN	O	fcrn	nn	10	SENT_121	20717/20721
8	and	CC	O	and		-1	SENT_121	20722/20725
9	Fc	NN	O	fc	conj_and	7	SENT_121	20726/20728
10	receptors	NNS	O	receptor	prep_of	5	SENT_121	20731/20740
11	,	,	O	,		-1	SENT_121	20740/20741
12	and	CC	O	and		-1	SENT_121	20742/20745
13	theoretically	RB	O	theoretically	advmod	15	SENT_121	20746/20759
14	very	RB	O	very	advmod	15	SENT_121	20760/20764
15	high	JJ	O	high	amod	16	SENT_121	20765/20769
16	concentrations	NNS	O	concentration	nsubj	20	SENT_121	20770/20784
17	of	IN	O	of		-1	SENT_121	20785/20787
18	IgG	NN	O	igg	prep_of	16	SENT_121	20788/20791
19	can	MD	O	can	aux	20	SENT_121	20792/20795
20	saturate	VB	O	saturate	conj_and	2	SENT_121	20796/20804
21	the	DT	O	the	det	23	SENT_121	20805/20808
22	FcRn	NN	O	fcrn	nn	23	SENT_121	20809/20813
23	receptors	NNS	O	receptor	dobj	20	SENT_121	20814/20823
24	.	.	O	.		-1	SENT_121	20823/20824

1	However	RB	O	however	advmod	8	SENT_122	20825/20832
2	,	,	O	,		-1	SENT_122	20832/20833
3	the	DT	O	the	det	4	SENT_122	20834/20837
4	concentration	NN	O	concentration	nsubj	8	SENT_122	20838/20851
5	required	VBN	O	require	partmod	4	SENT_122	20852/20860
6	is	VBZ	O	be	cop	8	SENT_122	20861/20863
7	far	RB	O	far	advmod	8	SENT_122	20864/20867
8	higher	JJR	O	higher		-1	SENT_122	20868/20874
9	than	IN	O	than		-1	SENT_122	20875/20879
10	circulating	VBG	O	circulate	prepc_than	8	SENT_122	20880/20891
11	IgG	NN	O	igg	nn	12	SENT_122	20892/20895
12	levels	NNS	O	level	dobj	10	SENT_122	20896/20902
13	and	CC	O	and		-1	SENT_122	20903/20906
14	therapeutic	JJ	O	therapeutic	amod	15	SENT_122	20907/20918
15	levels	NNS	O	level	conj_and	12	SENT_122	20919/20925
16	of	IN	O	of		-1	SENT_122	20926/20928
17	mAbs	NNS	O	mab	prep_of	15	SENT_122	20929/20933
18	(	CD	NUMBER	(	num	17	SENT_122	20934/20935
19	for	IN	O	for		-1	SENT_122	20935/20938
20	example	NN	O	example	prep_for	17	SENT_122	20939/20946
21	,	,	O	,		-1	SENT_122	20946/20947
22	endogenous	JJ	O	endogenous	amod	24	SENT_122	20948/20958
23	IgG	NN	O	igg	nn	24	SENT_122	20959/20962
24	levels	NNS	O	level	nsubj	28	SENT_122	20963/20969
25	in	IN	O	in		-1	SENT_122	20970/20972
26	normal	JJ	O	normal	amod	27	SENT_122	20973/20979
27	individuals	NNS	O	individual	prep_in	24	SENT_122	20980/20991
28	are	VBP	O	be	conj_and	8	SENT_122	20992/20995
29	about	IN	O	about		-1	SENT_122	20996/21001
30	10	CD	NUMBER	10	num	31	SENT_122	21002/21004
31	mg/mL	NN	O	mg/ml	prep_about	28	SENT_122	21005/21010
32	while	IN	O	while	mark	37	SENT_122	21011/21016
33	therapeutic	JJ	O	therapeutic	amod	34	SENT_122	21017/21028
34	levels	NNS	O	level	nsubj	37	SENT_122	21029/21035
35	of	IN	O	of		-1	SENT_122	21036/21038
36	mAbs	NNS	O	mab	prep_of	34	SENT_122	21039/21043
37	are	VBP	O	be	advcl	28	SENT_122	21044/21047
38	in	IN	O	in		-1	SENT_122	21048/21050
39	microgram	NN	O	microgram	prep_in	37	SENT_122	21051/21060
40	per	IN	O	per		-1	SENT_122	21061/21064
41	milligram	NN	O	milligram	nn	42	SENT_122	21065/21074
42	range	NN	O	range	prep_per	39	SENT_122	21075/21080
43	and	CC	O	and		-1	SENT_122	21081/21084
44	at	IN	O	at		-1	SENT_122	21085/21087
45	these	DT	O	these	det	46	SENT_122	21088/21093
46	concentrations	NNS	O	concentration	prep_at	51	SENT_122	21094/21108
47	FcRn	NN	O	fcrn	nsubj	51	SENT_122	21109/21113
48	is	VBZ	O	be	cop	51	SENT_122	21114/21116
49	not	RB	O	not	neg	51	SENT_122	21117/21120
50	saturable	JJ	O	saturable	amod	51	SENT_122	21121/21130
51	)	NN	O	)	conj_and	8	SENT_122	21130/21131
52	.	.	O	.		-1	SENT_122	21131/21132

1	To	TO	O	to		-1	SENT_123	21133/21135
2	date	NN	O	date	prep_to	5	SENT_123	21136/21140
3	,	,	O	,		-1	SENT_123	21140/21141
4	there	EX	O	there	expl	5	SENT_123	21142/21147
5	appears	VBZ	O	appear		-1	SENT_123	21148/21155
6	to	TO	O	to	aux	9	SENT_123	21156/21158
7	be	VB	O	be	cop	9	SENT_123	21159/21161
8	limited	JJ	O	limited	amod	9	SENT_123	21162/21169
9	evidence	NN	O	evidence	xcomp	5	SENT_123	21170/21178
10	of	IN	O	of		-1	SENT_123	21179/21181
11	a	DT	O	a	det	12	SENT_123	21182/21183
12	DI	NNP	O	DI	prep_of	9	SENT_123	21184/21186
13	mediated	VBN	O	mediate	partmod	12	SENT_123	21187/21195
14	by	IN	O	by		-1	SENT_123	21196/21198
15	non-specific	JJ	O	non-specific	amod	17	SENT_123	21199/21211
16	clearance	NN	O	clearance	nn	17	SENT_123	21212/21221
17	mechanism	NN	O	mechanism	agent	13	SENT_123	21222/21231
18	for	IN	O	for		-1	SENT_123	21232/21235
19	mAbs	NNS	O	mab	prep_for	17	SENT_123	21236/21240
20	in	IN	O	in		-1	SENT_123	21241/21243
21	combination	NN	O	combination	prep_in	19	SENT_123	21244/21255
22	.	.	O	.		-1	SENT_123	21255/21256

1	Specific	JJ	O	specific	amod	2	SENT_124	21257/21265
2	examples	NNS	O	example	nsubj	14	SENT_124	21266/21274
3	of	IN	O	of		-1	SENT_124	21275/21277
4	mAb	NN	O	mab	nn	5	SENT_124	21278/21281
5	combinations	NNS	O	combination	prep_of	2	SENT_124	21282/21294
6	where	WRB	O	where	advmod	12	SENT_124	21295/21300
7	no	DT	O	no	det	8	SENT_124	21301/21303
8	alteration	NN	O	alteration	nsubjpass	12	SENT_124	21304/21314
9	in	IN	O	in		-1	SENT_124	21315/21317
10	PK	NN	O	pk	prep_in	8	SENT_124	21318/21320
11	was	VBD	O	be	auxpass	12	SENT_124	21321/21324
12	observed	VBN	O	observe	rcmod	5	SENT_124	21325/21333
13	are	VBP	O	be	cop	14	SENT_124	21334/21337
14	trastuzumab	JJ	O	trastuzumab		-1	SENT_124	21338/21349
15	combined	VBN	O	combine	prep	14	SENT_124	21350/21358
16	with	IN	O	with	pcomp	15	SENT_124	21359/21363
17	bevacizumab	NN	O	bevacizumab	pobj	16	SENT_124	21364/21375
18	(	CD	NUMBER	(	number	19	SENT_124	21376/21377
19	20	CD	NUMBER	20	num	20	SENT_124	21377/21379
20	)	NN	O	)	dep	17	SENT_124	21379/21380
21	and	CC	O	and		-1	SENT_124	21381/21384
22	rituximab	NN	O	rituximab	conj_and	17	SENT_124	21385/21394
23	combined	VBN	O	combine	partmod	22	SENT_124	21395/21403
24	with	IN	O	with		-1	SENT_124	21404/21408
25	bevacizumab	NN	O	bevacizumab	prep_with	23	SENT_124	21409/21420
26	(	CD	NUMBER	(	number	27	SENT_124	21421/21422
27	21	CD	NUMBER	21	num	28	SENT_124	21422/21424
28	)	NN	O	)	dep	23	SENT_124	21424/21425
29	.	.	O	.		-1	SENT_124	21425/21426

1	However	RB	O	however	advmod	5	SENT_125	21427/21434
2	,	,	O	,		-1	SENT_125	21434/21435
3	it	PRP	O	it	nsubj	5	SENT_125	21436/21438
4	is	VBZ	O	be	cop	5	SENT_125	21439/21441
5	worth	JJ	O	worth		-1	SENT_125	21442/21447
6	noting	VBG	O	note	xcomp	5	SENT_125	21448/21454
7	that	IN	O	that	mark	19	SENT_125	21455/21459
8	a	DT	O	a	det	9	SENT_125	21460/21461
9	downregulation	NN	O	downregulation	nsubjpass	19	SENT_125	21462/21476
10	of	IN	O	of		-1	SENT_125	21477/21479
11	Fc	NN	O	fc	nn	12	SENT_125	21480/21482
12	receptors	NNS	O	receptor	prep_of	9	SENT_125	21485/21494
13	by	IN	O	by		-1	SENT_125	21495/21497
14	methotrexate	NN	O	methotrexate	nn	17	SENT_125	21498/21510
15	(	CD	NUMBER	(	num	17	SENT_125	21511/21512
16	MTX	NN	O	mtx	nn	17	SENT_125	21512/21515
17	)	NN	O	)	prep_by	12	SENT_125	21515/21516
18	is	VBZ	O	be	auxpass	19	SENT_125	21517/21519
19	observed	VBN	O	observe	ccomp	6	SENT_125	21520/21528
20	in	IN	O	in		-1	SENT_125	21529/21531
21	patients	NNS	O	patient	prep_in	19	SENT_125	21532/21540
22	with	IN	O	with		-1	SENT_125	21541/21545
23	rheumatoid	JJ	O	rheumatoid	amod	25	SENT_125	21546/21556
24	arthritis	NN	O	arthritis	nn	25	SENT_125	21557/21566
25	(	NN	O	(	prep_with	21	SENT_125	21567/21568
26	RA	NN	O	ra	prep	25	SENT_125	21568/21570
27	)	CD	NUMBER	)	dep	26	SENT_125	21570/21571
28	.	.	O	.		-1	SENT_125	21571/21572

1	It	PRP	O	it	nsubj	3	SENT_126	21573/21575
2	is	VBZ	O	be	cop	3	SENT_126	21576/21578
3	plausible	JJ	O	plausible		-1	SENT_126	21579/21588
4	that	IN	O	that	mark	16	SENT_126	21589/21593
5	the	DT	O	the	det	6	SENT_126	21594/21597
6	change	NN	O	change	nsubj	16	SENT_126	21598/21604
7	in	IN	O	in		-1	SENT_126	21605/21607
8	Fc	NN	O	fc	nn	9	SENT_126	21608/21610
9	receptors	NNS	O	receptor	prep_in	6	SENT_126	21613/21622
10	in	IN	O	in		-1	SENT_126	21623/21625
11	the	DT	O	the	det	12	SENT_126	21626/21629
12	presence	NN	O	presence	prep_in	9	SENT_126	21630/21638
13	of	IN	O	of		-1	SENT_126	21639/21641
14	MTX	NNP	O	MTX	prep_of	12	SENT_126	21642/21645
15	may	MD	O	may	aux	16	SENT_126	21646/21649
16	affect	VB	O	affect	ccomp	3	SENT_126	21650/21656
17	mAb	NN	O	mab	nn	18	SENT_126	21657/21660
18	clearance	NN	O	clearance	dobj	16	SENT_126	21661/21670
19	during	IN	O	during		-1	SENT_126	21671/21677
20	mAb	NN	O	mab	nn	21	SENT_126	21678/21681
21	treatment	NN	O	treatment	prep_during	16	SENT_126	21682/21691
22	in	IN	O	in		-1	SENT_126	21692/21694
23	combination	NN	O	combination	prep_in	21	SENT_126	21695/21706
24	with	IN	O	with		-1	SENT_126	21707/21711
25	MTX	NN	O	mtx	prep_with	23	SENT_126	21712/21715
26	in	IN	O	in		-1	SENT_126	21716/21718
27	RA	NN	O	ra	nn	28	SENT_126	21719/21721
28	patients	NNS	O	patient	prep_in	16	SENT_126	21722/21730
29	(	CD	NUMBER	(	number	30	SENT_126	21731/21732
30	22,23	CD	NUMBER	22,23	num	31	SENT_126	21732/21737
31	)	NN	O	)	dep	16	SENT_126	21737/21738
32	.	.	O	.		-1	SENT_126	21738/21739

1	Immunogenicity	NN	O	immunogenicity	nsubj	5	SENT_127	21775/21789
2	to	TO	O	to		-1	SENT_127	21790/21792
3	TP	NN	O	tp	prep_to	1	SENT_127	21793/21795
4	may	MD	O	may	aux	5	SENT_127	21796/21799
5	enhance	VB	O	enhance		-1	SENT_127	21800/21807
6	clearance	NN	O	clearance	dobj	5	SENT_127	21808/21817
7	from	IN	O	from		-1	SENT_127	21818/21822
8	the	DT	O	the	det	9	SENT_127	21823/21826
9	body	NN	O	body	prep_from	5	SENT_127	21827/21831
10	.	.	O	.		-1	SENT_127	21831/21832

1	Some	DT	O	some	det	2	SENT_128	21833/21837
2	evidence	NN	O	evidence	nsubj	3	SENT_128	21838/21846
3	exists	VBZ	O	exist		-1	SENT_128	21847/21853
4	suggesting	VBG	O	suggest	xcomp	3	SENT_128	21854/21864
5	an	DT	O	a	det	6	SENT_128	21865/21867
6	impact	NN	O	impact	dobj	4	SENT_128	21868/21874
7	of	IN	O	of		-1	SENT_128	21875/21877
8	immunosuppressive	JJ	O	immunosuppressive	amod	9	SENT_128	21878/21895
9	agents	NNS	O	agent	prep_of	6	SENT_128	21896/21902
10	on	IN	O	on		-1	SENT_128	21903/21905
11	mAb	NN	O	mab	nn	12	SENT_128	21906/21909
12	pharmacokinetics	NNS	O	pharmacokinetic	prep_on	4	SENT_128	21910/21926
13	,	,	O	,		-1	SENT_128	21926/21927
14	possibly	RB	O	possibly	advmod	28	SENT_128	21928/21936
15	due	JJ	O	due		-1	SENT_128	21937/21940
16	to	TO	O	to		-1	SENT_128	21941/21943
17	alteration	NN	O	alteration	prep_due_to	28	SENT_128	21944/21954
18	in	IN	O	in		-1	SENT_128	21955/21957
19	target	NN	O	target	nn	21	SENT_128	21958/21964
20	(	NN	O	(	nn	21	SENT_128	21965/21966
21	expression	NN	O	expression	prep_in	17	SENT_128	21966/21976
22	or	CC	O	or		-1	SENT_128	21977/21979
23	cell	NN	O	cell	nn	24	SENT_128	21980/21984
24	number	NN	O	number	conj_or	21	SENT_128	21985/21991
25	)	CD	NUMBER	)	num	26	SENT_128	21991/21992
26	and/or	NN	O	and/or	nsubj	27	SENT_128	21993/21999
27	reduced	VBD	O	reduce	rcmod	21	SENT_128	22000/22007
28	immunogenicity	NN	O	immunogenicity	appos	12	SENT_128	22008/22022
29	.	.	O	.		-1	SENT_128	22022/22023

1	An	DT	O	a	det	11	SENT_129	22024/22026
2	apparent	JJ	O	apparent	amod	11	SENT_129	22027/22035
3	DI	NNP	O	DI	dep	2	SENT_129	22036/22038
4	(	CD	NUMBER	(	num	3	SENT_129	22039/22040
5	i.e.	FW	O	i.e.	dep	3	SENT_129	22040/22044
6	,	,	O	,		-1	SENT_129	22044/22045
7	decrease	VB	O	decrease	appos	3	SENT_129	22046/22054
8	in	IN	O	in		-1	SENT_129	22055/22057
9	mAb	NN	O	mab	prep_in	7	SENT_129	22058/22061
10	clearance	NN	O	clearance	nn	11	SENT_129	22062/22071
11	)	NN	O	)	nsubjpass	13	SENT_129	22071/22072
12	was	VBD	O	be	auxpass	13	SENT_129	22073/22076
13	noted	VBN	O	note		-1	SENT_129	22077/22082
14	when	WRB	O	when	advmod	20	SENT_129	22083/22087
15	a	DT	O	a	det	16	SENT_129	22088/22089
16	combination	NN	O	combination	nsubjpass	20	SENT_129	22090/22101
17	with	IN	O	with		-1	SENT_129	22102/22106
18	MTX	NN	O	mtx	prep_with	16	SENT_129	22107/22110
19	was	VBD	O	be	auxpass	20	SENT_129	22111/22114
20	noted	VBN	O	note	advcl	13	SENT_129	22115/22120
21	for	IN	O	for		-1	SENT_129	22121/22124
22	infliximab	NN	O	infliximab	nn	23	SENT_129	22125/22135
23	(	NN	O	(	prep_for	20	SENT_129	22136/22137
24	23	CD	NUMBER	23	num	25	SENT_129	22137/22139
25	)	NN	O	)	dep	23	SENT_129	22139/22140
26	and	CC	O	and		-1	SENT_129	22141/22144
27	adalimumab	JJ	O	adalimumab	amod	28	SENT_129	22145/22155
28	(	NN	O	(	conj_and	23	SENT_129	22156/22157
29	24	CD	NUMBER	24	num	30	SENT_129	22157/22159
30	)	NN	O	)	dep	28	SENT_129	22159/22160
31	.	.	O	.		-1	SENT_129	22160/22161

1	This	DT	O	this	nsubjpass	3	SENT_130	22162/22166
2	was	VBD	O	be	auxpass	3	SENT_130	22167/22170
3	attributed	VBN	O	attribute		-1	SENT_130	22171/22181
4	to	TO	O	to		-1	SENT_130	22182/22184
5	MTX	NNP	ORGANIZATION	MTX	poss	8	SENT_130	22185/22188
6	's	POS	O	's		-1	SENT_130	22188/22190
7	immunosuppressive	JJ	O	immunosuppressive	amod	8	SENT_130	22191/22208
8	effect	NN	O	effect	prep_to	3	SENT_130	22209/22215
9	,	,	O	,		-1	SENT_130	22215/22216
10	decreasing	VBG	O	decrease	xcomp	3	SENT_130	22217/22227
11	immune	JJ	O	immune	amod	12	SENT_130	22228/22234
12	response	NN	O	response	dobj	10	SENT_130	22235/22243
13	to	TO	O	to		-1	SENT_130	22244/22246
14	the	DT	O	the	det	15	SENT_130	22247/22250
15	mAb	NN	O	mab	prep_to	10	SENT_130	22251/22254
16	.	.	O	.		-1	SENT_130	22254/22255

1	Additionally	RB	O	additionally	advmod	15	SENT_131	22256/22268
2	,	,	O	,		-1	SENT_131	22268/22269
3	the	DT	O	the	det	4	SENT_131	22270/22273
4	immunogenicity	NN	O	immunogenicity	nsubjpass	15	SENT_131	22274/22288
5	of	IN	O	of		-1	SENT_131	22289/22291
6	anti-TNF	JJ	O	anti-tnf	prep_of	4	SENT_131	22292/22300
7	-	:	O	-		-1	SENT_131	22300/22301
8	agents	NNS	O	agent	dep	6	SENT_131	22304/22310
9	in	IN	O	in		-1	SENT_131	22311/22313
10	autoimmune	JJ	O	autoimmune	amod	11	SENT_131	22314/22324
11	diseases	NNS	O	disease	prep_in	8	SENT_131	22325/22333
12	has	VBZ	O	have	aux	15	SENT_131	22334/22337
13	been	VBN	O	be	auxpass	15	SENT_131	22338/22342
14	recently	RB	DATE	recently	advmod	15	SENT_131	22343/22351
15	reviewed	VBN	O	review		-1	SENT_131	22352/22360
16	(	NN	O	(	nn	18	SENT_131	22361/22362
17	25	CD	NUMBER	25	num	18	SENT_131	22362/22364
18	)	NN	O	)	dobj	15	SENT_131	22364/22365
19	.	.	O	.		-1	SENT_131	22365/22366

1	Tertiary	JJ	O	tertiary	amod	3	SENT_132	22402/22410
2	carbohydrate	NN	O	carbohydrate	nn	3	SENT_132	22411/22423
3	structure	NN	O	structure	nsubj	6	SENT_132	22424/22433
4	can	MD	O	can	aux	6	SENT_132	22434/22437
5	theoretically	RB	O	theoretically	advmod	6	SENT_132	22438/22451
6	mediate	VB	O	mediate		-1	SENT_132	22452/22459
7	clearance	NN	O	clearance	dobj	6	SENT_132	22460/22469
8	through	IN	O	through		-1	SENT_132	22470/22477
9	carbohydrate-specific	JJ	O	carbohydrate-specific	amod	11	SENT_132	22478/22499
10	clearance	NN	O	clearance	nn	11	SENT_132	22500/22509
11	mechanisms	NNS	O	mechanism	prep_through	6	SENT_132	22510/22520
12	.	.	O	.		-1	SENT_132	22520/22521

1	However	RB	O	however	advmod	10	SENT_133	22522/22529
2	,	,	O	,		-1	SENT_133	22529/22530
3	no	DT	O	no	det	5	SENT_133	22531/22533
4	specific	JJ	O	specific	amod	5	SENT_133	22534/22542
5	example	NN	O	example	nsubjpass	10	SENT_133	22543/22550
6	of	IN	O	of		-1	SENT_133	22551/22553
7	TP-DI	NN	O	tp-di	prep_of	5	SENT_133	22554/22559
8	has	VBZ	O	have	aux	10	SENT_133	22560/22563
9	been	VBN	O	be	auxpass	10	SENT_133	22564/22568
10	cited	VBN	O	cite		-1	SENT_133	22569/22574
11	for	IN	O	for		-1	SENT_133	22575/22578
12	this	DT	O	this	det	14	SENT_133	22579/22583
13	possible	JJ	O	possible	amod	14	SENT_133	22584/22592
14	mechanism	NN	O	mechanism	prep_for	10	SENT_133	22593/22602
15	.	.	O	.		-1	SENT_133	22602/22603

1	TPs	NNS	O	tp	nsubj	9	SENT_134	22639/22642
2	such	JJ	O	such		-1	SENT_134	22643/22647
3	as	IN	O	as		-1	SENT_134	22648/22650
4	cytokines	NNS	O	cytokine	prep_such_as	1	SENT_134	22651/22660
5	and	CC	O	and		-1	SENT_134	22661/22664
6	cytokine	NN	O	cytokine	nn	7	SENT_134	22665/22673
7	modulators	NNS	O	modulator	conj_and	4	SENT_134	22674/22684
8	are	VBP	O	be	cop	9	SENT_134	22685/22688
9	likely	JJ	O	likely		-1	SENT_134	22689/22695
10	to	TO	O	to	aux	11	SENT_134	22696/22698
11	affect	VB	O	affect	xcomp	9	SENT_134	22699/22705
12	the	DT	O	the	det	13	SENT_134	22706/22709
13	pharmacokinetics	NNS	O	pharmacokinetic	dobj	11	SENT_134	22710/22726
14	of	IN	O	of		-1	SENT_134	22727/22729
15	a	DT	O	a	det	16	SENT_134	22730/22731
16	SMD	NN	O	smd	prep_of	13	SENT_134	22732/22735
17	.	.	O	.		-1	SENT_134	22735/22736

1	Therefore	RB	O	therefore	advmod	7	SENT_135	22737/22746
2	,	,	O	,		-1	SENT_135	22746/22747
3	special	JJ	O	special	amod	4	SENT_135	22748/22755
4	attention	NN	O	attention	nsubjpass	7	SENT_135	22756/22765
5	should	MD	O	should	aux	7	SENT_135	22766/22772
6	be	VB	O	be	auxpass	7	SENT_135	22773/22775
7	given	VBN	O	give		-1	SENT_135	22776/22781
8	to	TO	O	to		-1	SENT_135	22782/22784
9	narrow	JJ	O	narrow	amod	11	SENT_135	22785/22791
10	therapeutic	JJ	O	therapeutic	amod	11	SENT_135	22792/22803
11	range	NN	O	range	prep_to	7	SENT_135	22804/22809
12	(	CD	NUMBER	(	num	15	SENT_135	22810/22811
13	NTR	NN	O	ntr	nn	15	SENT_135	22811/22814
14	)	NN	O	)	nn	15	SENT_135	22814/22815
15	drugs	NNS	O	drug	dobj	7	SENT_135	22816/22821
16	in	IN	O	in		-1	SENT_135	22822/22824
17	combination	NN	O	combination	prep_in	15	SENT_135	22825/22836
18	with	IN	O	with		-1	SENT_135	22837/22841
19	cytokine/cytokine	JJ	O	cytokine/cytokine	amod	20	SENT_135	22842/22859
20	modulators	NNS	O	modulator	prep_with	17	SENT_135	22860/22870
21	.	.	O	.		-1	SENT_135	22870/22871

1	Two	CD	NUMBER	two	num	3	SENT_136	22872/22875
2	additional	JJ	O	additional	amod	3	SENT_136	22876/22886
3	categories	NNS	O	category	nsubj	16	SENT_136	22887/22897
4	of	IN	O	of		-1	SENT_136	22898/22900
5	DI	NNP	O	DI	prep_of	3	SENT_136	22901/22903
6	following	VBG	O	follow		-1	SENT_136	22904/22913
7	combination	NN	O	combination	prep_following	5	SENT_136	22914/22925
8	of	IN	O	of		-1	SENT_136	22926/22928
9	cytokines	NNS	O	cytokine	prep_of	7	SENT_136	22929/22938
10	and	CC	O	and		-1	SENT_136	22939/22942
11	cytokine	NN	O	cytokine	nn	12	SENT_136	22943/22951
12	modulators	NNS	O	modulator	conj_and	9	SENT_136	22952/22962
13	with	IN	O	with		-1	SENT_136	22963/22967
14	SMDs	NNS	O	smd	prep_with	9	SENT_136	22968/22972
15	are	VBP	O	be	cop	16	SENT_136	22973/22976
16	further	JJ	O	further		-1	SENT_136	22977/22984
17	discussed	VBN	O	discuss	partmod	16	SENT_136	22985/22994
18	below	IN	O	below	prep	17	SENT_136	22995/23000
19	:	:	O	:		-1	SENT_136	23000/23001

1	TP	NN	O	tp	nsubj	4	SENT_137	23018/23020
2	is	VBZ	O	be	cop	4	SENT_137	23021/23023
3	a	DT	O	a	det	4	SENT_137	23024/23025
4	cytokine	NN	O	cytokine		-1	SENT_137	23026/23034
5	or	CC	O	or		-1	SENT_137	23035/23037
6	a	DT	O	a	det	8	SENT_137	23038/23039
7	cytokine	NN	O	cytokine	nn	8	SENT_137	23040/23048
8	modulator	NN	O	modulator	conj_or	4	SENT_137	23049/23058
9	and	CC	O	and		-1	SENT_137	23059/23062
10	therefore	RB	O	therefore	advmod	11	SENT_137	23063/23072
11	affects	VBZ	O	affect	conj_and	4	SENT_137	23073/23080
12	SMD	NNP	O	SMD	nn	14	SENT_137	23081/23084
13	metabolism	NN	O	metabolism	nn	14	SENT_137	23085/23095
14	(	NN	O	(	dobj	11	SENT_137	23096/23097
15	1	CD	NUMBER	1	num	16	SENT_137	23097/23098
16	)	NN	O	)	dep	14	SENT_137	23098/23099
17	.	.	O	.		-1	SENT_137	23099/23100

1	When	WRB	O	when	advmod	13	SENT_138	23101/23105
2	muromonab	NN	O	muromonab	nn	5	SENT_138	23106/23115
3	and	CC	O	and		-1	SENT_138	23116/23119
4	Cyclosporin	NN	O	cyclosporin	conj_and	2	SENT_138	23120/23131
5	A	NN	O	a	nsubjpass	13	SENT_138	23132/23133
6	(	CD	NUMBER	(	num	7	SENT_138	23134/23135
7	CsA	NN	O	csa	dep	5	SENT_138	23135/23138
8	)	CD	NUMBER	)	number	9	SENT_138	23138/23139
9	(	CD	NUMBER	(	dep	5	SENT_138	23140/23141
10	26	CD	NUMBER	26	num	11	SENT_138	23141/23143
11	)	NN	O	)	dep	9	SENT_138	23143/23144
12	were	VBD	O	be	auxpass	13	SENT_138	23145/23149
13	given	VBN	O	give	advcl	17	SENT_138	23150/23155
14	in	IN	O	in		-1	SENT_138	23156/23158
15	combination	NN	O	combination	prep_in	13	SENT_138	23159/23170
16	there	EX	O	there	expl	17	SENT_138	23171/23176
17	was	VBD	O	be		-1	SENT_138	23177/23180
18	an	DT	O	a	det	19	SENT_138	23181/23183
19	increase	NN	O	increase	nsubj	17	SENT_138	23184/23192
20	in	IN	O	in		-1	SENT_138	23193/23195
21	CsA	NN	O	csa	nn	23	SENT_138	23196/23199
22	trough	NN	O	trough	nn	23	SENT_138	23200/23206
23	levels	NNS	O	level	prep_in	19	SENT_138	23207/23213
24	.	.	O	.		-1	SENT_138	23213/23214

1	The	DT	O	the	det	3	SENT_139	23215/23218
2	suggested	VBN	O	suggest	amod	3	SENT_139	23219/23228
3	mechanism	NN	O	mechanism	nsubj	8	SENT_139	23229/23238
4	for	IN	O	for		-1	SENT_139	23239/23242
5	this	DT	O	this	prep_for	3	SENT_139	23243/23247
6	is	VBZ	O	be	cop	8	SENT_139	23248/23250
7	T-cell	NN	O	t-cell	nn	8	SENT_139	23251/23257
8	activation	NN	O	activation		-1	SENT_139	23258/23268
9	and	CC	O	and		-1	SENT_139	23269/23272
10	subsequent	JJ	O	subsequent	amod	11	SENT_139	23273/23283
11	release	NN	O	release	conj_and	8	SENT_139	23284/23291
12	of	IN	O	of		-1	SENT_139	23292/23294
13	multiple	JJ	O	multiple	amod	14	SENT_139	23295/23303
14	cytokines	NNS	O	cytokine	prep_of	8	SENT_139	23304/23313
15	such	JJ	O	such		-1	SENT_139	23314/23318
16	as	IN	O	as		-1	SENT_139	23319/23321
17	IL-2	NN	O	il-2	prep_such_as	14	SENT_139	23322/23326
18	,	,	O	,		-1	SENT_139	23326/23327
19	IL-3	NN	O	il-3	appos	17	SENT_139	23328/23332
20	,	,	O	,		-1	SENT_139	23332/23333
21	TNF	NN	O	tnf	conj_and	19	SENT_139	23334/23337
22	,	,	O	,		-1	SENT_139	23339/23340
23	and	CC	O	and		-1	SENT_139	23341/23344
24	TNF	NN	O	tnf	conj_and	19	SENT_139	23345/23348
25	.	.	O	.		-1	SENT_139	23350/23351

1	Similarly	RB	O	similarly	advmod	11	SENT_140	23352/23361
2	,	,	O	,		-1	SENT_140	23361/23362
3	an	DT	O	a	det	4	SENT_140	23363/23365
4	increase	NN	O	increase	nsubjpass	11	SENT_140	23366/23374
5	in	IN	O	in		-1	SENT_140	23375/23377
6	trough	NN	O	trough	nn	7	SENT_140	23378/23384
7	level	NN	O	level	prep_in	4	SENT_140	23385/23390
8	of	IN	O	of		-1	SENT_140	23391/23393
9	tacrolimus	NN	O	tacrolimus	prep_of	7	SENT_140	23394/23404
10	was	VBD	O	be	auxpass	11	SENT_140	23405/23408
11	observed	VBN	O	observe		-1	SENT_140	23409/23417
12	in	IN	O	in		-1	SENT_140	23418/23420
13	combination	NN	O	combination	prep_in	11	SENT_140	23421/23432
14	with	IN	O	with		-1	SENT_140	23433/23437
15	basiliximab	NN	O	basiliximab	prep_with	11	SENT_140	23438/23449
16	(	CD	NUMBER	(	number	17	SENT_140	23450/23451
17	27	CD	NUMBER	27	num	18	SENT_140	23451/23453
18	)	NN	O	)	dep	15	SENT_140	23453/23454
19	and	CC	O	and		-1	SENT_140	23455/23458
20	an	DT	O	a	det	21	SENT_140	23459/23461
21	increase	NN	O	increase	conj_and	15	SENT_140	23462/23470
22	in	IN	O	in		-1	SENT_140	23471/23473
23	CsA	NN	O	csa	nn	24	SENT_140	23474/23477
24	levels	NNS	O	level	prep_in	21	SENT_140	23478/23484
25	when	WRB	O	when	advmod	26	SENT_140	23485/23489
26	combined	VBN	O	combine	advcl	11	SENT_140	23490/23498
27	with	IN	O	with		-1	SENT_140	23499/23503
28	basiliximab	NN	O	basiliximab	prep_with	26	SENT_140	23504/23515
29	(	CD	NUMBER	(	number	30	SENT_140	23516/23517
30	28	CD	NUMBER	28	num	31	SENT_140	23517/23519
31	)	NN	O	)	dobj	26	SENT_140	23519/23520
32	.	.	O	.		-1	SENT_140	23520/23521

1	For	IN	O	for		-1	SENT_141	23522/23525
2	both	DT	O	both	prep_for	11	SENT_141	23526/23530
3	of	IN	O	of		-1	SENT_141	23531/23533
4	these	DT	O	these	det	5	SENT_141	23534/23539
5	interactions	NNS	O	interaction	prep_of	2	SENT_141	23540/23552
6	,	,	O	,		-1	SENT_141	23552/23553
7	an	DT	O	a	det	9	SENT_141	23554/23556
8	indirect	JJ	O	indirect	amod	9	SENT_141	23557/23565
9	mechanism	NN	O	mechanism	nsubjpass	11	SENT_141	23566/23575
10	is	VBZ	O	be	auxpass	11	SENT_141	23576/23578
11	suggested	VBN	O	suggest		-1	SENT_141	23579/23588
12	.	.	O	.		-1	SENT_141	23588/23589

1	Binding	NN	O	binding	nsubj	11	SENT_142	23590/23597
2	of	IN	O	of		-1	SENT_142	23598/23600
3	the	DT	O	the	det	4	SENT_142	23601/23604
4	mAb	NN	O	mab	prep_of	1	SENT_142	23605/23608
5	to	TO	O	to		-1	SENT_142	23609/23611
6	IL-2R	NN	O	il-2r	prep_to	4	SENT_142	23612/23617
7	on	IN	O	on		-1	SENT_142	23618/23620
8	activated	VBN	O	activate	amod	9	SENT_142	23621/23630
9	T-cells	NNS	O	t-cell	prep_on	6	SENT_142	23631/23638
10	may	MD	O	may	aux	11	SENT_142	23639/23642
11	alter	VB	O	alter		-1	SENT_142	23643/23648
12	circulating	VBG	O	circulate	xcomp	11	SENT_142	23649/23660
13	IL-2Rs	NNS	O	il-2r	dobj	12	SENT_142	23661/23667
14	on	IN	O	on		-1	SENT_142	23668/23670
15	hepatic	JJ	O	hepatic	amod	18	SENT_142	23671/23678
16	and	CC	O	and		-1	SENT_142	23679/23682
17	intestinal	JJ	O	intestinal	conj_and	15	SENT_142	23683/23693
18	cells	NNS	O	cell	prep_on	12	SENT_142	23694/23699
19	and	CC	O	and		-1	SENT_142	23700/23703
20	could	MD	O	could	aux	22	SENT_142	23704/23709
21	possibly	RB	O	possibly	advmod	22	SENT_142	23710/23718
22	result	VB	O	result	conj_and	11	SENT_142	23719/23725
23	in	IN	O	in		-1	SENT_142	23726/23728
24	downregulation	NN	O	downregulation	prep_in	22	SENT_142	23729/23743
25	of	IN	O	of		-1	SENT_142	23744/23746
26	CYP3A4	NN	O	cyp3a4	nn	28	SENT_142	23747/23753
27	enzyme	NN	O	enzyme	nn	28	SENT_142	23754/23760
28	activity	NN	O	activity	prep_of	24	SENT_142	23761/23769
29	.	.	O	.		-1	SENT_142	23769/23770

1	Potential	JJ	O	potential	amod	2	SENT_143	23771/23780
2	DI	NNP	O	DI	nsubj	10	SENT_143	23781/23783
3	mediated	VBN	O	mediate	partmod	2	SENT_143	23784/23792
4	by	IN	O	by		-1	SENT_143	23793/23795
5	such	JJ	O	such	amod	7	SENT_143	23796/23800
6	indirect	JJ	O	indirect	amod	7	SENT_143	23801/23809
7	mechanisms	NNS	O	mechanism	agent	3	SENT_143	23810/23820
8	is	VBZ	O	be	cop	10	SENT_143	23821/23823
9	a	DT	O	a	det	10	SENT_143	23824/23825
10	concern	NN	O	concern		-1	SENT_143	23826/23833
11	and	CC	O	and		-1	SENT_143	23834/23837
12	currently	RB	DATE	currently	advmod	16	SENT_143	23838/23847
13	,	,	O	,		-1	SENT_143	23847/23848
14	precautionary	JJ	O	precautionary	amod	15	SENT_143	23849/23862
15	language	NN	O	language	nsubj	16	SENT_143	23863/23871
16	exists	VBZ	O	exist	conj_and	10	SENT_143	23872/23878
17	in	IN	O	in		-1	SENT_143	23879/23881
18	United	NNP	LOCATION	United	nn	21	SENT_143	23882/23888
19	States	NNPS	LOCATION	States	nn	21	SENT_143	23889/23895
20	Prescribing	NNP	O	Prescribing	nn	21	SENT_143	23896/23907
21	Information	NNP	O	Information	prep_in	16	SENT_143	23908/23919
22	for	IN	O	for		-1	SENT_143	23920/23923
23	cytokine	NN	O	cytokine	nn	24	SENT_143	23924/23932
24	modulators	NNS	O	modulator	prep_for	16	SENT_143	23933/23943
25	,	,	O	,		-1	SENT_143	23943/23944
26	rilonacept	NN	O	rilonacept	conj_and	24	SENT_143	23945/23955
27	,	,	O	,		-1	SENT_143	23955/23956
28	canakinumab	NN	O	canakinumab	conj_and	24	SENT_143	23957/23968
29	,	,	O	,		-1	SENT_143	23968/23969
30	golimumab	NN	O	golimumab	conj_and	24	SENT_143	23970/23979
31	,	,	O	,		-1	SENT_143	23979/23980
32	and	CC	O	and		-1	SENT_143	23981/23984
33	ustekinumab	JJ	O	ustekinumab	amod	34	SENT_143	23985/23996
34	(	NN	O	(	conj_and	24	SENT_143	23997/23998
35	29-32	CD	NUMBER	29-32	num	36	SENT_143	23998/24003
36	)	NN	O	)	dep	34	SENT_143	24003/24004
37	.	.	O	.		-1	SENT_143	24004/24005

1	Drug-disease	JJ	O	drug-disease	amod	2	SENT_144	24041/24053
2	interaction	NN	O	interaction	nsubj	5	SENT_144	24054/24065
3	is	VBZ	O	be	cop	5	SENT_144	24066/24068
4	a	DT	O	a	det	5	SENT_144	24069/24070
5	mechanism	NN	O	mechanism		-1	SENT_144	24071/24080
6	whereby	WRB	O	whereby	advmod	15	SENT_144	24081/24088
7	treatment	NN	O	treatment	nsubj	15	SENT_144	24089/24098
8	with	IN	O	with		-1	SENT_144	24099/24103
9	a	DT	O	a	det	13	SENT_144	24104/24105
10	cytokine	NN	O	cytokine	nn	13	SENT_144	24106/24114
11	or	CC	O	or		-1	SENT_144	24115/24117
12	cytokine	NN	O	cytokine	conj_or	10	SENT_144	24118/24126
13	modulator	NN	O	modulator	prep_with	7	SENT_144	24127/24136
14	could	MD	O	could	aux	15	SENT_144	24137/24142
15	normalize	VB	O	normalize	rcmod	5	SENT_144	24143/24152
16	previously	RB	DATE	previously	advmod	17	SENT_144	24153/24163
17	downregulated	VBN	O	downregulate	dep	15	SENT_144	24164/24177
18	CYP	NN	O	cyp	nn	19	SENT_144	24178/24181
19	enzymes	NNS	O	enzyme	dobj	17	SENT_144	24182/24189
20	.	.	O	.		-1	SENT_144	24189/24190

1	This	DT	O	this	nsubj	3	SENT_145	24191/24195
2	is	VBZ	O	be	cop	3	SENT_145	24196/24198
3	illustrated	JJ	O	illustrated		-1	SENT_145	24199/24210
4	conceptually	RB	O	conceptually	advmod	3	SENT_145	24211/24223
5	by	IN	O	by		-1	SENT_145	24224/24226
6	Morgan	NNP	PERSON	Morgan	prep_by	3	SENT_145	24227/24233
7	(	CD	NUMBER	(	number	8	SENT_145	24234/24235
8	6	CD	NUMBER	6	num	9	SENT_145	24235/24236
9	)	NN	O	)	dep	3	SENT_145	24236/24237
10	and	CC	O	and		-1	SENT_145	24238/24241
11	has	VBZ	O	have	aux	13	SENT_145	24242/24245
12	been	VBN	O	be	auxpass	13	SENT_145	24246/24250
13	demonstrated	VBN	O	demonstrate	conj_and	3	SENT_145	24251/24263
14	in	IN	O	in		-1	SENT_145	24264/24266
15	an	DT	O	a	det	38	SENT_145	24267/24269
16	in	FW	O	in	prep	37	SENT_145	24270/24272
17	vivo	FW	O	vivo	nn	19	SENT_145	24273/24277
18	DI	FW	O	di	nn	19	SENT_145	24278/24280
19	study	NN	O	study	pobj	16	SENT_145	24281/24286
20	for	IN	O	for		-1	SENT_145	24287/24290
21	tocilizumab	NN	O	tocilizumab	prep_for	19	SENT_145	24291/24302
22	+	CC	O	+		-1	SENT_145	24305/24306
23	omeprazole	NN	O	omeprazole	conj_+	21	SENT_145	24309/24319
24	and	CC	O	and		-1	SENT_145	24320/24323
25	tocilizumab	NN	O	tocilizumab	conj_and	23	SENT_145	24324/24335
26	+	CC	O	+		-1	SENT_145	24338/24339
27	simvastatin	NN	O	simvastatin	nn	29	SENT_145	24342/24353
28	drug	NN	O	drug	nn	29	SENT_145	24354/24358
29	combinations	NNS	O	combination	conj_+	23	SENT_145	24359/24371
30	but	CC	O	but		-1	SENT_145	24372/24375
31	not	RB	O	not		-1	SENT_145	24376/24379
32	for	IN	O	for		-1	SENT_145	24380/24383
33	tocilizumab	NN	O	tocilizumab	conj_negcc	21	SENT_145	24384/24395
34	+	CC	O	+		-1	SENT_145	24398/24399
35	dextromethorphan	NN	O	dextromethorphan	conj_+	33	SENT_145	24402/24418
36	(	CD	NUMBER	(	number	37	SENT_145	24419/24420
37	33	CD	NUMBER	33	nn	38	SENT_145	24420/24422
38	)	NN	O	)	prep_in	13	SENT_145	24422/24423
39	.	.	O	.		-1	SENT_145	24423/24424

1	A	DT	O	a	det	2	SENT_146	24425/24426
2	decrease	NN	O	decrease	nsubjpass	17	SENT_146	24427/24435
3	in	IN	O	in		-1	SENT_146	24436/24438
4	omeprazole	NN	O	omeprazole	prep_in	2	SENT_146	24439/24449
5	(	CD	PERCENT	(	num	8	SENT_146	24450/24451
6	28	CD	PERCENT	28	number	7	SENT_146	24451/24453
7	%	NN	PERCENT	%	amod	8	SENT_146	24453/24454
8	)	NN	O	)	dep	4	SENT_146	24454/24455
9	and	CC	O	and		-1	SENT_146	24456/24459
10	simvastatin	NN	O	simvastatin	conj_and	4	SENT_146	24460/24471
11	(	CD	PERCENT	(	number	12	SENT_146	24472/24473
12	57	CD	PERCENT	57	num	13	SENT_146	24473/24475
13	%	NN	PERCENT	%	dep	10	SENT_146	24475/24476
14	)	CD	NUMBER	)	num	15	SENT_146	24476/24477
15	exposure	NN	O	exposure	dep	10	SENT_146	24478/24486
16	was	VBD	O	be	auxpass	17	SENT_146	24487/24490
17	observed	VBN	O	observe		-1	SENT_146	24491/24499
18	when	WRB	O	when	advmod	19	SENT_146	24500/24504
19	combined	VBN	O	combine	advcl	17	SENT_146	24505/24513
20	with	IN	O	with		-1	SENT_146	24514/24518
21	tocilizumab	NN	O	tocilizumab	prep_with	19	SENT_146	24519/24530
22	.	.	O	.		-1	SENT_146	24530/24531

1	As	IN	O	as	mark	3	SENT_147	24586/24588
2	also	RB	O	also	advmod	3	SENT_147	24589/24593
3	highlighted	VBN	O	highlight	advcl	10	SENT_147	24594/24605
4	by	IN	O	by		-1	SENT_147	24606/24608
5	the	DT	O	the	det	7	SENT_147	24609/24612
6	Amgen	NNP	ORGANIZATION	Amgen	nn	7	SENT_147	24613/24618
7	speaker	NN	O	speaker	prep_by	3	SENT_147	24619/24626
8	that	IN	O	that	advmod	3	SENT_147	24627/24631
9	there	EX	O	there	expl	10	SENT_147	24632/24637
10	are	VBP	O	be		-1	SENT_147	24638/24641
11	considerable	JJ	O	considerable	amod	16	SENT_147	24642/24654
12	logistical	JJ	O	logistical	amod	13	SENT_147	24655/24665
13	constraints	NNS	O	constraint	nn	16	SENT_147	24666/24677
14	and	CC	O	and		-1	SENT_147	24678/24681
15	operational	JJ	O	operational	conj_and	13	SENT_147	24682/24693
16	challenges	NNS	O	challenge	nsubj	10	SENT_147	24694/24704
17	when	WRB	O	when	advmod	18	SENT_147	24705/24709
18	assessing	VBG	O	assess	advcl	10	SENT_147	24710/24719
19	TP-DI	NN	O	tp-di	dobj	18	SENT_147	24720/24725
20	in	IN	O	in		-1	SENT_147	24726/24728
21	the	DT	O	the	det	23	SENT_147	24729/24732
22	clinical	JJ	O	clinical	amod	23	SENT_147	24733/24741
23	setting	NN	O	setting	prep_in	18	SENT_147	24742/24749
24	especially	RB	O	especially	advmod	23	SENT_147	24750/24760
25	in	IN	O	in		-1	SENT_147	24761/24763
26	oncology	NN	O	oncology	prep_in	23	SENT_147	24764/24772
27	.	.	O	.		-1	SENT_147	24772/24773

1	Therefore	RB	O	therefore	advmod	11	SENT_148	24774/24783
2	,	,	O	,		-1	SENT_148	24783/24784
3	dedicated	JJ	O	dedicated	amod	5	SENT_148	24785/24794
4	DI	NN	O	di	nn	5	SENT_148	24795/24797
5	studies	NNS	O	study	nsubj	11	SENT_148	24798/24805
6	in	IN	O	in		-1	SENT_148	24806/24808
7	patients	NNS	O	patient	prep_in	5	SENT_148	24809/24817
8	are	VBP	O	be	cop	11	SENT_148	24818/24821
9	not	RB	O	not	neg	11	SENT_148	24822/24825
10	always	RB	O	always	advmod	11	SENT_148	24826/24832
11	possible	JJ	O	possible		-1	SENT_148	24833/24841
12	.	.	O	.		-1	SENT_148	24841/24842

1	A	DT	O	a	det	4	SENT_149	24843/24844
2	dedicated	JJ	O	dedicated	amod	4	SENT_149	24845/24854
3	TP-DI	NN	O	tp-di	nn	4	SENT_149	24855/24860
4	study	NN	O	study	nsubjpass	6	SENT_149	24861/24866
5	was	VBD	O	be	auxpass	6	SENT_149	24867/24870
6	conducted	VBN	O	conduct		-1	SENT_149	24871/24880
7	to	TO	O	to	aux	8	SENT_149	24881/24883
8	study	VB	O	study	xcomp	6	SENT_149	24884/24889
9	irinotecan	NN	O	irinotecan	dobj	8	SENT_149	24890/24900
10	+	CC	O	+		-1	SENT_149	24903/24904
11	bevacizumab	NN	O	bevacizumab	conj_+	9	SENT_149	24907/24918
12	when	WRB	O	when	advmod	17	SENT_149	24919/24923
13	a	DT	O	a	det	15	SENT_149	24924/24925
14	DI	NN	O	di	nn	15	SENT_149	24926/24928
15	alert	NN	O	alert	nsubjpass	17	SENT_149	24929/24934
16	was	VBD	O	be	auxpass	17	SENT_149	24935/24938
17	generated	VBN	O	generate	rcmod	11	SENT_149	24939/24948
18	in	IN	O	in		-1	SENT_149	24949/24951
19	a	DT	O	a	det	22	SENT_149	24952/24953
20	phase	NN	O	phase	nn	22	SENT_149	24954/24959
21	3	CD	NUMBER	3	num	22	SENT_149	24960/24961
22	study	NN	O	study	prep_in	17	SENT_149	24962/24967
23	with	IN	O	with		-1	SENT_149	24968/24972
24	this	DT	O	this	det	25	SENT_149	24973/24977
25	combination	NN	O	combination	prep_with	22	SENT_149	24978/24989
26	.	.	O	.		-1	SENT_149	24989/24990

1	The	DT	O	the	det	4	SENT_150	24991/24994
2	dedicated	JJ	O	dedicated	amod	4	SENT_150	24995/25004
3	DI	NNP	O	DI	nn	4	SENT_150	25005/25007
4	study	NN	O	study	nsubj	9	SENT_150	25008/25013
5	(	CD	NUMBER	(	number	6	SENT_150	25014/25015
6	34	CD	NUMBER	34	num	7	SENT_150	25015/25017
7	)	NN	O	)	npadvmod	8	SENT_150	25017/25018
8	however	RB	O	however	advmod	9	SENT_150	25019/25026
9	showed	VBD	O	show		-1	SENT_150	25027/25033
10	that	IN	O	that	mark	12	SENT_150	25034/25038
11	there	EX	O	there	expl	12	SENT_150	25039/25044
12	was	VBD	O	be	ccomp	9	SENT_150	25045/25048
13	no	DT	O	no	det	14	SENT_150	25049/25051
14	effect	NN	O	effect	nsubj	12	SENT_150	25052/25058
15	of	IN	O	of		-1	SENT_150	25059/25061
16	bevacizumab	NN	O	bevacizumab	prep_of	14	SENT_150	25062/25073
17	on	IN	O	on		-1	SENT_150	25074/25076
18	irinotecan	NN	O	irinotecan	nn	21	SENT_150	25077/25087
19	or	CC	O	or		-1	SENT_150	25088/25090
20	SN-38	NN	O	sn-38	conj_or	18	SENT_150	25091/25096
21	levels	NNS	O	level	prep_on	16	SENT_150	25097/25103
22	.	.	O	.		-1	SENT_150	25103/25104

1	In	IN	O	in		-1	SENT_151	25105/25107
2	other	JJ	O	other	amod	4	SENT_151	25108/25113
3	clinical	JJ	O	clinical	amod	4	SENT_151	25114/25122
4	studies	NNS	O	study	prep_in	16	SENT_151	25123/25130
5	as	RB	O	as	advmod	6	SENT_151	25131/25133
6	well	RB	O	well	advmod	16	SENT_151	25134/25138
7	,	,	O	,		-1	SENT_151	25138/25139
8	to	TO	O	to		-1	SENT_151	25140/25142
9	date	NN	O	date	prep_to	16	SENT_151	25143/25147
10	,	,	O	,		-1	SENT_151	25147/25148
11	no	DT	O	no	det	13	SENT_151	25149/25151
12	PK	NN	O	pk	nn	13	SENT_151	25152/25154
13	interactions	NNS	O	interaction	nsubjpass	16	SENT_151	25155/25167
14	have	VBP	O	have	aux	16	SENT_151	25168/25172
15	been	VBN	O	be	auxpass	16	SENT_151	25173/25177
16	observed	VBN	O	observe		-1	SENT_151	25178/25186
17	between	IN	O	between		-1	SENT_151	25187/25194
18	bevacizumab	NN	O	bevacizumab	prep_between	16	SENT_151	25195/25206
19	and	CC	O	and		-1	SENT_151	25207/25210
20	any	DT	O	any	conj_and	18	SENT_151	25211/25214
21	of	IN	O	of		-1	SENT_151	25215/25217
22	the	DT	O	the	det	24	SENT_151	25218/25221
23	following	VBG	O	follow	amod	24	SENT_151	25222/25231
24	agents	NNS	O	agent	prep_of	20	SENT_151	25232/25238
25	:	:	O	:		-1	SENT_151	25238/25239
26	capecitabine	NN	O	capecitabine	nn	39	SENT_151	25240/25252
27	,	,	O	,		-1	SENT_151	25252/25253
28	cisplatin	NN	O	cisplatin	dep	39	SENT_151	25254/25263
29	,	,	O	,		-1	SENT_151	25263/25264
30	5-fluorouracil	NN	O	5-fluorouracil	dep	39	SENT_151	25265/25279
31	,	,	O	,		-1	SENT_151	25279/25280
32	irinotecan	NN	O	irinotecan	dep	39	SENT_151	25281/25291
33	,	,	O	,		-1	SENT_151	25291/25292
34	oxaliplatin	NN	O	oxaliplatin	dep	39	SENT_151	25293/25304
35	,	,	O	,		-1	SENT_151	25304/25305
36	paclitaxel	NN	O	paclitaxel	dep	39	SENT_151	25306/25316
37	,	,	O	,		-1	SENT_151	25316/25317
38	interferon	NN	O	interferon	dep	39	SENT_151	25318/25328
39	alfa-2a	NN	O	alfa-2a	dep	20	SENT_151	25329/25336
40	,	,	O	,		-1	SENT_151	25336/25337
41	or	CC	O	or		-1	SENT_151	25338/25340
42	trastuzumab	NN	O	trastuzumab	conj_or	39	SENT_151	25341/25352
43	.	.	O	.		-1	SENT_151	25352/25353

1	On	IN	O	on		-1	SENT_152	25389/25391
2	the	DT	O	the	det	4	SENT_152	25392/25395
3	practical	JJ	O	practical	amod	4	SENT_152	25396/25405
4	level	NN	O	level	prep_on	24	SENT_152	25406/25411
5	,	,	O	,		-1	SENT_152	25411/25412
6	when	WRB	O	when	advmod	7	SENT_152	25413/25417
7	applying	VBG	O	apply	advcl	24	SENT_152	25418/25426
8	this	DT	O	this	det	10	SENT_152	25427/25431
9	historical	JJ	O	historical	amod	10	SENT_152	25432/25442
10	knowledge	NN	O	knowledge	dobj	7	SENT_152	25443/25452
11	to	TO	O	to	aux	12	SENT_152	25453/25455
12	evolve	VB	O	evolve	xcomp	7	SENT_152	25456/25462
13	a	DT	O	a	det	15	SENT_152	25463/25464
14	TP-DI	NN	O	tp-di	nn	15	SENT_152	25465/25470
15	strategy	NN	O	strategy	dobj	12	SENT_152	25471/25479
16	for	IN	O	for		-1	SENT_152	25480/25483
17	a	DT	O	a	det	18	SENT_152	25484/25485
18	mAb	NN	O	mab	prep_for	12	SENT_152	25486/25489
19	in	IN	O	in		-1	SENT_152	25490/25492
20	development	NN	O	development	prep_in	18	SENT_152	25493/25504
21	,	,	O	,		-1	SENT_152	25504/25505
22	it	PRP	O	it	nsubj	24	SENT_152	25506/25508
23	is	VBZ	O	be	cop	24	SENT_152	25509/25511
24	clear	JJ	O	clear		-1	SENT_152	25512/25517
25	that	IN	O	that	mark	32	SENT_152	25518/25522
26	an	DT	O	a	det	30	SENT_152	25523/25525
27	individualized	JJ	O	individualized	amod	30	SENT_152	25526/25540
28	and	CC	O	and		-1	SENT_152	25541/25544
29	iterative	JJ	O	iterative	conj_and	27	SENT_152	25545/25554
30	approach	NN	O	approach	nsubjpass	32	SENT_152	25555/25563
31	is	VBZ	O	be	auxpass	32	SENT_152	25564/25566
32	warranted	VBN	O	warrant	ccomp	24	SENT_152	25567/25576
33	.	.	O	.		-1	SENT_152	25576/25577

1	Genentech	NNP	ORGANIZATION	Genentech	poss	5	SENT_153	25578/25587
2	's	POS	O	's		-1	SENT_153	25587/25589
3	question-based	JJ	O	question-based	amod	5	SENT_153	25590/25604
4	risk	NN	O	risk	nn	5	SENT_153	25605/25609
5	assessment	NN	O	assessment		-1	SENT_153	25610/25620
6	DI	NNP	O	DI	nn	7	SENT_153	25621/25623
7	strategy	NN	O	strategy	dep	5	SENT_153	25624/25632
8	as	IN	O	as	mark	16	SENT_153	25633/25635
9	applied	VBN	O	apply	csubjpass	16	SENT_153	25636/25643
10	to	TO	O	to		-1	SENT_153	25644/25646
11	therapeutic	JJ	O	therapeutic	amod	12	SENT_153	25647/25658
12	mAbs	NNS	O	mab	prep_to	9	SENT_153	25659/25663
13	in	IN	O	in		-1	SENT_153	25664/25666
14	development	NN	O	development	prep_in	12	SENT_153	25667/25678
15	is	VBZ	O	be	auxpass	16	SENT_153	25679/25681
16	summarized	VBN	O	summarize	dep	7	SENT_153	25682/25692
17	in	IN	O	in		-1	SENT_153	25693/25695
18	Fig.	NN	O	fig.	prep_in	16	SENT_153	25696/25700
19	1	CD	NUMBER	1	num	18	SENT_153	25701/25702
20	.	.	O	.		-1	SENT_153	25702/25703

1	This	DT	O	this	det	2	SENT_154	25704/25708
2	process	NN	O	process	nsubjpass	4	SENT_154	25709/25716
3	is	VBZ	O	be	auxpass	4	SENT_154	25717/25719
4	incorporated	VBN	O	incorporate		-1	SENT_154	25720/25732
5	into	IN	O	into		-1	SENT_154	25733/25737
6	the	DT	O	the	det	9	SENT_154	25738/25741
7	clinical	JJ	O	clinical	amod	9	SENT_154	25742/25750
8	pharmacology	NN	O	pharmacology	nn	9	SENT_154	25751/25763
9	plan	NN	O	plan	prep_into	4	SENT_154	25764/25768
10	in	IN	O	in		-1	SENT_154	25769/25771
11	the	DT	O	the	det	13	SENT_154	25772/25775
12	early	JJ	O	early	amod	13	SENT_154	25776/25781
13	stages	NNS	O	stage	prep_in	9	SENT_154	25782/25788
14	of	IN	O	of		-1	SENT_154	25789/25791
15	development	NN	O	development	prep_of	13	SENT_154	25792/25803
16	and	CC	O	and		-1	SENT_154	25804/25807
17	utilizes	VBZ	O	utilize	conj_and	4	SENT_154	25808/25816
18	a	DT	O	a	det	20	SENT_154	25817/25818
19	scientific	JJ	O	scientific	amod	20	SENT_154	25819/25829
20	approach	NN	O	approach	dobj	17	SENT_154	25830/25838
21	to	TO	O	to		-1	SENT_154	25839/25841
22	assessing	VBG	O	assess	prepc_to	17	SENT_154	25842/25851
23	potential	JJ	O	potential	amod	24	SENT_154	25852/25861
24	mechanisms	NNS	O	mechanism	dobj	22	SENT_154	25862/25872
25	for	IN	O	for		-1	SENT_154	25873/25876
26	TP-DI	NN	O	tp-di	nn	27	SENT_154	25877/25882
27	risk	NN	O	risk	prep_for	22	SENT_154	25883/25887
28	in	IN	O	in		-1	SENT_154	25888/25890
29	the	DT	O	the	det	30	SENT_154	25891/25894
30	context	NN	O	context	prep_in	27	SENT_154	25895/25902
31	of	IN	O	of		-1	SENT_154	25903/25905
32	type	NN	O	type	prep_of	30	SENT_154	25906/25910
33	of	IN	O	of		-1	SENT_154	25911/25913
34	molecule	NN	O	molecule	nn	44	SENT_154	25914/25922
35	,	,	O	,		-1	SENT_154	25922/25923
36	indication	NN	O	indication	dep	44	SENT_154	25924/25934
37	,	,	O	,		-1	SENT_154	25934/25935
38	pharmacokinetics	NNS	O	pharmacokinetic	dep	44	SENT_154	25936/25952
39	,	,	O	,		-1	SENT_154	25952/25953
40	pharmacodynamics	NNS	O	pharmacodynamic	dep	44	SENT_154	25954/25970
41	,	,	O	,		-1	SENT_154	25970/25971
42	study	NN	O	study	dep	44	SENT_154	25972/25977
43	design	NN	O	design	nn	44	SENT_154	25978/25984
44	considerations	NNS	O	consideration	prep_of	32	SENT_154	25985/25999
45	,	,	O	,		-1	SENT_154	25999/26000
46	immunogenicity	NN	O	immunogenicity	appos	32	SENT_154	26001/26015
47	,	,	O	,		-1	SENT_154	26015/26016
48	drug	NN	O	drug	nn	49	SENT_154	26017/26021
49	combinations	NNS	O	combination	appos	32	SENT_154	26022/26034
50	,	,	O	,		-1	SENT_154	26034/26035
51	therapeutic	JJ	O	therapeutic	amod	52	SENT_154	26036/26047
52	index	NN	O	index	appos	49	SENT_154	26048/26053
53	of	IN	O	of		-1	SENT_154	26054/26056
54	drug	NN	O	drug	prep_of	52	SENT_154	26057/26061
55	,	,	O	,		-1	SENT_154	26061/26062
56	etc.	FW	O	etc.	dep	49	SENT_154	26063/26066
57	.	.	O	.		-1	SENT_154	26066/26067

1	A	DT	O	a	det	3	SENT_155	26068/26069
2	thorough	JJ	O	thorough	amod	3	SENT_155	26070/26078
3	knowledge	NN	O	knowledge	nsubj	11	SENT_155	26079/26088
4	of	IN	O	of		-1	SENT_155	26089/26091
5	all	DT	O	all	prep_of	3	SENT_155	26092/26095
6	of	IN	O	of		-1	SENT_155	26096/26098
7	the	DT	O	the	det	9	SENT_155	26099/26102
8	aforementioned	JJ	O	aforementioned	amod	9	SENT_155	26103/26117
9	components	NNS	O	component	prep_of	5	SENT_155	26118/26128
10	will	MD	O	will	aux	11	SENT_155	26129/26133
11	help	VB	O	help		-1	SENT_155	26134/26138
12	determine	VB	O	determine	xcomp	11	SENT_155	26139/26148
13	the	DT	O	the	det	14	SENT_155	26149/26152
14	need	NN	O	need	dobj	12	SENT_155	26153/26157
15	for	IN	O	for		-1	SENT_155	26158/26161
16	DI	NNP	O	DI	nn	17	SENT_155	26162/26164
17	assessment	NN	O	assessment	prep_for	12	SENT_155	26165/26175
18	and	CC	O	and		-1	SENT_155	26176/26179
19	for	IN	O	for		-1	SENT_155	26180/26183
20	data	NNS	O	datum	nn	21	SENT_155	26184/26188
21	collection	NN	O	collection	conj_and	17	SENT_155	26189/26199
22	on	IN	O	on		-1	SENT_155	26200/26202
23	a	DT	O	a	det	25	SENT_155	26203/26204
24	case-by-case	JJ	O	case-by-case	amod	25	SENT_155	26205/26217
25	basis	NN	O	basis	prep_on	21	SENT_155	26218/26223
26	when	WRB	O	when	advmod	30	SENT_155	26224/26228
27	a	DT	O	a	det	28	SENT_155	26229/26230
28	mAb	NN	O	mab	nsubjpass	30	SENT_155	26231/26234
29	is	VBZ	O	be	auxpass	30	SENT_155	26235/26237
30	combined	VBN	O	combine	advcl	12	SENT_155	26238/26246
31	with	IN	O	with		-1	SENT_155	26247/26251
32	a	DT	O	a	det	34	SENT_155	26252/26253
33	SMD	NN	O	smd	nn	34	SENT_155	26254/26257
34	and/or	NN	O	and/or	prep_with	30	SENT_155	26258/26264
35	with	IN	O	with		-1	SENT_155	26265/26269
36	another	DT	O	another	det	37	SENT_155	26270/26277
37	mAb	NN	O	mab	prep_with	30	SENT_155	26278/26281
38	.	.	O	.		-1	SENT_155	26281/26282

1	If	IN	O	if	mark	6	SENT_156	26283/26285
2	DI	NNP	O	DI	nn	3	SENT_156	26286/26288
3	assessment	NN	O	assessment	nsubj	6	SENT_156	26289/26299
4	is	VBZ	O	be	cop	6	SENT_156	26300/26302
5	scientifically	RB	O	scientifically	advmod	6	SENT_156	26303/26317
6	reasonable	JJ	O	reasonable	advcl	13	SENT_156	26318/26328
7	,	,	O	,		-1	SENT_156	26328/26329
8	the	DT	O	the	det	11	SENT_156	26330/26333
9	risk	NN	O	risk	nn	11	SENT_156	26334/26338
10	assessment	NN	O	assessment	nn	11	SENT_156	26339/26349
11	strategy	NN	O	strategy	nsubjpass	13	SENT_156	26350/26358
12	is	VBZ	O	be	auxpass	13	SENT_156	26359/26361
13	expected	VBN	O	expect		-1	SENT_156	26362/26370
14	to	TO	O	to	aux	15	SENT_156	26371/26373
15	guide	VB	O	guide	xcomp	13	SENT_156	26374/26379
16	the	DT	O	the	det	17	SENT_156	26380/26383
17	design	NN	O	design	dobj	15	SENT_156	26384/26390
18	and	CC	O	and		-1	SENT_156	26391/26394
19	conduct	NN	O	conduct	conj_and	17	SENT_156	26395/26402
20	of	IN	O	of		-1	SENT_156	26403/26405
21	the	DT	O	the	det	23	SENT_156	26406/26409
22	appropriate	JJ	O	appropriate	amod	23	SENT_156	26410/26421
23	study	NN	O	study	prep_of	17	SENT_156	26422/26427
24	.	.	O	.		-1	SENT_156	26427/26428

1	Fig.	NN	O	fig.		-1	SENT_157	26429/26433
2	1	CD	NUMBER	1	num	1	SENT_157	26434/26435

1	Genentech	NNP	ORGANIZATION	Genentech	poss	4	SENT_158	26452/26461
2	's	POS	O	's		-1	SENT_158	26461/26463
3	TP-DI	NN	O	tp-di	nn	4	SENT_158	26464/26469
4	strategy	NN	O	strategy		-1	SENT_158	26470/26478
5	as	IN	O	as	advmod	6	SENT_158	26479/26481
6	applied	VBN	O	apply	partmod	4	SENT_158	26482/26489
7	to	TO	O	to		-1	SENT_158	26490/26492
8	a	DT	O	a	det	9	SENT_158	26493/26494
9	mAb	NN	O	mab	prep_to	6	SENT_158	26495/26498
10	during	IN	O	during		-1	SENT_158	26499/26505
11	drug	NN	O	drug	nn	12	SENT_158	26506/26510
12	development	NN	O	development	prep_during	6	SENT_158	26511/26522
13	(	CD	NUMBER	(	num	16	SENT_158	26523/26524
14	DI	NNP	O	DI	nn	16	SENT_158	26524/26526
15	drug	NN	O	drug	nn	16	SENT_158	26527/26531
16	interactions	NNS	O	interaction	dep	12	SENT_158	26532/26544
17	,	,	O	,		-1	SENT_158	26544/26545
18	TP	NN	O	tp	nn	20	SENT_158	26546/26548
19	therapeutic	JJ	O	therapeutic	amod	20	SENT_158	26549/26560
20	protein	NN	O	protein	appos	16	SENT_158	26561/26568
21	,	,	O	,		-1	SENT_158	26568/26569
22	SMD	NNP	O	SMD	nn	25	SENT_158	26570/26573
23	small	JJ	O	small	amod	25	SENT_158	26574/26579
24	molecule	NN	O	molecule	nn	25	SENT_158	26580/26588
25	drug	NN	O	drug	appos	16	SENT_158	26589/26593
26	,	,	O	,		-1	SENT_158	26593/26594
27	CYP450	NN	O	cyp450	nn	29	SENT_158	26595/26601
28	cytochrome	NN	O	cytochrome	nn	29	SENT_158	26602/26612
29	P450	NN	O	p450	appos	16	SENT_158	26613/26617
30	,	,	O	,		-1	SENT_158	26617/26618
31	CL	NN	O	cl	nn	32	SENT_158	26619/26621
32	clearance	NN	O	clearance	appos	16	SENT_158	26622/26631
33	,	,	O	,		-1	SENT_158	26631/26632
34	NTR	NN	O	ntr	nn	37	SENT_158	26633/26636
35	narrow	JJ	O	narrow	amod	37	SENT_158	26637/26643
36	therapeutic	JJ	O	therapeutic	amod	37	SENT_158	26644/26655
37	range	NN	O	range	appos	16	SENT_158	26656/26661
38	,	,	O	,		-1	SENT_158	26661/26662
39	mAb	NN	O	mab	nn	41	SENT_158	26663/26666
40	monoclonal	JJ	O	monoclonal	amod	41	SENT_158	26667/26677
41	antibody	NN	O	antibody	appos	16	SENT_158	26678/26686
42	,	,	O	,		-1	SENT_158	26686/26687
43	PMC	NN	O	pmc	nn	45	SENT_158	26688/26691
44	post-marketing	JJ	O	post-marketing	amod	45	SENT_158	26692/26706
45	commitment	NN	O	commitment	appos	16	SENT_158	26707/26717
46	,	,	O	,		-1	SENT_158	26717/26718
47	SOC	NNP	O	SOC	nn	48	SENT_158	26719/26722
48	standard	NN	O	standard	appos	16	SENT_158	26723/26731
49	of	IN	O	of		-1	SENT_158	26732/26734
50	care	NN	O	care	nn	51	SENT_158	26735/26739
51	)	NN	O	)	prep_of	4	SENT_158	26739/26740

1	As	IN	O	as	mark	2	SENT_159	26795/26797
2	illustrated	VBN	O	illustrate	advcl	9	SENT_159	26798/26809
3	in	IN	O	in		-1	SENT_159	26810/26812
4	Fig.	NN	O	fig.	prep_in	2	SENT_159	26813/26817
5	1	CD	NUMBER	1	num	4	SENT_159	26818/26819
6	,	,	O	,		-1	SENT_159	26819/26820
7	Genentech	NNP	ORGANIZATION	Genentech	nsubj	9	SENT_159	26821/26830
8	may	MD	O	may	aux	9	SENT_159	26831/26834
9	conduct	VB	O	conduct		-1	SENT_159	26835/26842
10	DI	NNP	O	DI	nn	11	SENT_159	26843/26845
11	analyses	NNS	O	analysis	dobj	9	SENT_159	26846/26854
12	in	IN	O	in		-1	SENT_159	26855/26857
13	phase	NN	O	phase	nn	14	SENT_159	26858/26863
14	1b	NN	O	1b	prep_in	9	SENT_159	26864/26866
15	or	CC	O	or		-1	SENT_159	26867/26869
16	2	CD	NUMBER	2	num	21	SENT_159	26870/26871
17	or	CC	O	or		-1	SENT_159	26872/26874
18	phase	NN	O	phase	conj_or	16	SENT_159	26875/26880
19	3	CD	NUMBER	3	num	18	SENT_159	26881/26882
20	clinical	JJ	O	clinical	amod	21	SENT_159	26883/26891
21	studies	NNS	O	study	conj_or	14	SENT_159	26892/26899
22	for	IN	O	for		-1	SENT_159	26900/26903
23	select	JJ	O	select	amod	26	SENT_159	26904/26910
24	new	JJ	O	new	amod	26	SENT_159	26911/26914
25	molecular	JJ	O	molecular	amod	26	SENT_159	26915/26924
26	entities	NNS	O	entity	prep_for	21	SENT_159	26925/26933
27	if	IN	O	if	mark	35	SENT_159	26934/26936
28	the	DT	O	the	det	29	SENT_159	26937/26940
29	results	NNS	O	result	nsubj	35	SENT_159	26941/26948
30	of	IN	O	of		-1	SENT_159	26949/26951
31	a	DT	O	a	det	34	SENT_159	26952/26953
32	DI	NN	O	di	nn	34	SENT_159	26954/26956
33	risk	NN	O	risk	nn	34	SENT_159	26957/26961
34	assessment	NN	O	assessment	prep_of	29	SENT_159	26962/26972
35	leads	VBZ	O	lead	advcl	9	SENT_159	26973/26978
36	Genentech	NN	ORGANIZATION	genentech	dobj	35	SENT_159	26979/26988
37	to	TO	O	to	aux	38	SENT_159	26989/26991
38	believe	VB	O	believe	xcomp	35	SENT_159	26992/26999
39	that	IN	O	that	mark	45	SENT_159	27000/27004
40	a	DT	O	a	det	44	SENT_159	27005/27006
41	safety	NN	O	safety	nn	44	SENT_159	27007/27013
42	or	CC	O	or		-1	SENT_159	27014/27016
43	efficacy	NN	O	efficacy	conj_or	41	SENT_159	27017/27025
44	risk	NN	O	risk	nsubj	45	SENT_159	27026/27030
45	exists	VBZ	O	exist	ccomp	38	SENT_159	27031/27037
46	for	IN	O	for		-1	SENT_159	27038/27041
47	a	DT	O	a	det	49	SENT_159	27042/27043
48	treatment	NN	O	treatment	nn	49	SENT_159	27044/27053
49	combination	NN	O	combination	prep_for	45	SENT_159	27054/27065
50	.	.	O	.		-1	SENT_159	27065/27066

1	For	IN	O	for		-1	SENT_160	27067/27070
2	molecules	NNS	O	molecule	nsubj	3	SENT_160	27071/27080
3	exhibiting	VBG	O	exhibit	prepc_for	15	SENT_160	27081/27091
4	a	DT	O	a	det	8	SENT_160	27092/27093
5	clinically	RB	O	clinically	advmod	6	SENT_160	27094/27104
6	relevant	JJ	O	relevant	amod	8	SENT_160	27105/27113
7	DI	NN	O	di	nn	8	SENT_160	27114/27116
8	signal	NN	O	signal	dobj	3	SENT_160	27117/27123
9	,	,	O	,		-1	SENT_160	27123/27124
10	additional	JJ	O	additional	amod	12	SENT_160	27125/27135
11	confirmatory	JJ	O	confirmatory	amod	12	SENT_160	27136/27148
12	analyses	NNS	O	analysis	nsubjpass	15	SENT_160	27149/27157
13	may	MD	O	may	aux	15	SENT_160	27158/27161
14	be	VB	O	be	auxpass	15	SENT_160	27162/27164
15	conducted	VBN	O	conduct		-1	SENT_160	27165/27174
16	in	IN	O	in		-1	SENT_160	27175/27177
17	phase	NN	O	phase	nn	19	SENT_160	27178/27183
18	3	CD	NUMBER	3	num	19	SENT_160	27184/27185
19	studies	NNS	O	study	prep_in	15	SENT_160	27186/27193
20	.	.	O	.		-1	SENT_160	27193/27194

1	Risk-Based	JJ	O	risk-based	amod	2	SENT_161	27230/27240
2	Approach	NN	O	approach		-1	SENT_161	27241/27249
3	to	TO	O	to	aux	4	SENT_161	27250/27252
4	Assess	VB	O	assess	dep	2	SENT_161	27253/27259
5	Potential	JJ	O	potential	dobj	4	SENT_161	27260/27269
6	for	IN	O	for		-1	SENT_161	27270/27273
7	TP-DI	NN	O	tp-di	prep_for	5	SENT_161	27274/27279
8	in	IN	O	in		-1	SENT_161	27280/27282
9	Biogen	NNP	ORGANIZATION	Biogen	nn	10	SENT_161	27283/27289
10	Idec	NNP	ORGANIZATION	Idec	prep_in	4	SENT_161	27290/27294

1	When	WRB	O	when	advmod	2	SENT_162	27330/27334
2	considering	VBG	O	consider	advcl	5	SENT_162	27335/27346
3	DI	NNP	O	DI	dobj	2	SENT_162	27347/27349
4	,	,	O	,		-1	SENT_162	27349/27350
5	maintaining	VBG	O	maintain		-1	SENT_162	27351/27362
6	patient	NN	O	patient	nn	7	SENT_162	27363/27370
7	safety	NN	O	safety	dobj	5	SENT_162	27371/27377
8	and	CC	O	and		-1	SENT_162	27378/27381
9	drug	NN	O	drug	nn	10	SENT_162	27382/27386
10	efficacy	NN	O	efficacy	nsubj	12	SENT_162	27387/27395
11	is	VBZ	O	be	cop	12	SENT_162	27396/27398
12	paramount	JJ	O	paramount	conj_and	5	SENT_162	27399/27408
13	.	.	O	.		-1	SENT_162	27408/27409

1	In	IN	O	in		-1	SENT_163	27410/27412
2	addition	NN	O	addition		-1	SENT_163	27413/27421
3	to	TO	O	to		-1	SENT_163	27422/27424
4	ethical	JJ	O	ethical	amod	5	SENT_163	27425/27432
5	concerns	NNS	O	concern	prep_in_addition_to	11	SENT_163	27433/27441
6	,	,	O	,		-1	SENT_163	27441/27442
7	clinical	JJ	O	clinical	amod	9	SENT_163	27443/27451
8	DI	NN	O	di	nn	9	SENT_163	27452/27454
9	studies	NNS	O	study	nsubj	11	SENT_163	27455/27462
10	can	MD	O	can	aux	11	SENT_163	27463/27466
11	add	VB	O	add		-1	SENT_163	27467/27470
12	to	TO	O	to		-1	SENT_163	27471/27473
13	the	DT	O	the	det	14	SENT_163	27474/27477
14	cost	NN	O	cost	prep_to	11	SENT_163	27478/27482
15	and	CC	O	and		-1	SENT_163	27483/27486
16	timeline	NN	O	timeline	conj_and	14	SENT_163	27487/27495
17	of	IN	O	of		-1	SENT_163	27496/27498
18	drug	NN	O	drug	nn	19	SENT_163	27499/27503
19	development	NN	O	development	prep_of	14	SENT_163	27504/27515
20	.	.	O	.		-1	SENT_163	27515/27516

1	Therefore	RB	O	therefore	advmod	8	SENT_164	27517/27526
2	,	,	O	,		-1	SENT_164	27526/27527
3	these	DT	O	these	det	4	SENT_164	27528/27533
4	studies	NNS	O	study	nsubjpass	8	SENT_164	27534/27541
5	should	MD	O	should	aux	8	SENT_164	27542/27548
6	only	RB	O	only	advmod	8	SENT_164	27549/27553
7	be	VB	O	be	auxpass	8	SENT_164	27554/27556
8	performed	VBN	O	perform		-1	SENT_164	27557/27566
9	when	WRB	O	when	advmod	11	SENT_164	27567/27571
10	there	EX	O	there	expl	11	SENT_164	27572/27577
11	is	VBZ	O	be	advcl	8	SENT_164	27578/27580
12	a	DT	O	a	det	15	SENT_164	27581/27582
13	clear	JJ	O	clear	amod	15	SENT_164	27583/27588
14	scientific	JJ	O	scientific	amod	15	SENT_164	27589/27599
15	rationale	NN	O	rationale	nsubj	11	SENT_164	27600/27609
16	to	TO	O	to	aux	17	SENT_164	27610/27612
17	do	VB	O	do	infmod	15	SENT_164	27613/27615
18	so	RB	O	so	advmod	17	SENT_164	27616/27618
19	.	.	O	.		-1	SENT_164	27618/27619

1	Figure	NN	O	figure	nsubj	3	SENT_165	27620/27626
2	2	CD	NUMBER	2	num	1	SENT_165	27627/27628
3	provides	VBZ	O	provide		-1	SENT_165	27629/27637
4	a	DT	O	a	det	6	SENT_165	27638/27639
5	flow	NN	O	flow	nn	6	SENT_165	27640/27644
6	chart	NN	O	chart	dobj	3	SENT_165	27645/27650
7	for	IN	O	for		-1	SENT_165	27651/27654
8	Biogen	NNP	ORGANIZATION	Biogen	poss	11	SENT_165	27655/27661
9	's	POS	O	's		-1	SENT_165	27661/27663
10	risk-based	JJ	O	risk-based	amod	11	SENT_165	27664/27674
11	approach	NN	O	approach	prep_for	3	SENT_165	27675/27683
12	to	TO	O	to	aux	13	SENT_165	27684/27686
13	determine	VB	O	determine	infmod	11	SENT_165	27687/27696
14	the	DT	O	the	det	15	SENT_165	27697/27700
15	need	NN	O	need	dobj	13	SENT_165	27701/27705
16	for	IN	O	for		-1	SENT_165	27706/27709
17	interaction	NN	O	interaction	nn	18	SENT_165	27710/27721
18	studies	NNS	O	study	prep_for	13	SENT_165	27722/27729
19	where	WRB	O	where	advmod	24	SENT_165	27730/27735
20	the	DT	O	the	det	21	SENT_165	27736/27739
21	TP	NN	O	tp	nsubj	24	SENT_165	27740/27742
22	is	VBZ	O	be	cop	24	SENT_165	27743/27745
23	the	DT	O	the	det	24	SENT_165	27746/27749
24	perpetrator	NN	O	perpetrator	advcl	13	SENT_165	27750/27761
25	and	CC	O	and		-1	SENT_165	27762/27765
26	the	DT	O	the	det	27	SENT_165	27766/27769
27	SMD	NNP	O	SMD	nsubj	30	SENT_165	27770/27773
28	is	VBZ	O	be	cop	30	SENT_165	27774/27776
29	the	DT	O	the	det	30	SENT_165	27777/27780
30	victim	NN	O	victim	conj_and	3	SENT_165	27781/27787
31	.	.	O	.		-1	SENT_165	27787/27788

1	If	IN	O	if	mark	6	SENT_166	27789/27791
2	the	DT	O	the	det	3	SENT_166	27792/27795
3	TP	NN	O	tp	nsubj	6	SENT_166	27796/27798
4	is	VBZ	O	be	cop	6	SENT_166	27799/27801
5	a	DT	O	a	det	6	SENT_166	27802/27803
6	cytokine	NN	O	cytokine	csubjpass	43	SENT_166	27804/27812
7	or	CC	O	or		-1	SENT_166	27813/27815
8	modulates	VBZ	O	modulate	conj_or	6	SENT_166	27816/27825
9	a	DT	O	a	det	10	SENT_166	27826/27827
10	cytokine	NN	O	cytokine	dobj	8	SENT_166	27828/27836
11	which	WDT	O	which	nsubj	13	SENT_166	27837/27842
12	can	MD	O	can	aux	13	SENT_166	27843/27846
13	effect	VB	O	effect	rcmod	10	SENT_166	27847/27853
14	regulation	NN	O	regulation	dobj	13	SENT_166	27854/27864
15	of	IN	O	of		-1	SENT_166	27865/27867
16	various	JJ	O	various	amod	17	SENT_166	27868/27875
17	CYPs	NNS	O	cyp	prep_of	14	SENT_166	27876/27880
18	,	,	O	,		-1	SENT_166	27880/27881
19	and	CC	O	and		-1	SENT_166	27882/27885
20	these	DT	O	these	det	21	SENT_166	27886/27891
21	CYPs	NNS	O	cyp	nsubj	22	SENT_166	27892/27896
22	provide	VBP	O	provide	conj_and	6	SENT_166	27897/27904
23	the	DT	O	the	det	26	SENT_166	27905/27908
24	primary	JJ	O	primary	amod	26	SENT_166	27909/27916
25	clearance	NN	O	clearance	nn	26	SENT_166	27917/27926
26	pathway	NN	O	pathway	dobj	22	SENT_166	27927/27934
27	for	IN	O	for		-1	SENT_166	27935/27938
28	the	DT	O	the	det	30	SENT_166	27939/27942
29	co-administered	JJ	O	co-administered	amod	30	SENT_166	27943/27958
30	SMD	NN	O	smd	prep_for	22	SENT_166	27959/27962
31	,	,	O	,		-1	SENT_166	27962/27963
32	then	RB	O	then	advmod	30	SENT_166	27964/27968
33	a	DT	O	a	det	36	SENT_166	27969/27970
34	clinical	JJ	O	clinical	amod	36	SENT_166	27971/27979
35	DI	NNP	O	DI	nn	36	SENT_166	27980/27982
36	study	NN	O	study	dep	30	SENT_166	27983/27988
37	to	TO	O	to	aux	38	SENT_166	27989/27991
38	examine	VB	O	examine	xcomp	22	SENT_166	27992/27999
39	potential	JJ	O	potential	amod	40	SENT_166	28000/28009
40	interaction	NN	O	interaction	dobj	38	SENT_166	28010/28021
41	should	MD	O	should	aux	43	SENT_166	28022/28028
42	be	VB	O	be	auxpass	43	SENT_166	28029/28031
43	considered	VBN	O	consider		-1	SENT_166	28032/28042
44	.	.	O	.		-1	SENT_166	28042/28043

1	Consideration	NN	O	consideration	nsubjpass	5	SENT_167	28044/28057
2	should	MD	O	should	aux	5	SENT_167	28058/28064
3	also	RB	O	also	advmod	5	SENT_167	28065/28069
4	be	VB	O	be	auxpass	5	SENT_167	28070/28072
5	given	VBN	O	give		-1	SENT_167	28073/28078
6	to	TO	O	to		-1	SENT_167	28079/28081
7	whether	IN	O	whether	mark	10	SENT_167	28082/28089
8	the	DT	O	the	det	9	SENT_167	28090/28093
9	SMD	NNP	O	SMD	nsubj	10	SENT_167	28094/28097
10	has	VBZ	O	have	prepc_to	5	SENT_167	28098/28101
11	a	DT	O	a	det	12	SENT_167	28102/28103
12	NTR	NN	O	ntr	dobj	10	SENT_167	28104/28107
13	or	CC	O	or		-1	SENT_167	28108/28110
14	required	VBN	O	require	amod	17	SENT_167	28111/28119
15	therapeutic	JJ	O	therapeutic	amod	17	SENT_167	28120/28131
16	drug	NN	O	drug	nn	17	SENT_167	28132/28136
17	monitoring	NN	O	monitoring	conj_or	12	SENT_167	28137/28147
18	.	.	O	.		-1	SENT_167	28147/28148

1	If	IN	O	if	mark	6	SENT_168	28149/28151
2	these	DT	O	these	det	3	SENT_168	28152/28157
3	conditions	NNS	O	condition	nsubjpass	6	SENT_168	28158/28168
4	are	VBP	O	be	auxpass	6	SENT_168	28169/28172
5	not	RB	O	not	neg	6	SENT_168	28173/28176
6	met	VBN	O	meet	advcl	9	SENT_168	28177/28180
7	,	,	O	,		-1	SENT_168	28180/28181
8	there	EX	O	there	expl	9	SENT_168	28182/28187
9	is	VBZ	O	be		-1	SENT_168	28188/28190
10	no	DT	O	no	det	13	SENT_168	28191/28193
11	clear	JJ	O	clear	amod	13	SENT_168	28194/28199
12	scientific	JJ	O	scientific	amod	13	SENT_168	28200/28210
13	rationale	NN	O	rationale	nsubj	9	SENT_168	28211/28220
14	for	IN	O	for		-1	SENT_168	28221/28224
15	performing	VBG	O	perform	prepc_for	13	SENT_168	28225/28235
16	a	DT	O	a	det	18	SENT_168	28236/28237
17	DI	NNP	O	DI	nn	18	SENT_168	28238/28240
18	study	NN	O	study	dobj	15	SENT_168	28241/28246
19	.	.	O	.		-1	SENT_168	28246/28247

1	Likewise	RB	O	likewise	advmod	16	SENT_169	28248/28256
2	,	,	O	,		-1	SENT_169	28256/28257
3	for	IN	O	for		-1	SENT_169	28258/28261
4	other	JJ	O	other	amod	5	SENT_169	28262/28267
5	TPs	NNS	O	tp	prep_for	16	SENT_169	28268/28271
6	such	JJ	O	such		-1	SENT_169	28272/28276
7	as	IN	O	as		-1	SENT_169	28277/28279
8	mAbs	NNS	O	mab	prep_such_as	5	SENT_169	28280/28284
9	,	,	O	,		-1	SENT_169	28284/28285
10	there	EX	O	there	expl	16	SENT_169	28286/28291
11	must	MD	O	must	aux	16	SENT_169	28292/28296
12	be	VB	O	be	cop	16	SENT_169	28297/28299
13	a	DT	O	a	det	16	SENT_169	28300/28301
14	clear	JJ	O	clear	amod	15	SENT_169	28302/28307
15	mechanistic	JJ	O	mechanistic	amod	16	SENT_169	28308/28319
16	rationale	NN	O	rationale		-1	SENT_169	28320/28329
17	for	IN	O	for		-1	SENT_169	28330/28333
18	a	DT	O	a	det	20	SENT_169	28334/28335
19	potential	JJ	O	potential	amod	20	SENT_169	28336/28345
20	interaction	NN	O	interaction	prep_for	16	SENT_169	28346/28357
21	with	IN	O	with		-1	SENT_169	28358/28362
22	an	DT	O	a	det	23	SENT_169	28363/28365
23	SMD	NN	O	smd	prep_with	20	SENT_169	28366/28369
24	;	:	O	;		-1	SENT_169	28369/28370
25	otherwise	RB	O	otherwise	advmod	32	SENT_169	28371/28380
26	,	,	O	,		-1	SENT_169	28380/28381
27	no	DT	O	no	det	29	SENT_169	28382/28384
28	interaction	NN	O	interaction	nn	29	SENT_169	28385/28396
29	study	NN	O	study	nsubjpass	32	SENT_169	28397/28402
30	should	MD	O	should	aux	32	SENT_169	28403/28409
31	be	VB	O	be	auxpass	32	SENT_169	28410/28412
32	needed	VBN	O	need	parataxis	16	SENT_169	28413/28419
33	.	.	O	.		-1	SENT_169	28419/28420

1	An	DT	O	a	det	4	SENT_170	28421/28423
2	adequately	RB	O	adequately	advmod	3	SENT_170	28424/28434
3	powered	VBN	O	power	amod	4	SENT_170	28435/28442
4	population	NN	O	population	nsubjpass	10	SENT_170	28443/28453
5	PK	NN	O	pk	nn	6	SENT_170	28454/28456
6	approach	NN	O	approach	nsubjpass	10	SENT_170	28457/28465
7	should	MD	O	should	aux	10	SENT_170	28466/28472
8	also	RB	O	also	advmod	10	SENT_170	28473/28477
9	be	VB	O	be	auxpass	10	SENT_170	28478/28480
10	considered	VBN	O	consider	dep	16	SENT_170	28481/28491
11	(	RB	O	(	advmod	10	SENT_170	28492/28493
12	this	DT	DATE	this	nsubj	16	SENT_170	28493/28497
13	may	MD	DATE	may	aux	16	SENT_170	28498/28501
14	be	VB	O	be	cop	16	SENT_170	28502/28504
15	more	RBR	O	more	advmod	16	SENT_170	28505/28509
16	applicable	JJ	O	applicable		-1	SENT_170	28510/28520
17	to	TO	O	to		-1	SENT_170	28521/28523
18	the	DT	O	the	det	20	SENT_170	28524/28527
19	mAb	NN	O	mab	nn	20	SENT_170	28528/28531
20	stream	NN	O	stream	prep_to	16	SENT_170	28532/28538
21	in	IN	O	in		-1	SENT_170	28539/28541
22	the	DT	O	the	det	25	SENT_170	28542/28545
23	decision	NN	O	decision	nn	25	SENT_170	28546/28554
24	tree	NN	O	tree	nn	25	SENT_170	28555/28559
25	)	NN	O	)	prep_in	20	SENT_170	28559/28560
26	.	.	O	.		-1	SENT_170	28560/28561

1	Fig.	NN	O	fig.		-1	SENT_171	28562/28566
2	2	CD	NUMBER	2	num	1	SENT_171	28567/28568

1	Biogen	NNP	ORGANIZATION	Biogen	nn	2	SENT_172	28585/28591
2	Idec	NNP	ORGANIZATION	Idec	poss	5	SENT_172	28592/28596
3	's	POS	O	's		-1	SENT_172	28596/28598
4	risk-based	JJ	O	risk-based	amod	5	SENT_172	28599/28609
5	approach	NN	O	approach		-1	SENT_172	28610/28618
6	to	TO	O	to	aux	7	SENT_172	28619/28621
7	assess	VB	O	assess	infmod	5	SENT_172	28622/28628
8	potential	JJ	O	potential	dobj	7	SENT_172	28629/28638
9	for	IN	O	for		-1	SENT_172	28639/28642
10	TP-DI	NN	O	tp-di	prep_for	8	SENT_172	28643/28648
11	.	.	O	.		-1	SENT_172	28648/28649

1	(	NN	O	(	nn	2	SENT_173	28650/28651
2	TP	NN	O	tp		-1	SENT_173	28651/28653
3	therapeutic	JJ	O	therapeutic	amod	4	SENT_173	28654/28665
4	protein	NN	O	protein	dep	18	SENT_173	28666/28673
5	,	,	O	,		-1	SENT_173	28673/28674
6	mAb	NN	O	mab	nn	8	SENT_173	28675/28678
7	monoclonal	JJ	O	monoclonal	amod	8	SENT_173	28679/28689
8	antibody	NN	O	antibody	appos	4	SENT_173	28690/28698
9	,	,	O	,		-1	SENT_173	28698/28699
10	MOA	NNP	O	MOA	nn	11	SENT_173	28700/28703
11	mechanism	NN	O	mechanism	appos	4	SENT_173	28704/28713
12	of	IN	O	of		-1	SENT_173	28714/28716
13	action	NN	O	action	prep_of	11	SENT_173	28717/28723
14	,	,	O	,		-1	SENT_173	28723/28724
15	SMD	NNP	O	SMD	appos	4	SENT_173	28725/28728
16	small	JJ	O	small	amod	17	SENT_173	28729/28734
17	molecule	NN	O	molecule	dep	18	SENT_173	28735/28743
18	drug	NN	O	drug	dep	2	SENT_173	28744/28748
19	,	,	O	,		-1	SENT_173	28748/28749
20	CYP450	NN	O	cyp450	nn	27	SENT_173	28750/28756
21	cytochrome	NN	O	cytochrome	nn	27	SENT_173	28757/28767
22	P450	NN	O	p450	nn	27	SENT_173	28768/28772
23	,	,	O	,		-1	SENT_173	28772/28773
24	TDM	NN	O	tdm	nn	27	SENT_173	28774/28777
25	therapeutic	JJ	O	therapeutic	amod	27	SENT_173	28778/28789
26	drug	NN	O	drug	nn	27	SENT_173	28790/28794
27	monitoring	NN	O	monitoring	appos	18	SENT_173	28795/28805
28	,	,	O	,		-1	SENT_173	28805/28806
29	DI	NNP	O	DI	nn	31	SENT_173	28807/28809
30	drug	NN	O	drug	nn	31	SENT_173	28810/28814
31	interactions	NNS	O	interaction	appos	18	SENT_173	28815/28827
32	,	,	O	,		-1	SENT_173	28827/28828
33	POC	NN	O	poc	nn	34	SENT_173	28829/28832
34	proof	NN	O	proof	appos	18	SENT_173	28833/28838
35	of	IN	O	of		-1	SENT_173	28839/28841
36	concept	NN	O	concept	prep_of	34	SENT_173	28842/28849
37	,	,	O	,		-1	SENT_173	28849/28850
38	NTR	NN	O	ntr	nn	41	SENT_173	28851/28854
39	narrow	JJ	O	narrow	amod	41	SENT_173	28855/28861
40	therapeutic	JJ	O	therapeutic	amod	41	SENT_173	28862/28873
41	range	NN	O	range	appos	36	SENT_173	28874/28879
42	,	,	O	,		-1	SENT_173	28879/28880
43	POP	NNP	ORGANIZATION	POP	appos	18	SENT_173	28881/28884
44	-	:	O	-		-1	SENT_173	28884/28885
45	PK/PD	NN	O	pk/pd	dep	2	SENT_173	28886/28891
46	population-PK/PD	NN	O	population-pk/pd	nn	47	SENT_173	28892/28908
47	)	NN	O	)	dep	45	SENT_173	28908/28909

1	This	DT	O	this	det	5	SENT_174	28964/28968
2	"	``	O	"	punct	5	SENT_174	28969/28970
3	risk-based	JJ	O	risk-based	amod	5	SENT_174	28970/28980
4	"	''	O	"	punct	5	SENT_174	28980/28981
5	approach	NN	O	approach	nsubj	7	SENT_174	28982/28990
6	is	VBZ	O	be	cop	7	SENT_174	28991/28993
7	science	NN	O	science		-1	SENT_174	28994/29001
8	driven	VBN	O	drive	partmod	7	SENT_174	29002/29008
9	,	,	O	,		-1	SENT_174	29008/29009
10	eliminates	VBZ	O	eliminate	conj_and	7	SENT_174	29010/29020
11	the	DT	O	the	det	12	SENT_174	29021/29024
12	need	NN	O	need	dobj	10	SENT_174	29025/29029
13	for	IN	O	for		-1	SENT_174	29030/29033
14	unnecessary	JJ	O	unnecessary	amod	19	SENT_174	29034/29045
15	or	CC	O	or		-1	SENT_174	29046/29048
16	low	JJ	O	low	conj_or	14	SENT_174	29049/29052
17	value	NN	O	value	nn	19	SENT_174	29053/29058
18	clinical	JJ	O	clinical	amod	19	SENT_174	29059/29067
19	studies	NNS	O	study	prep_for	12	SENT_174	29068/29075
20	,	,	O	,		-1	SENT_174	29075/29076
21	reduces	VBZ	O	reduce	conj_and	7	SENT_174	29077/29084
22	cost	NN	O	cost	dobj	21	SENT_174	29085/29089
23	and	CC	O	and		-1	SENT_174	29090/29093
24	time	NN	O	time	conj_and	22	SENT_174	29094/29098
25	of	IN	O	of		-1	SENT_174	29099/29101
26	drug	NN	O	drug	nn	27	SENT_174	29102/29106
27	development	NN	O	development	prep_of	22	SENT_174	29107/29118
28	,	,	O	,		-1	SENT_174	29118/29119
29	and	CC	O	and		-1	SENT_174	29120/29123
30	is	VBZ	O	be	auxpass	31	SENT_174	29124/29126
31	expected	VBN	O	expect	conj_and	7	SENT_174	29127/29135
32	to	TO	O	to	aux	33	SENT_174	29136/29138
33	satisfy	VB	O	satisfy	xcomp	31	SENT_174	29139/29146
34	DI	NN	O	di	nn	35	SENT_174	29147/29149
35	requirements	NNS	O	requirement	dobj	33	SENT_174	29150/29162
36	.	.	O	.		-1	SENT_174	29162/29163

1	For	IN	O	for		-1	SENT_175	29164/29167
2	TP-SMD	NN	O	tp-smd	nn	3	SENT_175	29168/29174
3	combinations	NNS	O	combination	prep_for	15	SENT_175	29175/29187
4	where	WRB	O	where	advmod	9	SENT_175	29188/29193
5	a	DT	O	a	det	7	SENT_175	29194/29195
6	DI	NNP	O	DI	nn	7	SENT_175	29196/29198
7	study	NN	O	study	nsubjpass	9	SENT_175	29199/29204
8	is	VBZ	O	be	auxpass	9	SENT_175	29205/29207
9	indicated	VBN	O	indicate	rcmod	3	SENT_175	29208/29217
10	,	,	O	,		-1	SENT_175	29217/29218
11	bioanalytical	JJ	O	bioanalytical	amod	12	SENT_175	29219/29232
12	resources	NNS	O	resource	nsubjpass	15	SENT_175	29233/29242
13	can	MD	O	can	aux	15	SENT_175	29243/29246
14	be	VB	O	be	auxpass	15	SENT_175	29247/29249
15	optimized	VBN	O	optimize		-1	SENT_175	29250/29259
16	by	IN	O	by		-1	SENT_175	29260/29262
17	storing	VBG	O	store	agent	15	SENT_175	29263/29270
18	samples	NNS	O	sample	dobj	17	SENT_175	29271/29278
19	for	IN	O	for		-1	SENT_175	29279/29282
20	analysis	NN	O	analysis	prep_for	17	SENT_175	29283/29291
21	until	IN	O	until	mark	27	SENT_175	29292/29297
22	a	DT	O	a	det	23	SENT_175	29298/29299
23	proof	NN	O	proof	nsubjpass	27	SENT_175	29300/29305
24	of	IN	O	of		-1	SENT_175	29306/29308
25	concept	NN	O	concept	prep_of	23	SENT_175	29309/29316
26	is	VBZ	O	be	auxpass	27	SENT_175	29317/29319
27	established	VBN	O	establish	advcl	17	SENT_175	29320/29331
28	.	.	O	.		-1	SENT_175	29331/29332

1	Biogen	NNP	ORGANIZATION	Biogen	poss	8	SENT_176	29333/29339
2	's	POS	O	's		-1	SENT_176	29339/29341
3	"	``	O	"	punct	8	SENT_176	29342/29343
4	collect	VB	O	collect	dep	8	SENT_176	29343/29350
5	and	CC	O	and		-1	SENT_176	29351/29354
6	hold	VB	O	hold	conj_and	4	SENT_176	29355/29359
7	"	''	O	"	punct	8	SENT_176	29359/29360
8	strategy	NN	O	strategy	nsubj	14	SENT_176	29361/29369
9	for	IN	O	for		-1	SENT_176	29370/29373
10	assessing	VBG	O	assess	prepc_for	8	SENT_176	29374/29383
11	DI	NNP	O	DI	dobj	10	SENT_176	29384/29386
12	is	VBZ	O	be	cop	14	SENT_176	29387/29389
13	somewhat	RB	O	somewhat	advmod	14	SENT_176	29390/29398
14	unique	JJ	O	unique		-1	SENT_176	29399/29405
15	.	.	O	.		-1	SENT_176	29405/29406

1	Centocor	NNP	ORGANIZATION	Centocor	poss	3	SENT_177	29442/29450
2	's	POS	O	's		-1	SENT_177	29450/29452
3	Strategy	NNP	O	Strategy		-1	SENT_177	29453/29461
4	to	TO	O	to		-1	SENT_177	29462/29464
5	Address	NNP	O	Address	prep_to	3	SENT_177	29465/29472
6	TP-DI	NN	O	tp-di	dep	3	SENT_177	29473/29478

1	The	DT	O	the	det	2	SENT_178	29514/29517
2	presentation	NN	O	presentation	nsubj	26	SENT_178	29518/29530
3	briefly	NN	O	briefly	advmod	4	SENT_178	29531/29538
4	reviewed	VBN	O	review	dep	2	SENT_178	29539/29547
5	the	DT	O	the	det	6	SENT_178	29548/29551
6	pathways	NNS	O	pathway	dobj	4	SENT_178	29552/29560
7	for	IN	O	for		-1	SENT_178	29561/29564
8	disposition	NN	O	disposition	prep_for	4	SENT_178	29565/29576
9	of	IN	O	of		-1	SENT_178	29577/29579
10	SMDs	NNS	O	smd	prep_of	8	SENT_178	29580/29584
11	and	CC	O	and		-1	SENT_178	29585/29588
12	mAbs	NNS	O	mab	conj_and	10	SENT_178	29589/29593
13	to	TO	O	to	aux	14	SENT_178	29594/29596
14	explore	VB	O	explore	xcomp	4	SENT_178	29597/29604
15	plausible	JJ	O	plausible	amod	16	SENT_178	29605/29614
16	mechanisms	NNS	O	mechanism	dobj	14	SENT_178	29615/29625
17	of	IN	O	of		-1	SENT_178	29626/29628
18	interaction	NN	O	interaction	prep_of	16	SENT_178	29629/29640
19	and	CC	O	and		-1	SENT_178	29641/29644
20	discussed	VBN	O	discuss	conj_and	4	SENT_178	29645/29654
21	technical	JJ	O	technical	amod	22	SENT_178	29655/29664
22	considerations	NNS	O	consideration	dobj	20	SENT_178	29665/29679
23	and	CC	O	and		-1	SENT_178	29680/29683
24	strategic	JJ	O	strategic	amod	25	SENT_178	29684/29693
25	approaches	NNS	O	approach	conj_and	22	SENT_178	29694/29704
26	taken	VBN	O	take		-1	SENT_178	29705/29710
27	at	IN	O	at		-1	SENT_178	29711/29713
28	Centocor	NNP	ORGANIZATION	Centocor	prep_at	26	SENT_178	29714/29722
29	.	.	O	.		-1	SENT_178	29722/29723

1	As	IN	O	as	mark	3	SENT_179	29724/29726
2	there	EX	O	there	expl	3	SENT_179	29727/29732
3	is	VBZ	O	be	advcl	24	SENT_179	29733/29735
4	no	DT	O	no	det	6	SENT_179	29736/29738
5	global	JJ	O	global	amod	6	SENT_179	29739/29745
6	strategy	NN	O	strategy	nsubj	3	SENT_179	29746/29754
7	available	JJ	O	available	amod	6	SENT_179	29755/29764
8	to	TO	O	to	aux	9	SENT_179	29765/29767
9	address	VB	O	address	xcomp	7	SENT_179	29768/29775
10	potential	JJ	O	potential	amod	11	SENT_179	29776/29785
11	TP-DI	NN	O	tp-di	dobj	9	SENT_179	29786/29791
12	and	CC	O	and		-1	SENT_179	29792/29795
13	no	DT	O	no	det	15	SENT_179	29796/29798
14	regulatory	JJ	O	regulatory	amod	15	SENT_179	29799/29809
15	guidance	NN	O	guidance	conj_and	11	SENT_179	29810/29818
16	for	IN	O	for		-1	SENT_179	29819/29822
17	preclinical	JJ	O	preclinical	amod	20	SENT_179	29823/29834
18	and	CC	O	and		-1	SENT_179	29835/29838
19	clinical	JJ	O	clinical	conj_and	17	SENT_179	29839/29847
20	assessment	NN	O	assessment	prep_for	9	SENT_179	29848/29858
21	,	,	O	,		-1	SENT_179	29858/29859
22	Centocor	NNP	ORGANIZATION	Centocor	nsubj	24	SENT_179	29860/29868
23	has	VBZ	O	have	aux	24	SENT_179	29869/29872
24	adopted	VBN	O	adopt		-1	SENT_179	29873/29880
25	a	DT	O	a	det	26	SENT_179	29881/29882
26	risk	NN	O	risk	dobj	24	SENT_179	29883/29887
27	-	:	O	-		-1	SENT_179	29887/29888
28	based	VBN	O	base	dep	24	SENT_179	29889/29894
29	strategy	NN	O	strategy	dobj	28	SENT_179	29895/29903
30	for	IN	O	for		-1	SENT_179	29904/29907
31	the	DT	O	the	det	32	SENT_179	29908/29911
32	assessment	NN	O	assessment	prep_for	28	SENT_179	29912/29922
33	of	IN	O	of		-1	SENT_179	29923/29925
34	PK-based	JJ	O	pk-based	amod	37	SENT_179	29926/29934
35	mAb-DI	NN	O	mab-di	nn	37	SENT_179	29935/29941
36	(	NN	O	(	nn	37	SENT_179	29942/29943
37	Fig.	NN	O	fig.	prep_of	32	SENT_179	29943/29947
38	3	CD	NUMBER	3	num	39	SENT_179	29948/29949
39	)	NN	O	)	dobj	24	SENT_179	29949/29950
40	.	.	O	.		-1	SENT_179	29950/29951

1	The	DT	O	the	det	4	SENT_180	29952/29955
2	integrated	VBN	O	integrate	amod	4	SENT_180	29956/29966
3	risk	NN	O	risk	nn	4	SENT_180	29967/29971
4	assessment	NN	O	assessment	nsubjpass	6	SENT_180	29972/29982
5	is	VBZ	O	be	auxpass	6	SENT_180	29983/29985
6	designed	VBN	O	design		-1	SENT_180	29986/29994
7	to	TO	O	to	aux	8	SENT_180	29995/29997
8	utilize	VB	O	utilize	xcomp	6	SENT_180	29998/30005
9	existing	VBG	O	exist	amod	10	SENT_180	30006/30014
10	data	NNS	O	datum	dobj	8	SENT_180	30015/30019
11	and	CC	O	and		-1	SENT_180	30020/30023
12	knowledge	NN	O	knowledge	conj_and	10	SENT_180	30024/30033
13	,	,	O	,		-1	SENT_180	30033/30034
14	maintain	VBP	O	maintain	conj_and	8	SENT_180	30035/30043
15	clinical	JJ	O	clinical	amod	16	SENT_180	30044/30052
16	relevance	NN	O	relevance	dobj	14	SENT_180	30053/30062
17	,	,	O	,		-1	SENT_180	30062/30063
18	and	CC	O	and		-1	SENT_180	30064/30067
19	be	VB	O	be	cop	20	SENT_180	30068/30070
20	alert	JJ	O	alert	conj_and	8	SENT_180	30071/30076
21	and	CC	O	and		-1	SENT_180	30077/30080
22	open	JJ	O	open	conj_and	20	SENT_180	30081/30085
23	to	TO	O	to		-1	SENT_180	30086/30088
24	new	JJ	O	new	amod	25	SENT_180	30089/30092
25	information	NN	O	information	prep_to	20	SENT_180	30093/30104
26	.	.	O	.		-1	SENT_180	30104/30105

1	A	DT	O	a	det	2	SENT_181	30106/30107
2	framework	NN	O	framework	nsubjpass	4	SENT_181	30108/30117
3	is	VBZ	O	be	auxpass	4	SENT_181	30118/30120
4	built	VBN	O	build		-1	SENT_181	30121/30126
5	based	VBN	O	base		-1	SENT_181	30127/30132
6	on	IN	O	on	prepc_based_on	4	SENT_181	30133/30135
7	several	JJ	O	several	amod	9	SENT_181	30136/30143
8	key	JJ	O	key	amod	9	SENT_181	30144/30147
9	factors	NNS	O	factor	pobj	4	SENT_181	30148/30155
10	such	JJ	O	such		-1	SENT_181	30156/30160
11	as	IN	O	as		-1	SENT_181	30161/30163
12	the	DT	O	the	det	14	SENT_181	30164/30167
13	therapeutic	JJ	O	therapeutic	amod	14	SENT_181	30168/30179
14	target	NN	O	target	prep_such_as	9	SENT_181	30180/30186
15	,	,	O	,		-1	SENT_181	30186/30187
16	therapeutic	JJ	O	therapeutic	amod	17	SENT_181	30188/30199
17	window	NN	O	window	conj_and	14	SENT_181	30200/30206
18	of	IN	O	of		-1	SENT_181	30207/30209
19	the	DT	O	the	det	20	SENT_181	30210/30213
20	agents	NNS	O	agent	prep_of	17	SENT_181	30214/30220
21	,	,	O	,		-1	SENT_181	30220/30221
22	and	CC	O	and		-1	SENT_181	30222/30225
23	plausible	JJ	O	plausible	amod	24	SENT_181	30226/30235
24	mechanisms	NNS	O	mechanism	conj_and	14	SENT_181	30236/30246
25	.	.	O	.		-1	SENT_181	30246/30247

1	Preclinical	JJ	O	preclinical	amod	4	SENT_182	30248/30259
2	and	CC	O	and		-1	SENT_182	30260/30263
3	clinical	JJ	O	clinical	conj_and	1	SENT_182	30264/30272
4	studies	NNS	O	study	nsubjpass	12	SENT_182	30273/30280
5	for	IN	O	for		-1	SENT_182	30281/30284
6	the	DT	O	the	det	7	SENT_182	30285/30288
7	assessment	NN	O	assessment	prep_for	4	SENT_182	30289/30299
8	of	IN	O	of		-1	SENT_182	30300/30302
9	potential	JJ	O	potential	amod	10	SENT_182	30303/30312
10	mAb-DI	NN	O	mab-di	prep_of	7	SENT_182	30313/30319
11	are	VBP	O	be	auxpass	12	SENT_182	30320/30323
12	conducted	VBN	O	conduct		-1	SENT_182	30324/30333
13	on	IN	O	on		-1	SENT_182	30334/30336
14	a	DT	O	a	det	16	SENT_182	30337/30338
15	case-by-case	JJ	O	case-by-case	amod	16	SENT_182	30339/30351
16	basis	NN	O	basis	prep_on	12	SENT_182	30352/30357
17	.	.	O	.		-1	SENT_182	30357/30358

1	Potential	JJ	O	potential	amod	3	SENT_183	30359/30368
2	applicable	JJ	O	applicable	amod	3	SENT_183	30369/30379
3	approaches	NNS	O	approach	nsubj	4	SENT_183	30380/30390
4	encompass	VBP	O	encompass		-1	SENT_183	30391/30400
5	population	NN	O	population	nn	7	SENT_183	30401/30411
6	PK	NN	O	pk	nn	7	SENT_183	30412/30414
7	modeling	NN	O	modeling	dobj	4	SENT_183	30415/30423
8	based	VBN	O	base	partmod	7	SENT_183	30424/30429
9	assessment	NN	O	assessment	dobj	8	SENT_183	30430/30440
10	,	,	O	,		-1	SENT_183	30440/30441
11	dedicated	VBN	O	dedicate	partmod	9	SENT_183	30442/30451
12	or	CC	O	or		-1	SENT_183	30452/30454
13	"	``	O	"	punct	14	SENT_183	30455/30456
14	cocktail	NN	O	cocktail	conj_or	7	SENT_183	30456/30464
15	"	''	O	"	punct	14	SENT_183	30464/30465
16	clinical	JJ	O	clinical	amod	17	SENT_183	30466/30474
17	studies	NNS	O	study	dep	14	SENT_183	30475/30482
18	,	,	O	,		-1	SENT_183	30482/30483
19	and	CC	O	and		-1	SENT_183	30484/30487
20	mechanism-based	JJ	O	mechanism-based	conj_and	7	SENT_183	30488/30503
21	in	FW	O	in	nn	22	SENT_183	30504/30506
22	vitro	FW	O	vitro	advmod	23	SENT_183	30507/30512
23	evaluation	NN	O	evaluation	rcmod	20	SENT_183	30513/30523
24	.	.	O	.		-1	SENT_183	30523/30524

1	Fig.	NN	O	fig.		-1	SENT_184	30525/30529
2	3	CD	NUMBER	3	num	1	SENT_184	30530/30531

1	Centocor	NNP	ORGANIZATION	Centocor	poss	3	SENT_185	30548/30556
2	's	POS	O	's		-1	SENT_185	30556/30558
3	strategy	NN	O	strategy	nsubj	24	SENT_185	30559/30567
4	to	TO	O	to	aux	5	SENT_185	30568/30570
5	address	VB	O	address	infmod	3	SENT_185	30571/30578
6	TP-DI	NN	O	tp-di	nn	7	SENT_185	30579/30584
7	(	NN	O	(	dobj	5	SENT_185	30585/30586
8	TP-SMD	NN	O	tp-smd	nn	13	SENT_185	30586/30592
9	therapeutic	JJ	O	therapeutic	amod	13	SENT_185	30593/30604
10	protein-small	JJ	O	protein-small	amod	13	SENT_185	30605/30618
11	molecule	NN	O	molecule	nn	13	SENT_185	30619/30627
12	drug	NN	O	drug	nn	13	SENT_185	30628/30632
13	interaction	NN	O	interaction	dep	5	SENT_185	30633/30644
14	,	,	O	,		-1	SENT_185	30644/30645
15	PK	NN	O	pk	appos	13	SENT_185	30646/30648
16	pharmacokinetic	JJ	O	pharmacokinetic	amod	15	SENT_185	30649/30664
17	,	,	O	,		-1	SENT_185	30664/30665
18	PD	NN	O	pd	appos	13	SENT_185	30666/30668
19	pharmacodynamic	JJ	O	pharmacodynamic	amod	18	SENT_185	30669/30684
20	,	,	O	,		-1	SENT_185	30684/30685
21	DI	NNP	O	DI	nn	23	SENT_185	30686/30688
22	drug	NN	O	drug	nn	23	SENT_185	30689/30693
23	interactions	NNS	O	interaction	appos	13	SENT_185	30694/30706
24	)	VBP	O	)		-1	SENT_185	30706/30707

1	Session	NN	O	session		-1	SENT_186	30762/30769
2	III	CD	NUMBER	iii	num	1	SENT_186	30770/30773
3	:	:	O	:		-1	SENT_186	30773/30774
4	Regulatory	NNP	O	Regulatory	nn	5	SENT_186	30775/30785
5	Perspectives	NNS	O	perspective	dep	1	SENT_186	30786/30798

1	European	NNP	O	European	nn	3	SENT_187	30834/30842
2	Regulatory	NNP	O	Regulatory	nn	3	SENT_187	30843/30853
3	Perspective	NNP	O	Perspective		-1	SENT_187	30854/30865
4	on	IN	O	on		-1	SENT_187	30866/30868
5	TP-DI	NNP	O	TP-DI	nn	6	SENT_187	30869/30874
6	Strategy	NNP	O	Strategy	prep_on	3	SENT_187	30875/30883

1	The	DT	O	the	det	4	SENT_188	30919/30922
2	current	JJ	DATE	current	amod	4	SENT_188	30923/30930
3	European	JJ	O	european	amod	4	SENT_188	30931/30939
4	Guideline	NN	O	guideline	nsubjpass	11	SENT_188	30940/30949
5	on	IN	O	on		-1	SENT_188	30950/30952
6	the	DT	O	the	det	7	SENT_188	30953/30956
7	investigation	NN	O	investigation	prep_on	4	SENT_188	30957/30970
8	of	IN	O	of		-1	SENT_188	30971/30973
9	DI	NNP	O	DI	prep_of	7	SENT_188	30974/30976
10	was	VBD	O	be	auxpass	11	SENT_188	30977/30980
11	adopted	VBN	O	adopt		-1	SENT_188	30981/30988
12	a	DT	DATE	a	det	13	SENT_188	30989/30990
13	decade	NN	DATE	decade	npadvmod	14	SENT_188	30991/30997
14	ago	RB	DATE	ago	advmod	11	SENT_188	30998/31001
15	.	.	O	.		-1	SENT_188	31001/31002

1	In	IN	O	in		-1	SENT_189	31003/31005
2	April	NNP	DATE	April	prep_in	9	SENT_189	31006/31011
3	2010	CD	DATE	2010	num	2	SENT_189	31012/31016
4	,	,	O	,		-1	SENT_189	31016/31017
5	a	DT	O	a	det	7	SENT_189	31018/31019
6	draft-revised	JJ	O	draft-revised	amod	7	SENT_189	31020/31033
7	guideline	NN	O	guideline	nsubjpass	9	SENT_189	31034/31043
8	was	VBD	O	be	auxpass	9	SENT_189	31044/31047
9	adopted	VBN	O	adopt		-1	SENT_189	31048/31055
10	by	IN	O	by		-1	SENT_189	31056/31058
11	the	DT	O	the	det	12	SENT_189	31059/31062
12	Committee	NNP	ORGANIZATION	Committee	agent	9	SENT_189	31063/31072
13	for	IN	ORGANIZATION	for		-1	SENT_189	31073/31076
14	Medicinal	NNP	ORGANIZATION	Medicinal	nn	15	SENT_189	31077/31086
15	Products	NNPS	ORGANIZATION	Products	prep_for	9	SENT_189	31087/31095
16	for	IN	ORGANIZATION	for		-1	SENT_189	31096/31099
17	Human	JJ	ORGANIZATION	human	amod	18	SENT_189	31100/31105
18	Use	NN	ORGANIZATION	use	prep_for	15	SENT_189	31106/31109
19	(	CD	NUMBER	(	num	21	SENT_189	31110/31111
20	CHMP	NN	O	chmp	nn	21	SENT_189	31111/31115
21	)	NN	O	)	npadvmod	9	SENT_189	31115/31116
22	for	IN	O	for		-1	SENT_189	31117/31120
23	release	NN	O	release	prep_for	21	SENT_189	31121/31128
24	on	IN	O	on		-1	SENT_189	31129/31131
25	a	DT	O	a	det	29	SENT_189	31132/31133
26	6-month	JJ	DURATION	6-month	amod	29	SENT_189	31134/31141
27	public	JJ	O	public	amod	29	SENT_189	31142/31148
28	comment	NN	O	comment	nn	29	SENT_189	31149/31156
29	period	NN	O	period	prep_on	9	SENT_189	31157/31163
30	(	CD	NUMBER	(	number	31	SENT_189	31164/31165
31	35	CD	NUMBER	35	num	32	SENT_189	31165/31167
32	)	NN	O	)	dep	29	SENT_189	31167/31168
33	.	.	O	.		-1	SENT_189	31168/31169

1	The	DT	O	the	det	3	SENT_190	31170/31173
2	draft	NN	O	draft	nn	3	SENT_190	31174/31179
3	guideline	NN	O	guideline	nsubj	6	SENT_190	31180/31189
4	does	VBZ	O	do	aux	6	SENT_190	31190/31194
5	not	RB	O	not	neg	6	SENT_190	31195/31198
6	contain	VB	O	contain		-1	SENT_190	31199/31206
7	advice	NN	O	advice	nsubj	8	SENT_190	31207/31213
8	related	JJ	O	related	xcomp	6	SENT_190	31214/31221
9	to	TO	O	to		-1	SENT_190	31222/31224
10	TPs	NNS	O	tp	prep_to	8	SENT_190	31225/31228
11	.	.	O	.		-1	SENT_190	31228/31229

1	This	DT	O	this	nsubj	3	SENT_191	31230/31234
2	was	VBD	O	be	cop	3	SENT_191	31235/31238
3	intentional	JJ	O	intentional		-1	SENT_191	31239/31250
4	as	IN	O	as	mark	7	SENT_191	31251/31253
5	it	PRP	O	it	nsubjpass	7	SENT_191	31254/31256
6	was	VBD	O	be	auxpass	7	SENT_191	31257/31260
7	considered	VBN	O	consider	advcl	3	SENT_191	31261/31271
8	difficult	JJ	O	difficult	acomp	7	SENT_191	31272/31281
9	to	TO	O	to	aux	10	SENT_191	31282/31284
10	give	VB	O	give	xcomp	8	SENT_191	31285/31289
11	detailed	JJ	O	detailed	amod	12	SENT_191	31290/31298
12	advice	NN	O	advice	dobj	10	SENT_191	31299/31305
13	based	VBN	O	base		-1	SENT_191	31306/31311
14	on	IN	O	on	prepc_based_on	10	SENT_191	31312/31314
15	the	DT	O	the	det	17	SENT_191	31315/31318
16	available	JJ	O	available	amod	17	SENT_191	31319/31328
17	knowledge	NN	O	knowledge	pobj	10	SENT_191	31329/31338
18	.	.	O	.		-1	SENT_191	31338/31339

1	However	RB	O	however	advmod	6	SENT_192	31340/31347
2	,	,	O	,		-1	SENT_192	31347/31348
3	some	DT	O	some	det	4	SENT_192	31349/31353
4	advice	NN	O	advice	nsubjpass	6	SENT_192	31354/31360
5	is	VBZ	O	be	auxpass	6	SENT_192	31361/31363
6	given	VBN	O	give		-1	SENT_192	31364/31369
7	in	IN	O	in		-1	SENT_192	31370/31372
8	another	DT	O	another	det	10	SENT_192	31373/31380
9	specific	JJ	O	specific	amod	10	SENT_192	31381/31389
10	guideline	NN	O	guideline	prep_in	6	SENT_192	31390/31399
11	"	''	O	"	punct	10	SENT_192	31400/31401
12	The	DT	O	the	det	14	SENT_192	31401/31404
13	CHMP	NN	O	chmp	nn	14	SENT_192	31405/31409
14	guideline	NN	O	guideline	tmod	6	SENT_192	31410/31419
15	on	IN	O	on		-1	SENT_192	31420/31422
16	the	DT	O	the	det	18	SENT_192	31423/31426
17	clinical	JJ	O	clinical	amod	18	SENT_192	31427/31435
18	investigation	NN	O	investigation	prep_on	14	SENT_192	31436/31449
19	of	IN	O	of		-1	SENT_192	31450/31452
20	the	DT	O	the	det	21	SENT_192	31453/31456
21	pharmacokinetics	NNS	O	pharmacokinetic	prep_of	18	SENT_192	31457/31473
22	of	IN	O	of		-1	SENT_192	31474/31476
23	therapeutic	JJ	O	therapeutic	amod	24	SENT_192	31477/31488
24	proteins	NNS	O	protein	prep_of	21	SENT_192	31489/31497
25	"	``	O	"	punct	24	SENT_192	31497/31498
26	published	VBN	O	publish	partmod	24	SENT_192	31499/31508
27	in	IN	O	in		-1	SENT_192	31509/31511
28	2007	CD	DATE	2007	num	29	SENT_192	31512/31516
29	(	CD	NUMBER	(	prep_in	26	SENT_192	31517/31518
30	8	CD	NUMBER	8	num	31	SENT_192	31518/31519
31	)	NN	O	)	dep	14	SENT_192	31519/31520
32	.	.	O	.		-1	SENT_192	31520/31521

1	This	DT	O	this	det	2	SENT_193	31522/31526
2	guideline	NN	O	guideline	nsubj	3	SENT_193	31527/31536
3	states	VBZ	O	state		-1	SENT_193	31537/31543
4	that	IN	O	that	mark	9	SENT_193	31544/31548
5	some	DT	O	some	det	6	SENT_193	31549/31553
6	TPs	NNS	O	tp	nsubjpass	9	SENT_193	31554/31557
7	have	VBP	O	have	aux	9	SENT_193	31558/31562
8	been	VBN	O	be	auxpass	9	SENT_193	31563/31567
9	found	VBN	O	find	ccomp	3	SENT_193	31568/31573
10	to	TO	O	to	aux	11	SENT_193	31574/31576
11	cause	VB	O	cause	xcomp	9	SENT_193	31577/31582
12	DI	NNP	O	DI	dobj	11	SENT_193	31583/31585
13	and	CC	O	and		-1	SENT_193	31586/31589
14	that	IN	O	that	mark	22	SENT_193	31590/31594
15	the	DT	O	the	det	16	SENT_193	31595/31598
16	need	NN	O	need	nsubjpass	22	SENT_193	31599/31603
17	for	IN	O	for		-1	SENT_193	31604/31607
18	DI	NNP	O	DI	nn	19	SENT_193	31608/31610
19	studies	NNS	O	study	prep_for	16	SENT_193	31611/31618
20	should	MD	O	should	aux	22	SENT_193	31619/31625
21	be	VB	O	be	auxpass	22	SENT_193	31626/31628
22	considered	VBN	O	consider	conj_and	9	SENT_193	31629/31639
23	on	IN	O	on		-1	SENT_193	31640/31642
24	a	DT	O	a	det	26	SENT_193	31643/31644
25	case-by-case	JJ	O	case-by-case	amod	26	SENT_193	31645/31657
26	basis	NN	O	basis	prep_on	22	SENT_193	31658/31663
27	.	.	O	.		-1	SENT_193	31663/31664

1	Interaction	NN	O	interaction	nn	2	SENT_194	31665/31676
2	studies	NNS	O	study	nsubjpass	5	SENT_194	31677/31684
3	should	MD	O	should	aux	5	SENT_194	31685/31691
4	be	VB	O	be	auxpass	5	SENT_194	31692/31694
5	considered	VBN	O	consider		-1	SENT_194	31695/31705
6	when	WRB	O	when	advmod	9	SENT_194	31706/31710
7	the	DT	O	the	det	8	SENT_194	31711/31714
8	protein	NN	O	protein	nsubj	9	SENT_194	31715/31722
9	induces	VBZ	O	induce	dep	5	SENT_194	31723/31730
10	changes	NNS	O	change	nsubj	16	SENT_194	31731/31738
11	to	TO	O	to		-1	SENT_194	31739/31741
12	elimination	NN	O	elimination	nn	13	SENT_194	31742/31753
13	pathways	NNS	O	pathway	prep_to	10	SENT_194	31754/31762
14	(	NN	O	(	nn	16	SENT_194	31763/31764
15	receptors	NNS	O	receptor	nn	16	SENT_194	31764/31773
16	)	NN	O	)	xcomp	9	SENT_194	31773/31774
17	also	RB	O	also	advmod	18	SENT_194	31775/31779
18	involved	VBN	O	involve	partmod	16	SENT_194	31780/31788
19	in	IN	O	in		-1	SENT_194	31789/31791
20	the	DT	O	the	det	21	SENT_194	31792/31795
21	elimination	NN	O	elimination	prep_in	18	SENT_194	31796/31807
22	of	IN	O	of		-1	SENT_194	31808/31810
23	other	JJ	O	other	amod	24	SENT_194	31811/31816
24	drugs	NNS	O	drug	prep_of	21	SENT_194	31817/31822
25	or	CC	O	or		-1	SENT_194	31823/31825
26	when	WRB	O	when	advmod	33	SENT_194	31826/31830
27	suppression	NN	O	suppression	nsubj	33	SENT_194	31831/31842
28	of	IN	O	of		-1	SENT_194	31843/31845
29	the	DT	O	the	det	31	SENT_194	31846/31849
30	immunological	JJ	O	immunological	amod	31	SENT_194	31850/31863
31	system	NN	O	system	prep_of	27	SENT_194	31864/31870
32	is	VBZ	O	be	cop	33	SENT_194	31871/31873
33	likely	RB	O	likely	conj_or	9	SENT_194	31874/31880
34	,	,	O	,		-1	SENT_194	31880/31881
35	as	IN	O	as		-1	SENT_194	31882/31884
36	also	RB	O	also		-1	SENT_194	31885/31889
37	when	WRB	O	when	advmod	39	SENT_194	31890/31894
38	there	EX	O	there	expl	39	SENT_194	31895/31900
39	are	VBP	O	be	conj_and	9	SENT_194	31901/31904
40	possible	JJ	O	possible	amod	41	SENT_194	31905/31913
41	interactions	NNS	O	interaction	nsubj	39	SENT_194	31914/31926
42	with	IN	O	with		-1	SENT_194	31927/31931
43	endogenous	JJ	O	endogenous	amod	44	SENT_194	31932/31942
44	proteins	NNS	O	protein	prep_with	41	SENT_194	31943/31951
45	as	RB	O	as		-1	SENT_194	31952/31954
46	well	RB	O	well		-1	SENT_194	31955/31959
47	as	IN	O	as		-1	SENT_194	31960/31962
48	interactions	NNS	O	interaction	conj_and	41	SENT_194	31963/31975
49	due	JJ	O	due		-1	SENT_194	31976/31979
50	to	TO	O	to		-1	SENT_194	31980/31982
51	effect	NN	O	effect	prep_due_to	48	SENT_194	31983/31989
52	on	IN	O	on		-1	SENT_194	31990/31992
53	target	NN	O	target	prep_on	51	SENT_194	31993/31999
54	(	CD	NUMBER	(	num	53	SENT_194	32000/32001
55	e.g.	FW	O	e.g.	tmod	51	SENT_194	32001/32005
56	,	,	O	,		-1	SENT_194	32005/32006
57	receptor	NN	O	receptor	nn	59	SENT_194	32007/32015
58	)	NN	O	)	nn	59	SENT_194	32015/32016
59	expression	NN	O	expression	appos	55	SENT_194	32017/32027
60	.	.	O	.		-1	SENT_194	32027/32028

1	It	PRP	O	it	nsubjpass	3	SENT_195	32029/32031
2	is	VBZ	O	be	auxpass	3	SENT_195	32032/32034
3	pointed	VBN	O	point		-1	SENT_195	32035/32042
4	out	RP	O	out	prt	3	SENT_195	32043/32046
5	that	IN	O	that	mark	10	SENT_195	32047/32051
6	the	DT	O	the	det	8	SENT_195	32052/32055
7	interaction	NN	O	interaction	nn	8	SENT_195	32056/32067
8	studies	NNS	O	study	nsubj	10	SENT_195	32068/32075
9	generally	RB	O	generally	advmod	10	SENT_195	32076/32085
10	need	VBP	O	need	ccomp	3	SENT_195	32086/32090
11	to	TO	O	to	aux	12	SENT_195	32091/32093
12	be	VB	O	be	xcomp	10	SENT_195	32094/32096
13	of	IN	O	of		-1	SENT_195	32097/32099
14	multiple-dose	JJ	O	multiple-dose	amod	15	SENT_195	32100/32113
15	design	NN	O	design	prep_of	12	SENT_195	32114/32120
16	.	.	O	.		-1	SENT_195	32120/32121

1	The	DT	O	the	det	2	SENT_196	32157/32160
2	DI	NNP	O	DI	nsubj	12	SENT_196	32161/32163
3	at	IN	O	at		-1	SENT_196	32164/32166
4	an	DT	O	a	det	6	SENT_196	32167/32169
5	enzyme	NN	O	enzyme	nn	6	SENT_196	32170/32176
6	level	NN	O	level	prep_at	2	SENT_196	32177/32182
7	observed	VBN	O	observe	partmod	6	SENT_196	32183/32191
8	so	RB	O	so	advmod	9	SENT_196	32192/32194
9	far	RB	O	far	advmod	7	SENT_196	32195/32198
10	has	VBZ	O	have	aux	12	SENT_196	32199/32202
11	generally	RB	O	generally	advmod	12	SENT_196	32203/32212
12	been	VBN	O	be		-1	SENT_196	32213/32217
13	of	IN	O	of		-1	SENT_196	32218/32220
14	a	DT	O	a	det	16	SENT_196	32221/32222
15	moderate	JJ	O	moderate	amod	16	SENT_196	32223/32231
16	magnitude	NN	O	magnitude	prep_of	12	SENT_196	32232/32241
17	.	.	O	.		-1	SENT_196	32241/32242

1	The	DT	O	the	det	2	SENT_197	32243/32246
2	effects	NNS	O	effect	nsubj	5	SENT_197	32247/32254
3	seem	VBP	O	seem	cop	5	SENT_197	32255/32259
4	mainly	RB	O	mainly	advmod	5	SENT_197	32260/32266
5	relevant	JJ	O	relevant		-1	SENT_197	32267/32275
6	for	IN	O	for		-1	SENT_197	32276/32279
7	NTR	NN	O	ntr	nn	8	SENT_197	32280/32283
8	drugs	NNS	O	drug	prep_for	5	SENT_197	32284/32289
9	but	CC	O	but		-1	SENT_197	32290/32293
10	some	DT	O	some	det	11	SENT_197	32294/32298
11	increases	NNS	O	increase	nsubj	15	SENT_197	32299/32308
12	in	IN	O	in		-1	SENT_197	32309/32311
13	drug	NN	O	drug	nn	14	SENT_197	32312/32316
14	clearance	NN	O	clearance	prep_in	11	SENT_197	32317/32326
15	found	VBD	O	find	conj_but	5	SENT_197	32327/32332
16	could	MD	O	could	aux	18	SENT_197	32333/32338
17	also	RB	O	also	advmod	18	SENT_197	32339/32343
18	be	VB	O	be	ccomp	15	SENT_197	32344/32346
19	of	IN	O	of		-1	SENT_197	32347/32349
20	clinical	JJ	O	clinical	amod	21	SENT_197	32350/32358
21	relevance	NN	O	relevance	prep_of	18	SENT_197	32359/32368
22	for	IN	O	for		-1	SENT_197	32369/32372
23	other	JJ	O	other	amod	25	SENT_197	32373/32378
24	medicinal	JJ	O	medicinal	amod	25	SENT_197	32379/32388
25	products	NNS	O	product	prep_for	21	SENT_197	32389/32397
26	.	.	O	.		-1	SENT_197	32397/32398

1	In	IN	O	in		-1	SENT_198	32399/32401
2	some	DT	O	some	det	3	SENT_198	32402/32406
3	cases	NNS	O	case	prep_in	13	SENT_198	32407/32412
4	,	,	O	,		-1	SENT_198	32412/32413
5	the	DT	O	the	det	6	SENT_198	32414/32417
6	effect	NN	O	effect	nsubj	13	SENT_198	32418/32424
7	observed	VBN	O	observe	partmod	6	SENT_198	32425/32433
8	in	IN	O	in		-1	SENT_198	32434/32436
9	patients	NNS	O	patient	prep_in	7	SENT_198	32437/32445
10	is	VBZ	O	be	cop	13	SENT_198	32446/32448
11	actually	RB	O	actually	advmod	13	SENT_198	32449/32457
12	a	DT	O	a	det	13	SENT_198	32458/32459
13	normalization	NN	O	normalization		-1	SENT_198	32460/32473
14	of	IN	O	of		-1	SENT_198	32474/32476
15	enzyme	NN	O	enzyme	nn	16	SENT_198	32477/32483
16	expression	NN	O	expression	prep_of	13	SENT_198	32484/32494
17	.	.	O	.		-1	SENT_198	32494/32495

1	This	DT	O	this	nsubj	2	SENT_199	32496/32500
2	makes	VBZ	O	make		-1	SENT_199	32501/32506
3	translating	VBG	O	translate	xcomp	2	SENT_199	32507/32518
4	the	DT	O	the	det	5	SENT_199	32519/32522
5	effects	NNS	O	effect	dobj	3	SENT_199	32523/32530
6	into	IN	O	into		-1	SENT_199	32531/32535
7	practically	RB	O	practically	advmod	8	SENT_199	32536/32547
8	applicable	JJ	O	applicable	amod	10	SENT_199	32548/32558
9	labeling	NN	O	labeling	nn	10	SENT_199	32559/32567
10	advice	NN	O	advice	prep_into	3	SENT_199	32568/32574
11	difficult	JJ	O	difficult	rcmod	10	SENT_199	32575/32584
12	unless	IN	O	unless	mark	18	SENT_199	32585/32591
13	the	DT	O	the	det	15	SENT_199	32592/32595
14	affected	VBN	O	affect	amod	15	SENT_199	32596/32604
15	drug	NN	O	drug	nsubjpass	18	SENT_199	32605/32609
16	is	VBZ	O	be	auxpass	18	SENT_199	32610/32612
17	individually	RB	O	individually	advmod	18	SENT_199	32613/32625
18	titrated	VBN	O	titrate	dep	11	SENT_199	32626/32634
19	.	.	O	.		-1	SENT_199	32634/32635

1	The	DT	O	the	det	2	SENT_200	32636/32639
2	recommendation	NN	O	recommendation	nsubj	4	SENT_200	32640/32654
3	may	MD	O	may	aux	4	SENT_200	32655/32658
4	need	VB	O	need		-1	SENT_200	32659/32663
5	to	TO	O	to	aux	7	SENT_200	32664/32666
6	be	VB	O	be	cop	7	SENT_200	32667/32669
7	different	JJ	O	different	xcomp	4	SENT_200	32670/32679
8	depending	VBG	O	depend		-1	SENT_200	32680/32689
9	on	IN	O	on	prepc_depending_on	7	SENT_200	32690/32692
10	whether	IN	O	whether	mark	15	SENT_200	32693/32700
11	the	DT	O	the	det	13	SENT_200	32701/32704
12	affected	VBN	O	affect	amod	13	SENT_200	32705/32713
13	drug	NN	O	drug	nsubjpass	15	SENT_200	32714/32718
14	was	VBD	O	be	auxpass	15	SENT_200	32719/32722
15	initiated	VBN	O	initiate	pcomp	7	SENT_200	32723/32732
16	before	IN	O	before		-1	SENT_200	32733/32739
17	or	CC	O	or		-1	SENT_200	32740/32742
18	after	IN	O	after		-1	SENT_200	32743/32748
19	the	DT	O	the	det	20	SENT_200	32749/32752
20	manifest	JJ	O	manifest	prep_after	15	SENT_200	32753/32761
21	of	IN	O	of		-1	SENT_200	32762/32764
22	the	DT	O	the	det	23	SENT_200	32765/32768
23	disease	NN	O	disease	prep_of	20	SENT_200	32769/32776
24	.	.	O	.		-1	SENT_200	32776/32777

1	The	DT	O	the	det	4	SENT_201	32813/32816
2	optimal	JJ	O	optimal	amod	4	SENT_201	32817/32824
3	study	NN	O	study	nn	4	SENT_201	32825/32830
4	design	NN	O	design	nsubj	10	SENT_201	32831/32837
5	of	IN	O	of		-1	SENT_201	32838/32840
6	a	DT	O	a	det	8	SENT_201	32841/32842
7	TP-DI	NN	O	tp-di	nn	8	SENT_201	32843/32848
8	study	NN	O	study	prep_of	4	SENT_201	32849/32854
9	is	VBZ	O	be	cop	10	SENT_201	32855/32857
10	likely	JJ	O	likely		-1	SENT_201	32858/32864
11	to	TO	O	to	aux	15	SENT_201	32865/32867
12	be	VB	O	be	cop	15	SENT_201	32868/32870
13	a	DT	O	a	det	15	SENT_201	32871/32872
14	long	JJ	O	long	amod	15	SENT_201	32873/32877
15	duration	NN	O	duration	xcomp	10	SENT_201	32878/32886
16	in	FW	O	in	nn	17	SENT_201	32887/32889
17	vivo	FW	O	vivo	dep	18	SENT_201	32890/32894
18	investigation	NN	O	investigation	dep	15	SENT_201	32895/32908
19	,	,	O	,		-1	SENT_201	32908/32909
20	possibly	RB	O	possibly	advmod	18	SENT_201	32910/32918
21	with	IN	O	with		-1	SENT_201	32919/32923
22	repeated	VBN	O	repeat	amod	24	SENT_201	32924/32932
23	DI	NNP	O	DI	nn	24	SENT_201	32933/32935
24	measurements	NNS	O	measurement	prep_with	15	SENT_201	32936/32948
25	in	IN	O	in		-1	SENT_201	32949/32951
26	the	DT	O	the	det	29	SENT_201	32952/32955
27	target	NN	O	target	nn	29	SENT_201	32956/32962
28	patient	NN	O	patient	nn	29	SENT_201	32963/32970
29	population	NN	O	population	prep_in	10	SENT_201	32971/32981
30	.	.	O	.		-1	SENT_201	32981/32982

1	Due	JJ	O	due		-1	SENT_202	32983/32986
2	to	TO	O	to		-1	SENT_202	32987/32989
3	the	DT	O	the	det	4	SENT_202	32990/32993
4	challenges	NNS	O	challenge	prep_due_to	20	SENT_202	32994/33004
5	of	IN	O	of		-1	SENT_202	33005/33007
6	performing	VBG	O	perform	prepc_of	4	SENT_202	33008/33018
7	such	PDT	O	such	predet	9	SENT_202	33019/33023
8	a	DT	O	a	det	9	SENT_202	33024/33025
9	study	NN	O	study	dobj	6	SENT_202	33026/33031
10	,	,	O	,		-1	SENT_202	33031/33032
11	in	FW	O	in	nn	12	SENT_202	33033/33035
12	vitro	FW	O	vitro	advmod	6	SENT_202	33036/33041
13	methods	NNS	O	method	nsubjpass	20	SENT_202	33042/33049
14	which	WDT	O	which	nsubj	16	SENT_202	33050/33055
15	may	MD	O	may	aux	16	SENT_202	33056/33059
16	detect	VB	O	detect	rcmod	13	SENT_202	33060/33066
17	the	DT	O	the	det	18	SENT_202	33067/33070
18	interactions	NNS	O	interaction	dobj	16	SENT_202	33071/33083
19	are	VBP	O	be	auxpass	20	SENT_202	33084/33087
20	warranted	VBN	O	warrant		-1	SENT_202	33088/33097
21	as	IN	O	as		-1	SENT_202	33098/33100
22	general	JJ	O	general	amod	24	SENT_202	33101/33108
23	screening	NN	O	screening	nn	24	SENT_202	33109/33118
24	tools	NNS	O	tool	prep_as	20	SENT_202	33119/33124
25	.	.	O	.		-1	SENT_202	33124/33125

1	Possibly	RB	O	possibly	advmod	21	SENT_203	33126/33134
2	,	,	O	,		-1	SENT_203	33134/33135
3	cultured	VBN	O	culture	csubjpass	21	SENT_203	33136/33144
4	hepatocytes	NNS	O	hepatocyte	dobj	3	SENT_203	33145/33156
5	with	IN	O	with		-1	SENT_203	33157/33161
6	verified	VBN	O	verify	amod	7	SENT_203	33162/33170
7	presence	NN	O	presence	prep_with	3	SENT_203	33171/33179
8	of	IN	O	of		-1	SENT_203	33180/33182
9	enzyme	NN	O	enzyme	nn	11	SENT_203	33183/33189
10	regulatory	JJ	O	regulatory	amod	11	SENT_203	33190/33200
11	systems	NNS	O	system	prep_of	7	SENT_203	33201/33208
12	via	IN	O	via		-1	SENT_203	33209/33212
13	PXR	NN	O	pxr	prep_via	11	SENT_203	33213/33216
14	,	,	O	,		-1	SENT_203	33216/33217
15	CAR	NN	O	car	conj_and	13	SENT_203	33218/33221
16	,	,	O	,		-1	SENT_203	33221/33222
17	and	CC	O	and		-1	SENT_203	33223/33226
18	NF-k	NN	O	nf-k	conj_and	13	SENT_203	33227/33231
19	could	MD	O	could	aux	21	SENT_203	33234/33239
20	be	VB	O	be	auxpass	21	SENT_203	33240/33242
21	used	VBN	O	use		-1	SENT_203	33243/33247
22	for	IN	O	for		-1	SENT_203	33248/33251
23	effects	NNS	O	effect	prep_for	21	SENT_203	33252/33259
24	via	IN	O	via		-1	SENT_203	33260/33263
25	these	DT	O	these	det	26	SENT_203	33264/33269
26	pathways	NNS	O	pathway	prep_via	23	SENT_203	33270/33278
27	.	.	O	.		-1	SENT_203	33278/33279

1	However	RB	O	however	advmod	7	SENT_204	33280/33287
2	,	,	O	,		-1	SENT_204	33287/33288
3	other	JJ	O	other	amod	5	SENT_204	33289/33294
4	interaction	NN	O	interaction	nn	5	SENT_204	33295/33306
5	mechanisms	NNS	O	mechanism	nsubj	7	SENT_204	33307/33317
6	may	MD	O	may	aux	7	SENT_204	33318/33321
7	exist	VB	O	exist		-1	SENT_204	33322/33327
8	,	,	O	,		-1	SENT_204	33327/33328
9	which	WDT	O	which	nsubj	12	SENT_204	33329/33334
10	then	RB	O	then	advmod	12	SENT_204	33335/33339
11	also	RB	O	also	advmod	12	SENT_204	33340/33344
12	needs	VBZ	O	need	ccomp	7	SENT_204	33345/33350
13	verification	NN	O	verification	dobj	12	SENT_204	33351/33363
14	during	IN	O	during		-1	SENT_204	33364/33370
15	the	DT	O	the	det	16	SENT_204	33371/33374
16	culturing	NN	O	culturing	prep_during	12	SENT_204	33375/33384
17	.	.	O	.		-1	SENT_204	33384/33385

1	Other	JJ	O	other	nsubj	14	SENT_205	33386/33391
2	in	FW	O	in	prep	1	SENT_205	33392/33394
3	vitro	FW	O	vitro	nn	4	SENT_205	33395/33400
4	methods	NNS	O	method	pobj	2	SENT_205	33401/33408
5	to	TO	O	to	aux	6	SENT_205	33409/33411
6	investigate	VB	O	investigate	infmod	1	SENT_205	33412/33423
7	the	DT	O	the	det	8	SENT_205	33424/33427
8	effect	NN	O	effect	dobj	6	SENT_205	33428/33434
9	on	IN	O	on		-1	SENT_205	33435/33437
10	interleukins	NNS	O	interleukin	prep_on	6	SENT_205	33438/33450
11	may	MD	O	may	aux	14	SENT_205	33451/33454
12	be	VB	O	be	cop	14	SENT_205	33455/33457
13	a	DT	O	a	det	14	SENT_205	33458/33459
14	way	NN	O	way		-1	SENT_205	33460/33463
15	forward	RB	O	forward	advmod	14	SENT_205	33464/33471
16	to	TO	O	to	aux	17	SENT_205	33472/33474
17	screen	NN	O	screen	infmod	14	SENT_205	33475/33481
18	for	IN	O	for		-1	SENT_205	33482/33485
19	interaction	NN	O	interaction	nn	20	SENT_205	33486/33497
20	potential	NN	O	potential	prep_for	17	SENT_205	33498/33507
21	of	IN	O	of		-1	SENT_205	33508/33510
22	this	DT	O	this	det	24	SENT_205	33511/33515
23	specific	JJ	O	specific	amod	24	SENT_205	33516/33524
24	mechanism	NN	O	mechanism	prep_of	20	SENT_205	33525/33534
25	.	.	O	.		-1	SENT_205	33534/33535

1	However	RB	O	however	advmod	15	SENT_206	33536/33543
2	,	,	O	,		-1	SENT_206	33543/33544
3	due	JJ	O	due		-1	SENT_206	33545/33548
4	to	TO	O	to		-1	SENT_206	33549/33551
5	the	DT	O	the	det	6	SENT_206	33552/33555
6	lack	NN	O	lack	prep_due_to	15	SENT_206	33556/33560
7	of	IN	O	of		-1	SENT_206	33561/33563
8	experience	NN	O	experience	prep_of	6	SENT_206	33564/33574
9	with	IN	O	with		-1	SENT_206	33575/33579
10	these	DT	O	these	det	11	SENT_206	33580/33585
11	methods	NNS	O	method	prep_with	8	SENT_206	33586/33593
12	,	,	O	,		-1	SENT_206	33593/33594
13	it	PRP	O	it	nsubj	15	SENT_206	33595/33597
14	is	VBZ	O	be	cop	15	SENT_206	33598/33600
15	possible	JJ	O	possible		-1	SENT_206	33601/33609
16	that	IN	O	that	mark	22	SENT_206	33610/33614
17	the	DT	O	the	det	18	SENT_206	33615/33618
18	results	NNS	O	result	nsubjpass	22	SENT_206	33619/33626
19	may	MD	O	may	aux	22	SENT_206	33627/33630
20	only	RB	O	only	advmod	22	SENT_206	33631/33635
21	be	VB	O	be	auxpass	22	SENT_206	33636/33638
22	used	VBN	O	use	ccomp	15	SENT_206	33639/33643
23	qualitatively	RB	O	qualitatively	advmod	22	SENT_206	33644/33657
24	.	.	O	.		-1	SENT_206	33657/33658

1	According	VBG	O	accord		-1	SENT_207	33694/33703
2	to	TO	O	to	prepc_according_to	24	SENT_207	33704/33706
3	the	DT	O	the	det	4	SENT_207	33707/33710
4	labeling	NN	O	labeling	pobj	24	SENT_207	33711/33719
5	of	IN	O	of		-1	SENT_207	33720/33722
6	the	DT	O	the	det	7	SENT_207	33723/33726
7	TPs	NNS	O	tp	prep_of	4	SENT_207	33727/33730
8	registered	VBN	O	register	partmod	7	SENT_207	33731/33741
9	in	IN	O	in		-1	SENT_207	33742/33744
10	the	DT	DURATION	the	det	13	SENT_207	33745/33748
11	last	JJ	DURATION	last	amod	13	SENT_207	33749/33753
12	5	CD	DURATION	5	num	13	SENT_207	33754/33755
13	years	NNS	NUMBER	year	prep_in	8	SENT_207	33756/33761
14	on	IN	O	on		-1	SENT_207	33762/33764
15	the	DT	O	the	det	17	SENT_207	33765/33768
16	EU	NNP	LOCATION	EU	nn	17	SENT_207	33769/33771
17	market	NN	O	market	prep_on	8	SENT_207	33772/33778
18	,	,	O	,		-1	SENT_207	33778/33779
19	PK	NN	O	pk	nn	21	SENT_207	33780/33782
20	interaction	NN	O	interaction	nn	21	SENT_207	33783/33794
21	studies	NNS	O	study	nsubjpass	24	SENT_207	33795/33802
22	were	VBD	O	be	auxpass	24	SENT_207	33803/33807
23	not	RB	O	not	neg	24	SENT_207	33808/33811
24	performed	VBN	O	perform		-1	SENT_207	33812/33821
25	with	IN	O	with		-1	SENT_207	33822/33826
26	majority	NN	O	majority	prep_with	24	SENT_207	33827/33835
27	of	IN	O	of		-1	SENT_207	33836/33838
28	the	DT	O	the	det	29	SENT_207	33839/33842
29	drugs	NNS	O	drug	prep_of	26	SENT_207	33843/33848
30	.	.	O	.		-1	SENT_207	33848/33849

1	Slightly	RB	O	slightly	advmod	2	SENT_208	33850/33858
2	more	JJR	O	more	nsubj	9	SENT_208	33859/33863
3	than	IN	O	than		-1	SENT_208	33864/33868
4	one	CD	NUMBER	one	num	5	SENT_208	33869/33872
5	fifth	NN	ORDINAL	fifth	prep_than	2	SENT_208	33873/33878
6	of	IN	O	of		-1	SENT_208	33879/33881
7	the	DT	O	the	det	8	SENT_208	33882/33885
8	TPs	NNS	O	tp	prep_of	5	SENT_208	33886/33889
9	had	VBD	O	have		-1	SENT_208	33890/33893
10	a	DT	O	a	det	11	SENT_208	33894/33895
11	statement	NN	O	statement	dobj	9	SENT_208	33896/33905
12	in	IN	O	in		-1	SENT_208	33906/33908
13	the	DT	O	the	det	14	SENT_208	33909/33912
14	labeling	NN	O	labeling	prep_in	11	SENT_208	33913/33921
15	that	WDT	O	that	dobj	21	SENT_208	33922/33926
16	"	``	O	"	punct	21	SENT_208	33927/33928
17	Drug	NNP	O	Drug	nn	18	SENT_208	33928/33932
18	interactions	NNS	O	interaction	nsubjpass	21	SENT_208	33933/33945
19	were	VBD	O	be	auxpass	21	SENT_208	33946/33950
20	not	RB	O	not	neg	21	SENT_208	33951/33954
21	expected	VBN	O	expect	rcmod	14	SENT_208	33955/33963
22	"	``	O	"	advmod	21	SENT_208	33963/33964
23	.	.	O	.		-1	SENT_208	33964/33965

1	A	DT	O	a	det	3	SENT_209	33966/33967
2	small	JJ	O	small	amod	3	SENT_209	33968/33973
3	percentage	NN	O	percentage	nsubj	9	SENT_209	33974/33984
4	of	IN	O	of		-1	SENT_209	33985/33987
5	the	DT	O	the	det	8	SENT_209	33988/33991
6	approved	VBN	O	approve	amod	8	SENT_209	33992/34000
7	drug	NN	O	drug	nn	8	SENT_209	34001/34005
8	applications	NNS	O	application	prep_of	3	SENT_209	34006/34018
9	contained	VBD	O	contain		-1	SENT_209	34019/34028
10	results	NNS	O	result	dobj	9	SENT_209	34029/34036
11	from	IN	O	from		-1	SENT_209	34037/34041
12	conventional	JJ	O	conventional	amod	14	SENT_209	34042/34054
13	DI	NN	O	di	nn	14	SENT_209	34055/34057
14	studies	NNS	O	study	prep_from	9	SENT_209	34058/34065
15	.	.	O	.		-1	SENT_209	34065/34066

1	However	RB	O	however	advmod	16	SENT_210	34067/34074
2	,	,	O	,		-1	SENT_210	34074/34075
3	in	IN	O	in		-1	SENT_210	34076/34078
4	the	DT	O	the	det	5	SENT_210	34079/34082
5	labeling	NN	O	labeling	prep_in	16	SENT_210	34083/34091
6	of	IN	O	of		-1	SENT_210	34092/34094
7	almost	RB	O	almost	advmod	9	SENT_210	34095/34101
8	one	CD	NUMBER	one	num	9	SENT_210	34102/34105
9	tenth	NN	ORDINAL	tenth	prep_of	5	SENT_210	34106/34111
10	of	IN	O	of		-1	SENT_210	34112/34114
11	the	DT	O	the	det	12	SENT_210	34115/34118
12	products	NNS	O	product	prep_of	9	SENT_210	34119/34127
13	,	,	O	,		-1	SENT_210	34127/34128
14	it	PRP	O	it	nsubjpass	16	SENT_210	34129/34131
15	was	VBD	O	be	auxpass	16	SENT_210	34132/34135
16	stated	VBN	O	state		-1	SENT_210	34136/34142
17	that	IN	O	that	mark	23	SENT_210	34143/34147
18	effects	NNS	O	effect	nsubjpass	23	SENT_210	34148/34155
19	on	IN	O	on		-1	SENT_210	34156/34158
20	CYP	NN	O	cyp	nn	21	SENT_210	34159/34162
21	enzymes	NNS	O	enzyme	prep_on	18	SENT_210	34163/34170
22	were	VBD	O	be	auxpass	23	SENT_210	34171/34175
23	expected	VBN	O	expect	ccomp	16	SENT_210	34176/34184
24	although	IN	O	although	mark	26	SENT_210	34185/34193
25	not	RB	O	not	neg	26	SENT_210	34194/34197
26	studied	VBN	O	study	advcl	23	SENT_210	34198/34205
27	.	.	O	.		-1	SENT_210	34205/34206

1	Another	DT	O	another	det	2	SENT_211	34207/34214
2	tenth	NN	ORDINAL	tenth	nsubj	3	SENT_211	34215/34220
3	included	VBD	O	include		-1	SENT_211	34221/34229
4	information	NN	O	information	dobj	3	SENT_211	34230/34241
5	from	IN	O	from		-1	SENT_211	34242/34246
6	population	NN	O	population	nn	8	SENT_211	34247/34257
7	PK	NN	O	pk	nn	8	SENT_211	34258/34260
8	analyses	NNS	O	analysis	prep_from	3	SENT_211	34261/34269
9	.	.	O	.		-1	SENT_211	34269/34270

1	Evolution	NN	O	evolution		-1	SENT_212	34306/34315
2	of	IN	O	of		-1	SENT_212	34316/34318
3	Regulatory	JJ	O	regulatory	amod	5	SENT_212	34319/34329
4	Guidance	NNP	O	Guidance	nn	5	SENT_212	34330/34338
5	Development	NNP	O	Development	prep_of	1	SENT_212	34339/34350
6	by	IN	O	by		-1	SENT_212	34351/34353
7	the	DT	O	the	det	9	SENT_212	34354/34357
8	US	NNP	ORGANIZATION	US	nn	9	SENT_212	34358/34360
9	Food	NNP	ORGANIZATION	Food	prep_by	1	SENT_212	34361/34365
10	and	CC	ORGANIZATION	and		-1	SENT_212	34366/34369
11	Drug	NNP	ORGANIZATION	Drug	nn	12	SENT_212	34370/34374
12	Administration	NNP	ORGANIZATION	Administration	conj_and	9	SENT_212	34375/34389
13	for	IN	ORGANIZATION	for		-1	SENT_212	34390/34393
14	Small	JJ	ORGANIZATION	small	amod	15	SENT_212	34394/34399
15	Molecules	NNS	ORGANIZATION	molecule	prep_for	1	SENT_212	34400/34409
16	and	CC	O	and		-1	SENT_212	34410/34413
17	Application	NN	O	application	conj_and	15	SENT_212	34414/34425
18	to	TO	O	to		-1	SENT_212	34426/34428
19	Large	JJ	O	large	amod	21	SENT_212	34429/34434
20	Molecule	NNP	O	Molecule	nn	21	SENT_212	34435/34443
21	DI	NNP	O	DI	prep_to	1	SENT_212	34444/34446

1	Various	JJ	O	various	amod	5	SENT_213	34482/34489
2	intrinsic	JJ	O	intrinsic	amod	5	SENT_213	34490/34499
3	and	CC	O	and		-1	SENT_213	34500/34503
4	extrinsic	JJ	O	extrinsic	conj_and	2	SENT_213	34504/34513
5	factors	NNS	O	factor	nsubj	7	SENT_213	34514/34521
6	can	MD	O	can	aux	7	SENT_213	34522/34525
7	affect	VB	O	affect		-1	SENT_213	34526/34532
8	an	DT	O	a	det	10	SENT_213	34533/34535
9	individual	JJ	O	individual	amod	10	SENT_213	34536/34546
10	patient	NN	O	patient	poss	13	SENT_213	34547/34554
11	's	POS	O	's		-1	SENT_213	34554/34556
12	drug	NN	O	drug	nn	13	SENT_213	34557/34561
13	exposure	NN	O	exposure	dobj	7	SENT_213	34562/34570
14	and	CC	O	and		-1	SENT_213	34571/34574
15	response	NN	O	response	conj_and	13	SENT_213	34575/34583
16	(	CD	NUMBER	(	number	17	SENT_213	34584/34585
17	36	CD	NUMBER	36	num	18	SENT_213	34585/34587
18	)	NN	O	)	dep	15	SENT_213	34587/34588
19	.	.	O	.		-1	SENT_213	34588/34589

1	The	DT	O	the	det	3	SENT_214	34590/34593
2	US	NNP	LOCATION	US	nn	3	SENT_214	34594/34596
3	FDA	NNP	ORGANIZATION	FDA	nsubj	5	SENT_214	34597/34600
4	has	VBZ	O	have	aux	5	SENT_214	34601/34604
5	published	VBN	O	publish		-1	SENT_214	34605/34614
6	several	JJ	O	several	amod	8	SENT_214	34615/34622
7	guidance	NN	O	guidance	nn	8	SENT_214	34623/34631
8	documents	NNS	O	document	dobj	5	SENT_214	34632/34641
9	recommending	VBG	O	recommend	xcomp	5	SENT_214	34642/34654
10	how	WRB	O	how	advmod	14	SENT_214	34655/34658
11	and	CC	O	and	cc	10	SENT_214	34659/34662
12	when	WRB	O	when	dep	10	SENT_214	34663/34667
13	to	TO	O	to	aux	14	SENT_214	34668/34670
14	evaluate	VB	O	evaluate	ccomp	9	SENT_214	34671/34679
15	these	DT	O	these	det	16	SENT_214	34680/34685
16	factors	NNS	O	factor	dobj	14	SENT_214	34686/34693
17	,	,	O	,		-1	SENT_214	34693/34694
18	including	VBG	O	include		-1	SENT_214	34695/34704
19	DI	NNP	O	DI	prep_including	16	SENT_214	34705/34707
20	,	,	O	,		-1	SENT_214	34707/34708
21	during	IN	O	during		-1	SENT_214	34709/34715
22	drug	NN	O	drug	nn	24	SENT_214	34716/34720
23	development	NN	O	development	nn	24	SENT_214	34721/34732
24	(	NN	O	(	prep_during	5	SENT_214	34733/34734
25	37	CD	NUMBER	37	num	26	SENT_214	34734/34736
26	)	NN	O	)	dep	24	SENT_214	34736/34737
27	.	.	O	.		-1	SENT_214	34737/34738

1	The	DT	O	the	det	2	SENT_215	34739/34742
2	need	NN	O	need	nsubjpass	12	SENT_215	34743/34747
3	to	TO	O	to	aux	4	SENT_215	34748/34750
4	evaluate	VB	O	evaluate	infmod	2	SENT_215	34751/34759
5	DI	NNP	O	DI	dobj	4	SENT_215	34760/34762
6	during	IN	O	during		-1	SENT_215	34763/34769
7	drug	NN	O	drug	nn	8	SENT_215	34770/34774
8	development	NN	O	development	prep_during	4	SENT_215	34775/34786
9	can	MD	O	can	aux	12	SENT_215	34787/34790
10	not	RB	O	not	neg	12	SENT_215	34790/34793
11	be	VB	O	be	auxpass	12	SENT_215	34794/34796
12	overemphasized	VBN	O	overemphasize		-1	SENT_215	34797/34811
13	.	.	O	.		-1	SENT_215	34811/34812

1	Metabolism	NN	O	metabolism	nsubj	7	SENT_216	34813/34823
2	-	:	O	-		-1	SENT_216	34823/34824
3	and	CC	O	and		-1	SENT_216	34825/34828
4	transporter-based	JJ	O	transporter-based	amod	5	SENT_216	34829/34846
5	DI	NNP	O	DI	conj_and	1	SENT_216	34847/34849
6	have	VBP	O	have	aux	7	SENT_216	34850/34854
7	contributed	VBN	O	contribute		-1	SENT_216	34855/34866
8	to	TO	O	to		-1	SENT_216	34867/34869
9	adverse	JJ	O	adverse	amod	10	SENT_216	34870/34877
10	events	NNS	O	event	prep_to	7	SENT_216	34878/34884
11	with	IN	O	with		-1	SENT_216	34885/34889
12	some	DT	O	some	det	13	SENT_216	34890/34894
13	drugs	NNS	O	drug	prep_with	7	SENT_216	34895/34900
14	that	WDT	O	that	nsubjpass	16	SENT_216	34901/34905
15	were	VBD	O	be	auxpass	16	SENT_216	34906/34910
16	withdrawn	VBN	O	withdraw	rcmod	13	SENT_216	34911/34920
17	from	IN	O	from		-1	SENT_216	34921/34925
18	the	DT	O	the	det	20	SENT_216	34926/34929
19	US	NNP	LOCATION	US	nn	20	SENT_216	34930/34932
20	market	NN	O	market	prep_from	16	SENT_216	34933/34939
21	.	.	O	.		-1	SENT_216	34939/34940

1	Drug	NN	O	drug	nn	2	SENT_217	34941/34945
2	labels	NNS	O	label	nsubj	3	SENT_217	34946/34952
3	need	VBP	O	need		-1	SENT_217	34953/34957
4	to	TO	O	to	prep	3	SENT_217	34958/34960
5	and	CC	O	and		-1	SENT_217	34961/34964
6	have	VBP	O	have	aux	8	SENT_217	34965/34969
7	been	VBN	O	be	auxpass	8	SENT_217	34970/34974
8	updated	VBN	O	update	conj_and	3	SENT_217	34975/34982
9	to	TO	O	to	aux	10	SENT_217	34983/34985
10	include	VB	O	include	xcomp	8	SENT_217	34986/34993
11	information	NN	O	information	nsubj	12	SENT_217	34994/35005
12	related	JJ	O	related	xcomp	10	SENT_217	35006/35013
13	to	TO	O	to		-1	SENT_217	35014/35016
14	DI	NNP	O	DI	prep_to	12	SENT_217	35017/35019
15	.	.	O	.		-1	SENT_217	35019/35020

1	Recent	JJ	O	recent	amod	2	SENT_218	35021/35027
2	examples	NNS	O	example	nsubj	3	SENT_218	35028/35036
3	include	VBP	O	include		-1	SENT_218	35037/35044
4	clopidogrel	NN	O	clopidogrel	dobj	3	SENT_218	35045/35056
5	:	:	O	:		-1	SENT_218	35056/35057
6	its	PRP$	O	its	poss	7	SENT_218	35058/35061
7	interaction	NN	O	interaction	nsubjpass	24	SENT_218	35062/35073
8	with	IN	O	with		-1	SENT_218	35074/35078
9	CYP2C19	NN	O	cyp2c19	nn	10	SENT_218	35079/35086
10	inhibitors	NNS	O	inhibitor	prep_with	7	SENT_218	35087/35097
11	and	CC	O	and		-1	SENT_218	35098/35101
12	the	DT	O	the	det	13	SENT_218	35102/35105
13	use	NN	O	use	conj_and	7	SENT_218	35106/35109
14	in	IN	O	in		-1	SENT_218	35110/35112
15	patients	NNS	O	patient	prep_in	13	SENT_218	35113/35121
16	with	IN	O	with		-1	SENT_218	35122/35126
17	deficient	JJ	O	deficient	amod	20	SENT_218	35127/35136
18	CYP2C19	NN	O	cyp2c19	nn	20	SENT_218	35137/35144
19	enzyme	NN	O	enzyme	nn	20	SENT_218	35145/35151
20	activities	NNS	O	activity	prep_with	15	SENT_218	35152/35162
21	have	VBP	O	have	aux	24	SENT_218	35163/35167
22	been	VBN	O	be	auxpass	24	SENT_218	35168/35172
23	recently	RB	DATE	recently	advmod	24	SENT_218	35173/35181
24	added	VBN	O	add	parataxis	3	SENT_218	35182/35187
25	to	TO	O	to		-1	SENT_218	35188/35190
26	its	PRP$	O	its	poss	27	SENT_218	35191/35194
27	labeling	NN	O	labeling	prep_to	24	SENT_218	35195/35203
28	.	.	O	.		-1	SENT_218	35203/35204

1	In	IN	O	in		-1	SENT_219	35205/35207
2	addition	NN	O	addition	prep_in	38	SENT_219	35208/35216
3	,	,	O	,		-1	SENT_219	35216/35217
4	developing	VBG	O	develop	csubj	38	SENT_219	35218/35228
5	tools	NNS	O	tool	dobj	4	SENT_219	35229/35234
6	(	RB	O	(	advmod	4	SENT_219	35235/35236
7	in	FW	O	in	nn	9	SENT_219	35236/35238
8	vitro	FW	O	vitro	dep	9	SENT_219	35239/35244
9	methodologies	NNS	O	methodology	advmod	4	SENT_219	35245/35258
10	and	CC	O	and		-1	SENT_219	35259/35262
11	pharmacogenetics	NNS	O	pharmacogenetic	conj_and	9	SENT_219	35263/35279
12	evaluation	NN	O	evaluation	dep	4	SENT_219	35280/35290
13	)	CD	NUMBER	)	num	12	SENT_219	35290/35291
14	to	TO	O	to	aux	15	SENT_219	35292/35294
15	evaluate	VB	O	evaluate	infmod	12	SENT_219	35295/35303
16	the	DT	O	the	det	17	SENT_219	35304/35307
17	role	NN	O	role	dobj	15	SENT_219	35308/35312
18	of	IN	O	of		-1	SENT_219	35313/35315
19	various	JJ	O	various	amod	21	SENT_219	35316/35323
20	ATP-binding	JJ	O	atp-binding	amod	21	SENT_219	35324/35335
21	cassette	NN	O	cassette	prep_of	17	SENT_219	35336/35344
22	and	CC	O	and		-1	SENT_219	35345/35348
23	solute	JJ	O	solute	amod	25	SENT_219	35349/35355
24	carrier	NN	O	carrier	nn	25	SENT_219	35356/35363
25	transporters	NNS	O	transporter	conj_and	21	SENT_219	35364/35376
26	in	IN	O	in		-1	SENT_219	35377/35379
27	drug	NN	O	drug	nn	28	SENT_219	35380/35384
28	disposition	NN	O	disposition	prep_in	17	SENT_219	35385/35396
29	(	CD	NUMBER	(	num	31	SENT_219	35397/35398
30	38	CD	NUMBER	38	num	31	SENT_219	35398/35400
31	)	NN	O	)	tmod	15	SENT_219	35400/35401
32	and	CC	O	and		-1	SENT_219	35402/35405
33	thereby	RB	O	thereby	advmod	31	SENT_219	35406/35413
34	safety	NN	O	safety	conj_and	31	SENT_219	35414/35420
35	and	CC	O	and		-1	SENT_219	35421/35424
36	efficacy	NN	O	efficacy	conj_and	34	SENT_219	35425/35433
37	have	VBP	O	have	aux	38	SENT_219	35434/35438
38	increased	VBN	O	increase	dep	45	SENT_219	35439/35448
39	understanding	NN	O	understanding	dobj	38	SENT_219	35449/35462
40	of	IN	O	of		-1	SENT_219	35463/35465
41	DI	NNP	O	DI	prep_of	39	SENT_219	35466/35468
42	involving	VBG	O	involve	xcomp	38	SENT_219	35469/35478
43	statin	NN	O	statin	nn	44	SENT_219	35479/35485
44	drugs	NNS	O	drug	dobj	42	SENT_219	35486/35491
45	[	VBP	O	[		-1	SENT_219	35492/35493
46	e.g.	FW	O	e.g.	dobj	45	SENT_219	35493/35497
47	,	,	O	,		-1	SENT_219	35497/35498
48	rosuvastatin	NN	O	rosuvastatin	conj_and	46	SENT_219	35499/35511
49	and	CC	O	and		-1	SENT_219	35512/35515
50	organic	JJ	O	organic	amod	51	SENT_219	35516/35523
51	anion	NN	O	anion	conj_and	46	SENT_219	35524/35529
52	transporting	VBG	O	transport	xcomp	45	SENT_219	35530/35542
53	polypeptide	NN	O	polypeptide	nn	54	SENT_219	35543/35554
54	1B1	NN	O	1b1	dobj	52	SENT_219	35555/35558
55	(	CD	NUMBER	(	num	57	SENT_219	35559/35560
56	OATP1B1	NN	O	oatp1b1	nn	57	SENT_219	35560/35567
57	)	NN	O	)	nsubj	45	SENT_219	35567/35568
58	and	CC	O	and		-1	SENT_219	35569/35572
59	breast	NN	O	breast	nn	63	SENT_219	35573/35579
60	cancer	NN	O	cancer	nn	63	SENT_219	35580/35586
61	resistance	NN	O	resistance	nn	63	SENT_219	35587/35597
62	protein	NN	O	protein	nn	63	SENT_219	35598/35605
63	]	NN	O	]	conj_and	57	SENT_219	35605/35606
64	.	.	O	.		-1	SENT_219	35606/35607

1	The	DT	O	the	det	3	SENT_220	35608/35611
2	US	NNP	LOCATION	US	nn	3	SENT_220	35612/35614
3	FDA	NNP	ORGANIZATION	FDA	nsubj	5	SENT_220	35615/35618
4	has	VBZ	O	have	aux	5	SENT_220	35619/35622
5	proposed	VBN	O	propose		-1	SENT_220	35623/35631
6	various	JJ	O	various	amod	8	SENT_220	35632/35639
7	decision	NN	O	decision	nn	8	SENT_220	35640/35648
8	trees	NNS	O	tree	dobj	5	SENT_220	35649/35654
9	to	TO	O	to	aux	10	SENT_220	35655/35657
10	help	VB	O	help	xcomp	5	SENT_220	35658/35662
11	determine	VB	O	determine	ccomp	10	SENT_220	35663/35672
12	when	WRB	O	when	advmod	14	SENT_220	35673/35677
13	to	TO	O	to	aux	14	SENT_220	35678/35680
14	evaluate	VB	O	evaluate	xcomp	11	SENT_220	35681/35689
15	transporter-based	JJ	O	transporter-based	amod	16	SENT_220	35690/35707
16	DI	NNP	O	DI	dobj	14	SENT_220	35708/35710
17	during	IN	O	during		-1	SENT_220	35711/35717
18	drug	NN	O	drug	nn	19	SENT_220	35718/35722
19	development	NN	O	development	prep_during	14	SENT_220	35723/35734
20	(	CD	NUMBER	(	number	21	SENT_220	35735/35736
21	39	CD	NUMBER	39	num	22	SENT_220	35736/35738
22	)	NN	O	)	dep	11	SENT_220	35738/35739
23	.	.	O	.		-1	SENT_220	35739/35740

1	Further	RB	O	further	advmod	8	SENT_221	35741/35748
2	,	,	O	,		-1	SENT_221	35748/35749
3	TP-DI	NN	O	tp-di	nn	4	SENT_221	35750/35755
4	studies	NNS	O	study	nsubjpass	8	SENT_221	35756/35763
5	have	VBP	O	have	aux	8	SENT_221	35764/35768
6	been	VBN	O	be	auxpass	8	SENT_221	35769/35773
7	increasingly	RB	O	increasingly	advmod	8	SENT_221	35774/35786
8	conducted	VBN	O	conduct		-1	SENT_221	35787/35796
9	(	NN	O	(	nn	10	SENT_221	35797/35798
10	Fig.	NN	O	fig.	xcomp	8	SENT_221	35798/35802
11	4	CD	NUMBER	4	num	12	SENT_221	35803/35804
12	)	NN	O	)	dep	10	SENT_221	35804/35805
13	and	CC	O	and		-1	SENT_221	35806/35809
14	included	VBD	O	include	conj_and	8	SENT_221	35810/35818
15	in	IN	O	in		-1	SENT_221	35819/35821
16	the	DT	O	the	det	20	SENT_221	35822/35825
17	labeling	NN	O	labeling	nn	20	SENT_221	35826/35834
18	(	NN	O	(	nn	20	SENT_221	35835/35836
19	2	CD	NUMBER	2	num	20	SENT_221	35836/35837
20	)	NN	O	)	prep_in	14	SENT_221	35837/35838
21	.	.	O	.		-1	SENT_221	35838/35839

1	Continued	VBN	O	continue	amod	2	SENT_222	35840/35849
2	evaluation	NN	O	evaluation	nsubj	8	SENT_222	35850/35860
3	of	IN	O	of		-1	SENT_222	35861/35863
4	their	PRP$	O	they	poss	6	SENT_222	35864/35869
5	clinical	JJ	O	clinical	amod	6	SENT_222	35870/35878
6	significance	NN	O	significance	prep_of	2	SENT_222	35879/35891
7	will	MD	O	will	aux	8	SENT_222	35892/35896
8	help	VB	O	help		-1	SENT_222	35897/35901
9	the	DT	O	the	det	11	SENT_222	35902/35905
10	US	NNP	LOCATION	US	nn	11	SENT_222	35906/35908
11	FDA	NNP	ORGANIZATION	FDA	dobj	8	SENT_222	35909/35912
12	in	IN	O	in		-1	SENT_222	35913/35915
13	formulating	VBG	O	formulate	prepc_in	8	SENT_222	35916/35927
14	its	PRP$	O	its	poss	15	SENT_222	35928/35931
15	recommendations	NNS	O	recommendation	dobj	13	SENT_222	35932/35947
16	in	IN	O	in		-1	SENT_222	35948/35950
17	this	DT	O	this	det	18	SENT_222	35951/35955
18	area	NN	O	area	prep_in	13	SENT_222	35956/35960
19	.	.	O	.		-1	SENT_222	35960/35961

1	Recent	JJ	O	recent	amod	2	SENT_223	35962/35968
2	advancements	NNS	O	advancement	nsubj	14	SENT_223	35969/35981
3	in	IN	O	in		-1	SENT_223	35982/35984
4	the	DT	O	the	det	5	SENT_223	35985/35988
5	development	NN	O	development	prep_in	2	SENT_223	35989/36000
6	of	IN	O	of		-1	SENT_223	36001/36003
7	physiologically-based	JJ	O	physiologically-based	amod	9	SENT_223	36004/36025
8	PK	NN	O	pk	nn	9	SENT_223	36026/36028
9	modeling	NN	O	modeling	prep_of	5	SENT_223	36029/36037
10	for	IN	O	for		-1	SENT_223	36038/36041
11	SMDs	NNS	O	smd	prep_for	9	SENT_223	36042/36046
12	has	VBZ	O	have	aux	14	SENT_223	36047/36050
13	been	VBN	O	be	cop	14	SENT_223	36051/36055
14	critical	JJ	O	critical		-1	SENT_223	36056/36064
15	and	CC	O	and		-1	SENT_223	36065/36068
16	has	VBZ	O	have	aux	18	SENT_223	36069/36072
17	been	VBN	O	be	auxpass	18	SENT_223	36073/36077
18	used	VBN	O	use	conj_and	14	SENT_223	36078/36082
19	to	TO	O	to	aux	20	SENT_223	36083/36085
20	help	VB	O	help	xcomp	18	SENT_223	36086/36090
21	address	VB	O	address	xcomp	20	SENT_223	36091/36098
22	questions	NNS	O	question	dobj	21	SENT_223	36099/36108
23	including	VBG	O	include	partmod	22	SENT_223	36109/36118
24	in	FW	O	in	nn	25	SENT_223	36119/36121
25	vitro	FW	O	vitro	advmod	23	SENT_223	36122/36127
26	to	TO	O	to		-1	SENT_223	36128/36130
27	in	FW	O	in	dep	40	SENT_223	36131/36133
28	vivo	FW	O	vivo	nn	29	SENT_223	36134/36138
29	extrapolations	NNS	O	extrapolation	pobj	27	SENT_223	36139/36153
30	and	CC	O	and		-1	SENT_223	36154/36157
31	simulations	NNS	O	simulation	conj_and	27	SENT_223	36158/36169
32	of	IN	O	of		-1	SENT_223	36170/36172
33	the	DT	O	the	det	34	SENT_223	36173/36176
34	extent	NN	O	extent	prep_of	31	SENT_223	36177/36183
35	of	IN	O	of		-1	SENT_223	36184/36186
36	DI	NNP	O	DI	prep_of	34	SENT_223	36187/36189
37	under	IN	O	under		-1	SENT_223	36190/36195
38	various	JJ	O	various	amod	39	SENT_223	36196/36203
39	dosing	NN	O	dosing	prep_under	36	SENT_223	36204/36210
40	regimens	NNS	O	regimen	prep_to	23	SENT_223	36211/36219
41	of	IN	O	of		-1	SENT_223	36220/36222
42	the	DT	O	the	det	44	SENT_223	36223/36226
43	interacting	VBG	O	interact	amod	44	SENT_223	36227/36238
44	drugs	NNS	O	drug	prep_of	40	SENT_223	36239/36244
45	,	,	O	,		-1	SENT_223	36244/36245
46	in	IN	O	in		-1	SENT_223	36246/36248
47	patients	NNS	O	patient	prep_in	18	SENT_223	36249/36257
48	with	IN	O	with		-1	SENT_223	36258/36262
49	concomitant	JJ	O	concomitant	amod	51	SENT_223	36263/36274
50	renal	JJ	O	renal	amod	51	SENT_223	36275/36280
51	impairment	NN	O	impairment	prep_with	47	SENT_223	36281/36291
52	,	,	O	,		-1	SENT_223	36291/36292
53	in	IN	O	in		-1	SENT_223	36293/36295
54	patients	NNS	O	patient	prep_in	47	SENT_223	36296/36304
55	with	IN	O	with		-1	SENT_223	36305/36309
56	various	JJ	O	various	amod	57	SENT_223	36310/36317
57	genotypes	NNS	O	genotype	prep_with	54	SENT_223	36318/36327
58	of	IN	O	of		-1	SENT_223	36328/36330
59	metabolizing	VBG	O	metabolize	prepc_of	57	SENT_223	36331/36343
60	enzymes	NNS	O	enzyme	dobj	59	SENT_223	36344/36351
61	,	,	O	,		-1	SENT_223	36351/36352
62	etc.	FW	O	etc.	nn	63	SENT_223	36353/36357
63	(	FW	O	(	appos	60	SENT_223	36358/36359
64	40	CD	NUMBER	40	num	65	SENT_223	36359/36361
65	)	NN	O	)	dep	63	SENT_223	36361/36362
66	.	.	O	.		-1	SENT_223	36362/36363

1	Successful	JJ	O	successful	amod	2	SENT_224	36364/36374
2	collaboration	NN	O	collaboration	nsubj	40	SENT_224	36375/36388
3	between	IN	O	between		-1	SENT_224	36389/36396
4	academia	NN	O	academia	nn	6	SENT_224	36397/36405
5	,	,	O	,		-1	SENT_224	36405/36406
6	industry	NN	O	industry	prep_between	2	SENT_224	36407/36415
7	,	,	O	,		-1	SENT_224	36415/36416
8	and	CC	O	and		-1	SENT_224	36417/36420
9	government	NN	O	government	nn	10	SENT_224	36421/36431
10	agencies	NNS	O	agency	conj_and	6	SENT_224	36432/36440
11	in	IN	O	in		-1	SENT_224	36441/36443
12	this	DT	O	this	det	13	SENT_224	36444/36448
13	field	NN	O	field	prep_in	2	SENT_224	36449/36454
14	and	CC	O	and		-1	SENT_224	36455/36458
15	in	IN	O	in		-1	SENT_224	36459/36461
16	other	JJ	O	other	amod	17	SENT_224	36462/36467
17	areas	NNS	O	area	conj_and	13	SENT_224	36468/36473
18	,	,	O	,		-1	SENT_224	36473/36474
19	illustrated	VBN	O	illustrate	partmod	2	SENT_224	36475/36486
20	by	IN	O	by		-1	SENT_224	36487/36489
21	the	DT	O	the	det	22	SENT_224	36490/36493
22	establishment	NN	O	establishment	agent	19	SENT_224	36494/36507
23	of	IN	O	of		-1	SENT_224	36508/36510
24	the	DT	O	the	det	27	SENT_224	36511/36514
25	International	NNP	ORGANIZATION	International	nn	27	SENT_224	36515/36528
26	Transporter	NNP	ORGANIZATION	Transporter	nn	27	SENT_224	36529/36540
27	Consortium	NNP	ORGANIZATION	Consortium	prep_of	22	SENT_224	36541/36551
28	for	IN	O	for		-1	SENT_224	36552/36555
29	developing	VBG	O	develop	prepc_for	19	SENT_224	36556/36566
30	a	DT	O	a	det	32	SENT_224	36567/36568
31	white	JJ	O	white	amod	32	SENT_224	36569/36574
32	paper	NN	O	paper	dobj	29	SENT_224	36575/36580
33	for	IN	O	for	mark	35	SENT_224	36581/36584
34	transporters	NNS	O	transporter	nsubj	35	SENT_224	36585/36597
35	(	VBP	O	(	advcl	29	SENT_224	36598/36599
36	38	CD	NUMBER	38	num	37	SENT_224	36599/36601
37	)	CD	NUMBER	)	dobj	35	SENT_224	36601/36602
38	,	,	O	,		-1	SENT_224	36602/36603
39	are	VBP	O	be	cop	40	SENT_224	36604/36607
40	keys	NNS	O	key		-1	SENT_224	36608/36612
41	to	TO	O	to		-1	SENT_224	36613/36615
42	success	NN	O	success	prep_to	40	SENT_224	36616/36623
43	in	IN	O	in		-1	SENT_224	36624/36626
44	developing	VBG	O	develop	prepc_in	42	SENT_224	36627/36637
45	useful	JJ	O	useful	amod	46	SENT_224	36638/36644
46	information	NN	O	information	dobj	44	SENT_224	36645/36656
47	for	IN	O	for		-1	SENT_224	36657/36660
48	the	DT	O	the	det	52	SENT_224	36661/36664
49	safe	JJ	O	safe	amod	52	SENT_224	36665/36669
50	and	CC	O	and		-1	SENT_224	36670/36673
51	effective	JJ	O	effective	conj_and	49	SENT_224	36674/36683
52	use	NN	O	use	prep_for	44	SENT_224	36684/36687
53	of	IN	O	of		-1	SENT_224	36688/36690
54	SMDs	FW	O	smds	nn	55	SENT_224	36691/36695
55	(	FW	O	(	prep_of	52	SENT_224	36696/36697
56	41	CD	NUMBER	41	num	57	SENT_224	36697/36699
57	)	NN	O	)	dep	55	SENT_224	36699/36700
58	.	.	O	.		-1	SENT_224	36700/36701

1	It	PRP	O	it	nsubjpass	3	SENT_225	36702/36704
2	is	VBZ	O	be	auxpass	3	SENT_225	36705/36707
3	intended	VBN	O	intend		-1	SENT_225	36708/36716
4	that	IN	O	that	mark	8	SENT_225	36717/36721
5	similar	JJ	O	similar	amod	6	SENT_225	36722/36729
6	efforts	NNS	O	effort	nsubj	8	SENT_225	36730/36737
7	be	VB	O	be	cop	8	SENT_225	36738/36740
8	applicable	JJ	O	applicable	ccomp	3	SENT_225	36741/36751
9	to	TO	O	to		-1	SENT_225	36752/36754
10	TP-DI	NN	O	tp-di	prep_to	8	SENT_225	36755/36760
11	.	.	O	.		-1	SENT_225	36760/36761

1	Fig.	NN	O	fig.		-1	SENT_226	36762/36766
2	4	CD	NUMBER	4	num	1	SENT_226	36767/36768

1	TP-DI	NN	O	tp-di		-1	SENT_227	36785/36790
2	and	CC	O	and		-1	SENT_227	36791/36794
3	implications	NNS	O	implication	conj_and	1	SENT_227	36795/36807
4	for	IN	O	for		-1	SENT_227	36808/36811
5	drug	NN	O	drug	nn	7	SENT_227	36812/36816
6	development	NN	O	development	nn	7	SENT_227	36817/36828
7	(	NN	O	(	prep_for	1	SENT_227	36829/36830
8	2	CD	NUMBER	2	num	9	SENT_227	36830/36831
9	)	NN	O	)	dep	7	SENT_227	36831/36832
10	.	.	O	.		-1	SENT_227	36832/36833

1	Summary	NN	O	summary		-1	SENT_228	36834/36841
2	of	IN	O	of		-1	SENT_228	36842/36844
3	the	DT	O	the	det	4	SENT_228	36845/36848
4	types	NNS	O	type	prep_of	1	SENT_228	36849/36854
5	of	IN	O	of		-1	SENT_228	36855/36857
6	studies	NNS	O	study	prep_of	4	SENT_228	36858/36865
7	that	WDT	O	that	nsubjpass	10	SENT_228	36866/36870
8	have	VBP	O	have	aux	10	SENT_228	36871/36875
9	been	VBN	O	be	auxpass	10	SENT_228	36876/36880
10	used	VBN	O	use	rcmod	6	SENT_228	36881/36885
11	during	IN	O	during		-1	SENT_228	36886/36892
12	drug	NN	O	drug	nn	13	SENT_228	36893/36897
13	development	NN	O	development	prep_during	10	SENT_228	36898/36909
14	to	TO	O	to	aux	15	SENT_228	36910/36912
15	evaluate	VB	O	evaluate	xcomp	10	SENT_228	36913/36921
16	therapeutic	JJ	O	therapeutic	amod	17	SENT_228	36922/36933
17	protein	NN	O	protein	dobj	15	SENT_228	36934/36941
18	(	NN	O	(	nn	19	SENT_228	36942/36943
19	TP	NN	O	tp	dep	17	SENT_228	36943/36945
20	)	SYM	O	)	dep	17	SENT_228	36945/36946
21	-	:	O	-		-1	SENT_228	36946/36947
22	small	JJ	O	small	amod	26	SENT_228	36947/36952
23	molecule	NN	O	molecule	nn	26	SENT_228	36953/36961
24	drug	NN	O	drug	nn	26	SENT_228	36962/36966
25	(	NN	O	(	nn	26	SENT_228	36967/36968
26	D	NN	O	d	dep	1	SENT_228	36968/36969
27	)	CD	NUMBER	)	num	28	SENT_228	36969/36970
28	interactions	NNS	O	interaction	dep	26	SENT_228	36971/36983
29	.	.	O	.		-1	SENT_228	36983/36984

1	This	DT	O	this	nsubj	2	SENT_229	36985/36989
2	includes	VBZ	O	include		-1	SENT_229	36990/36998
3	an	DT	O	a	det	4	SENT_229	36999/37001
4	evaluation	NN	O	evaluation	dobj	2	SENT_229	37002/37012
5	of	IN	O	of		-1	SENT_229	37013/37015
6	the	DT	O	the	det	7	SENT_229	37016/37019
7	effect	NN	O	effect	prep_of	4	SENT_229	37020/37026
8	of	IN	O	of		-1	SENT_229	37027/37029
9	TP	NN	O	tp	prep_of	7	SENT_229	37030/37032
10	on	IN	O	on		-1	SENT_229	37033/37035
11	D	NN	O	d	nn	13	SENT_229	37036/37037
12	(	CD	NUMBER	(	num	13	SENT_229	37038/37039
13	TP	NN	O	tp	prep_on	9	SENT_229	37039/37041
14	-	:	O	-		-1	SENT_229	37044/37045
15	>	JJR	O	>	amod	17	SENT_229	37045/37046
16	D	NN	O	d	nn	17	SENT_229	37049/37050
17	)	NN	O	)	dep	4	SENT_229	37050/37051
18	and	CC	O	and		-1	SENT_229	37052/37055
19	the	DT	O	the	det	20	SENT_229	37056/37059
20	effect	NN	O	effect	conj_and	17	SENT_229	37060/37066
21	of	IN	O	of		-1	SENT_229	37067/37069
22	D	NN	O	d	prep_of	20	SENT_229	37070/37071
23	on	IN	O	on		-1	SENT_229	37072/37074
24	TP	NN	O	tp	nn	26	SENT_229	37075/37077
25	(	NN	O	(	nn	26	SENT_229	37078/37079
26	D	NN	O	d	prep_on	22	SENT_229	37079/37080
27	-	:	O	-		-1	SENT_229	37083/37084
28	>	JJR	O	>	amod	30	SENT_229	37084/37085
29	TP	NN	O	tp	nn	30	SENT_229	37088/37090
30	)	NN	O	)	dep	4	SENT_229	37090/37091
31	.	.	O	.		-1	SENT_229	37091/37092

1	The	DT	O	the	det	3	SENT_230	37093/37096
2	broken	JJ	O	broken	amod	3	SENT_230	37097/37103
3	lines	NNS	O	line	nsubj	4	SENT_230	37104/37109
4	suggest	VBP	O	suggest		-1	SENT_230	37110/37117
5	the	DT	O	the	det	7	SENT_230	37118/37121
6	limited	JJ	O	limited	amod	7	SENT_230	37122/37129
7	use	NN	O	use	dobj	4	SENT_230	37130/37133
8	of	IN	O	of	prep	7	SENT_230	37134/37136
9	in	FW	O	in	nn	10	SENT_230	37137/37139
10	vitro	FW	O	vitro	dep	11	SENT_230	37140/37145
11	studies	NNS	O	study	dep	8	SENT_230	37146/37153
12	for	IN	O	for		-1	SENT_230	37154/37157
13	informing	VBG	O	inform	prepc_for	4	SENT_230	37158/37167
14	in	FW	O	in	nn	15	SENT_230	37168/37170
15	vivo	FW	O	vivo	advmod	13	SENT_230	37171/37175
16	study	NN	O	study	nn	17	SENT_230	37176/37181
17	design	NN	O	design	dobj	13	SENT_230	37182/37188
18	or	CC	O	or		-1	SENT_230	37189/37191
19	labeling	NN	O	labeling	conj_or	17	SENT_230	37192/37200
20	(	CD	NUMBER	(	num	23	SENT_230	37201/37202
21	CYP	NN	O	cyp	nn	23	SENT_230	37202/37205
22	cytochrome	NN	O	cytochrome	nn	23	SENT_230	37206/37216
23	P450	NN	O	p450	dep	17	SENT_230	37217/37221
24	,	,	O	,		-1	SENT_230	37221/37222
25	population	NN	O	population	appos	17	SENT_230	37223/37233
26	PK	NNP	O	PK	nn	28	SENT_230	37234/37236
27	population	NN	O	population	nn	28	SENT_230	37237/37247
28	pharmacokinetics	NNS	O	pharmacokinetic	nsubj	29	SENT_230	37248/37264
29	)	VBP	O	)	rcmod	25	SENT_230	37264/37265

1	Regulatory	JJ	O	regulatory	amod	2	SENT_231	37320/37330
2	Perspectives	NNS	O	perspective		-1	SENT_231	37331/37343
3	on	IN	O	on		-1	SENT_231	37344/37346
4	TP-DI	NN	O	tp-di	nn	5	SENT_231	37347/37352
5	Evaluation	NN	O	evaluation	prep_on	2	SENT_231	37353/37363
6	--	:	O	--		-1	SENT_231	37363/37365
7	Case	NNP	O	Case	nn	8	SENT_231	37365/37369
8	Studies	NNPS	O	Studies	dep	2	SENT_231	37370/37377

1	Table	NNP	O	Table	nsubj	18	SENT_232	37413/37418
2	I	PRP	O	I	nsubj	3	SENT_232	37419/37420
3	summarizes	VBZ	O	summarize	rcmod	1	SENT_232	37421/37431
4	DI	NNP	O	DI	nn	5	SENT_232	37432/37434
5	studies	NNS	O	study	nsubj	6	SENT_232	37435/37442
6	included	VBD	O	include	ccomp	3	SENT_232	37443/37451
7	in	IN	O	in		-1	SENT_232	37452/37454
8	the	DT	O	the	det	12	SENT_232	37455/37458
9	US	NNP	LOCATION	US	nn	12	SENT_232	37459/37461
10	FDA-approved	JJ	O	fda-approved	amod	12	SENT_232	37462/37474
11	package	NN	O	package	nn	12	SENT_232	37475/37482
12	inserts	NNS	O	insert	prep_in	6	SENT_232	37483/37490
13	for	IN	O	for		-1	SENT_232	37491/37494
14	new	JJ	O	new	amod	17	SENT_232	37495/37498
15	molecular	JJ	O	molecular	amod	17	SENT_232	37499/37508
16	entity	NN	O	entity	nn	17	SENT_232	37509/37515
17	TPs	NNS	O	tp	prep_for	6	SENT_232	37516/37519
18	approved	VBN	O	approve		-1	SENT_232	37520/37528
19	by	IN	O	by		-1	SENT_232	37529/37531
20	the	DT	DATE	the	det	21	SENT_232	37532/37535
21	end	NN	DATE	end	prep_by	18	SENT_232	37536/37539
22	of	IN	DATE	of		-1	SENT_232	37540/37542
23	February	NNP	DATE	February	prep_of	21	SENT_232	37543/37551
24	2010	CD	DATE	2010	num	23	SENT_232	37552/37556
25	(	CD	NUMBER	(	number	26	SENT_232	37557/37558
26	1	CD	NUMBER	1	num	27	SENT_232	37558/37559
27	)	NN	O	)	dobj	18	SENT_232	37559/37560
28	.	.	O	.		-1	SENT_232	37560/37561

1	Various	JJ	O	various	amod	3	SENT_233	37562/37569
2	possible	JJ	O	possible	amod	3	SENT_233	37570/37578
3	mechanisms	NNS	O	mechanism	nsubjpass	8	SENT_233	37579/37589
4	of	IN	O	of		-1	SENT_233	37590/37592
5	PK	NN	O	pk	nn	6	SENT_233	37593/37595
6	TP-DI	NN	O	tp-di	prep_of	3	SENT_233	37596/37601
7	were	VBD	O	be	auxpass	8	SENT_233	37602/37606
8	presented	VBN	O	present		-1	SENT_233	37607/37616
9	with	IN	O	with		-1	SENT_233	37617/37621
10	examples	NNS	O	example	prep_with	8	SENT_233	37622/37630
11	and	CC	O	and		-1	SENT_233	37631/37634
12	labeling	VBG	O	label	conj_and	8	SENT_233	37635/37643
13	impact	NN	O	impact	nsubj	17	SENT_233	37644/37650
14	(	CD	NUMBER	(	num	17	SENT_233	37651/37652
15	Table	NNP	O	Table	nn	17	SENT_233	37652/37657
16	II	NNP	O	II	nn	17	SENT_233	37658/37660
17	)	NN	O	)	xcomp	12	SENT_233	37660/37661
18	.	.	O	.		-1	SENT_233	37661/37662

1	Table	NNP	O	Table		-1	SENT_234	37663/37668
2	I	PRP	O	I	dep	1	SENT_234	37669/37670

1	Summary	NN	O	summary	nsubj	10	SENT_235	37687/37694
2	of	IN	O	of		-1	SENT_235	37695/37697
3	Drug	NN	O	drug	nn	5	SENT_235	37698/37702
4	Interaction	NN	O	interaction	nn	5	SENT_235	37703/37714
5	Studies	NNS	O	study	prep_of	1	SENT_235	37715/37722
6	in	IN	O	in		-1	SENT_235	37723/37725
7	the	DT	O	the	det	9	SENT_235	37726/37729
8	US	NNP	LOCATION	US	nn	9	SENT_235	37730/37732
9	FDA	NNP	ORGANIZATION	FDA	prep_in	5	SENT_235	37733/37736
10	Approved	VBD	O	approve		-1	SENT_235	37737/37745
11	Package	NN	O	package	nn	12	SENT_235	37746/37753
12	Inserts	NNS	O	insert	dobj	10	SENT_235	37754/37761
13	for	IN	O	for		-1	SENT_235	37762/37765
14	New	NNP	O	New	nn	17	SENT_235	37766/37769
15	Molecular	JJ	O	molecular	amod	17	SENT_235	37770/37779
16	Entity	NN	O	entity	nn	17	SENT_235	37780/37786
17	TPs	NNS	O	tp	prep_for	12	SENT_235	37787/37790
18	Approved	VBN	O	approve	partmod	12	SENT_235	37791/37799
19	by	IN	O	by		-1	SENT_235	37800/37802
20	the	DT	DATE	the	det	21	SENT_235	37803/37806
21	End	NN	DATE	end	agent	18	SENT_235	37807/37810
22	of	IN	DATE	of		-1	SENT_235	37811/37813
23	February	NNP	DATE	February	prep_of	21	SENT_235	37814/37822
24	2010	CD	DATE	2010	num	23	SENT_235	37823/37827
25	(	CD	NUMBER	(	tmod	18	SENT_235	37828/37829
26	Adapted	VBN	O	adapt	partmod	25	SENT_235	37829/37836
27	from	IN	O	from		-1	SENT_235	37837/37841
28	Reference	NNP	O	Reference	prep_from	26	SENT_235	37842/37851
29	1	CD	NUMBER	1	num	28	SENT_235	37852/37853
30	)	CD	NUMBER	)	dep	25	SENT_235	37853/37854

1	CategoryDedicated	VBN	O	categorydedicate		-1	SENT_236	37871/37888
2	studiesSome	NN	O	studiessome	nn	4	SENT_236	37889/37900
3	informationNo	NN	O	informationno	nn	4	SENT_236	37901/37914
4	informationTotal	NN	O	informationtotal	dobj	1	SENT_236	37915/37931
5	(	CD	PERCENT	(	num	6	SENT_236	37932/37933
6	%	NN	PERCENT	%	dep	4	SENT_236	37933/37934
7	)	CD	NUMBER	)	num	8	SENT_236	37934/37935
8	Cytokines	NNS	O	cytokine	dep	17	SENT_236	37937/37946
9	2	CD	NUMBER	2	number	10	SENT_236	37948/37949
10	7	CD	NUMBER	7	dep	8	SENT_236	37951/37952
11	2	CD	NUMBER	2	num	12	SENT_236	37954/37955
12	11	CD	NUMBER	11	dep	10	SENT_236	37957/37959
13	(	NN	O	(	dep	17	SENT_236	37960/37961
14	14	CD	NUMBER	14	num	13	SENT_236	37961/37963
15	)	CD	NUMBER	)	num	17	SENT_236	37963/37964
16	Growth	NN	O	growth	nn	17	SENT_236	37966/37972
17	factors	NNS	O	factor	dep	22	SENT_236	37973/37980
18	0	CD	NUMBER	0	num	19	SENT_236	37982/37983
19	2	CD	NUMBER	2	dep	17	SENT_236	37985/37986
20	8	CD	NUMBER	8	number	21	SENT_236	37988/37989
21	10	CD	NUMBER	10	dep	19	SENT_236	37991/37993
22	(	NN	O	(	dep	25	SENT_236	37994/37995
23	13	CD	NUMBER	13	num	22	SENT_236	37995/37997
24	)	CD	NUMBER	)	num	25	SENT_236	37997/37998
25	Enzymes	NNS	O	enzyme	dep	34	SENT_236	38000/38007
26	1	CD	NUMBER	1	number	27	SENT_236	38009/38010
27	7	CD	NUMBER	7	dep	25	SENT_236	38012/38013
28	9	CD	NUMBER	9	num	30	SENT_236	38015/38016
29	17	CD	NUMBER	17	num	30	SENT_236	38018/38020
30	(	NN	O	(	dep	27	SENT_236	38021/38022
31	22	CD	NUMBER	22	num	34	SENT_236	38022/38024
32	)	CD	NUMBER	)	num	34	SENT_236	38024/38025
33	Monoclonal	JJ	O	monoclonal	amod	34	SENT_236	38027/38037
34	antibodies	NNS	O	antibody	dep	39	SENT_236	38038/38048
35	6	CD	NUMBER	6	number	36	SENT_236	38050/38051
36	13	CD	NUMBER	13	dep	34	SENT_236	38053/38055
37	10	CD	NUMBER	10	num	38	SENT_236	38057/38059
38	29	CD	NUMBER	29	dep	36	SENT_236	38061/38063
39	(	NN	O	(	dep	42	SENT_236	38064/38065
40	38	CD	NUMBER	38	num	39	SENT_236	38065/38067
41	)	CD	NUMBER	)	num	42	SENT_236	38067/38068
42	Miscellaneous	NNP	ORGANIZATION	Miscellaneous	dep	52	SENT_236	38070/38083
43	0	CD	NUMBER	0	num	42	SENT_236	38085/38086
44	6	CD	NUMBER	6	num	47	SENT_236	38088/38089
45	3	CD	NUMBER	3	number	46	SENT_236	38091/38092
46	9	CD	NUMBER	9	amod	47	SENT_236	38094/38095
47	(	NN	O	(	dep	42	SENT_236	38096/38097
48	12	CD	NUMBER	12	number	49	SENT_236	38097/38099
49	)	CD	NUMBER	)	num	50	SENT_236	38099/38100
50	Total	JJ	O	total	dep	47	SENT_236	38102/38107
51	9	CD	NUMBER	9	num	52	SENT_236	38109/38110
52	(	NN	O	(	dep	59	SENT_236	38111/38112
53	12	CD	PERCENT	12	num	54	SENT_236	38112/38114
54	%	NN	PERCENT	%	dep	52	SENT_236	38114/38115
55	)	CD	NUMBER	)	number	56	SENT_236	38115/38116
56	35	CD	NUMBER	35	num	57	SENT_236	38118/38120
57	(	NN	O	(	dep	54	SENT_236	38121/38122
58	46	CD	PERCENT	46	num	59	SENT_236	38122/38124
59	%	NN	PERCENT	%	dep	67	SENT_236	38124/38125
60	)	CD	NUMBER	)	number	61	SENT_236	38125/38126
61	32	CD	NUMBER	32	num	62	SENT_236	38128/38130
62	(	NN	O	(	dep	59	SENT_236	38131/38132
63	42	CD	PERCENT	42	num	64	SENT_236	38132/38134
64	%	NN	PERCENT	%	dep	62	SENT_236	38134/38135
65	)	CD	NUMBER	)	number	66	SENT_236	38135/38136
66	76	CD	NUMBER	76	num	64	SENT_236	38138/38140
67	(	NN	O	(	dep	69	SENT_236	38141/38142
68	100	CD	NUMBER	100	num	67	SENT_236	38142/38145
69	)	CD	NUMBER	)	dep	4	SENT_236	38145/38146

1	Reproduced	VBN	O	reproduce		-1	SENT_237	38167/38177
2	from	IN	O	from		-1	SENT_237	38178/38182
3	(	CD	NUMBER	(	number	4	SENT_237	38183/38184
4	1	CD	NUMBER	1	num	5	SENT_237	38184/38185
5	)	NN	O	)	prep_from	1	SENT_237	38185/38186
6	with	IN	O	with		-1	SENT_237	38187/38191
7	permission	NN	O	permission	prep_with	1	SENT_237	38192/38202
8	from	IN	O	from		-1	SENT_237	38203/38207
9	Adis	NNP	PERSON	Adis	prep_from	1	SENT_237	38208/38212
10	,	,	O	,		-1	SENT_237	38212/38213
11	a	DT	O	a	det	16	SENT_237	38214/38215
12	Wolters	NNP	ORGANIZATION	Wolters	nn	16	SENT_237	38216/38223
13	Kluwer	NNP	ORGANIZATION	Kluwer	nn	16	SENT_237	38224/38230
14	business	NN	O	business	nn	16	SENT_237	38231/38239
15	(	CD	NUMBER	(	num	16	SENT_237	38240/38241
16	(	NN	O	(	nn	17	SENT_237	38241/38242
17	C	NN	O	c	appos	9	SENT_237	38242/38243
18	)	CD	NUMBER	)	num	22	SENT_237	38243/38244
19	Adis	NNP	ORGANIZATION	Adis	nn	22	SENT_237	38245/38249
20	Data	NNP	ORGANIZATION	Data	nn	22	SENT_237	38250/38254
21	Information	NNP	ORGANIZATION	Information	nn	22	SENT_237	38255/38266
22	BV	NN	ORGANIZATION	bv	dep	17	SENT_237	38267/38269
23	2010	CD	DATE	2010	num	22	SENT_237	38270/38274
24	.	.	O	.		-1	SENT_237	38274/38275

1	All	DT	O	all	det	2	SENT_238	38276/38279
2	rights	NNS	O	rights	nsubj	3	SENT_238	38280/38286
3	reserved	VBD	O	reserve		-1	SENT_238	38287/38295
4	)	CD	NUMBER	)	dobj	3	SENT_238	38295/38296

1	Table	NNP	O	Table	nn	2	SENT_239	38313/38318
2	II	NNP	O	II		-1	SENT_239	38319/38321

1	Examples	NNS	O	example		-1	SENT_240	38338/38346
2	of	IN	O	of		-1	SENT_240	38347/38349
3	Labeling	VBG	O	label	prepc_of	1	SENT_240	38350/38358
4	Dealing	VBG	O	deal	xcomp	3	SENT_240	38359/38366
5	with	IN	O	with		-1	SENT_240	38367/38371
6	TP-DI	NN	O	tp-di	nn	7	SENT_240	38372/38377
7	(	NN	O	(	prep_with	4	SENT_240	38378/38379
8	that	WDT	O	that	dobj	13	SENT_240	38379/38383
9	Result	NN	O	result	nsubj	13	SENT_240	38384/38390
10	in	IN	O	in		-1	SENT_240	38391/38393
11	Pharmacokinetic	JJ	O	pharmacokinetic	amod	12	SENT_240	38394/38409
12	Changes	NNS	O	change	prep_in	9	SENT_240	38410/38417
13	)	VBP	O	)	rcmod	7	SENT_240	38417/38418

1	Drug	NN	O	drug	nn	3	SENT_241	38435/38439
2	nameLabeling	NN	O	namelabeling	nn	3	SENT_241	38440/38452
3	language	NN	O	language		-1	SENT_241	38453/38461
4	1	CD	NUMBER	1	dep	3	SENT_241	38463/38464
5	.	.	O	.		-1	SENT_241	38464/38465

1	CYP	NN	O	cyp	nn	3	SENT_242	38466/38469
2	enzyme	NN	O	enzyme	nn	3	SENT_242	38470/38476
3	modulation	NN	O	modulation	nsubj	31	SENT_242	38477/38487
4	by	IN	O	by		-1	SENT_242	38488/38490
5	cytokines	NNS	O	cytokine	prep_by	3	SENT_242	38491/38500
6	and	CC	O	and		-1	SENT_242	38501/38504
7	cytokine	NN	O	cytokine	nn	8	SENT_242	38505/38513
8	modulators	NNS	O	modulator	conj_and	5	SENT_242	38514/38524
9	Tocilizumab	JJ	O	tocilizumab	amod	12	SENT_242	38526/38537
10	(	NN	O	(	nn	12	SENT_242	38538/38539
11	Actemra	NN	O	actemra	nn	12	SENT_242	38539/38546
12	)	NN	O	)	dep	17	SENT_242	38546/38547
13	7	CD	NUMBER	7	num	14	SENT_242	38549/38550
14	Drug	NN	O	drug	dep	12	SENT_242	38551/38555
15	interactions	NNS	O	interaction	dep	17	SENT_242	38556/38568
16	7.2	CD	NUMBER	7.2	num	17	SENT_242	38570/38573
17	Interactions	NNS	O	interaction	dep	22	SENT_242	38574/38586
18	with	IN	O	with		-1	SENT_242	38587/38591
19	CYP450	NN	O	cyp450	nn	20	SENT_242	38592/38598
20	substrates	NNS	O	substrate	prep_with	17	SENT_242	38599/38609
21	The	DT	O	the	det	22	SENT_242	38611/38614
22	effect	NN	O	effect	dep	3	SENT_242	38615/38621
23	of	IN	O	of		-1	SENT_242	38622/38624
24	tocilizumab	NN	O	tocilizumab	prep_of	22	SENT_242	38625/38636
25	on	IN	O	on		-1	SENT_242	38637/38639
26	CYP	NN	O	cyp	nn	27	SENT_242	38640/38643
27	enzymes	NNS	O	enzyme	prep_on	3	SENT_242	38644/38651
28	may	MD	O	may	aux	31	SENT_242	38652/38655
29	be	VB	O	be	cop	31	SENT_242	38656/38658
30	clinically	RB	O	clinically	advmod	31	SENT_242	38659/38669
31	relevant	JJ	O	relevant		-1	SENT_242	38670/38678
32	for	IN	O	for		-1	SENT_242	38679/38682
33	CYP450	NN	O	cyp450	nn	34	SENT_242	38683/38689
34	substrates	NNS	O	substrate	prep_for	31	SENT_242	38690/38700
35	with	IN	O	with		-1	SENT_242	38701/38705
36	narrow	JJ	O	narrow	amod	38	SENT_242	38706/38712
37	therapeutic	JJ	O	therapeutic	amod	38	SENT_242	38713/38724
38	index	NN	O	index	prep_with	31	SENT_242	38725/38730
39	,	,	O	,		-1	SENT_242	38730/38731
40	where	WRB	O	where	advmod	45	SENT_242	38732/38737
41	the	DT	O	the	det	42	SENT_242	38738/38741
42	dose	NN	O	dose	nsubjpass	45	SENT_242	38742/38746
43	is	VBZ	O	be	auxpass	45	SENT_242	38747/38749
44	individually	RB	O	individually	advmod	45	SENT_242	38750/38762
45	adjusted	VBN	O	adjust	advcl	31	SENT_242	38763/38771
46	.	.	O	.		-1	SENT_242	38771/38772

1	Upon	IN	O	upon		-1	SENT_243	38773/38777
2	initiation	NN	O	initiation	prep_upon	40	SENT_243	38778/38788
3	or	CC	O	or		-1	SENT_243	38789/38791
4	discontinuation	NN	O	discontinuation	conj_or	2	SENT_243	38792/38807
5	of	IN	O	of		-1	SENT_243	38808/38810
6	ACTEMRA	NNP	LOCATION	ACTEMRA	prep_of	2	SENT_243	38811/38818
7	,	,	O	,		-1	SENT_243	38818/38819
8	in	IN	O	in		-1	SENT_243	38820/38822
9	patients	NNS	O	patient	prep_in	40	SENT_243	38823/38831
10	being	VBG	O	be	auxpass	11	SENT_243	38832/38837
11	treated	VBN	O	treat	partmod	9	SENT_243	38838/38845
12	with	IN	O	with		-1	SENT_243	38846/38850
13	these	DT	O	these	det	14	SENT_243	38851/38856
14	types	NNS	O	type	prep_with	11	SENT_243	38857/38862
15	of	IN	O	of		-1	SENT_243	38863/38865
16	medicinal	JJ	O	medicinal	amod	17	SENT_243	38866/38875
17	products	NNS	O	product	prep_of	14	SENT_243	38876/38884
18	,	,	O	,		-1	SENT_243	38884/38885
19	therapeutic	JJ	O	therapeutic	amod	20	SENT_243	38886/38897
20	monitoring	NN	O	monitoring	appos	17	SENT_243	38898/38908
21	of	IN	O	of		-1	SENT_243	38909/38911
22	effect	NN	O	effect	prep_of	17	SENT_243	38912/38918
23	(	CD	NUMBER	(	num	22	SENT_243	38919/38920
24	e.g.	FW	O	e.g.	amod	17	SENT_243	38920/38924
25	,	,	O	,		-1	SENT_243	38924/38925
26	warfarin	NN	O	warfarin	nn	27	SENT_243	38926/38934
27	)	NN	O	)	dep	24	SENT_243	38934/38935
28	or	CC	O	or		-1	SENT_243	38936/38938
29	drug	NN	O	drug	nn	30	SENT_243	38939/38943
30	concentration	NN	O	concentration	conj_or	27	SENT_243	38944/38957
31	(	CD	NUMBER	(	dep	27	SENT_243	38958/38959
32	e.g.	FW	O	e.g.	dep	31	SENT_243	38959/38963
33	,	,	O	,		-1	SENT_243	38963/38964
34	cyclosporine	NN	O	cyclosporine	nn	37	SENT_243	38965/38977
35	or	CC	O	or		-1	SENT_243	38978/38980
36	theophylline	NN	O	theophylline	conj_or	34	SENT_243	38981/38993
37	)	NN	O	)	nsubjpass	40	SENT_243	38993/38994
38	should	MD	O	should	aux	40	SENT_243	38995/39001
39	be	VB	O	be	auxpass	40	SENT_243	39002/39004
40	performed	VBN	O	perform		-1	SENT_243	39005/39014
41	and	CC	O	and		-1	SENT_243	39015/39018
42	the	DT	O	the	det	44	SENT_243	39019/39022
43	individual	JJ	O	individual	amod	44	SENT_243	39023/39033
44	dose	NN	O	dose	nsubj	49	SENT_243	39034/39038
45	of	IN	O	of		-1	SENT_243	39039/39041
46	the	DT	O	the	det	48	SENT_243	39042/39045
47	medicinal	JJ	O	medicinal	amod	48	SENT_243	39046/39055
48	product	NN	O	product	prep_of	44	SENT_243	39056/39063
49	adjusted	VBN	O	adjust	conj_and	40	SENT_243	39064/39072
50	as	IN	O	as		-1	SENT_243	39073/39075
51	needed	VBN	O	need	prep_as	49	SENT_243	39076/39082
52	.	.	O	.		-1	SENT_243	39082/39083

1	Prescribers	NNS	O	prescriber	nsubj	3	SENT_244	39084/39095
2	should	MD	O	should	aux	3	SENT_244	39096/39102
3	exercise	VB	O	exercise		-1	SENT_244	39103/39111
4	caution	NN	O	caution	dobj	3	SENT_244	39112/39119
5	when	WRB	O	when	advmod	8	SENT_244	39120/39124
6	ACTEMRA	NNP	ORGANIZATION	ACTEMRA	nsubjpass	8	SENT_244	39125/39132
7	is	VBZ	O	be	auxpass	8	SENT_244	39133/39135
8	co-administered	VBN	O	co-administer	advcl	3	SENT_244	39136/39151
9	with	IN	O	with		-1	SENT_244	39152/39156
10	CYP3A4	NN	O	cyp3a4	nn	12	SENT_244	39157/39163
11	substrate	NN	O	substrate	nn	12	SENT_244	39164/39173
12	drugs	NNS	O	drug	prep_with	8	SENT_244	39174/39179
13	where	WRB	O	where	advmod	18	SENT_244	39180/39185
14	decrease	NN	O	decrease	nsubj	18	SENT_244	39186/39194
15	in	IN	O	in		-1	SENT_244	39195/39197
16	effectiveness	NN	O	effectiveness	prep_in	14	SENT_244	39198/39211
17	is	VBZ	O	be	cop	18	SENT_244	39212/39214
18	undesirable	JJ	O	undesirable	rcmod	12	SENT_244	39215/39226
19	,	,	O	,		-1	SENT_244	39226/39227
20	e.g.	FW	O	e.g.	appos	12	SENT_244	39228/39232
21	,	,	O	,		-1	SENT_244	39232/39233
22	oral	JJ	O	oral	amod	23	SENT_244	39234/39238
23	contraceptives	NNS	O	contraceptive	appos	20	SENT_244	39239/39253
24	,	,	O	,		-1	SENT_244	39253/39254
25	lovastatin	NN	O	lovastatin	appos	20	SENT_244	39255/39265
26	,	,	O	,		-1	SENT_244	39265/39266
27	atorvastatin	NN	O	atorvastatin	appos	20	SENT_244	39267/39279
28	,	,	O	,		-1	SENT_244	39279/39280
29	etc.	FW	O	etc.	appos	20	SENT_244	39281/39284
30	.	.	O	.		-1	SENT_244	39284/39285

1	The	DT	O	the	det	2	SENT_245	39286/39289
2	effect	NN	O	effect	nsubj	10	SENT_245	39290/39296
3	of	IN	O	of		-1	SENT_245	39297/39299
4	tocilizumab	NN	O	tocilizumab	prep_of	2	SENT_245	39300/39311
5	on	IN	O	on		-1	SENT_245	39312/39314
6	CYP450	NN	O	cyp450	nn	8	SENT_245	39315/39321
7	enzyme	NN	O	enzyme	nn	8	SENT_245	39322/39328
8	activity	NN	O	activity	prep_on	4	SENT_245	39329/39337
9	may	MD	O	may	aux	10	SENT_245	39338/39341
10	persist	VB	O	persist		-1	SENT_245	39342/39349
11	for	IN	O	for		-1	SENT_245	39350/39353
12	several	JJ	DURATION	several	amod	13	SENT_245	39354/39361
13	weeks	NNS	DURATION	week	prep_for	10	SENT_245	39362/39367
14	after	IN	O	after		-1	SENT_245	39368/39373
15	stopping	VBG	O	stop	prepc_after	10	SENT_245	39374/39382
16	therapy	NN	O	therapy	nn	17	SENT_245	39383/39390
17	[	NN	O	[	nsubj	18	SENT_245	39391/39392
18	see	VBP	O	see	ccomp	15	SENT_245	39392/39395
19	Clinical	JJ	O	clinical	amod	21	SENT_245	39396/39404
20	Pharmacology	NN	O	pharmacology	nn	21	SENT_245	39405/39417
21	(	NN	O	(	dobj	18	SENT_245	39418/39419
22	12.3	CD	NUMBER	12.3	number	23	SENT_245	39419/39423
23	)	CD	NUMBER	)	dep	21	SENT_245	39423/39424
24	]	NN	O	]	dep	23	SENT_245	39424/39425
25	2	CD	NUMBER	2	num	24	SENT_245	39427/39428
26	.	.	O	.		-1	SENT_245	39428/39429

1	Immunosuppressive	JJ	O	immunosuppressive	amod	6	SENT_246	39430/39447
2	effect	NN	O	effect	nn	6	SENT_246	39448/39454
3	Infliximab	NNP	O	Infliximab	nn	6	SENT_246	39456/39466
4	(	NNP	O	(	nn	6	SENT_246	39467/39468
5	Remicade	NNP	O	Remicade	nn	6	SENT_246	39468/39476
6	)	NN	O	)	nsubj	23	SENT_246	39476/39477
7	7	CD	NUMBER	7	num	9	SENT_246	39479/39480
8	Drug	NN	O	drug	nn	9	SENT_246	39481/39485
9	interactions	NNS	O	interaction	dep	6	SENT_246	39486/39498
10	7.3	CD	NUMBER	7.3	num	11	SENT_246	39500/39503
11	Methotrexate	NNP	O	Methotrexate	dep	6	SENT_246	39504/39516
12	(	CD	NUMBER	(	num	11	SENT_246	39517/39518
13	MTX	NNP	O	MTX	dep	11	SENT_246	39518/39521
14	)	CD	NUMBER	)	num	13	SENT_246	39521/39522
15	and	CC	O	and		-1	SENT_246	39523/39526
16	other	JJ	O	other	amod	18	SENT_246	39527/39532
17	concomitant	JJ	O	concomitant	amod	18	SENT_246	39533/39544
18	medications	NNS	O	medication	conj_and	11	SENT_246	39545/39556
19	Concomitant	JJ	O	concomitant	amod	21	SENT_246	39558/39569
20	MTX	NN	O	mtx	nn	21	SENT_246	39570/39573
21	use	NN	O	use	dep	18	SENT_246	39574/39577
22	may	MD	O	may	aux	23	SENT_246	39578/39581
23	decrease	VB	O	decrease		-1	SENT_246	39582/39590
24	the	DT	O	the	det	25	SENT_246	39591/39594
25	incidence	NN	O	incidence	dobj	23	SENT_246	39595/39604
26	of	IN	O	of		-1	SENT_246	39605/39607
27	anti-infliximab	JJ	O	anti-infliximab	amod	29	SENT_246	39608/39623
28	antibody	NN	O	antibody	nn	29	SENT_246	39624/39632
29	production	NN	O	production	prep_of	25	SENT_246	39633/39643
30	and	CC	O	and		-1	SENT_246	39644/39647
31	increase	NN	O	increase	nn	33	SENT_246	39648/39656
32	infliximab	NN	O	infliximab	nn	33	SENT_246	39657/39667
33	concentrations	NNS	O	concentration	conj_and	25	SENT_246	39668/39682
34	3	CD	NUMBER	3	dep	33	SENT_246	39684/39685
35	.	.	O	.		-1	SENT_246	39685/39686

1	Mechanisms	NNS	O	mechanism	nsubj	12	SENT_247	39687/39697
2	to	TO	O	to	aux	4	SENT_247	39698/39700
3	be	VB	O	be	auxpass	4	SENT_247	39701/39703
4	elucidated	VBN	O	elucidate	infmod	1	SENT_247	39704/39714
5	Palifermin	JJ	O	palifermin	amod	11	SENT_247	39716/39726
6	(	NN	O	(	nn	11	SENT_247	39727/39728
7	Kepivance	NN	O	kepivance	nn	11	SENT_247	39728/39737
8	)	NN	O	)	nn	11	SENT_247	39737/39738
9	7	CD	NUMBER	7	num	11	SENT_247	39740/39741
10	Drug	NN	O	drug	nn	11	SENT_247	39742/39746
11	interactions	NNS	O	interaction	xcomp	4	SENT_247	39747/39759
12	Avoid	VBP	O	avoid		-1	SENT_247	39761/39766
13	co-administration	NN	O	co-administration	dobj	12	SENT_247	39767/39784
14	of	IN	O	of		-1	SENT_247	39785/39787
15	palifermin	NN	O	palifermin	prep_of	13	SENT_247	39788/39798
16	with	IN	O	with		-1	SENT_247	39799/39803
17	heparin	NN	O	heparin	prep_with	12	SENT_247	39804/39811
18	.	.	O	.		-1	SENT_247	39811/39812

1	If	IN	O	if	mark	4	SENT_248	39813/39815
2	heparin	NN	O	heparin	nsubjpass	4	SENT_248	39816/39823
3	is	VBZ	O	be	auxpass	4	SENT_248	39824/39826
4	used	VBN	O	use	advcl	11	SENT_248	39827/39831
5	to	TO	O	to	aux	6	SENT_248	39832/39834
6	maintain	VB	O	maintain	xcomp	4	SENT_248	39835/39843
7	an	DT	O	a	det	9	SENT_248	39844/39846
8	intravenous	JJ	O	intravenous	amod	9	SENT_248	39847/39858
9	line	NN	O	line	dobj	6	SENT_248	39859/39863
10	,	,	O	,		-1	SENT_248	39863/39864
11	rinse	VB	O	rinse	dep	49	SENT_248	39865/39870
12	the	DT	O	the	det	13	SENT_248	39871/39874
13	line	NN	O	line	dobj	11	SENT_248	39875/39879
14	with	IN	O	with		-1	SENT_248	39880/39884
15	saline	NN	O	saline	prep_with	11	SENT_248	39885/39891
16	prior	RB	O	prior	advmod	15	SENT_248	39892/39897
17	to	TO	O	to	prep	16	SENT_248	39898/39900
18	and	CC	O	and		-1	SENT_248	39901/39904
19	after	IN	O	after		-1	SENT_248	39905/39910
20	Kepivance	NNP	PERSON	Kepivance	nn	24	SENT_248	39911/39920
21	administration	NN	O	administration	nn	24	SENT_248	39921/39935
22	Trastuzumab	NNP	O	Trastuzumab	nn	24	SENT_248	39937/39948
23	(	NNP	O	(	nn	24	SENT_248	39949/39950
24	Herceptin	NNP	ORGANIZATION	Herceptin	prep_after	40	SENT_248	39950/39959
25	)	NN	O	)	nn	28	SENT_248	39959/39960
26	7	CD	NUMBER	7	num	28	SENT_248	39962/39963
27	Drug	NN	O	drug	nn	28	SENT_248	39964/39968
28	interactions	NNS	O	interaction	npadvmod	40	SENT_248	39969/39981
29	In	IN	O	in		-1	SENT_248	39983/39985
30	clinical	JJ	O	clinical	amod	31	SENT_248	39986/39994
31	studies	NNS	O	study	prep_in	40	SENT_248	39995/40002
32	,	,	O	,		-1	SENT_248	40002/40003
33	administration	NN	O	administration	nsubj	40	SENT_248	40004/40018
34	of	IN	O	of		-1	SENT_248	40019/40021
35	paclitaxel	NN	O	paclitaxel	prep_of	33	SENT_248	40022/40032
36	in	IN	O	in		-1	SENT_248	40033/40035
37	combination	NN	O	combination	prep_in	35	SENT_248	40036/40047
38	with	IN	O	with		-1	SENT_248	40048/40052
39	Herceptin	NN	O	herceptin	prep_with	37	SENT_248	40053/40062
40	resulted	VBD	O	result	conj_and	11	SENT_248	40063/40071
41	in	IN	O	in		-1	SENT_248	40072/40074
42	a	DT	O	a	det	44	SENT_248	40075/40076
43	1.5-fold	JJ	O	1.5-fold	amod	44	SENT_248	40077/40085
44	increase	NN	O	increase	prep_in	40	SENT_248	40086/40094
45	in	IN	O	in		-1	SENT_248	40095/40097
46	Trastuzumab	JJ	LOCATION	trastuzumab	amod	48	SENT_248	40098/40109
47	serum	NN	O	serum	nn	48	SENT_248	40110/40115
48	levels	NNS	O	level	prep_in	40	SENT_248	40116/40122
49	[	VBP	O	[		-1	SENT_248	40123/40124
50	see	VB	O	see	xcomp	49	SENT_248	40124/40127
51	Clinical	JJ	O	clinical	amod	53	SENT_248	40128/40136
52	Pharmacology	NN	O	pharmacology	nn	53	SENT_248	40137/40149
53	(	NN	O	(	dobj	50	SENT_248	40150/40151
54	12.3	CD	NUMBER	12.3	tmod	50	SENT_248	40151/40155
55	)	CD	NUMBER	)	num	56	SENT_248	40155/40156
56	]	NN	O	]	nsubj	49	SENT_248	40156/40157

1	CYP	NN	O	cyp		-1	SENT_249	40178/40181
2	enzyme	NN	O	enzyme	nn	3	SENT_249	40182/40188
3	modulation	NN	O	modulation	dep	1	SENT_249	40189/40199
4	by	IN	O	by		-1	SENT_249	40200/40202
5	cytokines	NNS	O	cytokine	prep_by	3	SENT_249	40203/40212
6	and	CC	O	and		-1	SENT_249	40213/40216
7	cytokine	NN	O	cytokine	nn	8	SENT_249	40217/40225
8	modulators	NNS	O	modulator	conj_and	5	SENT_249	40226/40236

1	Tocilizumab	NNP	O	Tocilizumab	nsubjpass	3	SENT_250	40272/40283
2	was	VBD	O	be	auxpass	3	SENT_250	40284/40287
3	used	VBN	O	use		-1	SENT_250	40288/40292
4	as	IN	O	as		-1	SENT_250	40293/40295
5	an	DT	O	a	det	6	SENT_250	40296/40298
6	example	NN	O	example	prep_as	3	SENT_250	40299/40306
7	to	TO	O	to	aux	8	SENT_250	40307/40309
8	illustrate	VB	O	illustrate	xcomp	3	SENT_250	40310/40320
9	the	DT	O	the	det	10	SENT_250	40321/40324
10	effect	NN	O	effect	dobj	8	SENT_250	40325/40331
11	of	IN	O	of		-1	SENT_250	40332/40334
12	cytokine	NN	O	cytokine	nn	13	SENT_250	40335/40343
13	modulators	NNS	O	modulator	prep_of	10	SENT_250	40344/40354
14	on	IN	O	on		-1	SENT_250	40355/40357
15	CYP	NN	O	cyp	nn	16	SENT_250	40358/40361
16	enzymes	NNS	O	enzyme	prep_on	8	SENT_250	40362/40369
17	.	.	O	.		-1	SENT_250	40369/40370

1	CYP	NN	O	cyp	nn	2	SENT_251	40371/40374
2	enzymes	NNS	O	enzyme	nsubjpass	7	SENT_251	40375/40382
3	in	IN	O	in		-1	SENT_251	40383/40385
4	the	DT	O	the	det	5	SENT_251	40386/40389
5	liver	NN	O	liver	prep_in	2	SENT_251	40390/40395
6	are	VBP	O	be	auxpass	7	SENT_251	40396/40399
7	downregulated	VBN	O	downregulate		-1	SENT_251	40400/40413
8	by	IN	O	by		-1	SENT_251	40414/40416
9	infection	NN	O	infection	nn	12	SENT_251	40417/40426
10	and	CC	O	and		-1	SENT_251	40427/40430
11	inflammation	NN	O	inflammation	conj_and	9	SENT_251	40431/40443
12	stimuli	NNS	O	stimulus	agent	7	SENT_251	40444/40451
13	including	VBG	O	include		-1	SENT_251	40452/40461
14	cytokines	NNS	O	cytokine	prep_including	12	SENT_251	40462/40471
15	such	JJ	O	such		-1	SENT_251	40472/40476
16	as	IN	O	as		-1	SENT_251	40477/40479
17	IL-6	NN	O	il-6	prep_such_as	14	SENT_251	40480/40484
18	.	.	O	.		-1	SENT_251	40484/40485

1	Inhibition	NN	O	inhibition	nsubj	12	SENT_252	40486/40496
2	of	IN	O	of		-1	SENT_252	40497/40499
3	IL-6	NN	O	il-6	nn	4	SENT_252	40500/40504
4	signaling	NN	O	signaling	prep_of	1	SENT_252	40505/40514
5	in	IN	O	in		-1	SENT_252	40515/40517
6	RA	NN	O	ra	nn	7	SENT_252	40518/40520
7	patients	NNS	O	patient	prep_in	4	SENT_252	40521/40529
8	treated	VBN	O	treat	partmod	7	SENT_252	40530/40537
9	with	IN	O	with		-1	SENT_252	40538/40542
10	tocilizumab	NN	O	tocilizumab	prep_with	8	SENT_252	40543/40554
11	may	MD	O	may	aux	12	SENT_252	40555/40558
12	restore	VB	O	restore		-1	SENT_252	40559/40566
13	CYP	NN	O	cyp	nn	14	SENT_252	40567/40570
14	activities	NNS	O	activity	dobj	12	SENT_252	40571/40581
15	to	TO	O	to		-1	SENT_252	40582/40584
16	higher	JJR	O	higher	amod	17	SENT_252	40585/40591
17	levels	NNS	O	level	prep_to	12	SENT_252	40592/40598
18	than	IN	O	than		-1	SENT_252	40599/40603
19	those	DT	O	those	prep_than	12	SENT_252	40604/40609
20	not	RB	O	not	neg	21	SENT_252	40610/40613
21	treated	VBN	O	treat	partmod	19	SENT_252	40614/40621
22	with	IN	O	with		-1	SENT_252	40622/40626
23	tocilizumab	JJ	O	tocilizumab	prep_with	21	SENT_252	40627/40638
24	leading	VBG	O	lead	amod	23	SENT_252	40639/40646
25	to	TO	O	to		-1	SENT_252	40647/40649
26	increased	VBN	O	increase	amod	27	SENT_252	40650/40659
27	metabolism	NN	O	metabolism	prep_to	23	SENT_252	40660/40670
28	of	IN	O	of		-1	SENT_252	40671/40673
29	drugs	NNS	O	drug	prep_of	27	SENT_252	40674/40679
30	that	WDT	O	that	nsubj	33	SENT_252	40680/40684
31	are	VBP	O	be	cop	33	SENT_252	40685/40688
32	CYP	NNP	O	CYP	nn	33	SENT_252	40689/40692
33	substrates	NNS	O	substrate	rcmod	29	SENT_252	40693/40703
34	.	.	O	.		-1	SENT_252	40703/40704

1	As	IN	O	as	mark	11	SENT_253	40705/40707
2	stated	VBN	O	state	csubj	11	SENT_253	40708/40714
3	earlier	RBR	O	earlier	advmod	2	SENT_253	40715/40722
4	in	IN	O	in		-1	SENT_253	40723/40725
5	this	DT	O	this	det	6	SENT_253	40726/40730
6	paper	NN	O	paper	prep_in	2	SENT_253	40731/40736
7	,	,	O	,		-1	SENT_253	40736/40737
8	in	FW	O	in	dep	2	SENT_253	40738/40740
9	vivo	FW	O	vivo	nn	10	SENT_253	40741/40745
10	studies	NNS	O	study	pobj	8	SENT_253	40746/40753
11	showed	VBD	O	show	advcl	36	SENT_253	40754/40760
12	that	IN	O	that	mark	27	SENT_253	40761/40765
13	the	DT	O	the	det	14	SENT_253	40766/40769
14	exposure	NN	O	exposure	nsubj	27	SENT_253	40770/40778
15	of	IN	O	of		-1	SENT_253	40779/40781
16	omeprazole	NN	O	omeprazole	prep_of	14	SENT_253	40782/40792
17	(	CD	NUMBER	(	num	16	SENT_253	40793/40794
18	a	DT	O	a	det	19	SENT_253	40794/40795
19	substrate	NN	O	substrate	dep	16	SENT_253	40796/40805
20	of	IN	O	of		-1	SENT_253	40806/40808
21	CYP2C19	NN	O	cyp2c19	nn	24	SENT_253	40809/40816
22	and	CC	O	and		-1	SENT_253	40817/40820
23	CYP3A4	NN	O	cyp3a4	conj_and	21	SENT_253	40821/40827
24	)	NN	O	)	prep_of	19	SENT_253	40827/40828
25	and	CC	O	and		-1	SENT_253	40829/40832
26	simvastatin	NN	O	simvastatin	conj_and	24	SENT_253	40833/40844
27	(	VBP	O	(	ccomp	11	SENT_253	40845/40846
28	a	DT	O	a	det	29	SENT_253	40846/40847
29	substrate	NN	O	substrate	dobj	27	SENT_253	40848/40857
30	of	IN	O	of		-1	SENT_253	40858/40860
31	CYP3A4	NN	O	cyp3a4	prep_of	29	SENT_253	40861/40867
32	and	CC	O	and		-1	SENT_253	40868/40871
33	transporter	NN	O	transporter	conj_and	31	SENT_253	40872/40883
34	OATP1B1	NN	O	oatp1b1	nsubj	36	SENT_253	40884/40891
35	)	CD	NUMBER	)	num	34	SENT_253	40891/40892
36	decreased	VBD	O	decrease		-1	SENT_253	40893/40902
37	1	CD	DURATION	1	num	38	SENT_253	40903/40904
38	week	NN	NUMBER	week	dobj	36	SENT_253	40905/40909
39	following	VBG	O	follow		-1	SENT_253	40910/40919
40	a	DT	O	a	det	42	SENT_253	40920/40921
41	single	JJ	O	single	amod	42	SENT_253	40922/40928
42	dose	NN	O	dose	prep_following	38	SENT_253	40929/40933
43	of	IN	O	of		-1	SENT_253	40934/40936
44	tocilizumab	NN	O	tocilizumab	prep_of	42	SENT_253	40937/40948
45	.	.	O	.		-1	SENT_253	40948/40949

1	Immunosuppressive	JJ	O	immunosuppressive	amod	2	SENT_254	40985/41002
2	effect	NN	O	effect		-1	SENT_254	41003/41009

1	MTX	NNP	O	MTX	nsubj	7	SENT_255	41045/41048
2	,	,	O	,		-1	SENT_255	41048/41049
3	an	DT	O	a	det	5	SENT_255	41050/41052
4	immunosuppressive	JJ	O	immunosuppressive	amod	5	SENT_255	41053/41070
5	agent	NN	O	agent	appos	1	SENT_255	41071/41076
6	,	,	O	,		-1	SENT_255	41076/41077
7	reduced	VBD	O	reduce		-1	SENT_255	41078/41085
8	the	DT	O	the	det	10	SENT_255	41086/41089
9	apparent	JJ	O	apparent	amod	10	SENT_255	41090/41098
10	clearance	NN	O	clearance	nsubj	14	SENT_255	41099/41108
11	of	IN	O	of		-1	SENT_255	41109/41111
12	infliximab	NN	O	infliximab	prep_of	10	SENT_255	41112/41122
13	likely	RB	O	likely	advmod	14	SENT_255	41123/41129
14	due	JJ	O	due	xcomp	7	SENT_255	41130/41133
15	to	TO	O	to		-1	SENT_255	41134/41136
16	the	DT	O	the	det	18	SENT_255	41137/41140
17	reduced	VBN	O	reduce	amod	18	SENT_255	41141/41148
18	incidence	NN	O	incidence	prep_to	14	SENT_255	41149/41158
19	of	IN	O	of		-1	SENT_255	41159/41161
20	anti-infliximab	JJ	O	anti-infliximab	amod	21	SENT_255	41162/41177
21	formation	NN	O	formation	prep_of	18	SENT_255	41178/41187
22	.	.	O	.		-1	SENT_255	41187/41188

1	At	IN	O	at		-1	SENT_256	41189/41191
2	8	CD	DURATION	8	num	3	SENT_256	41192/41193
3	weeks	NNS	NUMBER	week	prep_at	18	SENT_256	41194/41199
4	after	IN	O	after		-1	SENT_256	41200/41205
5	a	DT	O	a	det	7	SENT_256	41206/41207
6	maintenance	NN	O	maintenance	nn	7	SENT_256	41208/41219
7	dose	NN	O	dose	prep_after	3	SENT_256	41220/41224
8	of	IN	O	of		-1	SENT_256	41225/41227
9	3-10	CD	NUMBER	3-10	num	10	SENT_256	41228/41232
10	mg/kg	NN	O	mg/kg	prep_of	7	SENT_256	41233/41238
11	of	IN	O	of		-1	SENT_256	41239/41241
12	infliximab	NN	O	infliximab	prep_of	10	SENT_256	41242/41252
13	,	,	O	,		-1	SENT_256	41252/41253
14	median	JJ	O	median	amod	17	SENT_256	41254/41260
15	infliximab	NN	O	infliximab	nn	17	SENT_256	41261/41271
16	serum	NN	O	serum	nn	17	SENT_256	41272/41277
17	concentrations	NNS	O	concentration	nsubj	18	SENT_256	41278/41292
18	ranged	VBD	O	range		-1	SENT_256	41293/41299
19	from	IN	O	from		-1	SENT_256	41300/41304
20	approximately	RB	O	approximately	quantmod	21	SENT_256	41305/41318
21	0.5-6	CD	NUMBER	0.5-6	num	22	SENT_256	41319/41324
22	mcg/mL	NN	O	mcg/ml	prep_from	18	SENT_256	41325/41331
23	;	:	O	;		-1	SENT_256	41331/41332
24	however	RB	O	however	advmod	32	SENT_256	41333/41340
25	,	,	O	,		-1	SENT_256	41340/41341
26	infliximab	NN	O	infliximab	nn	27	SENT_256	41342/41352
27	concentrations	NNS	O	concentration	nsubj	32	SENT_256	41353/41367
28	were	VBD	O	be	cop	32	SENT_256	41368/41372
29	not	RB	O	not	neg	32	SENT_256	41373/41376
30	detectable	JJ	O	detectable	amod	31	SENT_256	41377/41387
31	(	NN	O	(	dep	32	SENT_256	41388/41389
32	<	JJR	O	<	parataxis	18	SENT_256	41389/41390
33	0.1	CD	NUMBER	0.1	num	35	SENT_256	41390/41393
34	mcg/mL	NN	O	mcg/ml	nn	35	SENT_256	41394/41400
35	)	NN	O	)	dep	32	SENT_256	41400/41401
36	in	IN	O	in		-1	SENT_256	41402/41404
37	patients	NNS	O	patient	prep_in	35	SENT_256	41405/41413
38	who	WP	O	who	nsubj	39	SENT_256	41414/41417
39	tested	VBD	O	test	rcmod	32	SENT_256	41418/41424
40	positive	JJ	O	positive	amod	47	SENT_256	41425/41433
41	for	IN	O	for		-1	SENT_256	41434/41437
42	antibodies	NNS	O	antibody	prep_for	40	SENT_256	41438/41448
43	to	TO	O	to		-1	SENT_256	41449/41451
44	infliximab	NN	O	infliximab	nn	45	SENT_256	41452/41462
45	(	NN	O	(	prep_to	42	SENT_256	41463/41464
46	42	CD	NUMBER	42	num	45	SENT_256	41464/41466
47	)	NN	O	)	dobj	39	SENT_256	41466/41467
48	.	.	O	.		-1	SENT_256	41467/41468

1	The	DT	O	the	det	2	SENT_257	41469/41472
2	incidence	NN	O	incidence	nsubj	8	SENT_257	41473/41482
3	of	IN	O	of		-1	SENT_257	41483/41485
4	anti-infliximab	JJ	O	anti-infliximab	amod	5	SENT_257	41486/41501
5	antibody	NN	O	antibody	prep_of	2	SENT_257	41502/41510
6	was	VBD	O	be	cop	8	SENT_257	41511/41514
7	21	CD	PERCENT	21	num	8	SENT_257	41515/41517
8	%	NN	PERCENT	%		-1	SENT_257	41517/41518
9	and	CC	O	and		-1	SENT_257	41519/41522
10	7	CD	PERCENT	7	num	11	SENT_257	41523/41524
11	%	NN	PERCENT	%	conj_and	8	SENT_257	41524/41525
12	,	,	O	,		-1	SENT_257	41525/41526
13	respectively	RB	O	respectively	advmod	8	SENT_257	41527/41539
14	in	IN	O	in		-1	SENT_257	41540/41542
15	the	DT	O	the	det	16	SENT_257	41543/41546
16	absence	NN	O	absence	prep_in	8	SENT_257	41547/41554
17	and	CC	O	and		-1	SENT_257	41555/41558
18	presence	NN	O	presence	conj_and	16	SENT_257	41559/41567
19	of	IN	O	of		-1	SENT_257	41568/41570
20	MTX	NN	O	mtx	prep_of	16	SENT_257	41571/41574
21	at	IN	O	at	advmod	16	SENT_257	41575/41577
22	12	CD	DURATION	12	num	23	SENT_257	41578/41580
23	weeks	NNS	NUMBER	week	pobj	21	SENT_257	41581/41586
24	after	IN	O	after		-1	SENT_257	41587/41592
25	last	JJ	O	last	amod	27	SENT_257	41593/41597
26	infliximab	NN	O	infliximab	nn	27	SENT_257	41598/41608
27	infusion	NN	O	infusion	prep_after	21	SENT_257	41609/41617
28	at	IN	O	at		-1	SENT_257	41618/41620
29	a	DT	O	a	det	33	SENT_257	41621/41622
30	3	CD	NUMBER	3	num	33	SENT_257	41623/41624
31	mg/kg	NN	O	mg/kg	nn	33	SENT_257	41625/41630
32	dose	NN	O	dose	nn	33	SENT_257	41631/41635
33	(	NN	O	(	prep_at	21	SENT_257	41636/41637
34	23	CD	NUMBER	23	num	35	SENT_257	41637/41639
35	)	NN	O	)	dep	16	SENT_257	41639/41640
36	.	.	O	.		-1	SENT_257	41640/41641

1	Mechanisms	NNS	O	mechanism	nsubjpass	4	SENT_258	41677/41687
2	to	TO	O	to	aux	4	SENT_258	41688/41690
3	be	VB	O	be	auxpass	4	SENT_258	41691/41693
4	elucidated	VBN	O	elucidate		-1	SENT_258	41694/41704

1	The	DT	O	the	det	2	SENT_259	41740/41743
2	mechanism	NN	O	mechanism	nsubjpass	35	SENT_259	41744/41753
3	for	IN	O	for		-1	SENT_259	41754/41757
4	the	DT	O	the	det	7	SENT_259	41758/41761
5	observed	VBN	O	observe	amod	7	SENT_259	41762/41770
6	fivefold	JJ	O	fivefold	amod	7	SENT_259	41771/41779
7	increase	NN	O	increase	prep_for	2	SENT_259	41780/41788
8	in	IN	O	in		-1	SENT_259	41789/41791
9	the	DT	O	the	det	11	SENT_259	41792/41795
10	systemic	JJ	O	systemic	amod	11	SENT_259	41796/41804
11	exposure	NN	O	exposure	prep_in	7	SENT_259	41805/41813
12	of	IN	O	of		-1	SENT_259	41814/41816
13	palifermin	NN	O	palifermin	prep_of	11	SENT_259	41817/41827
14	,	,	O	,		-1	SENT_259	41827/41828
15	a	DT	O	a	det	20	SENT_259	41829/41830
16	recombinant	JJ	O	recombinant	amod	20	SENT_259	41831/41842
17	human	JJ	O	human	amod	20	SENT_259	41843/41848
18	keratinocyte	NN	O	keratinocyte	nn	20	SENT_259	41849/41861
19	growth	NN	O	growth	nn	20	SENT_259	41862/41868
20	factor	NN	O	factor	appos	13	SENT_259	41869/41875
21	,	,	O	,		-1	SENT_259	41875/41876
22	when	WRB	O	when	advmod	24	SENT_259	41877/41881
23	it	PRP	O	it	nsubj	24	SENT_259	41882/41884
24	was	VBD	O	be	rcmod	2	SENT_259	41885/41888
25	co	SYM	O	co	dep	27	SENT_259	41889/41891
26	-	:	O	-		-1	SENT_259	41891/41892
27	administered	VBN	O	administer	ccomp	24	SENT_259	41893/41905
28	with	IN	O	with		-1	SENT_259	41906/41910
29	heparin	NN	O	heparin	prep_with	27	SENT_259	41911/41918
30	,	,	O	,		-1	SENT_259	41918/41919
31	has	VBZ	O	have	aux	35	SENT_259	41920/41923
32	not	RB	O	not	neg	35	SENT_259	41924/41927
33	been	VBN	O	be	auxpass	35	SENT_259	41928/41932
34	fully	RB	O	fully	advmod	35	SENT_259	41933/41938
35	elucidated	VBN	O	elucidate		-1	SENT_259	41939/41949
36	.	.	O	.		-1	SENT_259	41949/41950

1	Also	RB	O	also	advmod	13	SENT_260	41951/41955
2	the	DT	O	the	det	3	SENT_260	41956/41959
3	mechanism	NN	O	mechanism	nsubj	13	SENT_260	41960/41969
4	for	IN	O	for		-1	SENT_260	41970/41973
5	paclitaxel	NN	O	paclitaxel	nn	7	SENT_260	41974/41984
6	increasing	VBG	O	increase	amod	7	SENT_260	41985/41995
7	trastuzumab	NN	O	trastuzumab	prep_for	3	SENT_260	41996/42007
8	systemic	JJ	O	systemic	amod	9	SENT_260	42008/42016
9	exposure	NN	O	exposure	dep	7	SENT_260	42017/42025
10	is	VBZ	O	be	cop	13	SENT_260	42026/42028
11	not	RB	O	not	neg	13	SENT_260	42029/42032
12	clear	JJ	O	clear	amod	13	SENT_260	42033/42038
13	(	NN	O	(		-1	SENT_260	42039/42040
14	Table	NNP	O	Table	nn	16	SENT_260	42040/42045
15	II	NNP	O	II	nn	16	SENT_260	42046/42048
16	)	NN	O	)	dep	13	SENT_260	42048/42049
17	.	.	O	.		-1	SENT_260	42049/42050

1	Possible	JJ	O	possible	amod	2	SENT_261	42086/42094
2	mechanisms	NNS	O	mechanism	nsubjpass	8	SENT_261	42095/42105
3	of	IN	O	of		-1	SENT_261	42106/42108
4	PD	NN	O	pd	nn	5	SENT_261	42109/42111
5	interactions	NNS	O	interaction	prep_of	2	SENT_261	42112/42124
6	were	VBD	O	be	auxpass	8	SENT_261	42125/42129
7	also	RB	O	also	advmod	8	SENT_261	42130/42134
8	discussed	VBN	O	discuss		-1	SENT_261	42135/42144
9	with	IN	O	with		-1	SENT_261	42145/42149
10	labelling	NN	O	labelling	nn	11	SENT_261	42150/42159
11	impact	NN	O	impact	prep_with	8	SENT_261	42160/42166
12	(	CD	NUMBER	(	num	15	SENT_261	42167/42168
13	Table	NNP	O	Table	nn	15	SENT_261	42168/42173
14	III	NNP	O	III	nn	15	SENT_261	42174/42177
15	)	NN	O	)	dep	11	SENT_261	42177/42178
16	.	.	O	.		-1	SENT_261	42178/42179

1	Table	NNP	O	Table	nn	2	SENT_262	42180/42185
2	III	NNP	O	III		-1	SENT_262	42186/42189

1	Examples	NNS	O	example		-1	SENT_263	42206/42214
2	of	IN	O	of		-1	SENT_263	42215/42217
3	Labeling	VBG	O	label	prepc_of	1	SENT_263	42218/42226
4	Dealing	VBG	O	deal	xcomp	3	SENT_263	42227/42234
5	with	IN	O	with		-1	SENT_263	42235/42239
6	TP-DI	NN	O	tp-di	nn	7	SENT_263	42240/42245
7	(	NN	O	(	prep_with	4	SENT_263	42246/42247
8	that	WDT	O	that	dobj	13	SENT_263	42247/42251
9	Result	NN	O	result	nsubj	13	SENT_263	42252/42258
10	in	IN	O	in		-1	SENT_263	42259/42261
11	Pharmacodynamic	JJ	O	pharmacodynamic	amod	12	SENT_263	42262/42277
12	Changes	NNS	O	change	prep_in	9	SENT_263	42278/42285
13	)	VBP	O	)	rcmod	7	SENT_263	42285/42286

1	Drug	NN	O	drug	nn	3	SENT_264	42303/42307
2	nameLabeling	NN	O	namelabeling	nn	3	SENT_264	42308/42320
3	language	NN	O	language		-1	SENT_264	42321/42329
4	1	CD	NUMBER	1	dep	3	SENT_264	42331/42332
5	.	.	O	.		-1	SENT_264	42332/42333

1	Growth	NN	O	growth	nn	2	SENT_265	42334/42340
2	factors	NNS	O	factor	nsubj	3	SENT_265	42341/42348
3	(	VBP	O	(		-1	SENT_265	42349/42350
4	Palifermin	NN	O	palifermin	nn	7	SENT_265	42350/42360
5	and	CC	O	and		-1	SENT_265	42361/42364
6	G-CSF	NN	O	g-csf	conj_and	4	SENT_265	42365/42370
7	)	NN	O	)	dobj	3	SENT_265	42370/42371
8	and	CC	O	and		-1	SENT_265	42372/42375
9	chemotherapy	NN	O	chemotherapy	nn	12	SENT_265	42376/42388
10	Palifermin	NN	O	palifermin	nn	12	SENT_265	42390/42400
11	(	NN	O	(	nn	12	SENT_265	42401/42402
12	Kepivance	NN	O	kepivance	conj_and	7	SENT_265	42402/42411
13	)	CD	NUMBER	)	num	15	SENT_265	42411/42412
14	Drug	NN	O	drug	nn	15	SENT_265	42414/42418
15	interactions	NNS	O	interaction	nsubj	18	SENT_265	42419/42431
16	Do	VBP	O	do	aux	18	SENT_265	42433/42435
17	not	RB	O	not	neg	18	SENT_265	42436/42439
18	administer	VB	O	administer	dep	3	SENT_265	42440/42450
19	Kepivance	NN	PERSON	kepivance	dobj	18	SENT_265	42451/42460
20	within	IN	O	within	prep	18	SENT_265	42461/42467
21	24	CD	NUMBER	24	num	22	SENT_265	42468/42470
22	h	NN	O	h	npadvmod	23	SENT_265	42471/42472
23	before	IN	O	before	pcomp	20	SENT_265	42473/42479
24	,	,	O	,		-1	SENT_265	42479/42480
25	during	IN	O	during	conj_or	20	SENT_265	42481/42487
26	infusion	NN	O	infusion	pobj	25	SENT_265	42488/42496
27	of	IN	O	of	prep	26	SENT_265	42497/42499
28	,	,	O	,		-1	SENT_265	42499/42500
29	or	CC	O	or		-1	SENT_265	42501/42503
30	within	IN	O	within	conj_or	20	SENT_265	42504/42510
31	24	CD	NUMBER	24	num	32	SENT_265	42511/42513
32	h	NN	O	h	pobj	30	SENT_265	42514/42515
33	after	IN	O	after	mark	39	SENT_265	42516/42521
34	administration	NN	O	administration	nsubj	39	SENT_265	42522/42536
35	of	IN	O	of		-1	SENT_265	42537/42539
36	myelotoxic	JJ	O	myelotoxic	amod	38	SENT_265	42540/42550
37	chemotherapy	NN	O	chemotherapy	nn	38	SENT_265	42551/42563
38	[	NN	O	[	prep_of	34	SENT_265	42564/42565
39	see	VBP	O	see	dep	32	SENT_265	42565/42568
40	Dosage	NN	O	dosage	nn	45	SENT_265	42569/42575
41	and	CC	O	and		-1	SENT_265	42576/42579
42	Administration	NN	O	administration	conj_and	40	SENT_265	42580/42594
43	(	NN	O	(	nn	45	SENT_265	42595/42596
44	2.2	CD	NUMBER	2.2	num	45	SENT_265	42596/42599
45	)	NN	O	)	dobj	39	SENT_265	42599/42600
46	and	CC	O	and		-1	SENT_265	42601/42604
47	Clinical	JJ	O	clinical	amod	48	SENT_265	42605/42613
48	Studies	NNS	O	study	nsubj	49	SENT_265	42614/42621
49	(	VBP	O	(	conj_and	39	SENT_265	42622/42623
50	14	CD	NUMBER	14	num	52	SENT_265	42623/42625
51	)	CD	NUMBER	)	num	52	SENT_265	42625/42626
52	]	NN	O	]	dobj	49	SENT_265	42626/42627
53	.	.	O	.		-1	SENT_265	42627/42628

1	In	IN	O	in	dep	113	SENT_266	42629/42631
2	a	DT	O	a	dep	113	SENT_266	42632/42633
3	clinical	JJ	O	clinical	dep	113	SENT_266	42634/42642
4	trial	NN	O	trial	dep	113	SENT_266	42643/42648
5	,	,	O	,		-1	SENT_266	42648/42649
6	administration	NN	O	administration	dep	113	SENT_266	42650/42664
7	of	IN	O	of	dep	113	SENT_266	42665/42667
8	Kepivance	NN	LOCATION	kepivance	dep	113	SENT_266	42668/42677
9	within	IN	O	within	dep	113	SENT_266	42678/42684
10	24	CD	NUMBER	24	dep	113	SENT_266	42685/42687
11	h	NN	O	h	dep	113	SENT_266	42688/42689
12	of	IN	O	of	dep	113	SENT_266	42690/42692
13	chemotherapy	NN	O	chemotherapy	dep	113	SENT_266	42693/42705
14	resulted	VBD	O	result	dep	113	SENT_266	42706/42714
15	in	IN	O	in	dep	113	SENT_266	42715/42717
16	increased	VBN	O	increase	dep	113	SENT_266	42718/42727
17	severity	NN	O	severity	dep	113	SENT_266	42728/42736
18	and	CC	O	and	dep	113	SENT_266	42737/42740
19	duration	NN	O	duration	dep	113	SENT_266	42741/42749
20	of	IN	O	of	dep	113	SENT_266	42750/42752
21	oral	JJ	O	oral	dep	113	SENT_266	42753/42757
22	mucositis	NN	O	mucositis	dep	113	SENT_266	42758/42767
23	Filgrastim	NN	O	filgrastim	dep	113	SENT_266	42769/42779
24	(	CD	NUMBER	(	dep	113	SENT_266	42780/42781
25	Neupogen	NNP	ORGANIZATION	Neupogen	dep	113	SENT_266	42781/42789
26	)	CD	NUMBER	)	dep	113	SENT_266	42789/42790
27	Precautions	NNS	O	precaution	dep	113	SENT_266	42792/42803
28	Because	IN	O	because	dep	113	SENT_266	42805/42812
29	of	IN	O	of	dep	113	SENT_266	42813/42815
30	the	DT	O	the	dep	113	SENT_266	42816/42819
31	potential	JJ	O	potential	dep	113	SENT_266	42820/42829
32	sensitivity	NN	O	sensitivity	dep	113	SENT_266	42830/42841
33	of	IN	O	of	dep	113	SENT_266	42842/42844
34	rapidly	RB	O	rapidly	dep	113	SENT_266	42845/42852
35	dividing	VBG	O	divide	dep	113	SENT_266	42853/42861
36	myeloid	JJ	O	myeloid	dep	113	SENT_266	42862/42869
37	cells	NNS	O	cell	dep	113	SENT_266	42870/42875
38	to	TO	O	to	dep	113	SENT_266	42876/42878
39	cytotoxic	JJ	O	cytotoxic	dep	113	SENT_266	42879/42888
40	chemotherapy	NN	O	chemotherapy	dep	113	SENT_266	42889/42901
41	do	VBP	O	do	dep	113	SENT_266	42905/42907
42	not	RB	O	not	dep	113	SENT_266	42908/42911
43	use	VB	O	use	dep	113	SENT_266	42912/42915
44	NEUPOGEN	NNP	O	NEUPOGEN	dep	113	SENT_266	42916/42924
45	in	IN	O	in	dep	113	SENT_266	42927/42929
46	the	DT	O	the	dep	113	SENT_266	42930/42933
47	period	NN	O	period	dep	113	SENT_266	42934/42940
48	24	CD	NUMBER	24	dep	113	SENT_266	42941/42943
49	h	NN	O	h	dep	113	SENT_266	42944/42945
50	before	IN	O	before	dep	113	SENT_266	42946/42952
51	through	IN	O	through	dep	113	SENT_266	42953/42960
52	24	CD	NUMBER	24	dep	113	SENT_266	42961/42963
53	h	NN	O	h	dep	113	SENT_266	42964/42965
54	after	IN	O	after	dep	113	SENT_266	42966/42971
55	the	DT	O	the	dep	113	SENT_266	42972/42975
56	administration	NN	O	administration	dep	113	SENT_266	42976/42990
57	of	IN	O	of	dep	113	SENT_266	42991/42993
58	cytotoxic	JJ	O	cytotoxic	dep	113	SENT_266	42994/43003
59	chemotherapy	NN	O	chemotherapy	dep	113	SENT_266	43004/43016
60	(	NN	O	(	dep	113	SENT_266	43017/43018
61	see	VBP	O	see	dep	113	SENT_266	43018/43021
62	Dosage	NNP	O	Dosage	dep	113	SENT_266	43022/43028
63	and	CC	O	and	dep	113	SENT_266	43029/43032
64	Administration	NNP	ORGANIZATION	Administration	dep	113	SENT_266	43033/43047
65	)	CD	NUMBER	)	dep	113	SENT_266	43047/43048
66	Pegfilgrastim	NNP	O	Pegfilgrastim	dep	113	SENT_266	43050/43063
67	(	CD	NUMBER	(	dep	113	SENT_266	43064/43065
68	Neulasta	NNP	O	Neulasta	dep	113	SENT_266	43065/43073
69	)	CD	NUMBER	)	dep	113	SENT_266	43073/43074
70	NEULASTA	NNP	O	NEULASTA	dep	113	SENT_266	43076/43084
71	should	MD	O	should	dep	113	SENT_266	43087/43093
72	not	RB	O	not	dep	113	SENT_266	43094/43097
73	be	VB	O	be	dep	113	SENT_266	43098/43100
74	administered	VBN	O	administer	dep	113	SENT_266	43101/43113
75	in	IN	O	in	dep	113	SENT_266	43114/43116
76	the	DT	O	the	dep	113	SENT_266	43117/43120
77	period	NN	O	period	dep	113	SENT_266	43121/43127
78	between	IN	O	between	dep	113	SENT_266	43128/43135
79	14	CD	DURATION	14	dep	113	SENT_266	43136/43138
80	days	NNS	NUMBER	day	dep	113	SENT_266	43139/43143
81	before	IN	O	before	dep	113	SENT_266	43144/43150
82	and	CC	O	and	dep	113	SENT_266	43151/43154
83	24	CD	NUMBER	24	dep	113	SENT_266	43155/43157
84	h	NN	O	h	dep	113	SENT_266	43158/43159
85	after	IN	O	after	dep	113	SENT_266	43160/43165
86	administration	NN	O	administration	dep	113	SENT_266	43166/43180
87	of	IN	O	of	dep	113	SENT_266	43181/43183
88	cytotoxic	JJ	O	cytotoxic	dep	113	SENT_266	43184/43193
89	chemotherapy	NN	O	chemotherapy	dep	113	SENT_266	43194/43206
90	(	NN	O	(	dep	113	SENT_266	43207/43208
91	see	VBP	O	see	dep	113	SENT_266	43208/43211
92	Dosage	NN	O	dosage	dep	113	SENT_266	43212/43218
93	and	CC	O	and	dep	113	SENT_266	43219/43222
94	Administration	NN	O	administration	dep	113	SENT_266	43223/43237
95	)	NN	O	)	dep	113	SENT_266	43237/43238
96	because	IN	O	because	dep	113	SENT_266	43239/43246
97	of	IN	O	of	dep	113	SENT_266	43247/43249
98	the	DT	O	the	dep	113	SENT_266	43250/43253
99	potential	NN	O	potential	dep	113	SENT_266	43254/43263
100	for	IN	O	for	dep	113	SENT_266	43264/43267
101	an	DT	O	a	dep	113	SENT_266	43268/43270
102	increase	NN	O	increase	dep	113	SENT_266	43271/43279
103	in	IN	O	in	dep	113	SENT_266	43280/43282
104	sensitivity	NN	O	sensitivity	dep	113	SENT_266	43283/43294
105	of	IN	O	of	dep	113	SENT_266	43295/43297
106	rapidly	RB	O	rapidly	dep	113	SENT_266	43298/43305
107	dividing	VBG	O	divide	dep	113	SENT_266	43306/43314
108	myeloid	JJ	O	myeloid	dep	113	SENT_266	43315/43322
109	cells	NNS	O	cell	dep	113	SENT_266	43323/43328
110	to	TO	O	to	dep	113	SENT_266	43329/43331
111	cytotoxic	JJ	O	cytotoxic	dep	113	SENT_266	43332/43341
112	chemotherapy	NN	O	chemotherapy	dep	113	SENT_266	43342/43354
113	2	CD	NUMBER	2		-1	SENT_266	43356/43357
114	.	.	O	.		-1	SENT_266	43357/43358

1	Growth	NN	O	growth	nn	2	SENT_267	43359/43365
2	factors	NNS	O	factor		-1	SENT_267	43366/43373
3	and	CC	O	and		-1	SENT_267	43374/43377
4	myeloablative	JJ	O	myeloablative	amod	6	SENT_267	43378/43391
5	therapy	NN	O	therapy	nn	6	SENT_267	43392/43399
6	Oprelvekin	NN	O	oprelvekin	conj_and	2	SENT_267	43401/43411
7	(	CD	NUMBER	(	num	10	SENT_267	43412/43413
8	Neumega	NNP	O	Neumega	nn	10	SENT_267	43413/43420
9	)	CD	NUMBER	)	num	10	SENT_267	43420/43421
10	Warnings	NNS	O	warning	dep	2	SENT_267	43423/43431
11	(	CD	NUMBER	(	num	12	SENT_267	43432/43433
12	Neumega	NNP	O	Neumega	dep	10	SENT_267	43433/43440
13	)	CD	NUMBER	)	num	12	SENT_267	43440/43441
14	Increased	VBN	O	increase	amod	15	SENT_267	43443/43452
15	toxicity	NN	O	toxicity	nsubjpass	22	SENT_267	43453/43461
16	following	VBG	O	follow		-1	SENT_267	43462/43471
17	myeloablative	JJ	O	myeloablative	amod	19	SENT_267	43472/43485
18	therapy	NN	O	therapy	nn	19	SENT_267	43486/43493
19	Neumega	NNP	O	Neumega	prep_following	15	SENT_267	43495/43502
20	is	VBZ	O	be	auxpass	22	SENT_267	43503/43505
21	not	RB	O	not	neg	22	SENT_267	43506/43509
22	indicated	VBN	O	indicate	rcmod	2	SENT_267	43510/43519
23	following	VBG	O	follow		-1	SENT_267	43520/43529
24	myeloablative	JJ	O	myeloablative	amod	25	SENT_267	43530/43543
25	chemotherapy	NN	O	chemotherapy	prep_following	22	SENT_267	43544/43556
26	.	.	O	.		-1	SENT_267	43556/43557

1	In	IN	O	in		-1	SENT_268	43558/43560
2	a	DT	O	a	prep_in	16	SENT_268	43561/43562
3	randomized	VBN	O	randomize	partmod	2	SENT_268	43563/43573
4	,	,	O	,		-1	SENT_268	43573/43574
5	placebo-controlled	JJ	O	placebo-controlled	amod	6	SENT_268	43575/43593
6	phase	NN	O	phase	appos	2	SENT_268	43594/43599
7	2	CD	NUMBER	2	num	8	SENT_268	43600/43601
8	study	NN	O	study	dep	6	SENT_268	43602/43607
9	,	,	O	,		-1	SENT_268	43607/43608
10	the	DT	O	the	det	11	SENT_268	43609/43612
11	effectiveness	NN	O	effectiveness	nsubjpass	16	SENT_268	43613/43626
12	of	IN	O	of		-1	SENT_268	43627/43629
13	Neumega	NNP	O	Neumega	prep_of	11	SENT_268	43630/43637
14	was	VBD	O	be	auxpass	16	SENT_268	43638/43641
15	not	RB	O	not	neg	16	SENT_268	43642/43645
16	demonstrated	VBN	O	demonstrate		-1	SENT_268	43646/43658
17	(	NN	O	(	nsubj	18	SENT_268	43659/43660
18	see	VB	O	see	ccomp	16	SENT_268	43660/43663
19	Clinical	JJ	O	clinical	amod	20	SENT_268	43664/43672
20	Studies	NNS	O	study	dobj	18	SENT_268	43673/43680
21	,	,	O	,		-1	SENT_268	43680/43681
22	Study	NN	O	study	appos	20	SENT_268	43682/43687
23	in	IN	O	in		-1	SENT_268	43688/43690
24	Patients	NNS	O	patient	prep_in	22	SENT_268	43691/43699
25	Following	VBG	O	follow		-1	SENT_268	43700/43709
26	Myeloablative	JJ	O	myeloablative	amod	28	SENT_268	43710/43723
27	Chemotherapy	NN	O	chemotherapy	nn	28	SENT_268	43724/43736
28	)	NN	O	)	prep_following	24	SENT_268	43736/43737
29	.	.	O	.		-1	SENT_268	43737/43738

1	In	IN	O	in		-1	SENT_269	43739/43741
2	this	DT	O	this	det	3	SENT_269	43742/43746
3	study	NN	O	study	prep_in	21	SENT_269	43747/43752
4	,	,	O	,		-1	SENT_269	43752/43753
5	a	DT	O	a	det	9	SENT_269	43754/43755
6	statistically	RB	O	statistically	advmod	7	SENT_269	43756/43769
7	significant	JJ	O	significant	amod	9	SENT_269	43770/43781
8	increased	VBN	O	increase	amod	9	SENT_269	43782/43791
9	incidence	NN	O	incidence	nsubjpass	21	SENT_269	43792/43801
10	in	IN	O	in		-1	SENT_269	43802/43804
11	edema	NN	O	edema	prep_in	9	SENT_269	43805/43810
12	,	,	O	,		-1	SENT_269	43810/43811
13	conjunctival	JJ	O	conjunctival	amod	14	SENT_269	43812/43824
14	bleeding	NN	O	bleeding	conj_and	11	SENT_269	43825/43833
15	,	,	O	,		-1	SENT_269	43833/43834
16	hypotension	NN	O	hypotension	conj_and	11	SENT_269	43835/43846
17	,	,	O	,		-1	SENT_269	43846/43847
18	and	CC	O	and		-1	SENT_269	43848/43851
19	tachycardia	NN	O	tachycardia	conj_and	11	SENT_269	43852/43863
20	was	VBD	O	be	auxpass	21	SENT_269	43864/43867
21	observed	VBN	O	observe		-1	SENT_269	43868/43876
22	in	IN	O	in		-1	SENT_269	43877/43879
23	patients	NNS	O	patient	prep_in	21	SENT_269	43880/43888
24	receiving	VBG	O	receive	partmod	23	SENT_269	43889/43898
25	Neumega	NNP	O	Neumega	dobj	24	SENT_269	43899/43906
26	as	IN	O	as		-1	SENT_269	43907/43909
27	compared	VBN	O	compare	prepc_as	24	SENT_269	43910/43918
28	to	TO	O	to	pcomp	27	SENT_269	43919/43921
29	placebo	NN	O	placebo	pobj	28	SENT_269	43922/43929
30	.	.	O	.		-1	SENT_269	43929/43930

1	The	DT	O	the	nsubjpass	10	SENT_270	43932/43935
2	following	VBG	O	follow	amod	1	SENT_270	43936/43945
3	severe	JJ	O	severe	amod	1	SENT_270	43946/43952
4	or	CC	O	or		-1	SENT_270	43953/43955
5	fatal	JJ	O	fatal	conj_or	3	SENT_270	43956/43961
6	adverse	JJ	O	adverse	amod	7	SENT_270	43962/43969
7	reactions	NNS	O	reaction	nsubjpass	10	SENT_270	43970/43979
8	have	VBP	O	have	aux	10	SENT_270	43980/43984
9	been	VBN	O	be	auxpass	10	SENT_270	43985/43989
10	reported	VBN	O	report		-1	SENT_270	43990/43998
11	in	IN	O	in		-1	SENT_270	43999/44001
12	post	NN	O	post	prep_in	10	SENT_270	44002/44006
13	-	:	O	-		-1	SENT_270	44006/44007
14	marketing	NN	O	marketing	nn	15	SENT_270	44008/44017
15	use	NN	O	use	dep	12	SENT_270	44018/44021
16	in	IN	O	in		-1	SENT_270	44022/44024
17	patients	NNS	O	patient	prep_in	15	SENT_270	44025/44033
18	who	WP	O	who	nsubj	19	SENT_270	44034/44037
19	received	VBD	O	receive	rcmod	17	SENT_270	44038/44046
20	Neumega	NNP	O	Neumega	dobj	19	SENT_270	44047/44054
21	following	VBG	O	follow		-1	SENT_270	44055/44064
22	bone	NN	O	bone	nn	24	SENT_270	44065/44069
23	marrow	NN	O	marrow	nn	24	SENT_270	44070/44076
24	transplantation	NN	O	transplantation	prep_following	20	SENT_270	44077/44092
25	:	:	O	:		-1	SENT_270	44092/44093
26	fluid	NN	O	fluid	nn	27	SENT_270	44094/44099
27	retention	NN	O	retention	dep	31	SENT_270	44100/44109
28	or	CC	O	or		-1	SENT_270	44110/44112
29	overload	NN	O	overload	conj_or	27	SENT_270	44113/44121
30	(	CD	NUMBER	(	dep	31	SENT_270	44122/44123
31	e.g.	FW	O	e.g.	dep	53	SENT_270	44123/44127
32	,	,	O	,		-1	SENT_270	44127/44128
33	facial	JJ	O	facial	amod	34	SENT_270	44129/44135
34	edema	NN	O	edema	conj_and	31	SENT_270	44136/44141
35	,	,	O	,		-1	SENT_270	44141/44142
36	pulmonary	JJ	O	pulmonary	amod	38	SENT_270	44143/44152
37	edema	NN	O	edema	nn	38	SENT_270	44153/44158
38	)	NN	O	)	conj_and	31	SENT_270	44158/44159
39	,	,	O	,		-1	SENT_270	44159/44160
40	capillary	JJ	O	capillary	amod	42	SENT_270	44161/44170
41	leak	NN	O	leak	nn	42	SENT_270	44171/44175
42	syndrome	NN	O	syndrome	conj_and	31	SENT_270	44176/44184
43	,	,	O	,		-1	SENT_270	44184/44185
44	pleural	JJ	O	pleural	amod	47	SENT_270	44186/44193
45	and	CC	O	and		-1	SENT_270	44194/44197
46	pericardial	JJ	O	pericardial	conj_and	44	SENT_270	44198/44209
47	effusion	NN	O	effusion	conj_and	31	SENT_270	44210/44218
48	,	,	O	,		-1	SENT_270	44218/44219
49	papilledema	NN	O	papilledema	conj_and	31	SENT_270	44220/44231
50	and	CC	O	and		-1	SENT_270	44232/44235
51	renal	JJ	O	renal	amod	52	SENT_270	44236/44241
52	failure	NN	O	failure	conj_and	31	SENT_270	44242/44249
53	3	CD	NUMBER	3	dep	10	SENT_270	44251/44252
54	.	.	O	.		-1	SENT_270	44252/44253

1	Increased	VBN	O	increase	amod	2	SENT_271	44254/44263
2	toxicities	NNS	O	toxicity	nsubj	19	SENT_271	44264/44274
3	with	IN	O	with		-1	SENT_271	44275/44279
4	concurrent	JJ	O	concurrent	amod	7	SENT_271	44280/44290
5	therapy	NN	O	therapy	nn	7	SENT_271	44291/44298
6	(	NN	O	(	nn	7	SENT_271	44299/44300
7	proleukin	NN	O	proleukin	prep_with	2	SENT_271	44300/44309
8	and	CC	O	and		-1	SENT_271	44310/44313
9	psychotropic	NN	O	psychotropic	npadvmod	15	SENT_271	44314/44326
10	,	,	O	,		-1	SENT_271	44326/44327
11	nephrotoxic	NN	O	nephrotoxic	npadvmod	15	SENT_271	44328/44339
12	,	,	O	,		-1	SENT_271	44339/44340
13	myelotoxic	JJ	O	myelotoxic	amod	15	SENT_271	44341/44351
14	,	,	O	,		-1	SENT_271	44351/44352
15	cardiotoxic	JJ	O	cardiotoxic	conj_and	7	SENT_271	44353/44364
16	or	CC	O	or		-1	SENT_271	44365/44367
17	hepatotoxic	JJ	O	hepatotoxic	amod	18	SENT_271	44368/44379
18	drugs	NNS	O	drug	conj_or	7	SENT_271	44380/44385
19	)	VBP	O	)		-1	SENT_271	44385/44386
20	Aldesleukin	NNP	ORGANIZATION	Aldesleukin	nsubj	25	SENT_271	44388/44399
21	(	CD	NUMBER	(	num	25	SENT_271	44400/44401
22	Proleukin	NNP	O	Proleukin	nn	25	SENT_271	44401/44410
23	)	NNP	O	)	nn	25	SENT_271	44410/44411
24	Drug	NNP	O	Drug	nn	25	SENT_271	44413/44417
25	interactions	NNS	O	interaction	xcomp	19	SENT_271	44418/44430
26	PROLEUKIN	NNP	O	PROLEUKIN	nsubj	28	SENT_271	44432/44441
27	may	MD	O	may	aux	28	SENT_271	44442/44445
28	affect	VB	O	affect	rcmod	25	SENT_271	44446/44452
29	central	JJ	O	central	amod	31	SENT_271	44453/44460
30	nervous	JJ	O	nervous	amod	31	SENT_271	44461/44468
31	function	NN	O	function	dobj	28	SENT_271	44469/44477
32	.	.	O	.		-1	SENT_271	44477/44478

1	Therefore	RB	O	therefore	advmod	66	SENT_272	44479/44488
2	,	,	O	,		-1	SENT_272	44488/44489
3	interactions	NNS	O	interaction	nsubj	5	SENT_272	44490/44502
4	could	MD	O	could	aux	5	SENT_272	44503/44508
5	occur	VB	O	occur	parataxis	66	SENT_272	44509/44514
6	following	VBG	O	follow		-1	SENT_272	44515/44524
7	concomitant	JJ	O	concomitant	amod	8	SENT_272	44525/44536
8	administration	NN	O	administration	prep_following	5	SENT_272	44537/44551
9	of	IN	O	of		-1	SENT_272	44552/44554
10	psychotropic	JJ	O	psychotropic	amod	11	SENT_272	44555/44567
11	drugs	NNS	O	drug	prep_of	8	SENT_272	44568/44573
12	(	VBP	O	(	rcmod	11	SENT_272	44574/44575
13	e.g.	FW	O	e.g.	nsubj	24	SENT_272	44575/44579
14	,	,	O	,		-1	SENT_272	44579/44580
15	narcotics	NNS	O	narcotic	appos	13	SENT_272	44581/44590
16	,	,	O	,		-1	SENT_272	44590/44591
17	analgesics	NNS	O	analgesic	appos	13	SENT_272	44592/44602
18	,	,	O	,		-1	SENT_272	44602/44603
19	antiemetics	NNS	O	antiemetic	appos	13	SENT_272	44604/44615
20	,	,	O	,		-1	SENT_272	44615/44616
21	sedatives	NNS	O	sedative	appos	13	SENT_272	44617/44626
22	,	,	O	,		-1	SENT_272	44626/44627
23	tranquilizers	NNS	O	tranquilizer	appos	13	SENT_272	44628/44641
24	)	VBP	O	)	ccomp	12	SENT_272	44641/44642
25	Concurrent	JJ	O	concurrent	amod	26	SENT_272	44644/44654
26	administration	NN	O	administration	nsubj	29	SENT_272	44655/44669
27	of	IN	O	of		-1	SENT_272	44670/44672
28	drugs	NNS	O	drug	prep_of	26	SENT_272	44673/44678
29	possessing	VBG	O	possess	dep	24	SENT_272	44679/44689
30	nephrotoxic	JJ	O	nephrotoxic	amod	31	SENT_272	44690/44701
31	(	NN	O	(	dobj	29	SENT_272	44702/44703
32	e.g.	FW	O	e.g.	dep	49	SENT_272	44703/44707
33	,	,	O	,		-1	SENT_272	44707/44708
34	aminoglycosides	NNS	O	aminoglycoside	appos	32	SENT_272	44709/44724
35	,	,	O	,		-1	SENT_272	44724/44725
36	indomethacin	NN	LOCATION	indomethacin	nn	37	SENT_272	44726/44738
37	)	NN	O	)	appos	32	SENT_272	44738/44739
38	,	,	O	,		-1	SENT_272	44739/44740
39	myelotoxic	JJ	O	myelotoxic	amod	40	SENT_272	44741/44751
40	(	NN	O	(	appos	32	SENT_272	44752/44753
41	e.g.	FW	O	e.g.	dep	40	SENT_272	44753/44757
42	,	,	O	,		-1	SENT_272	44757/44758
43	cytotoxic	JJ	O	cytotoxic	amod	44	SENT_272	44759/44768
44	chemotherapy	NN	O	chemotherapy	appos	32	SENT_272	44769/44781
45	)	NN	O	)	nn	48	SENT_272	44781/44782
46	,	,	O	,		-1	SENT_272	44782/44783
47	cardiotoxic	JJ	O	cardiotoxic	amod	48	SENT_272	44784/44795
48	(	NN	O	(	dep	49	SENT_272	44796/44797
49	e.g.	FW	O	e.g.	dep	29	SENT_272	44797/44801
50	,	,	O	,		-1	SENT_272	44801/44802
51	doxorubicin	NN	O	doxorubicin	nn	52	SENT_272	44803/44814
52	)	NN	O	)	appos	49	SENT_272	44814/44815
53	or	CC	O	or		-1	SENT_272	44816/44818
54	hepatotoxic	JJ	O	hepatotoxic	amod	55	SENT_272	44819/44830
55	(	NN	O	(	conj_or	49	SENT_272	44831/44832
56	e.g.	FW	O	e.g.	dep	55	SENT_272	44832/44836
57	,	,	O	,		-1	SENT_272	44836/44837
58	methotrexate	NN	O	methotrexate	nsubj	66	SENT_272	44838/44850
59	,	,	O	,		-1	SENT_272	44850/44851
60	asparaginase	NN	O	asparaginase	nn	62	SENT_272	44852/44864
61	)	NN	O	)	nn	62	SENT_272	44864/44865
62	effects	NNS	O	effect	appos	58	SENT_272	44866/44873
63	with	IN	O	with		-1	SENT_272	44874/44878
64	PROLEUKIN	NN	O	proleukin	prep_with	62	SENT_272	44879/44888
65	may	MD	O	may	aux	66	SENT_272	44889/44892
66	increase	VB	O	increase		-1	SENT_272	44893/44901
67	toxicity	NN	O	toxicity	dobj	66	SENT_272	44902/44910
68	in	IN	O	in		-1	SENT_272	44911/44913
69	these	DT	O	these	det	71	SENT_272	44914/44919
70	organ	NN	O	organ	nn	71	SENT_272	44920/44925
71	systems	NNS	O	system	prep_in	66	SENT_272	44926/44933
72	.	.	O	.		-1	SENT_272	44933/44934

1	The	DT	O	the	det	2	SENT_273	44935/44938
2	safety	NN	O	safety	nsubjpass	16	SENT_273	44939/44945
3	and	CC	O	and		-1	SENT_273	44946/44949
4	efficacy	NN	O	efficacy	conj_and	2	SENT_273	44950/44958
5	of	IN	O	of		-1	SENT_273	44959/44961
6	PROLEUKIN	NNP	O	PROLEUKIN	prep_of	2	SENT_273	44962/44971
7	in	IN	O	in		-1	SENT_273	44972/44974
8	combination	NN	O	combination	prep_in	6	SENT_273	44975/44986
9	with	IN	O	with		-1	SENT_273	44987/44991
10	any	DT	O	any	det	12	SENT_273	44992/44995
11	antineoplastic	JJ	O	antineoplastic	amod	12	SENT_273	44996/45010
12	agents	NNS	O	agent	prep_with	8	SENT_273	45011/45017
13	have	VBP	O	have	aux	16	SENT_273	45018/45022
14	not	RB	O	not	neg	16	SENT_273	45023/45026
15	been	VBN	O	be	auxpass	16	SENT_273	45027/45031
16	established	VBN	O	establish	ccomp	20	SENT_273	45032/45043
17	In	IN	O	in		-1	SENT_273	45045/45047
18	addition	NN	O	addition	prep_in	16	SENT_273	45048/45056
19	,	,	O	,		-1	SENT_273	45056/45057
20	reduced	VBD	O	reduce		-1	SENT_273	45058/45065
21	kidney	NN	O	kidney	nn	24	SENT_273	45066/45072
22	and	CC	O	and		-1	SENT_273	45073/45076
23	liver	NN	O	liver	conj_and	21	SENT_273	45077/45082
24	function	NN	O	function	nsubj	30	SENT_273	45083/45091
25	secondary	JJ	O	secondary	amod	24	SENT_273	45092/45101
26	to	TO	O	to		-1	SENT_273	45102/45104
27	PROLEUKIN	NN	O	proleukin	nn	28	SENT_273	45105/45114
28	treatment	NN	O	treatment	prep_to	25	SENT_273	45115/45124
29	may	MD	O	may	aux	30	SENT_273	45125/45128
30	delay	VB	O	delay	ccomp	20	SENT_273	45129/45134
31	elimination	NN	O	elimination	dobj	30	SENT_273	45135/45146
32	of	IN	O	of		-1	SENT_273	45147/45149
33	concomitant	JJ	O	concomitant	amod	34	SENT_273	45150/45161
34	medications	NNS	O	medication	prep_of	31	SENT_273	45162/45173
35	and	CC	O	and		-1	SENT_273	45174/45177
36	increase	VB	O	increase	conj_and	30	SENT_273	45178/45186
37	the	DT	O	the	det	38	SENT_273	45187/45190
38	risk	NN	O	risk	dobj	36	SENT_273	45191/45195
39	of	IN	O	of		-1	SENT_273	45196/45198
40	adverse	JJ	O	adverse	amod	41	SENT_273	45199/45206
41	events	NNS	O	event	prep_of	38	SENT_273	45207/45213
42	from	IN	O	from		-1	SENT_273	45214/45218
43	those	DT	O	those	det	44	SENT_273	45219/45224
44	drugs	NNS	O	drug	prep_from	36	SENT_273	45225/45230
45	4	CD	NUMBER	4	nsubj	20	SENT_273	45232/45233
46	.	.	O	.		-1	SENT_273	45233/45234

1	Increased	VBN	O	increase	amod	2	SENT_274	45235/45244
2	infections	NNS	O	infection		-1	SENT_274	45245/45255
3	with	IN	O	with		-1	SENT_274	45256/45260
4	concurrent	JJ	O	concurrent	amod	11	SENT_274	45261/45271
5	therapy	NN	O	therapy	nn	11	SENT_274	45272/45279
6	Etanercept	NNP	O	Etanercept	nn	11	SENT_274	45281/45291
7	(	NNP	O	(	nn	11	SENT_274	45292/45293
8	Enbrel	NNP	O	Enbrel	nn	11	SENT_274	45293/45299
9	)	NNP	O	)	nn	11	SENT_274	45299/45300
10	Drug	NNP	O	Drug	nn	11	SENT_274	45302/45306
11	Interactions	NNS	O	interaction	prep_with	2	SENT_274	45307/45319
12	In	IN	O	in		-1	SENT_274	45321/45323
13	a	DT	O	a	det	14	SENT_274	45324/45325
14	study	NN	O	study	prep_in	42	SENT_274	45326/45331
15	in	IN	O	in		-1	SENT_274	45332/45334
16	which	WDT	O	which	prep_in	23	SENT_274	45335/45340
17	patients	NNS	O	patient	nsubjpass	23	SENT_274	45341/45349
18	with	IN	O	with		-1	SENT_274	45350/45354
19	active	JJ	O	active	amod	20	SENT_274	45355/45361
20	Rheumatoid	JJ	O	rheumatoid	amod	21	SENT_274	45362/45372
21	Arthritis	NNP	O	Arthritis	prep_with	17	SENT_274	45373/45382
22	were	VBD	O	be	auxpass	23	SENT_274	45383/45387
23	treated	VBN	O	treat	rcmod	14	SENT_274	45388/45395
24	for	IN	O	for		-1	SENT_274	45396/45399
25	24	CD	DURATION	24	num	26	SENT_274	45403/45405
26	weeks	NNS	NUMBER	week	prep_for	23	SENT_274	45406/45411
27	with	IN	O	with		-1	SENT_274	45412/45416
28	concurrent	JJ	O	concurrent	amod	29	SENT_274	45417/45427
29	Enbrel	NNP	O	Enbrel	prep_with	26	SENT_274	45428/45434
30	and	CC	O	and		-1	SENT_274	45435/45438
31	anakinra	NN	O	anakinra	nn	32	SENT_274	45439/45447
32	therapy	NN	O	therapy	conj_and	29	SENT_274	45448/45455
33	,	,	O	,		-1	SENT_274	45455/45456
34	a	DT	O	a	det	37	SENT_274	45457/45458
35	7	CD	PERCENT	7	number	36	SENT_274	45459/45460
36	%	NN	PERCENT	%	amod	37	SENT_274	45460/45461
37	rate	NN	O	rate	nsubjpass	42	SENT_274	45462/45466
38	of	IN	O	of		-1	SENT_274	45467/45469
39	serious	JJ	O	serious	amod	40	SENT_274	45470/45477
40	infections	NNS	O	infection	prep_of	37	SENT_274	45478/45488
41	was	VBD	O	be	auxpass	42	SENT_274	45489/45492
42	observed	VBN	O	observe	rcmod	11	SENT_274	45493/45501
43	,	,	O	,		-1	SENT_274	45501/45502
44	which	WDT	O	which	nsubj	46	SENT_274	45503/45508
45	was	VBD	O	be	cop	46	SENT_274	45509/45512
46	higher	JJR	O	higher	rcmod	2	SENT_274	45513/45519
47	than	IN	O	than		-1	SENT_274	45520/45524
48	that	DT	O	that	prep_than	46	SENT_274	45525/45529
49	observed	VBN	O	observe	partmod	2	SENT_274	45530/45538
50	with	IN	O	with		-1	SENT_274	45539/45543
51	Enbrel	NN	O	enbrel	prep_with	49	SENT_274	45544/45550
52	alone	RB	O	alone	advmod	51	SENT_274	45551/45556
53	(	RB	O	(	advmod	55	SENT_274	45557/45558
54	0	CD	PERCENT	0	num	55	SENT_274	45558/45559
55	%	NN	PERCENT	%	rcmod	51	SENT_274	45559/45560
56	)	CD	NUMBER	)	dep	55	SENT_274	45560/45561
57	.	.	O	.		-1	SENT_274	45561/45562

1	Two	CD	PERCENT	two	num	2	SENT_275	45563/45566
2	percent	NN	PERCENT	percent	nsubj	11	SENT_275	45567/45574
3	of	IN	O	of		-1	SENT_275	45575/45577
4	patients	NNS	O	patient	prep_of	2	SENT_275	45578/45586
5	treated	VBN	O	treat	partmod	4	SENT_275	45587/45594
6	concurrently	RB	O	concurrently	advmod	5	SENT_275	45595/45607
7	with	IN	O	with		-1	SENT_275	45608/45612
8	Enbrel	NN	O	enbrel	prep_with	5	SENT_275	45613/45619
9	and	CC	O	and		-1	SENT_275	45620/45623
10	anakinra	NN	O	anakinra	conj_and	8	SENT_275	45624/45632
11	developed	VBD	O	develop		-1	SENT_275	45633/45642
12	neutropenia	NN	O	neutropenia	nn	14	SENT_275	45643/45654
13	(	CD	NUMBER	(	num	14	SENT_275	45655/45656
14	ANC	NNP	ORGANIZATION	ANC	dobj	11	SENT_275	45656/45659
15	<	JJR	O	<	amod	14	SENT_275	45660/45661
16	1	CD	NUMBER	1	num	18	SENT_275	45661/45662
17	109/l	NN	O	109/l	nn	18	SENT_275	45670/45675
18	)	NN	O	)	tmod	11	SENT_275	45675/45676
19	5	CD	NUMBER	5	dep	18	SENT_275	45678/45679
20	.	.	O	.		-1	SENT_275	45679/45680

1	Increased	VBN	O	increase	amod	3	SENT_276	45681/45690
2	myelotoxicity	JJ	O	myelotoxicity	amod	3	SENT_276	45691/45704
3	(	NN	O	(	nsubjpass	21	SENT_276	45705/45706
4	interferon	NN	O	interferon	nn	5	SENT_276	45706/45716
5	alfa-2b	NN	O	alfa-2b	nsubj	9	SENT_276	45717/45724
6	and	CC	O	and		-1	SENT_276	45725/45728
7	myelosuppressive	JJ	O	myelosuppressive	amod	8	SENT_276	45729/45745
8	agents	NNS	O	agent	conj_and	5	SENT_276	45746/45752
9	)	VBP	O	)	rcmod	3	SENT_276	45752/45753
10	Interferon	NN	O	interferon	nn	11	SENT_276	45755/45765
11	alfa-2b	NN	O	alfa-2b	nsubj	18	SENT_276	45766/45773
12	(	CD	NUMBER	(	num	18	SENT_276	45774/45775
13	Intron	NNP	O	Intron	nn	18	SENT_276	45775/45781
14	A	NNP	O	A	nn	18	SENT_276	45782/45783
15	)	NNP	O	)	nn	18	SENT_276	45783/45784
16	Drug	NNP	O	Drug	nn	18	SENT_276	45786/45790
17	interactions	NNS	O	interaction	nn	18	SENT_276	45791/45803
18	Caution	NN	O	caution	xcomp	9	SENT_276	45805/45812
19	should	MD	O	should	aux	21	SENT_276	45813/45819
20	be	VB	O	be	auxpass	21	SENT_276	45820/45822
21	exercised	VBN	O	exercise		-1	SENT_276	45823/45832
22	when	WRB	O	when	advmod	23	SENT_276	45833/45837
23	administering	VBG	O	administer	advcl	21	SENT_276	45838/45851
24	INTRON	NNP	O	INTRON	nn	26	SENT_276	45852/45858
25	A	NNP	O	A	nn	26	SENT_276	45859/45860
26	therapy	NN	O	therapy	dobj	23	SENT_276	45861/45868
27	in	IN	O	in		-1	SENT_276	45869/45871
28	combination	NN	O	combination	prep_in	26	SENT_276	45872/45883
29	with	IN	O	with		-1	SENT_276	45884/45888
30	other	JJ	O	other	amod	33	SENT_276	45889/45894
31	potentially	RB	O	potentially	advmod	32	SENT_276	45895/45906
32	myelosuppressive	JJ	O	myelosuppressive	amod	33	SENT_276	45907/45923
33	agents	NNS	O	agent	prep_with	23	SENT_276	45924/45930
34	such	JJ	O	such		-1	SENT_276	45931/45935
35	as	IN	O	as		-1	SENT_276	45936/45938
36	zidovudine	NN	O	zidovudine	prep_such_as	33	SENT_276	45939/45949

1	Conclusions	NNS	O	conclusion		-1	SENT_277	46008/46019

1	DI	NN	O	di	nn	2	SENT_278	46055/46057
2	studies	NNS	O	study	nsubjpass	5	SENT_278	46058/46065
3	are	VBP	O	be	auxpass	5	SENT_278	46066/46069
4	regularly	RB	O	regularly	advmod	5	SENT_278	46070/46079
5	conducted	VBN	O	conduct		-1	SENT_278	46080/46089
6	with	IN	O	with		-1	SENT_278	46090/46094
7	conventional	JJ	O	conventional	amod	8	SENT_278	46095/46107
8	SMDs	NNS	O	smd	prep_with	5	SENT_278	46108/46112
9	,	,	O	,		-1	SENT_278	46112/46113
10	but	CC	O	but		-1	SENT_278	46114/46117
11	few	JJ	O	few	amod	13	SENT_278	46118/46121
12	DI	NN	O	di	nn	13	SENT_278	46122/46124
13	studies	NNS	O	study	nsubjpass	16	SENT_278	46125/46132
14	have	VBP	O	have	aux	16	SENT_278	46133/46137
15	been	VBN	O	be	auxpass	16	SENT_278	46138/46142
16	performed	VBN	O	perform	conj_but	5	SENT_278	46143/46152
17	with	IN	O	with		-1	SENT_278	46153/46157
18	TPs	NNS	O	tp	prep_with	16	SENT_278	46158/46161
19	.	.	O	.		-1	SENT_278	46161/46162

1	In	IN	O	in		-1	SENT_279	46163/46165
2	this	DT	O	this	det	3	SENT_279	46166/46170
3	workshop	NN	O	workshop	prep_in	12	SENT_279	46171/46179
4	,	,	O	,		-1	SENT_279	46179/46180
5	industry	NN	O	industry	nsubj	12	SENT_279	46181/46189
6	,	,	O	,		-1	SENT_279	46189/46190
7	academic	JJ	O	academic	appos	5	SENT_279	46191/46199
8	,	,	O	,		-1	SENT_279	46199/46200
9	and	CC	O	and		-1	SENT_279	46201/46204
10	regulatory	JJ	O	regulatory	amod	11	SENT_279	46205/46215
11	speakers	NNS	O	speaker	conj_and	7	SENT_279	46216/46224
12	highlighted	VBD	O	highlight		-1	SENT_279	46225/46236
13	important	JJ	O	important	amod	15	SENT_279	46237/46246
14	emerging	VBG	O	emerge	amod	15	SENT_279	46247/46255
15	themes	NNS	O	theme	dobj	12	SENT_279	46256/46262
16	for	IN	O	for		-1	SENT_279	46263/46266
17	consideration	NN	O	consideration	prep_for	15	SENT_279	46267/46280
18	in	IN	O	in		-1	SENT_279	46281/46283
19	DI	NNP	O	DI	nn	20	SENT_279	46284/46286
20	assessment	NN	O	assessment	prep_in	17	SENT_279	46287/46297
21	for	IN	O	for		-1	SENT_279	46298/46301
22	TPs	NNS	O	tp	prep_for	15	SENT_279	46302/46305
23	such	JJ	O	such		-1	SENT_279	46306/46310
24	as	IN	O	as		-1	SENT_279	46311/46313
25	:	:	O	:		-1	SENT_279	46313/46314
26	molecule	NN	O	molecule	nn	27	SENT_279	46315/46323
27	type	NN	O	type	prep_such_as	22	SENT_279	46324/46328
28	,	,	O	,		-1	SENT_279	46328/46329
29	target	NN	O	target	conj_and	27	SENT_279	46330/46336
30	,	,	O	,		-1	SENT_279	46336/46337
31	indication	NN	O	indication	conj_and	27	SENT_279	46338/46348
32	,	,	O	,		-1	SENT_279	46348/46349
33	and	CC	O	and		-1	SENT_279	46350/46353
34	disease	NN	O	disease	nn	35	SENT_279	46354/46361
35	biology	NN	O	biology	conj_and	27	SENT_279	46362/46369
36	.	.	O	.		-1	SENT_279	46369/46370

1	Speakers	NNS	O	speaker	nsubj	3	SENT_280	46371/46379
2	also	RB	O	also	advmod	3	SENT_280	46380/46384
3	discussed	VBD	O	discuss		-1	SENT_280	46385/46394
4	recent	JJ	O	recent	amod	5	SENT_280	46395/46401
5	reports	NNS	O	report	dobj	3	SENT_280	46402/46409
6	regarding	VBG	O	regard		-1	SENT_280	46410/46419
7	the	DT	O	the	det	8	SENT_280	46420/46423
8	regulation	NN	O	regulation	prep_regarding	5	SENT_280	46424/46434
9	of	IN	O	of		-1	SENT_280	46435/46437
10	CYP	NN	O	cyp	nn	11	SENT_280	46438/46441
11	enzymes	NNS	O	enzyme	prep_of	8	SENT_280	46442/46449
12	and	CC	O	and		-1	SENT_280	46450/46453
13	transporters	NNS	O	transporter	conj_and	11	SENT_280	46454/46466
14	in	IN	O	in		-1	SENT_280	46467/46469
15	inflammatory	JJ	O	inflammatory	amod	16	SENT_280	46470/46482
16	states	NNS	O	state	prep_in	8	SENT_280	46483/46489
17	.	.	O	.		-1	SENT_280	46489/46490

1	The	DT	O	the	det	2	SENT_281	46491/46494
2	use	NN	O	use	nsubj	16	SENT_281	46495/46498
3	of	IN	O	of		-1	SENT_281	46499/46501
4	cytokines	NNS	O	cytokine	prep_of	2	SENT_281	46502/46511
5	,	,	O	,		-1	SENT_281	46511/46512
6	cytokine	NN	O	cytokine	nn	7	SENT_281	46513/46521
7	modulators	NNS	O	modulator	conj_and	4	SENT_281	46522/46532
8	,	,	O	,		-1	SENT_281	46532/46533
9	and	CC	O	and		-1	SENT_281	46534/46537
10	immunosuppressant-containing	JJ	O	immunosuppressant-containing	amod	11	SENT_281	46538/46566
11	combinations	NNS	O	combination	conj_and	4	SENT_281	46567/46579
12	in	IN	O	in		-1	SENT_281	46580/46582
13	inflammatory	JJ	O	inflammatory	amod	14	SENT_281	46583/46595
14	indications	NNS	O	indication	prep_in	11	SENT_281	46596/46607
15	may	MD	O	may	aux	16	SENT_281	46608/46611
16	have	VB	O	have		-1	SENT_281	46612/46616
17	potential	JJ	O	potential	dobj	16	SENT_281	46617/46626
18	for	IN	O	for		-1	SENT_281	46627/46630
19	DI	NNP	O	DI	prep_for	17	SENT_281	46631/46633
20	,	,	O	,		-1	SENT_281	46633/46634
21	in	IN	O	in		-1	SENT_281	46635/46637
22	particular	JJ	O	particular	prep_in	16	SENT_281	46638/46648
23	when	WRB	O	when	advmod	26	SENT_281	46649/46653
24	TPs	NNS	O	tp	nsubjpass	26	SENT_281	46654/46657
25	are	VBP	O	be	auxpass	26	SENT_281	46658/46661
26	combined	VBN	O	combine	rcmod	22	SENT_281	46662/46670
27	with	IN	O	with		-1	SENT_281	46671/46675
28	NTR	NN	O	ntr	nn	29	SENT_281	46676/46679
29	drugs	NNS	O	drug	prep_with	26	SENT_281	46680/46685
30	.	.	O	.		-1	SENT_281	46685/46686

1	A	DT	O	a	det	2	SENT_282	46687/46688
2	question	NN	O	question	nsubj	28	SENT_282	46689/46697
3	-	:	O	-		-1	SENT_282	46697/46698
4	and	CC	O	and		-1	SENT_282	46699/46702
5	risk-based	JJ	O	risk-based	amod	6	SENT_282	46703/46713
6	(	NN	O	(	conj_and	2	SENT_282	46714/46715
7	the	DT	O	the	det	8	SENT_282	46715/46718
8	definition	NN	O	definition	nsubj	14	SENT_282	46719/46729
9	of	IN	O	of		-1	SENT_282	46730/46732
10	risk	NN	O	risk	prep_of	8	SENT_282	46733/46737
11	will	MD	O	will	aux	14	SENT_282	46738/46742
12	be	VB	O	be	cop	14	SENT_282	46743/46745
13	individualized	JJ	O	individualized	amod	14	SENT_282	46746/46760
14	)	NN	O	)	rcmod	6	SENT_282	46760/46761
15	integrated	VBN	O	integrate	partmod	14	SENT_282	46762/46772
16	approach	NN	O	approach	dobj	15	SENT_282	46773/46781
17	depending	VBG	O	depend		-1	SENT_282	46782/46791
18	on	IN	O	on	prepc_depending_on	15	SENT_282	46792/46794
19	the	DT	O	the	det	20	SENT_282	46795/46798
20	mechanism	NN	O	mechanism	pobj	15	SENT_282	46799/46808
21	of	IN	O	of		-1	SENT_282	46809/46811
22	action	NN	O	action	prep_of	20	SENT_282	46812/46818
23	of	IN	O	of		-1	SENT_282	46819/46821
24	TPs	NNS	O	tp	prep_of	22	SENT_282	46822/46825
25	and	CC	O	and		-1	SENT_282	46826/46829
26	patient	NN	O	patient	nn	27	SENT_282	46830/46837
27	population	NN	O	population	conj_and	24	SENT_282	46838/46848
28	appears	VBZ	O	appear		-1	SENT_282	46849/46856
29	to	TO	O	to	aux	31	SENT_282	46857/46859
30	have	VB	O	have	aux	31	SENT_282	46860/46864
31	evolved	VBN	O	evolve	xcomp	28	SENT_282	46865/46872
32	and	CC	O	and		-1	SENT_282	46873/46876
33	is	VBZ	O	be	auxpass	34	SENT_282	46877/46879
34	used	VBN	O	use	conj_and	28	SENT_282	46880/46884
35	within	IN	O	within		-1	SENT_282	46885/46891
36	companies	NNS	O	company	prep_within	34	SENT_282	46892/46901
37	like	IN	O	like		-1	SENT_282	46902/46906
38	Genentech	NNP	ORGANIZATION	Genentech	prep_like	36	SENT_282	46907/46916
39	,	,	O	,		-1	SENT_282	46916/46917
40	Biogen	NNP	ORGANIZATION	Biogen	nn	41	SENT_282	46918/46924
41	Idec	NNP	ORGANIZATION	Idec	conj_and	38	SENT_282	46925/46929
42	,	,	O	,		-1	SENT_282	46929/46930
43	Amgen	NNP	ORGANIZATION	Amgen	conj_and	38	SENT_282	46931/46936
44	and	CC	O	and		-1	SENT_282	46937/46940
45	Centocor	NNP	ORGANIZATION	Centocor	conj_and	38	SENT_282	46941/46949
46	.	.	O	.		-1	SENT_282	46949/46950

1	Critical	JJ	O	critical	amod	3	SENT_283	46951/46959
2	knowledge	NN	O	knowledge	nn	3	SENT_283	46960/46969
3	gaps	NNS	O	gap	nsubjpass	10	SENT_283	46970/46974
4	and	CC	O	and		-1	SENT_283	46975/46978
5	areas	NNS	O	area	conj_and	3	SENT_283	46979/46984
6	needing	VBG	O	need	partmod	3	SENT_283	46985/46992
7	further	JJ	O	further	amod	8	SENT_283	46993/47000
8	research	NN	O	research	dobj	6	SENT_283	47001/47009
9	were	VBD	O	be	auxpass	10	SENT_283	47010/47014
10	identified	VBN	O	identify		-1	SENT_283	47015/47025
11	(	RB	O	(	amod	14	SENT_283	47026/47027
12	Table	NNP	O	Table	tmod	11	SENT_283	47027/47032
13	IV	CD	NUMBER	iv	num	12	SENT_283	47033/47035
14	)	NN	O	)	dobj	10	SENT_283	47035/47036
15	.	.	O	.		-1	SENT_283	47036/47037

1	The	DT	O	the	det	3	SENT_284	47038/47041
2	US	NNP	LOCATION	US	nn	3	SENT_284	47042/47044
3	FDA	NNP	ORGANIZATION	FDA	nsubj	5	SENT_284	47045/47048
4	is	VBZ	O	be	aux	5	SENT_284	47049/47051
5	updating	VBG	O	update		-1	SENT_284	47052/47060
6	its	PRP$	O	its	poss	7	SENT_284	47061/47064
7	recommendations	NNS	O	recommendation	dobj	5	SENT_284	47065/47080
8	to	TO	O	to		-1	SENT_284	47081/47083
9	sponsors	NNS	O	sponsor	prep_to	5	SENT_284	47084/47092
10	of	IN	O	of		-1	SENT_284	47093/47095
11	new	JJ	O	new	amod	13	SENT_284	47096/47099
12	drug	NN	O	drug	nn	13	SENT_284	47100/47104
13	applications	NNS	O	application	prep_of	9	SENT_284	47105/47117
14	and	CC	O	and		-1	SENT_284	47118/47121
15	biologics	NNS	O	biologic	nn	17	SENT_284	47122/47131
16	license	NN	O	license	nn	17	SENT_284	47132/47139
17	applications	NNS	O	application	conj_and	13	SENT_284	47140/47152
18	who	WP	O	who	nsubj	20	SENT_284	47153/47156
19	are	VBP	O	be	aux	20	SENT_284	47157/47160
20	conducting	VBG	O	conduct	rcmod	9	SENT_284	47161/47171
21	in	FW	O	in	prep	20	SENT_284	47172/47174
22	vitro	FW	O	vitro	nn	23	SENT_284	47175/47180
23	and/or	FW	O	and/or	pobj	21	SENT_284	47181/47187
24	in	FW	O	in	nn	25	SENT_284	47188/47190
25	vivo	FW	O	vivo	advmod	27	SENT_284	47191/47195
26	interaction	NN	O	interaction	nn	27	SENT_284	47196/47207
27	studies	NNS	O	study	rcmod	23	SENT_284	47208/47215
28	with	IN	O	with		-1	SENT_284	47216/47220
29	TPs	NNS	O	tp	prep_with	27	SENT_284	47221/47224
30	(	CD	NUMBER	(	number	31	SENT_284	47225/47226
31	7	CD	NUMBER	7	num	32	SENT_284	47226/47227
32	)	NN	O	)	dep	29	SENT_284	47227/47228
33	.	.	O	.		-1	SENT_284	47228/47229

1	This	DT	O	this	det	2	SENT_285	47230/47234
2	guidance	NN	O	guidance	nsubjpass	4	SENT_285	47235/47243
3	is	VBZ	O	be	auxpass	4	SENT_285	47244/47246
4	expected	VBN	O	expect		-1	SENT_285	47247/47255
5	to	TO	O	to	aux	6	SENT_285	47256/47258
6	address	VB	O	address	xcomp	4	SENT_285	47259/47266
7	some	DT	O	some	nsubj	11	SENT_285	47267/47271
8	of	IN	O	of		-1	SENT_285	47272/47274
9	the	DT	O	the	det	10	SENT_285	47275/47278
10	challenges	NNS	O	challenge	prep_of	7	SENT_285	47279/47289
11	unique	JJ	O	unique	xcomp	6	SENT_285	47290/47296
12	to	TO	O	to		-1	SENT_285	47297/47299
13	biologics	NNS	O	biologic	prep_to	11	SENT_285	47300/47309
14	.	.	O	.		-1	SENT_285	47309/47310

1	Table	NNP	O	Table		-1	SENT_286	47311/47316
2	IV	CD	NUMBER	iv	dep	1	SENT_286	47317/47319

1	Summary	NN	O	summary		-1	SENT_287	47336/47343
2	of	IN	O	of		-1	SENT_287	47344/47346
3	Knowledge	NN	O	knowledge	nn	4	SENT_287	47347/47356
4	Gaps	NNS	O	gap	prep_of	1	SENT_287	47357/47361
5	and	CC	O	and		-1	SENT_287	47362/47365
6	Areas	NNS	O	area	conj_and	4	SENT_287	47366/47371
7	Needing	VBG	O	need	partmod	4	SENT_287	47372/47379
8	Further	JJ	O	further	amod	9	SENT_287	47380/47387
9	Research	NN	O	research	dobj	7	SENT_287	47388/47396

1	Knowledge	NN	O	knowledge	nn	2	SENT_288	47413/47422
2	gaps	NNS	O	gap	nsubjpass	7	SENT_288	47423/47427
3	Several	JJ	O	several	amod	5	SENT_288	47429/47436
4	knowledge	NN	O	knowledge	nn	5	SENT_288	47437/47446
5	gaps	NNS	O	gap	dep	2	SENT_288	47447/47451
6	were	VBD	O	be	auxpass	7	SENT_288	47452/47456
7	identified	VBN	O	identify		-1	SENT_288	47457/47467
8	that	WDT	O	that	nsubj	9	SENT_288	47468/47472
9	require	VBP	O	require	ccomp	7	SENT_288	47473/47480
10	further	JJ	O	further	amod	12	SENT_288	47481/47488
11	cross	NN	O	cross	nn	12	SENT_288	47489/47494
12	collaboration	NN	O	collaboration	dobj	9	SENT_288	47495/47508
13	between	IN	O	between		-1	SENT_288	47509/47516
14	academia	NN	O	academia	prep_between	12	SENT_288	47517/47525
15	,	,	O	,		-1	SENT_288	47525/47526
16	industry	NN	O	industry	conj_and	14	SENT_288	47527/47535
17	and	CC	O	and		-1	SENT_288	47536/47539
18	regulators	NNS	O	regulator	conj_and	14	SENT_288	47540/47550
19	.	.	O	.		-1	SENT_288	47550/47551

1	While	IN	O	while	dep	254	SENT_289	47552/47557
2	there	EX	O	there	dep	254	SENT_289	47558/47563
3	is	VBZ	O	be	dep	254	SENT_289	47564/47566
4	extensive	JJ	O	extensive	dep	254	SENT_289	47567/47576
5	literature	NN	O	literature	dep	254	SENT_289	47577/47587
6	on	IN	O	on	dep	254	SENT_289	47588/47590
7	the	DT	O	the	dep	254	SENT_289	47591/47594
8	effects	NNS	O	effect	dep	254	SENT_289	47595/47602
9	of	IN	O	of	dep	254	SENT_289	47603/47605
10	cytokines	NNS	O	cytokine	dep	254	SENT_289	47606/47615
11	and	CC	O	and	dep	254	SENT_289	47616/47619
12	cytokine	NN	O	cytokine	dep	254	SENT_289	47620/47628
13	modulators	NNS	O	modulator	dep	254	SENT_289	47629/47639
14	in	IN	O	in	dep	254	SENT_289	47640/47642
15	CYPa	NN	O	cypa	dep	254	SENT_289	47643/47647
16	enzyme	NN	O	enzyme	dep	254	SENT_289	47648/47654
17	levels	NNS	O	level	dep	254	SENT_289	47655/47661
18	(	VBP	O	(	dep	254	SENT_289	47662/47663
19	1,2,5,16	CD	NUMBER	1,2,5,16	dep	254	SENT_289	47663/47671
20	)	CD	NUMBER	)	dep	254	SENT_289	47671/47672
21	there	EX	O	there	dep	254	SENT_289	47673/47678
22	is	VBZ	O	be	dep	254	SENT_289	47679/47681
23	a	DT	O	a	dep	254	SENT_289	47682/47683
24	knowledge	NN	O	knowledge	dep	254	SENT_289	47684/47693
25	gap	NN	O	gap	dep	254	SENT_289	47694/47697
26	in	IN	O	in	dep	254	SENT_289	47698/47700
27	our	PRP$	O	we	dep	254	SENT_289	47701/47704
28	understanding	NN	O	understanding	dep	254	SENT_289	47705/47718
29	of	IN	O	of	dep	254	SENT_289	47719/47721
30	how	WRB	O	how	dep	254	SENT_289	47722/47725
31	in	FW	O	in	dep	254	SENT_289	47726/47728
32	vitro	FW	O	vitro	dep	254	SENT_289	47729/47734
33	assessment	NN	O	assessment	dep	254	SENT_289	47735/47745
34	of	IN	O	of	dep	254	SENT_289	47746/47748
35	cytokines	NNS	O	cytokine	dep	254	SENT_289	47749/47758
36	and	CC	O	and	dep	254	SENT_289	47759/47762
37	cytokine	NN	O	cytokine	dep	254	SENT_289	47763/47771
38	modulators	NNS	O	modulator	dep	254	SENT_289	47772/47782
39	alter	VBP	O	alter	dep	254	SENT_289	47783/47788
40	CYP	NN	O	cyp	dep	254	SENT_289	47789/47792
41	enzyme	NN	O	enzyme	dep	254	SENT_289	47793/47799
42	levels/activity	NN	O	levels/activity	dep	254	SENT_289	47800/47815
43	and	CC	O	and	dep	254	SENT_289	47816/47819
44	how	WRB	O	how	dep	254	SENT_289	47820/47823
45	this	DT	O	this	dep	254	SENT_289	47824/47828
46	can	MD	O	can	dep	254	SENT_289	47829/47832
47	translate	VB	O	translate	dep	254	SENT_289	47833/47842
48	to	TO	O	to	dep	254	SENT_289	47843/47845
49	meaningful	JJ	O	meaningful	dep	254	SENT_289	47846/47856
50	in	FW	O	in	dep	254	SENT_289	47857/47859
51	vivo	FW	O	vivo	dep	254	SENT_289	47860/47864
52	changes	NNS	O	change	dep	254	SENT_289	47865/47872
53	in	IN	O	in	dep	254	SENT_289	47873/47875
54	exposure	NN	O	exposure	dep	254	SENT_289	47876/47884
55	Determine	NN	O	determine	dep	254	SENT_289	47890/47899
56	appropriateness	NN	O	appropriateness	dep	254	SENT_289	47900/47915
57	of	IN	O	of	dep	254	SENT_289	47916/47918
58	in	FW	O	in	dep	254	SENT_289	47919/47921
59	vitro	FW	O	vitro	dep	254	SENT_289	47922/47927
60	systems	NNS	O	system	dep	254	SENT_289	47928/47935
61	to	TO	O	to	dep	254	SENT_289	47936/47938
62	study	VB	O	study	dep	254	SENT_289	47939/47944
63	in	FW	O	in	dep	254	SENT_289	47945/47947
64	vivo	FW	O	vivo	dep	254	SENT_289	47948/47952
65	TP-DIb	NN	O	tp-dib	dep	254	SENT_289	47953/47959
66	TP-DI	NN	O	tp-di	dep	254	SENT_289	47965/47970
67	mechanisms	NNS	O	mechanism	dep	254	SENT_289	47971/47981
68	proposed	VBD	O	propose	dep	254	SENT_289	47982/47990
69	need	NN	O	need	dep	254	SENT_289	47991/47995
70	to	TO	O	to	dep	254	SENT_289	47996/47998
71	be	VB	O	be	dep	254	SENT_289	47999/48001
72	validated	VBN	O	validate	dep	254	SENT_289	48002/48011
73	with	IN	O	with	dep	254	SENT_289	48012/48016
74	actual	JJ	O	actual	dep	254	SENT_289	48017/48023
75	in	FW	O	in	dep	254	SENT_289	48024/48026
76	vitro	FW	O	vitro	dep	254	SENT_289	48027/48032
77	data	NNS	O	datum	dep	254	SENT_289	48033/48037
78	wherever	WRB	O	wherever	dep	254	SENT_289	48038/48046
79	possible	JJ	O	possible	dep	254	SENT_289	48047/48055
80	Technical	NNP	O	Technical	dep	254	SENT_289	48061/48070
81	optimization	NN	O	optimization	dep	254	SENT_289	48071/48083
82	and	CC	O	and	dep	254	SENT_289	48084/48087
83	validation	NN	O	validation	dep	254	SENT_289	48088/48098
84	of	IN	O	of	dep	254	SENT_289	48099/48101
85	in	FW	O	in	dep	254	SENT_289	48102/48104
86	vitro	FW	O	vitro	dep	254	SENT_289	48105/48110
87	systems	NNS	O	system	dep	254	SENT_289	48111/48118
88	for	IN	O	for	dep	254	SENT_289	48119/48122
89	studying	VBG	O	study	dep	254	SENT_289	48123/48131
90	TP-DI	NNP	O	TP-DI	dep	254	SENT_289	48132/48137
91	Determine	NNP	O	Determine	dep	254	SENT_289	48143/48152
92	what	WDT	O	what	dep	254	SENT_289	48153/48157
93	systems/cell	NN	O	systems/cell	dep	254	SENT_289	48158/48170
94	types	NNS	O	type	dep	254	SENT_289	48171/48176
95	are	VBP	O	be	dep	254	SENT_289	48177/48180
96	appropriate	JJ	O	appropriate	dep	254	SENT_289	48181/48192
97	for	IN	O	for	dep	254	SENT_289	48193/48196
98	studying	VBG	O	study	dep	254	SENT_289	48197/48205
99	TP-DI	NNP	O	TP-DI	dep	254	SENT_289	48206/48211
100	Develop	VB	O	develop	dep	254	SENT_289	48217/48224
101	methodology	NN	O	methodology	dep	254	SENT_289	48225/48236
102	that	WDT	O	that	dep	254	SENT_289	48237/48241
103	is	VBZ	O	be	dep	254	SENT_289	48242/48244
104	robust	JJ	O	robust	dep	254	SENT_289	48245/48251
105	,	,	O	,		-1	SENT_289	48251/48252
106	reproducible	JJ	O	reproducible	dep	254	SENT_289	48253/48265
107	and	CC	O	and	dep	254	SENT_289	48266/48269
108	relevant	JJ	O	relevant	dep	254	SENT_289	48270/48278
109	to	TO	O	to	dep	254	SENT_289	48279/48281
110	in	FW	O	in	dep	254	SENT_289	48282/48284
111	vivo	FW	O	vivo	dep	254	SENT_289	48285/48289
112	data	NNS	O	datum	dep	254	SENT_289	48290/48294
113	Develop	VB	O	develop	dep	254	SENT_289	48300/48307
114	a	DT	O	a	dep	254	SENT_289	48308/48309
115	more	RBR	O	more	dep	254	SENT_289	48310/48314
116	mechanistic	JJ	O	mechanistic	dep	254	SENT_289	48315/48326
117	understanding	NN	O	understanding	dep	254	SENT_289	48327/48340
118	of	IN	O	of	dep	254	SENT_289	48341/48343
119	how	WRB	O	how	dep	254	SENT_289	48344/48347
120	TPsc	NN	O	tpsc	dep	254	SENT_289	48348/48352
121	alter	VBP	O	alter	dep	254	SENT_289	48353/48358
122	CYP	NN	O	cyp	dep	254	SENT_289	48359/48362
123	activity	NN	O	activity	dep	254	SENT_289	48363/48371
124	in	FW	O	in	dep	254	SENT_289	48372/48374
125	vitro	FW	O	vitro	dep	254	SENT_289	48375/48380
126	and	CC	O	and	dep	254	SENT_289	48381/48384
127	in	FW	O	in	dep	254	SENT_289	48385/48387
128	vivo	FW	O	vivo	dep	254	SENT_289	48388/48392
129	Understand	JJ	O	understand	dep	254	SENT_289	48398/48408
130	whether	IN	O	whether	dep	254	SENT_289	48409/48416
131	other	JJ	O	other	dep	254	SENT_289	48417/48422
132	drug	NN	O	drug	dep	254	SENT_289	48423/48427
133	metabolizing	VBG	O	metabolize	dep	254	SENT_289	48428/48440
134	enzymes	NNS	O	enzyme	dep	254	SENT_289	48441/48448
135	(	CD	NUMBER	(	dep	254	SENT_289	48449/48450
136	besides	IN	O	besides	dep	254	SENT_289	48450/48457
137	CYP	NN	O	cyp	dep	254	SENT_289	48458/48461
138	)	NN	O	)	dep	254	SENT_289	48461/48462
139	and	CC	O	and	dep	254	SENT_289	48463/48466
140	transporters	NNS	O	transporter	dep	254	SENT_289	48467/48479
141	are	VBP	O	be	dep	254	SENT_289	48480/48483
142	involved	VBN	O	involve	dep	254	SENT_289	48484/48492
143	in	IN	O	in	dep	254	SENT_289	48493/48495
144	TP-DI	NN	O	tp-di	dep	254	SENT_289	48496/48501
145	Inflammation	NN	O	inflammation	dep	254	SENT_289	48507/48519
146	and	CC	O	and	dep	254	SENT_289	48520/48523
147	effect	NN	O	effect	dep	254	SENT_289	48524/48530
148	on	IN	O	on	dep	254	SENT_289	48531/48533
149	CYP	NNP	O	CYP	dep	254	SENT_289	48534/48537
150	Better	NNP	O	Better	dep	254	SENT_289	48543/48549
151	understand	VB	O	understand	dep	254	SENT_289	48550/48560
152	how	WRB	O	how	dep	254	SENT_289	48561/48564
153	constant	JJ	O	constant	dep	254	SENT_289	48565/48573
154	and	CC	O	and	dep	254	SENT_289	48574/48577
155	intermittent	JJ	O	intermittent	dep	254	SENT_289	48578/48590
156	inflammation	NN	O	inflammation	dep	254	SENT_289	48591/48603
157	could	MD	O	could	dep	254	SENT_289	48604/48609
158	cause	VB	O	cause	dep	254	SENT_289	48610/48615
159	a	DT	O	a	dep	254	SENT_289	48616/48617
160	change	NN	O	change	dep	254	SENT_289	48618/48624
161	in	IN	O	in	dep	254	SENT_289	48625/48627
162	cytokines	NNS	O	cytokine	dep	254	SENT_289	48628/48637
163	and	CC	O	and	dep	254	SENT_289	48638/48641
164	thereby	RB	O	thereby	dep	254	SENT_289	48642/48649
165	affect	VB	O	affect	dep	254	SENT_289	48650/48656
166	CYP	NNP	O	CYP	dep	254	SENT_289	48657/48660
167	Understand	NNP	O	Understand	dep	254	SENT_289	48666/48676
168	whether	IN	O	whether	dep	254	SENT_289	48677/48684
169	and	CC	O	and	dep	254	SENT_289	48685/48688
170	how	WRB	O	how	dep	254	SENT_289	48689/48692
171	this	DT	O	this	dep	254	SENT_289	48693/48697
172	can	MD	O	can	dep	254	SENT_289	48698/48701
173	be	VB	O	be	dep	254	SENT_289	48702/48704
174	translated	VBN	O	translate	dep	254	SENT_289	48705/48715
175	into	IN	O	into	dep	254	SENT_289	48716/48720
176	understanding	VBG	O	understand	dep	254	SENT_289	48721/48734
177	TP-DI	NN	O	tp-di	dep	254	SENT_289	48735/48740
178	in	IN	O	in	dep	254	SENT_289	48741/48743
179	the	DT	O	the	dep	254	SENT_289	48744/48747
180	clinical	JJ	O	clinical	dep	254	SENT_289	48748/48756
181	setting	NN	O	setting	dep	254	SENT_289	48757/48764
182	Give	VB	O	give	dep	254	SENT_289	48770/48774
183	priority	NN	O	priority	dep	254	SENT_289	48775/48783
184	to	TO	O	to	dep	254	SENT_289	48784/48786
185	generate	VB	O	generate	dep	254	SENT_289	48787/48795
186	in	FW	O	in	dep	254	SENT_289	48796/48798
187	vitro	FW	O	vitro	dep	254	SENT_289	48799/48804
188	data	NNS	O	datum	dep	254	SENT_289	48805/48809
189	to	TO	O	to	dep	254	SENT_289	48810/48812
190	grow	VB	O	grow	dep	254	SENT_289	48813/48817
191	our	PRP$	O	we	dep	254	SENT_289	48818/48821
192	knowledge	NN	O	knowledge	dep	254	SENT_289	48822/48831
193	base	NN	O	base	dep	254	SENT_289	48832/48836
194	Priority	NN	O	priority	dep	254	SENT_289	48842/48850
195	to	TO	O	to	dep	254	SENT_289	48851/48853
196	(	CD	NUMBER	(	dep	254	SENT_289	48854/48855
197	1	CD	NUMBER	1	dep	254	SENT_289	48855/48856
198	)	NN	O	)	dep	254	SENT_289	48856/48857
199	cytokines	NNS	O	cytokine	dep	254	SENT_289	48858/48867
200	(	VBP	O	(	dep	254	SENT_289	48868/48869
201	2	CD	NUMBER	2	dep	254	SENT_289	48869/48870
202	)	CD	NUMBER	)	dep	254	SENT_289	48870/48871
203	TPs	NNS	O	tp	dep	254	SENT_289	48872/48875
204	that	WDT	O	that	dep	254	SENT_289	48876/48880
205	are	VBP	O	be	dep	254	SENT_289	48881/48884
206	cytokine	NN	O	cytokine	dep	254	SENT_289	48885/48893
207	modulators	NNS	O	modulator	dep	254	SENT_289	48894/48904
208	Priority	NN	O	priority	dep	254	SENT_289	48910/48918
209	for	IN	O	for	dep	254	SENT_289	48919/48922
210	studying	VBG	O	study	dep	254	SENT_289	48923/48931
211	existing	VBG	O	exist	dep	254	SENT_289	48932/48940
212	proposed	JJ	O	proposed	dep	254	SENT_289	48941/48949
213	mechanisms	NNS	O	mechanism	dep	254	SENT_289	48950/48960
214	of	IN	O	of	dep	254	SENT_289	48961/48963
215	TP-DI	NN	O	tp-di	dep	254	SENT_289	48964/48969
216	Priority	NN	O	priority	dep	254	SENT_289	48975/48983
217	to	TO	O	to	dep	254	SENT_289	48984/48986
218	understand	VB	O	understand	dep	254	SENT_289	48987/48997
219	various	JJ	O	various	dep	254	SENT_289	48998/49005
220	mechanism	NN	O	mechanism	dep	254	SENT_289	49006/49015
221	via	IN	O	via	dep	254	SENT_289	49016/49019
222	which	WDT	O	which	dep	254	SENT_289	49020/49025
223	TPs	NNS	O	tp	dep	254	SENT_289	49026/49029
224	could	MD	O	could	dep	254	SENT_289	49030/49035
225	cause	VB	O	cause	dep	254	SENT_289	49036/49041
226	TP-DI	NNP	O	TP-DI	dep	254	SENT_289	49042/49047
227	Develop	VB	O	develop	dep	254	SENT_289	49053/49060
228	exploratory	JJ	O	exploratory	dep	254	SENT_289	49061/49072
229	multiphase/physiological/systems	NNS	O	multiphase/physiological/systems	dep	254	SENT_289	49073/49105
230	biology	NN	O	biology	dep	254	SENT_289	49106/49113
231	models	NNS	O	model	dep	254	SENT_289	49114/49120
232	to	TO	O	to	dep	254	SENT_289	49121/49123
233	study	VB	O	study	dep	254	SENT_289	49124/49129
234	cytokine	NN	O	cytokine	dep	254	SENT_289	49130/49138
235	mediated	JJ	O	mediated	dep	254	SENT_289	49139/49147
236	effect	NN	O	effect	dep	254	SENT_289	49148/49154
237	on	IN	O	on	dep	254	SENT_289	49155/49157
238	CYP	NNP	O	CYP	dep	254	SENT_289	49158/49161
239	Data	NNP	O	Data	dep	254	SENT_289	49167/49171
240	analyses	NNS	O	analysis	dep	254	SENT_289	49172/49180
241	gap	NN	O	gap	dep	254	SENT_289	49181/49184
242	--	:	O	--		-1	SENT_289	49184/49186
243	assess	VB	O	assess	dep	254	SENT_289	49186/49192
244	best	JJS	O	best	dep	254	SENT_289	49193/49197
245	practice	NN	O	practice	dep	254	SENT_289	49198/49206
246	for	IN	O	for	dep	254	SENT_289	49207/49210
247	including	VBG	O	include	dep	254	SENT_289	49211/49220
248	concomitant	JJ	O	concomitant	dep	254	SENT_289	49221/49232
249	medications	NNS	O	medication	dep	254	SENT_289	49233/49244
250	in	IN	O	in	dep	254	SENT_289	49245/49247
251	assessing	VBG	O	assess	dep	254	SENT_289	49248/49257
252	TP-DI	NN	O	tp-di	dep	254	SENT_289	49258/49263
253	via	IN	O	via	dep	254	SENT_289	49264/49267
254	POP-PKd	NN	O	pop-pkd		-1	SENT_289	49268/49275

1	a	DT	O	a	det	2	SENT_290	49296/49297
2	CYP	NN	O	cyp		-1	SENT_290	49298/49301
3	cytochromes	NNS	O	cytochrome	dep	2	SENT_290	49302/49313
4	P450	NN	O	p450	dep	2	SENT_290	49314/49318

1	b	NN	O	b	nn	2	SENT_291	49354/49355
2	TP-DI	NN	O	tp-di		-1	SENT_291	49356/49361
3	therapeutic	JJ	O	therapeutic	amod	5	SENT_291	49362/49373
4	protein-drug	JJ	O	protein-drug	amod	5	SENT_291	49374/49386
5	interactions	NNS	O	interaction	dep	2	SENT_291	49387/49399

1	c	NN	O	c	nsubj	2	SENT_292	49435/49436
2	TPs	VBZ	O	tp		-1	SENT_292	49437/49440
3	Therapeutic	JJ	O	therapeutic	amod	4	SENT_292	49441/49452
4	proteins	NNS	O	protein	dobj	2	SENT_292	49453/49461

1	d	NN	O	d	nn	4	SENT_293	49497/49498
2	POP-PK	NN	O	pop-pk	nn	4	SENT_293	49499/49505
3	population	NN	O	population	nn	4	SENT_293	49506/49516
4	pharmacokinetics	NNS	O	pharmacokinetic		-1	SENT_293	49517/49533

1	1	CD	NUMBER	1		-1	SENT_294	49569/49570

1	Programming	NNP	O	Programming	nn	2	SENT_295	49587/49598
2	Committee	NNP	O	Committee		-1	SENT_295	49599/49608
3	:	:	O	:		-1	SENT_295	49608/49609
4	Sandhya	NNP	PERSON	Sandhya	nn	5	SENT_295	49610/49617
5	Girish	NNP	PERSON	Girish	dep	2	SENT_295	49618/49624
6	,	,	O	,		-1	SENT_295	49624/49625
7	Ph.D.	NNP	O	Ph.D.	nn	13	SENT_295	49626/49631
8	,	,	O	,		-1	SENT_295	49631/49632
9	Genentech	NNP	ORGANIZATION	Genentech	appos	13	SENT_295	49633/49642
10	,	,	ORGANIZATION	,		-1	SENT_295	49642/49643
11	Inc.	NNP	ORGANIZATION	Inc.	appos	13	SENT_295	49644/49648
12	,	,	O	,		-1	SENT_295	49648/49649
13	Co-Chair	NNP	O	Co-Chair	conj_and	5	SENT_295	49650/49658
14	;	:	O	;		-1	SENT_295	49658/49659
15	Amita	NNP	PERSON	Amita	nn	24	SENT_295	49660/49665
16	Joshi	NNP	PERSON	Joshi	nn	24	SENT_295	49666/49671
17	,	,	O	,		-1	SENT_295	49671/49672
18	Ph.D.	NNP	O	Ph.D.	appos	24	SENT_295	49673/49678
19	,	,	O	,		-1	SENT_295	49678/49679
20	Genentech	NNP	ORGANIZATION	Genentech	appos	24	SENT_295	49680/49689
21	,	,	ORGANIZATION	,		-1	SENT_295	49689/49690
22	Inc.	NNP	ORGANIZATION	Inc.	appos	24	SENT_295	49691/49695
23	,	,	O	,		-1	SENT_295	49695/49696
24	Co-Chair	NNP	O	Co-Chair	conj_and	5	SENT_295	49697/49705
25	;	:	O	;		-1	SENT_295	49705/49706
26	Steven	NNP	PERSON	Steven	nn	33	SENT_295	49707/49713
27	W	NNP	PERSON	W	nn	33	SENT_295	49714/49715
28	Martin	NNP	PERSON	Martin	nn	33	SENT_295	49716/49722
29	,	,	O	,		-1	SENT_295	49722/49723
30	Ph.D.	NNP	O	Ph.D.	appos	33	SENT_295	49724/49729
31	,	,	O	,		-1	SENT_295	49729/49730
32	Pfizer	NNP	ORGANIZATION	Pfizer	appos	33	SENT_295	49731/49737
33	Inc.	NNP	ORGANIZATION	Inc.	conj_and	5	SENT_295	49738/49742
34	;	:	O	;		-1	SENT_295	49742/49743
35	Mark	NNP	PERSON	Mark	nn	42	SENT_295	49744/49748
36	C	NNP	PERSON	C	nn	42	SENT_295	49749/49750
37	Peterson	NNP	PERSON	Peterson	nn	42	SENT_295	49751/49759
38	,	,	O	,		-1	SENT_295	49759/49760
39	Ph.D.	NNP	O	Ph.D.	appos	42	SENT_295	49761/49766
40	,	,	O	,		-1	SENT_295	49766/49767
41	Biogen	NNP	ORGANIZATION	Biogen	appos	42	SENT_295	49768/49774
42	Idec	NNP	ORGANIZATION	Idec	conj_and	5	SENT_295	49775/49779
43	;	:	O	;		-1	SENT_295	49779/49780
44	Lei	NNP	PERSON	Lei	nn	50	SENT_295	49781/49784
45	Zhang	NNP	PERSON	Zhang	nn	50	SENT_295	49785/49790
46	,	,	O	,		-1	SENT_295	49790/49791
47	Ph.D.	NNP	O	Ph.D.	appos	50	SENT_295	49792/49797
48	,	,	O	,		-1	SENT_295	49797/49798
49	US	NNP	ORGANIZATION	US	appos	50	SENT_295	49799/49801
50	Food	NNP	ORGANIZATION	Food	conj_and	5	SENT_295	49802/49806
51	and	CC	ORGANIZATION	and		-1	SENT_295	49807/49810
52	Drug	NNP	ORGANIZATION	Drug	nn	53	SENT_295	49811/49815
53	Administration	NNP	ORGANIZATION	Administration	conj_and	50	SENT_295	49816/49830
54	;	:	O	;		-1	SENT_295	49830/49831
55	Hong	NNP	LOCATION	Hong	nn	61	SENT_295	49832/49836
56	Zhao	NNP	LOCATION	Zhao	nn	61	SENT_295	49837/49841
57	,	,	O	,		-1	SENT_295	49841/49842
58	Ph.D.	NNP	O	Ph.D.	appos	61	SENT_295	49843/49848
59	,	,	O	,		-1	SENT_295	49848/49849
60	US	NNP	ORGANIZATION	US	appos	61	SENT_295	49850/49852
61	Food	NNP	ORGANIZATION	Food	conj_and	5	SENT_295	49853/49857
62	and	CC	ORGANIZATION	and		-1	SENT_295	49858/49861
63	Drug	NNP	ORGANIZATION	Drug	nn	64	SENT_295	49862/49866
64	Administration	NNP	ORGANIZATION	Administration	conj_and	5	SENT_295	49867/49881

1	2	CD	NUMBER	2		-1	SENT_296	49898/49899

1	Moderators	NNS	O	moderator	dep	144	SENT_297	49916/49926
2	and	CC	O	and	dep	144	SENT_297	49927/49930
3	Speakers	NNS	O	speaker	dep	144	SENT_297	49931/49939
4	:	:	O	:		-1	SENT_297	49939/49940
5	Sandhya	NNP	PERSON	Sandhya	dep	144	SENT_297	49941/49948
6	Girish	NNP	PERSON	Girish	dep	144	SENT_297	49949/49955
7	,	,	O	,		-1	SENT_297	49955/49956
8	Genentech	NNP	ORGANIZATION	Genentech	dep	144	SENT_297	49957/49966
9	,	,	ORGANIZATION	,		-1	SENT_297	49966/49967
10	Inc.	NNP	ORGANIZATION	Inc.	dep	144	SENT_297	49968/49972
11	;	:	O	;		-1	SENT_297	49972/49973
12	Steven	NNP	PERSON	Steven	dep	144	SENT_297	49974/49980
13	W.	NNP	PERSON	W.	dep	144	SENT_297	49981/49983
14	Martin	NNP	PERSON	Martin	dep	144	SENT_297	49984/49990
15	,	,	O	,		-1	SENT_297	49990/49991
16	Ph.D.	NNP	O	Ph.D.	dep	144	SENT_297	49992/49997
17	,	,	O	,		-1	SENT_297	49997/49998
18	Pfizer	NNP	ORGANIZATION	Pfizer	dep	144	SENT_297	49999/50005
19	Inc.	NNP	ORGANIZATION	Inc.	dep	144	SENT_297	50006/50010
20	;	:	O	;		-1	SENT_297	50010/50011
21	Joseph	NNP	PERSON	Joseph	dep	144	SENT_297	50012/50018
22	Balthazar	NNP	PERSON	Balthazar	dep	144	SENT_297	50019/50028
23	,	,	O	,		-1	SENT_297	50028/50029
24	Ph.D.	NNP	O	Ph.D.	dep	144	SENT_297	50030/50035
25	,	,	O	,		-1	SENT_297	50035/50036
26	University	NNP	ORGANIZATION	University	dep	144	SENT_297	50037/50047
27	at	IN	ORGANIZATION	at	dep	144	SENT_297	50048/50050
28	Buffalo	NNP	ORGANIZATION	Buffalo	dep	144	SENT_297	50051/50058
29	,	,	O	,		-1	SENT_297	50058/50059
30	The	DT	ORGANIZATION	the	dep	144	SENT_297	50060/50063
31	State	NNP	ORGANIZATION	State	dep	144	SENT_297	50064/50069
32	University	NNP	ORGANIZATION	University	dep	144	SENT_297	50070/50080
33	of	IN	ORGANIZATION	of	dep	144	SENT_297	50081/50083
34	New	NNP	ORGANIZATION	New	dep	144	SENT_297	50084/50087
35	York	NNP	ORGANIZATION	York	dep	144	SENT_297	50088/50092
36	;	:	O	;		-1	SENT_297	50092/50093
37	Raymond	NNP	PERSON	Raymond	dep	144	SENT_297	50094/50101
38	Evers	NNP	PERSON	Evers	dep	144	SENT_297	50102/50107
39	,	,	O	,		-1	SENT_297	50107/50108
40	Ph.D.	NNP	O	Ph.D.	dep	144	SENT_297	50109/50114
41	,	,	O	,		-1	SENT_297	50114/50115
42	Merck	NNP	ORGANIZATION	Merck	dep	144	SENT_297	50116/50121
43	&	CC	ORGANIZATION	&	dep	144	SENT_297	50122/50123
44	Co.	NNP	ORGANIZATION	Co.	dep	144	SENT_297	50124/50127
45	,	,	O	,		-1	SENT_297	50127/50128
46	Inc.	NNP	ORGANIZATION	Inc.	dep	144	SENT_297	50129/50133
47	;	:	O	;		-1	SENT_297	50133/50134
48	Honghui	NNP	PERSON	Honghui	dep	144	SENT_297	50135/50142
49	Zhou	NNP	PERSON	Zhou	dep	144	SENT_297	50143/50147
50	,	,	O	,		-1	SENT_297	50147/50148
51	Ph.D.	NNP	O	Ph.D.	dep	144	SENT_297	50149/50154
52	,	,	O	,		-1	SENT_297	50154/50155
53	FCP	NNP	O	FCP	dep	144	SENT_297	50156/50159
54	,	,	O	,		-1	SENT_297	50159/50160
55	Centocor	NNP	ORGANIZATION	Centocor	dep	144	SENT_297	50161/50169
56	R&D	NNP	ORGANIZATION	R&D	dep	144	SENT_297	50170/50173
57	,	,	O	,		-1	SENT_297	50173/50174
58	Johnson	NNP	ORGANIZATION	Johnson	dep	144	SENT_297	50175/50182
59	&	CC	ORGANIZATION	&	dep	144	SENT_297	50183/50184
60	Johnson	NNP	ORGANIZATION	Johnson	dep	144	SENT_297	50185/50192
61	;	:	O	;		-1	SENT_297	50192/50193
62	Lei	NNP	PERSON	Lei	dep	144	SENT_297	50194/50197
63	Zhang	NNP	PERSON	Zhang	dep	144	SENT_297	50198/50203
64	,	,	O	,		-1	SENT_297	50203/50204
65	Ph.D.	NNP	O	Ph.D.	dep	144	SENT_297	50205/50210
66	,	,	O	,		-1	SENT_297	50210/50211
67	US	NNP	ORGANIZATION	US	dep	144	SENT_297	50212/50214
68	Food	NNP	ORGANIZATION	Food	dep	144	SENT_297	50215/50219
69	and	CC	ORGANIZATION	and	dep	144	SENT_297	50220/50223
70	Drug	NNP	ORGANIZATION	Drug	dep	144	SENT_297	50224/50228
71	Administration	NNP	ORGANIZATION	Administration	dep	144	SENT_297	50229/50243
72	;	:	O	;		-1	SENT_297	50243/50244
73	Hong	NNP	LOCATION	Hong	dep	144	SENT_297	50245/50249
74	Zhao	NNP	LOCATION	Zhao	dep	144	SENT_297	50250/50254
75	,	,	O	,		-1	SENT_297	50254/50255
76	Ph.D.	NNP	O	Ph.D.	dep	144	SENT_297	50256/50261
77	,	,	O	,		-1	SENT_297	50261/50262
78	US	NNP	ORGANIZATION	US	dep	144	SENT_297	50263/50265
79	Food	NNP	ORGANIZATION	Food	dep	144	SENT_297	50266/50270
80	and	CC	ORGANIZATION	and	dep	144	SENT_297	50271/50274
81	Drug	NNP	ORGANIZATION	Drug	dep	144	SENT_297	50275/50279
82	Administration	NNP	ORGANIZATION	Administration	dep	144	SENT_297	50280/50294
83	;	:	O	;		-1	SENT_297	50294/50295
84	Min	NNP	DURATION	Min	dep	144	SENT_297	50296/50299
85	Zhu	NNP	PERSON	Zhu	dep	144	SENT_297	50300/50303
86	,	,	O	,		-1	SENT_297	50303/50304
87	Ph.D.	NNP	O	Ph.D.	dep	144	SENT_297	50305/50310
88	,	,	O	,		-1	SENT_297	50310/50311
89	Amgen	NNP	ORGANIZATION	Amgen	dep	144	SENT_297	50312/50317
90	Inc.	NNP	ORGANIZATION	Inc.	dep	144	SENT_297	50318/50322
91	;	:	O	;		-1	SENT_297	50322/50323
92	Amita	NNP	PERSON	Amita	dep	144	SENT_297	50324/50329
93	Joshi	NNP	PERSON	Joshi	dep	144	SENT_297	50330/50335
94	,	,	O	,		-1	SENT_297	50335/50336
95	Ph.D.	NNP	O	Ph.D.	dep	144	SENT_297	50337/50342
96	,	,	O	,		-1	SENT_297	50342/50343
97	Genentech	NNP	ORGANIZATION	Genentech	dep	144	SENT_297	50344/50353
98	,	,	ORGANIZATION	,		-1	SENT_297	50353/50354
99	Inc.	NNP	ORGANIZATION	Inc.	dep	144	SENT_297	50355/50359
100	;	:	O	;		-1	SENT_297	50359/50360
101	Lewis	NNP	PERSON	Lewis	dep	144	SENT_297	50361/50366
102	Klunk	NNP	PERSON	Klunk	dep	144	SENT_297	50367/50372
103	,	,	O	,		-1	SENT_297	50372/50373
104	Ph.D.	NNP	O	Ph.D.	dep	144	SENT_297	50374/50379
105	,	,	O	,		-1	SENT_297	50379/50380
106	Biogen	NNP	ORGANIZATION	Biogen	dep	144	SENT_297	50381/50387
107	Idec	NNP	ORGANIZATION	Idec	dep	144	SENT_297	50388/50392
108	;	:	O	;		-1	SENT_297	50392/50393
109	Chao	NNP	PERSON	Chao	dep	144	SENT_297	50394/50398
110	Han	NNP	PERSON	Han	dep	144	SENT_297	50399/50402
111	,	,	O	,		-1	SENT_297	50402/50403
112	Ph.D.	NNP	O	Ph.D.	dep	144	SENT_297	50404/50409
113	,	,	O	,		-1	SENT_297	50409/50410
114	Centocor	NNP	ORGANIZATION	Centocor	dep	144	SENT_297	50411/50419
115	R&D	NNP	ORGANIZATION	R&D	dep	144	SENT_297	50420/50423
116	,	,	O	,		-1	SENT_297	50423/50424
117	Johnson	NNP	ORGANIZATION	Johnson	dep	144	SENT_297	50425/50432
118	&	CC	ORGANIZATION	&	dep	144	SENT_297	50433/50434
119	Johnson	NNP	ORGANIZATION	Johnson	dep	144	SENT_297	50435/50442
120	;	:	O	;		-1	SENT_297	50442/50443
121	Eva	NNP	PERSON	Eva	dep	144	SENT_297	50444/50447
122	Gil	NNP	PERSON	Gil	dep	144	SENT_297	50448/50451
123	Berglund	NNP	PERSON	Berglund	dep	144	SENT_297	50452/50460
124	,	,	O	,		-1	SENT_297	50460/50461
125	Ph.D.	NNP	O	Ph.D.	dep	144	SENT_297	50462/50467
126	,	,	O	,		-1	SENT_297	50467/50468
127	Medical	NNP	ORGANIZATION	Medical	dep	144	SENT_297	50469/50476
128	Products	NNP	ORGANIZATION	Products	dep	144	SENT_297	50477/50485
129	Agency	NNP	ORGANIZATION	Agency	dep	144	SENT_297	50486/50492
130	,	,	O	,		-1	SENT_297	50492/50493
131	Uppsala	NNP	LOCATION	Uppsala	dep	144	SENT_297	50494/50501
132	,	,	O	,		-1	SENT_297	50501/50502
133	Sweden	NNP	LOCATION	Sweden	dep	144	SENT_297	50503/50509
134	;	:	O	;		-1	SENT_297	50509/50510
135	Shiew-Mei	NNP	PERSON	Shiew-Mei	dep	144	SENT_297	50511/50520
136	Huang	NNP	PERSON	Huang	dep	144	SENT_297	50521/50526
137	,	,	O	,		-1	SENT_297	50526/50527
138	Ph.D.	NNP	O	Ph.D.	dep	144	SENT_297	50528/50533
139	,	,	O	,		-1	SENT_297	50533/50534
140	US	NNP	ORGANIZATION	US	dep	144	SENT_297	50535/50537
141	Food	NNP	ORGANIZATION	Food	dep	144	SENT_297	50538/50542
142	and	CC	ORGANIZATION	and	dep	144	SENT_297	50543/50546
143	Drug	NNP	ORGANIZATION	Drug	dep	144	SENT_297	50547/50551
144	Administration	NNP	ORGANIZATION	Administration		-1	SENT_297	50552/50566

1	The	DT	O	the	det	2	SENT_298	50602/50605
2	authors	NNS	O	author	nsubj	3	SENT_298	50606/50613
3	thank	VBP	O	thank		-1	SENT_298	50614/50619
4	the	DT	O	the	det	5	SENT_298	50620/50623
5	sponsor	NN	O	sponsor	dobj	3	SENT_298	50624/50631
6	and	CC	O	and		-1	SENT_298	50632/50635
7	co-sponsors	NNS	O	co-sponsor	conj_and	5	SENT_298	50636/50647
8	for	IN	O	for		-1	SENT_298	50648/50651
9	their	PRP$	O	they	poss	10	SENT_298	50652/50657
10	support	NN	O	support	prep_for	5	SENT_298	50658/50665
11	.	.	O	.		-1	SENT_298	50665/50666

1	This	DT	O	this	det	2	SENT_299	50667/50671
2	workshop	NN	O	workshop	nsubjpass	4	SENT_299	50672/50680
3	was	VBD	O	be	auxpass	4	SENT_299	50681/50684
4	sponsored	VBN	O	sponsor		-1	SENT_299	50685/50694
5	by	IN	O	by		-1	SENT_299	50695/50697
6	American	NNP	ORGANIZATION	American	nn	7	SENT_299	50698/50706
7	Association	NNP	ORGANIZATION	Association	agent	4	SENT_299	50707/50718
8	of	IN	ORGANIZATION	of		-1	SENT_299	50719/50721
9	Pharmaceutical	NNP	ORGANIZATION	Pharmaceutical	nn	10	SENT_299	50722/50736
10	Scientists	NNS	ORGANIZATION	scientist	prep_of	7	SENT_299	50737/50747
11	and	CC	O	and		-1	SENT_299	50748/50751
12	co	SYM	O	co	dep	14	SENT_299	50752/50754
13	-	:	O	-		-1	SENT_299	50754/50755
14	sponsored	VBN	O	sponsor	conj_and	4	SENT_299	50756/50765
15	by	IN	O	by		-1	SENT_299	50766/50768
16	ISSX	NN	ORGANIZATION	issx	nn	19	SENT_299	50769/50773
17	(	CD	NUMBER	(	num	19	SENT_299	50774/50775
18	International	NNP	ORGANIZATION	International	nn	19	SENT_299	50775/50788
19	Society	NNP	ORGANIZATION	Society	prep_by	14	SENT_299	50789/50796
20	for	IN	ORGANIZATION	for		-1	SENT_299	50797/50800
21	Study	NNP	ORGANIZATION	Study	prep_for	19	SENT_299	50801/50806
22	of	IN	ORGANIZATION	of		-1	SENT_299	50807/50809
23	Xenobiotics	NNPS	ORGANIZATION	Xenobiotics	prep_of	21	SENT_299	50810/50821
24	)	CD	NUMBER	)	dep	23	SENT_299	50821/50822
25	,	,	O	,		-1	SENT_299	50822/50823
26	Drug	NNP	ORGANIZATION	Drug	nn	28	SENT_299	50824/50828
27	Information	NNP	ORGANIZATION	Information	nn	28	SENT_299	50829/50840
28	Association	NNP	ORGANIZATION	Association	nn	29	SENT_299	50841/50852
29	(	NN	O	(	conj_and	23	SENT_299	50853/50854
30	DIA	NNP	O	DIA	dep	29	SENT_299	50854/50857
31	)	CD	NUMBER	)	num	30	SENT_299	50857/50858
32	,	,	O	,		-1	SENT_299	50858/50859
33	and	CC	O	and		-1	SENT_299	50860/50863
34	Biotechnology	NNP	ORGANIZATION	Biotechnology	nn	36	SENT_299	50864/50877
35	Industry	NNP	ORGANIZATION	Industry	nn	36	SENT_299	50878/50886
36	Organization	NNP	ORGANIZATION	Organization	conj_and	23	SENT_299	50887/50899
37	(	NN	O	(	nn	39	SENT_299	50900/50901
38	BIO	NN	O	bio	nn	39	SENT_299	50901/50904
39	)	NN	O	)	dep	36	SENT_299	50904/50905
40	.	.	O	.		-1	SENT_299	50905/50906

1	References	NNS	O	reference		-1	SENT_300	50942/50952

1	1.LeeJIZhangLMenAYKennaLAHuangSMCYP-medicated	JJ	O	1.leejizhanglmenaykennalahuangsmcyp-medicated	amod	4	SENT_301	50969/51014
2	therapeutic	JJ	O	therapeutic	amod	4	SENT_301	51015/51026
3	protein-drug	JJ	O	protein-drug	amod	4	SENT_301	51027/51039
4	interactions	NNS	O	interaction		-1	SENT_301	51040/51052
5	clinical	JJ	O	clinical	amod	6	SENT_301	51053/51061
6	findings	NNS	O	finding	dep	4	SENT_301	51062/51070
7	,	,	O	,		-1	SENT_301	51070/51071
8	proposed	VBN	O	propose	amod	9	SENT_301	51072/51080
9	mechanisms	NNS	O	mechanism	appos	4	SENT_301	51081/51091
10	and	CC	O	and		-1	SENT_301	51092/51095
11	regulatory	JJ	O	regulatory	amod	13	SENT_301	51096/51106
12	implicationsClin	NN	O	implicationsclin	nn	13	SENT_301	51107/51123
13	Pharmacokinet201049529531010	NN	O	pharmacokinet201049529531010	conj_and	9	SENT_301	51124/51152
14	.2165	CD	NUMBER	.2165	dep	13	SENT_301	51152/51157
15	/	:	O	/	punct	16	SENT_301	51157/51158
16	11319980-000000000-00000203843922	CD	NUMBER	11319980-000000000-00000203843922	dep	14	SENT_301	51158/51191
17	.	.	O	.		-1	SENT_301	51191/51192

1	HuangS	SYM	O	huangs	dep	8	SENT_302	51192/51198
2	-	:	O	-		-1	SENT_302	51198/51199
3	MZhaoHLeeJIReynoldsKZhangLTempleRTherapeutic	JJ	O	mzhaohleejireynoldskzhangltemplertherapeutic	amod	5	SENT_302	51200/51244
4	protein-drug	JJ	O	protein-drug	amod	5	SENT_302	51245/51257
5	interactions	NNS	O	interaction	npadvmod	8	SENT_302	51258/51270
6	and	CC	O	and		-1	SENT_302	51271/51274
7	implications	NNS	O	implication	conj_and	5	SENT_302	51275/51287
8	for	IN	O	for		-1	SENT_302	51288/51291
9	drug	NN	O	drug	nn	11	SENT_302	51292/51296
10	developmentClin	NNP	O	developmentClin	nn	11	SENT_302	51297/51312
11	Pharmacol	NNP	O	Pharmacol	pobj	8	SENT_302	51313/51322
12	Ther20108749750310	NN	O	ther20108749750310	dep	11	SENT_302	51323/51341
13	.1038	CD	NUMBER	.1038	num	12	SENT_302	51341/51346
14	/	:	O	/	punct	16	SENT_302	51346/51347
15	clpt	JJ	O	clpt	amod	16	SENT_302	51347/51351
16	.2009.308202005133	NN	O	.2009.308202005133	dep	11	SENT_302	51351/51369
17	.	.	O	.		-1	SENT_302	51369/51370

1	SeitzKZhouHPharmacokinetic	JJ	O	seitzkzhouhpharmacokinetic	amod	4	SENT_303	51370/51396
2	drug-drug	JJ	O	drug-drug	amod	4	SENT_303	51397/51406
3	interaction	NN	O	interaction	nn	4	SENT_303	51407/51418
4	potentials	NNS	O	potential		-1	SENT_303	51419/51429
5	for	IN	O	for		-1	SENT_303	51430/51433
6	therapeutic	JJ	O	therapeutic	amod	8	SENT_303	51434/51445
7	monoclonal	JJ	O	monoclonal	amod	8	SENT_303	51446/51456
8	antibodies	NNS	O	antibody	prep_for	4	SENT_303	51457/51467
9	:	:	O	:		-1	SENT_303	51467/51468
10	reality	NN	O	reality	nn	12	SENT_303	51469/51476
11	checkJ	NN	O	checkj	nn	12	SENT_303	51477/51483
12	Clin	NN	O	clin	dep	4	SENT_303	51484/51488
13	Pharmacol2007471104111810	NN	O	pharmacol2007471104111810	dep	12	SENT_303	51489/51514
14	.1177	CD	NUMBER	.1177	num	13	SENT_303	51514/51519
15	/	:	O	/	punct	16	SENT_303	51519/51520
16	0091270007306958177666984	CD	NUMBER	0091270007306958177666984	dep	13	SENT_303	51520/51545
17	.	.	O	.		-1	SENT_303	51546/51547

1	ZhouHDavisHMRisk-based	JJ	O	zhouhdavishmrisk-based	amod	2	SENT_304	51547/51569
2	strategy	NN	O	strategy		-1	SENT_304	51570/51578
3	for	IN	O	for		-1	SENT_304	51579/51582
4	the	DT	O	the	det	5	SENT_304	51583/51586
5	assessment	NN	O	assessment	prep_for	2	SENT_304	51587/51597
6	of	IN	O	of		-1	SENT_304	51598/51600
7	pharmacokinetic	JJ	O	pharmacokinetic	amod	8	SENT_304	51601/51616
8	drug	NN	O	drug	prep_of	5	SENT_304	51617/51621
9	-	:	O	-		-1	SENT_304	51621/51622
10	drug	NN	O	drug	nn	11	SENT_304	51623/51627
11	interactions	NNS	O	interaction	dep	2	SENT_304	51628/51640
12	for	IN	O	for		-1	SENT_304	51641/51644
13	therapeutic	JJ	O	therapeutic	amod	17	SENT_304	51645/51656
14	monoclonal	JJ	O	monoclonal	amod	17	SENT_304	51657/51667
15	antibodiesDrug	NN	O	antibodiesdrug	nn	17	SENT_304	51668/51682
16	Discov	NNP	O	Discov	nn	17	SENT_304	51683/51689
17	Today200914	NNP	O	Today200914	prep_for	11	SENT_304	51690/51701
18	17-1889189810	CD	NUMBER	17-1889189810	num	19	SENT_304	51702/51715
19	.1016	CD	NUMBER	.1016	dep	11	SENT_304	51715/51720
20	/	:	O	/	punct	2	SENT_304	51720/51721
21	j.	NN	O	j.	nsubj	22	SENT_304	51721/51723
22	drudis	VBZ	O	drudi	dep	2	SENT_304	51723/51729
23	.2009.05.014195201835	CD	NUMBER	.2009.05.014195201835	dobj	22	SENT_304	51729/51750
24	.	.	O	.		-1	SENT_304	51750/51751

1	MahmoodIGreenMDDrug	NNP	O	MahmoodIGreenMDDrug		-1	SENT_305	51751/51770
2	interaction	NN	O	interaction	nn	3	SENT_305	51771/51782
3	studies	NNS	O	study	dep	1	SENT_305	51783/51790
4	of	IN	O	of		-1	SENT_305	51791/51793
5	therapeutic	JJ	O	therapeutic	amod	6	SENT_305	51794/51805
6	proteins	NNS	O	protein	prep_of	3	SENT_305	51806/51814
7	or	CC	O	or		-1	SENT_305	51815/51817
8	monoclonal	JJ	O	monoclonal	amod	11	SENT_305	51818/51828
9	antibodiesJ	NN	O	antibodiesj	nn	11	SENT_305	51829/51840
10	Clin	NN	O	clin	nn	11	SENT_305	51841/51845
11	Pharmacol2007471540155410	NN	O	pharmacol2007471540155410	conj_or	3	SENT_305	51846/51871
12	.1177	CD	NUMBER	.1177	dep	11	SENT_305	51871/51876
13	/	:	O	/	punct	1	SENT_305	51876/51877
14	0091270007308616179624226	CD	NUMBER	0091270007308616179624226	dep	1	SENT_305	51877/51902
15	.	.	O	.		-1	SENT_305	51902/51903

1	MorganETImpact	NN	O	morganetimpact	dep	11	SENT_306	51903/51917
2	of	IN	O	of		-1	SENT_306	51918/51920
3	infectious	JJ	O	infectious	amod	6	SENT_306	51921/51931
4	and	CC	O	and		-1	SENT_306	51932/51935
5	inflammatory	JJ	O	inflammatory	conj_and	3	SENT_306	51936/51948
6	disease	NN	O	disease	prep_of	1	SENT_306	51949/51956
7	on	IN	O	on		-1	SENT_306	51957/51959
8	cytochrome	NN	O	cytochrome	prep_on	6	SENT_306	51960/51970
9	P450-mediated	JJ	O	p450-mediated	amod	10	SENT_306	51971/51984
10	drug	NN	O	drug	dep	11	SENT_306	51985/51989
11	metabolism	NN	O	metabolism	dep	15	SENT_306	51990/52000
12	and	CC	O	and		-1	SENT_306	52001/52004
13	pharmacokineticsClin	NN	O	pharmacokineticsclin	nn	14	SENT_306	52005/52025
14	Pharmacol	NN	O	pharmacol	conj_and	11	SENT_306	52026/52035
15	Ther200985443443810	NN	O	ther200985443443810	dep	19	SENT_306	52036/52055
16	.1038	CD	NUMBER	.1038	num	15	SENT_306	52055/52060
17	/	:	O	/	punct	19	SENT_306	52060/52061
18	clpt	JJ	O	clpt	amod	19	SENT_306	52061/52065
19	.2008.302192123147	NN	O	.2008.302192123147		-1	SENT_306	52065/52083
20	.	.	O	.		-1	SENT_306	52083/52084

1	US	NNP	ORGANIZATION	US	nn	2	SENT_307	52084/52086
2	Food	NNP	ORGANIZATION	Food		-1	SENT_307	52087/52091
3	and	CC	ORGANIZATION	and		-1	SENT_307	52092/52095
4	Drug	NNP	ORGANIZATION	Drug	nn	5	SENT_307	52096/52100
5	Administration	NNP	ORGANIZATION	Administration	conj_and	2	SENT_307	52101/52115
6	.	.	O	.		-1	SENT_307	52115/52116

1	Draft	NN	O	draft	nn	2	SENT_308	52117/52122
2	Guidance	NN	O	guidance		-1	SENT_308	52123/52131
3	for	IN	O	for		-1	SENT_308	52132/52135
4	industry	NN	O	industry	prep_for	2	SENT_308	52136/52144
5	:	:	O	:		-1	SENT_308	52144/52145
6	drug	NN	O	drug	dep	2	SENT_308	52146/52150
7	interaction	NN	O	interaction	nn	8	SENT_308	52151/52162
8	studies	NNS	O	study	dep	6	SENT_308	52163/52170
9	--	:	O	--		-1	SENT_308	52170/52172
10	study	NN	O	study	nn	11	SENT_308	52172/52177
11	design	NN	O	design	dep	2	SENT_308	52178/52184
12	,	,	O	,		-1	SENT_308	52184/52185
13	data	NN	O	datum	nn	14	SENT_308	52186/52190
14	analysis	NN	O	analysis	conj_and	11	SENT_308	52191/52199
15	and	CC	O	and		-1	SENT_308	52200/52203
16	implications	NNS	O	implication	conj_and	11	SENT_308	52204/52216
17	for	IN	O	for		-1	SENT_308	52217/52220
18	dosing	NN	O	dosing	prep_for	16	SENT_308	52221/52227
19	and	CC	O	and		-1	SENT_308	52228/52231
20	labelling	NN	O	labelling	conj_and	18	SENT_308	52232/52241
21	.	.	O	.		-1	SENT_308	52241/52242

1	Rockville	NNP	LOCATION	Rockville		-1	SENT_309	52243/52252
2	,	,	O	,		-1	SENT_309	52252/52253
3	MD.	NNP	O	MD.	appos	1	SENT_309	52254/52257
4	2006	CD	DATE	2006	num	3	SENT_309	52258/52262
5	.	.	O	.		-1	SENT_309	52262/52263

1	http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInfor	NN	O	http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinfor		-1	SENT_310	52264/52332
2	mation/Guidances/ucm072101	NN	O	mation/guidances/ucm072101	dep	1	SENT_310	52333/52359
3	.	.	O	.		-1	SENT_310	52359/52360

1	pdf	NN	O	pdf		-1	SENT_311	52360/52363
2	or	CC	O	or		-1	SENT_311	52364/52366
3	FDA	NNP	ORGANIZATION	FDA	nn	5	SENT_311	52367/52370
4	Drug	NNP	O	Drug	nn	5	SENT_311	52371/52375
5	Interaction	NN	O	interaction	conj_or	1	SENT_311	52376/52387
6	and	CC	O	and		-1	SENT_311	52388/52391
7	Drug	NNP	O	Drug	nn	9	SENT_311	52392/52396
8	Development	NNP	O	Development	nn	9	SENT_311	52397/52408
9	website	NN	O	website	conj_and	5	SENT_311	52409/52416
10	:	:	O	:		-1	SENT_311	52416/52417
11	http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResour	NN	O	http://www.fda.gov/drugs/developmentapprovalprocess/developmentresour	nn	12	SENT_311	52418/52487
12	ces/DrugInteractionsLabeling/ucm080499	NN	O	ces/druginteractionslabeling/ucm080499	dep	1	SENT_311	52488/52526
13	.	.	O	.		-1	SENT_311	52526/52527

1	htm	NN	O	htm		-1	SENT_312	52527/52530
2	.	.	O	.		-1	SENT_312	52530/52531

1	Accessed	VBN	O	access		-1	SENT_313	52532/52540
2	04	CD	DATE	04	dobj	1	SENT_313	52541/52543
3	Jan	NNP	DATE	Jan	tmod	1	SENT_313	52544/52547
4	2010.8	CD	NUMBER	2010.8	num	3	SENT_313	52548/52554
5	.	.	O	.		-1	SENT_313	52554/52555

1	European	JJ	ORGANIZATION	european		-1	SENT_314	52555/52563
2	Medicines	NNP	ORGANIZATION	Medicines	nn	3	SENT_314	52564/52573
3	Agency	NNP	ORGANIZATION	Agency	dep	1	SENT_314	52574/52580
4	.	.	O	.		-1	SENT_314	52580/52581

1	Guideline	NN	O	guideline	dep	14	SENT_315	52582/52591
2	on	IN	O	on		-1	SENT_315	52592/52594
3	the	DT	O	the	det	5	SENT_315	52595/52598
4	clinical	JJ	O	clinical	amod	5	SENT_315	52599/52607
5	investigation	NN	O	investigation	prep_on	14	SENT_315	52608/52621
6	of	IN	O	of		-1	SENT_315	52622/52624
7	the	DT	O	the	det	8	SENT_315	52625/52628
8	pharmacokinetics	NNS	O	pharmacokinetic	prep_of	5	SENT_315	52629/52645
9	of	IN	O	of		-1	SENT_315	52646/52648
10	therapeutic	JJ	O	therapeutic	amod	12	SENT_315	52649/52660
11	proteins	NNS	O	protein	nn	12	SENT_315	52661/52669
12	CHMP/EWP/89249	NN	O	chmp/ewp/89249	prep_of	8	SENT_315	52670/52684
13	/	:	O	/	punct	14	SENT_315	52684/52685
14	2004	CD	DATE	2004		-1	SENT_315	52685/52689
15	.	.	O	.		-1	SENT_315	52689/52690

1	London	NNP	LOCATION	London		-1	SENT_316	52691/52697
2	,	,	O	,		-1	SENT_316	52697/52698
3	UK	NNP	LOCATION	UK	appos	1	SENT_316	52699/52701
4	.	.	O	.		-1	SENT_316	52701/52702

1	2007	CD	DATE	2007		-1	SENT_317	52703/52707
2	.	.	O	.		-1	SENT_317	52707/52708

1	http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/gen	NN	O	http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/gen		-1	SENT_318	52709/52781
2	eral_content_000370	NN	O	eral_content_000370	dep	1	SENT_318	52782/52801
3	.	.	O	.		-1	SENT_318	52801/52802

1	jsp	NN	O	jsp		-1	SENT_319	52802/52805
2	&	CC	O	&	cc	3	SENT_319	52805/52806
3	murl	NN	O	murl	dep	1	SENT_319	52806/52810
4	=	JJ	O	=	amod	5	SENT_319	52810/52811
5	menus/regulations/regulations	NNS	O	menus/regulations/regulations	dep	3	SENT_319	52811/52840
6	.	.	O	.		-1	SENT_319	52840/52841

1	jsp	NN	O	jsp		-1	SENT_320	52841/52844
2	&	CC	O	&		-1	SENT_320	52844/52845
3	mid	JJ	O	mid	amod	6	SENT_320	52845/52848
4	=	JJ	O	=	amod	6	SENT_320	52848/52849
5	WC0b01ac058	NN	O	wc0b01ac058	nn	6	SENT_320	52849/52860
6	0032ec5	NN	O	0032ec5	conj_and	1	SENT_320	52861/52868
7	.	.	O	.		-1	SENT_320	52868/52869

1	Accessed	VBN	O	access		-1	SENT_321	52870/52878
2	15	CD	DATE	15	dobj	1	SENT_321	52879/52881
3	Jan	NNP	DATE	Jan	tmod	1	SENT_321	52882/52885
4	2011.9	CD	NUMBER	2011.9	num	3	SENT_321	52886/52892
5	.	.	O	.		-1	SENT_321	52892/52893

1	PageauxGPLe	NN	O	pageauxgple	nn	2	SENT_322	52893/52904
2	BricquirYBerthouFBressotNPicotM	NN	O	bricquiryberthoufbressotnpicotm		-1	SENT_322	52905/52936
3	-	:	O	-		-1	SENT_322	52936/52937
4	CBlancFEffects	NNS	O	cblancfeffect	dep	14	SENT_322	52938/52952
5	of	IN	O	of		-1	SENT_322	52953/52955
6	interferon-alpha	NN	O	interferon-alpha	prep_of	4	SENT_322	52956/52972
7	on	IN	O	on		-1	SENT_322	52973/52975
8	cytochrome	NN	O	cytochrome	nn	9	SENT_322	52976/52986
9	P-450	NN	O	p-450	prep_on	6	SENT_322	52987/52992
10	isoforms	NNS	O	isoform	dep	14	SENT_322	52993/53001
11	1A2	NN	O	1a2	nn	14	SENT_322	53002/53005
12	and	CC	O	and		-1	SENT_322	53006/53009
13	3A	NN	O	3a	conj_and	11	SENT_322	53010/53012
14	activities	NNS	O	activity	dep	23	SENT_322	53013/53023
15	in	IN	O	in		-1	SENT_322	53024/53026
16	patients	NNS	O	patient	prep_in	14	SENT_322	53027/53035
17	with	IN	O	with		-1	SENT_322	53036/53040
18	chronic	JJ	O	chronic	amod	22	SENT_322	53041/53048
19	hepatitis	NN	O	hepatitis	nn	22	SENT_322	53049/53058
20	CEur	NN	O	ceur	nn	22	SENT_322	53059/53063
21	J	NN	O	j	nn	22	SENT_322	53064/53065
22	Gastroenterol	NN	O	gastroenterol	prep_with	16	SENT_322	53066/53079
23	Hepatol1998	NN	O	hepatol1998	dep	26	SENT_322	53080/53091
24	1049149510.1097	CD	NUMBER	1049149510.1097	num	23	SENT_322	53092/53107
25	/	:	O	/	punct	26	SENT_322	53107/53108
26	00042737-199806000-00010985506510	CD	NUMBER	00042737-199806000-00010985506510	dep	2	SENT_322	53108/53141
27	.	.	O	.		-1	SENT_322	53141/53142

1	BecquemontLChazouilleresOSer	NNP	O	BecquemontLChazouilleresOSer	nn	2	SENT_323	53142/53170
2	fatyLPoirierJMBrolyFJailonPEffect	NN	O	fatylpoirierjmbrolyfjailonpeffect		-1	SENT_323	53171/53204
3	of	IN	O	of		-1	SENT_323	53205/53207
4	interferon	NN	O	interferon	prep_of	2	SENT_323	53208/53218
5	-	:	O	-		-1	SENT_323	53221/53222
6	ribavirin	NNP	O	ribavirin	nn	7	SENT_323	53222/53231
7	bitherapy	NN	O	bitherapy	dep	2	SENT_323	53232/53241
8	on	IN	O	on		-1	SENT_323	53242/53244
9	cytochrome	NN	O	cytochrome	nn	11	SENT_323	53245/53255
10	P450	NN	O	p450	nn	11	SENT_323	53256/53260
11	1A2	NN	O	1a2	prep_on	7	SENT_323	53261/53264
12	and	CC	O	and		-1	SENT_323	53265/53268
13	2D6	NN	O	2d6	conj_and	11	SENT_323	53269/53272
14	and	CC	O	and		-1	SENT_323	53273/53276
15	N-acetyltransferase-2	NN	O	n-acetyltransferase-2	nn	16	SENT_323	53277/53298
16	activities	NNS	O	activity	conj_and	11	SENT_323	53299/53309
17	in	IN	O	in		-1	SENT_323	53310/53312
18	patients	NNS	O	patient	prep_in	2	SENT_323	53313/53321
19	with	IN	O	with		-1	SENT_323	53322/53326
20	chronic	JJ	O	chronic	amod	24	SENT_323	53327/53334
21	hepatitis	NN	O	hepatitis	nn	24	SENT_323	53335/53344
22	CClin	NN	O	cclin	nn	24	SENT_323	53345/53350
23	Pharmacol	NN	O	pharmacol	nn	24	SENT_323	53351/53360
24	Ther20027148849510	NN	O	ther20027148849510	prep_with	2	SENT_323	53361/53379
25	.1067	CD	NUMBER	.1067	dep	24	SENT_323	53379/53384
26	/	:	O	/	punct	2	SENT_323	53384/53385
27	mcp	NN	O	mcp	dep	2	SENT_323	53385/53388
28	.2002.124468	CD	NUMBER	.2002.124468	num	29	SENT_323	53388/53400
29	1208735211	CD	NUMBER	1208735211	dep	27	SENT_323	53401/53411
30	.	.	O	.		-1	SENT_323	53411/53412

1	ElkahwajiJRobinMABersonATinelMLetteronPLabbeGDecrease	NN	O	elkahwajijrobinmabersonatinelmletteronplabbegdecrease		-1	SENT_324	53412/53465
2	in	IN	O	in		-1	SENT_324	53466/53468
3	hepatic	JJ	O	hepatic	amod	5	SENT_324	53469/53476
4	cytochrome	NN	O	cytochrome	nn	5	SENT_324	53477/53487
5	P450	NN	O	p450	prep_in	1	SENT_324	53488/53492
6	after	IN	O	after	prep	5	SENT_324	53493/53498
7	interleukine-2	NN	O	interleukine-2	nn	9	SENT_324	53499/53513
8	immunotherapyBiochem	NN	O	immunotherapybiochem	nn	9	SENT_324	53514/53534
9	Pharmacol19995795195410	NN	O	pharmacol19995795195410	dep	6	SENT_324	53535/53558
10	.1016	CD	NUMBER	.1016	dep	9	SENT_324	53558/53563
11	/	:	O	/	punct	9	SENT_324	53563/53564
12	S0006-2952	NN	O	s0006-2952	dep	9	SENT_324	53564/53574
13	(	CD	NUMBER	(	number	14	SENT_324	53574/53575
14	98	CD	NUMBER	98	num	15	SENT_324	53575/53577
15	)	NN	O	)	dep	12	SENT_324	53577/53578
16	00372-41008633012	CD	NUMBER	00372-41008633012	tmod	5	SENT_324	53578/53595
17	.	.	O	.		-1	SENT_324	53596/53597

1	GorskiJCHallSDBeckerPAffrimeMBCutlerDLHaehner-DanielsBIn	FW	O	gorskijchallsdbeckerpaffrimembcutlerdlhaehner-danielsbin	nn	3	SENT_325	53597/53653
2	vivo	FW	O	vivo	nn	3	SENT_325	53654/53658
3	effects	NNS	O	effect		-1	SENT_325	53659/53666
4	of	IN	O	of		-1	SENT_325	53667/53669
5	interleukin-10	NN	O	interleukin-10	prep_of	3	SENT_325	53670/53684
6	on	IN	O	on		-1	SENT_325	53685/53687
7	human	JJ	O	human	amod	12	SENT_325	53688/53693
8	cytochrome	NN	O	cytochrome	nn	12	SENT_325	53694/53704
9	P450	NN	O	p450	nn	12	SENT_325	53705/53709
10	activityClin	NN	O	activityclin	nn	12	SENT_325	53710/53722
11	Pharmacol	NN	O	pharmacol	nn	12	SENT_325	53723/53732
12	Ther20006732431	NN	O	ther20006732431	prep_on	3	SENT_325	53733/53748
13	0.1067	CD	NUMBER	0.1067	dep	12	SENT_325	53749/53755
14	/	:	O	/	punct	15	SENT_325	53755/53756
15	mcp	NN	O	mcp	dep	12	SENT_325	53756/53759
16	.2000.1038601066885113	CD	NUMBER	.2000.1038601066885113	num	15	SENT_325	53759/53781
17	.	.	O	.		-1	SENT_325	53781/53782

1	IslamMFryeRFRichardsTJSbeitanIDonellySSGluePD	NN	O	islammfryerfrichardstjsbeitanidonellyssgluepd	nn	3	SENT_326	53782/53827
2	ifferential	JJ	O	ifferential	amod	3	SENT_326	53828/53839
3	effect	NN	O	effect		-1	SENT_326	53840/53846
4	of	IN	O	of		-1	SENT_326	53847/53849
5	IFN	NN	O	ifn	nn	7	SENT_326	53850/53853
6	-2	CD	NUMBER	-2	num	7	SENT_326	53855/53857
7	b	NN	O	b	prep_of	3	SENT_326	53857/53858
8	on	IN	O	on		-1	SENT_326	53859/53861
9	the	DT	O	the	det	13	SENT_326	53862/53865
10	cytochrome	NN	O	cytochrome	nn	13	SENT_326	53866/53876
11	P450	NN	O	p450	nn	13	SENT_326	53877/53881
12	enzyme	NN	O	enzyme	nn	13	SENT_326	53882/53888
13	system	NN	O	system	prep_on	7	SENT_326	53889/53895
14	:	:	O	:		-1	SENT_326	53895/53896
15	A	DT	O	a	det	17	SENT_326	53897/53898
16	potential	JJ	O	potential	amod	17	SENT_326	53899/53908
17	basis	NN	O	basis	dep	3	SENT_326	53909/53914
18	of	IN	O	of		-1	SENT_326	53915/53917
19	IFN	NN	ORGANIZATION	ifn	nn	20	SENT_326	53918/53921
20	toxicity	NN	O	toxicity	prep_of	17	SENT_326	53922/53930
21	and	CC	O	and		-1	SENT_326	53931/53934
22	its	PRP$	O	its	poss	23	SENT_326	53935/53938
23	modulation	NN	O	modulation	conj_and	17	SENT_326	53939/53949
24	by	IN	O	by		-1	SENT_326	53950/53952
25	other	JJ	O	other	amod	28	SENT_326	53953/53958
26	drugsClin	NN	O	drugsclin	nn	28	SENT_326	53959/53968
27	Cancer	NN	O	cancer	nn	28	SENT_326	53969/53975
28	Res20028248024871217187314	NN	O	res20028248024871217187314	prep_by	23	SENT_326	53976/54002
29	.	.	O	.		-1	SENT_326	54002/54003

1	SunmanJAHawkeRLLeCluyseELKashubaADKupffer	NN	O	sunmanjahawkerllecluyseelkashubaadkupffer	nn	2	SENT_327	54003/54044
2	cell	NN	O	cell	dep	4	SENT_327	54045/54049
3	-	:	O	-		-1	SENT_327	54049/54050
4	mediated	VBN	O	mediate		-1	SENT_327	54051/54059
5	IL-2	NN	O	il-2	nn	6	SENT_327	54060/54064
6	suppression	NN	O	suppression	dobj	4	SENT_327	54065/54076
7	of	IN	O	of		-1	SENT_327	54077/54079
8	CYP3A	NN	O	cyp3a	nn	9	SENT_327	54080/54085
9	activity	NN	O	activity	prep_of	6	SENT_327	54086/54094
10	in	IN	O	in		-1	SENT_327	54095/54097
11	human	JJ	O	human	amod	15	SENT_327	54098/54103
12	hepatocytesDrug	NN	O	hepatocytesdrug	nn	15	SENT_327	54104/54119
13	Metab	NNP	O	Metab	nn	15	SENT_327	54120/54125
14	Dis	NNP	O	Dis	nn	15	SENT_327	54126/54129
15	pos20043235936310	NN	O	pos20043235936310	prep_in	4	SENT_327	54130/54147
16	.1124	CD	NUMBER	.1124	num	15	SENT_327	54147/54152
17	/	:	O	/	punct	18	SENT_327	54152/54153
18	dmd	NN	O	dmd	dep	15	SENT_327	54153/54156
19	.32.3.3591497787115	CD	NUMBER	.32.3.3591497787115	num	18	SENT_327	54156/54175
20	.	.	O	.		-1	SENT_327	54175/54176

1	VeeMLLecureurVStiegerBFardelOReg	NNP	O	VeeMLLecureurVStiegerBFardelOReg	nn	2	SENT_328	54176/54208
2	ulation	NN	O	ulation	nsubj	10	SENT_328	54209/54216
3	of	IN	O	of		-1	SENT_328	54217/54219
4	drug	NN	O	drug	nn	6	SENT_328	54220/54224
5	transporter	NN	O	transporter	nn	6	SENT_328	54225/54236
6	expression	NN	O	expression	prep_of	2	SENT_328	54237/54247
7	in	IN	O	in		-1	SENT_328	54248/54250
8	human	JJ	O	human	amod	9	SENT_328	54251/54256
9	hepatocytes	NNS	O	hepatocyte	prep_in	6	SENT_328	54257/54268
10	exposed	VBN	O	expose		-1	SENT_328	54269/54276
11	to	TO	O	to		-1	SENT_328	54277/54279
12	the	DT	O	the	det	26	SENT_328	54280/54283
13	proinflammatory	JJ	O	proinflammatory	amod	26	SENT_328	54284/54299
14	cytokines	NNS	O	cytokine	nn	26	SENT_328	54300/54309
15	tumor	NN	O	tumor	nn	26	SENT_328	54310/54315
16	necrosis	NN	O	necrosis	nn	26	SENT_328	54316/54324
17	factor	NN	O	factor	nn	26	SENT_328	54325/54331
18	-	:	O	-		-1	SENT_328	54331/54332
19	or	CC	O	or	cc	22	SENT_328	54335/54337
20	interleukin-6Drug	NN	O	interleukin-6drug	nn	22	SENT_328	54338/54355
21	Metab	NN	O	metab	nn	22	SENT_328	54356/54361
22	D	NN	O	d	dep	26	SENT_328	54362/54363
23	ispos20083768569310	NN	O	ispos20083768569310	dep	22	SENT_328	54364/54383
24	.1124	CD	NUMBER	.1124	num	23	SENT_328	54383/54388
25	/	:	O	/	punct	22	SENT_328	54388/54389
26	dmd	NN	O	dmd	prep_to	10	SENT_328	54389/54392
27	.108.0236301907497316	CD	NUMBER	.108.0236301907497316	tmod	10	SENT_328	54392/54413
28	.	.	O	.		-1	SENT_328	54413/54414

1	AitkenARichardsonTAMorganETR	NN	O	aitkenarichardsontamorganetr	nn	2	SENT_329	54414/54442
2	egulation	NN	O	egulation		-1	SENT_329	54443/54452
3	of	IN	O	of		-1	SENT_329	54453/54455
4	drug-metabolizing	JJ	O	drug-metabolizing	amod	5	SENT_329	54456/54473
5	enzymes	NNS	O	enzyme	prep_of	2	SENT_329	54474/54481
6	and	CC	O	and		-1	SENT_329	54482/54485
7	transporters	NNS	O	transporter	conj_and	5	SENT_329	54486/54498
8	in	IN	O	in		-1	SENT_329	54499/54501
9	inflammationAnnu	NNP	O	inflammationAnnu	nn	12	SENT_329	54502/54518
10	Rev	NN	O	rev	nn	12	SENT_329	54519/54522
11	Pharmacol	NN	O	pharmacol	nn	12	SENT_329	54523/54532
12	Toxicol20064612314910	NN	O	toxicol20064612314910	prep_in	2	SENT_329	54533/54554
13	.1146	CD	NUMBER	.1146	dep	12	SENT_329	54554/54559
14	/	:	O	/	punct	2	SENT_329	54559/54560
15	annurev	NN	O	annurev	dep	2	SENT_329	54560/54567
16	.	.	O	.		-1	SENT_329	54567/54568

1	pharmtox	NN	O	pharmtox		-1	SENT_330	54568/54576
2	.46.120604.1410591640	CD	NUMBER	.46.120604.1410591640	number	3	SENT_330	54576/54597
3	290117	CD	NUMBER	290117	num	1	SENT_330	54598/54604
4	.	.	O	.		-1	SENT_330	54604/54605

1	VincentiFMendezRPescovitzMRajagopalanPRWilkinsonAHButtKA	NN	O	vincentifmendezrpescovitzmrajagopalanprwilkinsonahbuttka	nn	3	SENT_331	54605/54661
2	phase	NN	O	phase	nn	3	SENT_331	54662/54667
3	I/II	NN	O	i/ii		-1	SENT_331	54668/54672
4	randomized	VBN	O	randomize	partmod	3	SENT_331	54673/54683
5	open-label	JJ	O	open-label	amod	7	SENT_331	54684/54694
6	multicenter	JJ	O	multicenter	amod	7	SENT_331	54695/54706
7	trial	NN	O	trial	dep	4	SENT_331	54707/54712
8	of	IN	O	of		-1	SENT_331	54713/54715
9	efalizumab	NN	O	efalizumab	prep_of	7	SENT_331	54716/54726
10	,	,	O	,		-1	SENT_331	54726/54727
11	a	DT	O	a	det	13	SENT_331	54728/54729
12	humanized	JJ	O	humanized	amod	13	SENT_331	54730/54739
13	anti-CD11a	NN	O	anti-cd11a	dep	4	SENT_331	54740/54750
14	,	,	O	,		-1	SENT_331	54750/54751
15	anti-LFA-1	NN	O	anti-lfa-1	dep	21	SENT_331	54752/54762
16	in	IN	O	in		-1	SENT_331	54763/54765
17	renal	JJ	O	renal	amod	20	SENT_331	54766/54771
18	transplantationAm	NN	O	transplantationam	nn	20	SENT_331	54772/54789
19	J	NN	O	j	nn	20	SENT_331	54790/54791
20	Transplant200771770177710	NN	O	transplant200771770177710	prep_in	21	SENT_331	54792/54817
21	.1111	CD	NUMBER	.1111	dep	13	SENT_331	54817/54822
22	/	:	O	/	punct	21	SENT_331	54822/54823
23	j.	SYM	O	j.	dep	24	SENT_331	54823/54825
24	1600	CD	DURATION	1600	dep	26	SENT_331	54825/54829
25	-	:	DURATION	-		-1	SENT_331	54829/54830
26	6143.2007.01845	CD	DURATION	6143.2007.01845	dep	3	SENT_331	54831/54846
27	.	.	O	.		-1	SENT_331	54846/54847

1	x1756463718	NN	O	x1756463718		-1	SENT_332	54847/54858
2	.	.	O	.		-1	SENT_332	54858/54859

1	GenoveseMCCohenSMorelandLLiumDRobbinsSNewmarkRComb	NN	O	genovesemccohensmorelandlliumdrobbinssnewmarkrcomb	nn	3	SENT_333	54859/54909
2	ination	NN	O	ination	nn	3	SENT_333	54910/54917
3	therapy	NN	O	therapy		-1	SENT_333	54918/54925
4	with	IN	O	with		-1	SENT_333	54926/54930
5	etanercept	NN	O	etanercept	prep_with	3	SENT_333	54931/54941
6	and	CC	O	and		-1	SENT_333	54942/54945
7	anakinra	NN	O	anakinra	conj_and	5	SENT_333	54946/54954
8	in	IN	O	in		-1	SENT_333	54955/54957
9	the	DT	O	the	det	10	SENT_333	54958/54961
10	treatment	NN	O	treatment	prep_in	3	SENT_333	54962/54971
11	of	IN	O	of		-1	SENT_333	54972/54974
12	patients	NNS	O	patient	prep_of	3	SENT_333	54975/54983
13	with	IN	O	with		-1	SENT_333	54984/54988
14	rheumatoid	JJ	O	rheumatoid	amod	15	SENT_333	54989/54999
15	arthritis	NN	O	arthritis	prep_with	3	SENT_333	55000/55009
16	who	WP	O	who	nsubjpass	19	SENT_333	55010/55013
17	have	VBP	O	have	aux	19	SENT_333	55014/55018
18	been	VBN	O	be	auxpass	19	SENT_333	55019/55023
19	treated	VBN	O	treat	rcmod	15	SENT_333	55024/55031
20	unsuccessfully	RB	O	unsuccessfully	advmod	19	SENT_333	55032/55046
21	with	IN	O	with		-1	SENT_333	55047/55051
22	methotrexateArthritis	NN	O	methotrexatearthritis	nn	23	SENT_333	55052/55073
23	Rheum20045051412141910	NN	O	rheum20045051412141910	prep_with	19	SENT_333	55074/55096
24	.1002	CD	NUMBER	.1002	num	23	SENT_333	55096/55101
25	/	:	O	/	punct	26	SENT_333	55101/55102
26	art	NN	O	art	dep	15	SENT_333	55102/55105
27	.202211514641019	CD	NUMBER	.202211514641019	num	26	SENT_333	55105/55121
28	.	.	O	.		-1	SENT_333	55121/55122

1	HerbstRS	NN	O	herbstr	nn	4	SENT_334	55122/55130
2	JohnsonDHMininbergECarboneDPHendersonTKimESPhase	NN	O	johnsondhmininbergecarbonedphendersontkimesphase	nn	4	SENT_334	55131/55179
3	I/II	NN	O	i/ii	nn	4	SENT_334	55180/55184
4	trial	NN	O	trial		-1	SENT_334	55185/55190
5	evaluating	VBG	O	evaluate	partmod	4	SENT_334	55191/55201
6	the	DT	O	the	det	13	SENT_334	55202/55205
7	anti-vascular	JJ	O	anti-vascular	amod	13	SENT_334	55206/55219
8	endothelial	JJ	O	endothelial	amod	13	SENT_334	55220/55231
9	growth	NN	O	growth	nn	13	SENT_334	55232/55238
10	factor	NN	O	factor	nn	13	SENT_334	55239/55245
11	monoclonal	JJ	O	monoclonal	amod	13	SENT_334	55246/55256
12	antibody	NN	O	antibody	nn	13	SENT_334	55257/55265
13	bevacizumab	NN	O	bevacizumab	dobj	5	SENT_334	55266/55277
14	in	IN	O	in		-1	SENT_334	55278/55280
15	combination	NN	O	combination	prep_in	5	SENT_334	55281/55292
16	with	IN	O	with		-1	SENT_334	55293/55297
17	the	DT	O	the	det	18	SENT_334	55298/55301
18	HER-1	NN	O	her-1	prep_with	15	SENT_334	55302/55307
19	/	:	O	/	punct	36	SENT_334	55307/55308
20	epidermal	JJ	O	epidermal	amod	27	SENT_334	55308/55317
21	growth	NN	O	growth	nn	27	SENT_334	55318/55324
22	factor	NN	O	factor	nn	27	SENT_334	55325/55331
23	receptor	NN	O	receptor	nn	27	SENT_334	55332/55340
24	tyrosine	NN	O	tyrosine	nn	27	SENT_334	55341/55349
25	kinase	NN	O	kinase	nn	27	SENT_334	55350/55356
26	inhibitor	NN	O	inhibitor	nn	27	SENT_334	55357/55366
27	erlotinib	NN	O	erlotinib	dep	36	SENT_334	55367/55376
28	for	IN	O	for		-1	SENT_334	55377/55380
29	patients	NNS	O	patient	prep_for	27	SENT_334	55381/55389
30	with	IN	O	with		-1	SENT_334	55390/55394
31	recurrent	JJ	O	recurrent	amod	35	SENT_334	55395/55404
32	non-small-cell	JJ	O	non-small-cell	amod	35	SENT_334	55405/55419
33	lung	NN	O	lung	nn	35	SENT_334	55420/55424
34	cancerJ	NN	O	cancerj	nn	35	SENT_334	55425/55432
35	Clin	NN	O	clin	prep_with	29	SENT_334	55433/55437
36	Oncol200523112544255510	NN	O	oncol200523112544255510	parataxis	5	SENT_334	55438/55461
37	.1200	CD	NUMBER	.1200	num	36	SENT_334	55461/55466
38	/	:	O	/	punct	36	SENT_334	55466/55467
39	JCO	NNP	O	JCO	dep	5	SENT_334	55467/55470
40	.2005.02.4771575346220	CD	NUMBER	.2005.02.4771575346220	dep	39	SENT_334	55470/55492
41	.	.	O	.		-1	SENT_334	55492/55493

1	PegramMDChanDDickm	NNP	O	PegramMDChanDDickm	nn	3	SENT_335	55493/55511
2	annRAPhase	NNP	O	annRAPhase	nn	3	SENT_335	55512/55522
3	II	NNP	O	II	nsubj	4	SENT_335	55523/55525
4	combined	VBD	O	combine		-1	SENT_335	55526/55534
5	biological	JJ	O	biological	amod	6	SENT_335	55535/55545
6	therapy	NN	O	therapy	dobj	4	SENT_335	55546/55553
7	targeting	VBG	O	target	xcomp	4	SENT_335	55554/55563
8	the	DT	O	the	det	10	SENT_335	55564/55567
9	HER2	NN	O	her2	nn	10	SENT_335	55568/55572
10	proto-oncogene	NN	O	proto-oncogene	dobj	7	SENT_335	55573/55587
11	and	CC	O	and		-1	SENT_335	55588/55591
12	vascular	JJ	O	vascular	amod	15	SENT_335	55592/55600
13	endothelial	JJ	O	endothelial	amod	15	SENT_335	55601/55612
14	growth	NN	O	growth	nn	15	SENT_335	55613/55619
15	factor	NN	O	factor	conj_and	10	SENT_335	55620/55626
16	using	VBG	O	use	partmod	15	SENT_335	55627/55632
17	trastuzumab	NN	O	trastuzumab	nn	20	SENT_335	55633/55644
18	(	NN	O	(	nn	20	SENT_335	55645/55646
19	T	NN	O	t	nn	20	SENT_335	55646/55647
20	)	NN	O	)	dobj	16	SENT_335	55647/55648
21	and	CC	O	and		-1	SENT_335	55649/55652
22	bevacizumab	NN	O	bevacizumab	nn	23	SENT_335	55653/55664
23	(	NN	O	(	conj_and	20	SENT_335	55665/55666
24	B	NN	O	b	nn	25	SENT_335	55666/55667
25	)	NN	O	)	nsubj	32	SENT_335	55667/55668
26	as	IN	O	as		-1	SENT_335	55669/55671
27	first	JJ	ORDINAL	first	amod	29	SENT_335	55672/55677
28	line	NN	O	line	nn	29	SENT_335	55678/55682
29	therapy	NN	O	therapy	prep_as	25	SENT_335	55683/55690
30	of	IN	O	of		-1	SENT_335	55691/55693
31	HER2	NN	O	her2	prep_of	29	SENT_335	55694/55698
32	amplified	VBD	O	amplify	rcmod	20	SENT_335	55699/55708
33	breast	NN	O	breast	nn	34	SENT_335	55709/55715
34	cancer	NN	O	cancer	iobj	32	SENT_335	55716/55722
35	[	CD	NUMBER	[	npadvmod	36	SENT_335	55723/55724
36	abstract	JJ	O	abstract	amod	34	SENT_335	55724/55732
37	301	CD	NUMBER	301	number	38	SENT_335	55733/55736
38	]	CD	NUMBER	]	dobj	32	SENT_335	55736/55737
39	Breast	NN	O	breast	nn	42	SENT_335	55737/55743
40	Cancer	NN	O	cancer	nn	42	SENT_335	55744/55750
41	Res	NNP	O	Res	nn	42	SENT_335	55751/55754
42	Treat2006100suppl	NNP	O	Treat2006100suppl	tmod	16	SENT_335	55755/55772
43	1S2821	NN	O	1s2821	dep	42	SENT_335	55773/55779
44	.	.	O	.		-1	SENT_335	55779/55780

1	GanjooKNAnCSRobertsonMJGordonLISenJAWeisenbachJRituximab	NNP	O	GanjooKNAnCSRobertsonMJGordonLISenJAWeisenbachJRituximab		-1	SENT_336	55780/55836
2	,	,	O	,		-1	SENT_336	55836/55837
3	bevacizumab	NN	O	bevacizumab	conj_and	1	SENT_336	55838/55849
4	and	CC	O	and		-1	SENT_336	55850/55853
5	CHOP	NN	O	chop	nn	8	SENT_336	55854/55858
6	(	CD	NUMBER	(	num	8	SENT_336	55859/55860
7	RA-CHOP	NN	O	ra-chop	nn	8	SENT_336	55860/55867
8	)	NN	O	)	conj_and	1	SENT_336	55867/55868
9	in	IN	O	in		-1	SENT_336	55869/55871
10	untreated	JJ	O	untreated	amod	11	SENT_336	55872/55881
11	diffuse	JJ	O	diffuse	amod	14	SENT_336	55882/55889
12	large	JJ	O	large	amod	14	SENT_336	55890/55895
13	B-cell	NN	O	b-cell	nn	14	SENT_336	55896/55902
14	lymphoma	NN	O	lymphoma	prep_in	8	SENT_336	55903/55911
15	:	:	O	:		-1	SENT_336	55911/55912
16	safety	NN	O	safety	nn	18	SENT_336	55913/55919
17	,	,	O	,		-1	SENT_336	55919/55920
18	biomarker	NN	O	biomarker	nn	22	SENT_336	55921/55930
19	and	CC	O	and		-1	SENT_336	55931/55934
20	pharmacokinetic	JJ	O	pharmacokinetic	conj_and	18	SENT_336	55935/55950
21	analysisLeuk	NN	O	analysisleuk	nn	22	SENT_336	55951/55963
22	Lymphoma2006476998100510	NN	O	lymphoma2006476998100510	dep	1	SENT_336	55964/55988
23	.1080	CD	NUMBER	.1080	dep	22	SENT_336	55988/55993
24	/	:	O	/	punct	25	SENT_336	55993/55994
25	104281906005638211684018822	CD	NUMBER	104281906005638211684018822	dep	23	SENT_336	55994/56021
26	.	.	O	.		-1	SENT_336	56021/56022

1	WijngaardenSvan	NNP	PERSON	WijngaardenSvan	nn	4	SENT_337	56022/56037
2	RoonJAvan	NNP	PERSON	RoonJAvan	nn	4	SENT_337	56038/56047
3	de	IN	PERSON	de	amod	4	SENT_337	56048/56050
4	WinkelJGBijlsmaJWLafeberFPDown-regulation	NNP	PERSON	WinkelJGBijlsmaJWLafeberFPDown-regulation		-1	SENT_337	56051/56092
5	of	IN	O	of		-1	SENT_337	56093/56095
6	activating	VBG	O	activate	prepc_of	4	SENT_337	56096/56106
7	Fcgamma	NN	O	fcgamma	nn	8	SENT_337	56107/56114
8	receptors	NNS	O	receptor	dobj	6	SENT_337	56115/56124
9	on	IN	O	on	prep	6	SENT_337	56125/56127
10	monocytes	NNS	O	monocyte	dep	20	SENT_337	56128/56137
11	of	IN	O	of		-1	SENT_337	56138/56140
12	patients	NNS	O	patient	prep_of	10	SENT_337	56141/56149
13	with	IN	O	with		-1	SENT_337	56150/56154
14	rheumatoid	JJ	O	rheumatoid	amod	15	SENT_337	56155/56165
15	arthritis	NN	O	arthritis	prep_with	12	SENT_337	56166/56175
16	upon	IN	O	upon		-1	SENT_337	56176/56180
17	methotrexate	NN	O	methotrexate	prep_upon	15	SENT_337	56181/56193
18	treatmentRheumatology	NN	O	treatmentrheumatology	dep	20	SENT_337	56194/56215
19	(	CD	NUMBER	(	num	18	SENT_337	56216/56217
20	Oxford	NNP	ORGANIZATION	Oxford	dep	25	SENT_337	56217/56223
21	)	CD	NUMBER	)	num	20	SENT_337	56223/56224
22	200544672973410.1093	CD	NUMBER	200544672973410.1093	dep	20	SENT_337	56224/56244
23	/	:	O	/	punct	25	SENT_337	56244/56245
24	rheumatology/keh58315757966	CD	NUMBER	rheumatology/keh58315757966	num	25	SENT_337	56245/56272
25	23	CD	NUMBER	23	dep	9	SENT_337	56273/56275
26	.	.	O	.		-1	SENT_337	56275/56276

1	MainiRNBreedveldFCKaldenJRSmolenJSDavisDMacfarlaneJDTherapeutic	JJ	O	mainirnbreedveldfckaldenjrsmolenjsdavisdmacfarlanejdtherapeutic	amod	2	SENT_338	56276/56339
2	efficacy	NN	O	efficacy		-1	SENT_338	56340/56348
3	of	IN	O	of		-1	SENT_338	56349/56351
4	multiple	JJ	O	multiple	amod	6	SENT_338	56352/56360
5	intravenous	JJ	O	intravenous	amod	6	SENT_338	56361/56372
6	infusions	NNS	O	infusion	prep_of	2	SENT_338	56373/56382
7	of	IN	O	of		-1	SENT_338	56383/56385
8	anti-tumor	JJ	O	anti-tumor	amod	10	SENT_338	56386/56396
9	necrosis	NN	O	necrosis	nn	10	SENT_338	56397/56405
10	factor	NN	O	factor	prep_of	6	SENT_338	56406/56412
11	monoclonal	JJ	O	monoclonal	amod	12	SENT_338	56416/56426
12	antibody	NN	O	antibody	dep	10	SENT_338	56427/56435
13	combined	VBN	O	combine	partmod	12	SENT_338	56436/56444
14	with	IN	O	with		-1	SENT_338	56445/56449
15	low-dose	JJ	O	low-dose	amod	17	SENT_338	56450/56458
16	weekly	JJ	SET	weekly	amod	17	SENT_338	56459/56465
17	methotrexate	NN	O	methotrexate	prep_with	13	SENT_338	56466/56478
18	in	IN	O	in	prep	17	SENT_338	56479/56481
19	rheumatoid	JJ	O	rheumatoid	amod	21	SENT_338	56482/56492
20	arthritisArthritis	NN	O	arthritisarthritis	nn	21	SENT_338	56493/56511
21	Rheum19984191552156310	NN	O	rheum19984191552156310	dep	18	SENT_338	56512/56534
22	.1002	CD	NUMBER	.1002	dep	21	SENT_338	56534/56539
23	/	:	O	/	punct	21	SENT_338	56539/56540
24	1529-0131	CD	DURATION	1529-0131	dep	21	SENT_338	56540/56549
25	(	CD	NUMBER	(	number	26	SENT_338	56549/56550
26	199809	CD	NUMBER	199809	num	27	SENT_338	56550/56556
27	)	NN	O	)	dep	24	SENT_338	56556/56557
28	41:9	CD	NUMBER	41:9	num	29	SENT_338	56557/56561
29	<	JJR	O	<	tmod	13	SENT_338	56561/56562
30	1552	CD	DATE	1552	dep	29	SENT_338	56562/56566
31	:	:	O	:		-1	SENT_338	56567/56568
32	:	:	O	:		-1	SENT_338	56568/56569
33	AID-ART5	NN	O	aid-art5	dep	34	SENT_338	56569/56577
34	>	JJR	O	>	dep	2	SENT_338	56577/56578
35	3.0	CD	NUMBER	3.0	dep	34	SENT_338	56578/56581
36	.	.	O	.		-1	SENT_338	56581/56582

1	CO	NNP	O	CO		-1	SENT_339	56582/56584
2	;	:	O	;		-1	SENT_339	56584/56585
3	2-W975108724	NN	O	2-w975108724	dep	1	SENT_339	56585/56597
4	.	.	O	.		-1	SENT_339	56597/56598

1	Humira	NNP	LOCATION	Humira		-1	SENT_340	56598/56604
2	(	CD	NUMBER	(	num	1	SENT_340	56607/56608
3	Adalimumab	NNP	O	Adalimumab	dep	1	SENT_340	56608/56618
4	)	CD	NUMBER	)	num	3	SENT_340	56618/56619
5	[	CD	NUMBER	[	num	8	SENT_340	56620/56621
6	packet	NN	O	packet	nn	8	SENT_340	56621/56627
7	insert	NN	O	insert	nn	8	SENT_340	56628/56634
8	]	NN	O	]	dep	3	SENT_340	56634/56635
9	.	.	O	.		-1	SENT_340	56635/56636

1	Chicago	NNP	LOCATION	Chicago		-1	SENT_341	56637/56644
2	,	,	O	,		-1	SENT_341	56644/56645
3	IL	NN	O	il	appos	1	SENT_341	56646/56648
4	.	.	O	.		-1	SENT_341	56648/56649

1	Abbott	NNP	ORGANIZATION	Abbott	nn	2	SENT_342	56650/56656
2	Laboratories	NNPS	ORGANIZATION	Laboratories		-1	SENT_342	56657/56669
3	;	:	O	;		-1	SENT_342	56669/56670
4	2010.25	CD	NUMBER	2010.25	dep	2	SENT_342	56671/56678
5	.	.	O	.		-1	SENT_342	56678/56679

1	Emi	NNP	O	Emi	nn	5	SENT_343	56679/56682
2	AikawaNde	NNP	O	AikawaNde	nn	5	SENT_343	56683/56692
3	CarvalhoJFArtur	NNP	O	CarvalhoJFArtur	nn	5	SENT_343	56693/56708
4	Almeida	NNP	O	Almeida	nn	5	SENT_343	56709/56716
5	SilvaCBonfaEImmunogenicity	NNP	O	SilvaCBonfaEImmunogenicity		-1	SENT_343	56717/56743
6	of	IN	O	of		-1	SENT_343	56744/56746
7	anti-TNF	JJ	O	anti-tnf	amod	18	SENT_343	56747/56755
8	-	:	O	-		-1	SENT_343	56755/56756
9	agents	NNS	O	agent	dep	15	SENT_343	56759/56765
10	in	IN	O	in		-1	SENT_343	56766/56768
11	autoimmune	JJ	O	autoimmune	amod	13	SENT_343	56769/56779
12	diseasesClin	NN	O	diseasesclin	nn	13	SENT_343	56780/56792
13	Rev	NN	O	rev	prep_in	9	SENT_343	56793/56796
14	Allergy	NNP	O	Allergy	nn	15	SENT_343	56797/56804
15	Immunol201038828910	NN	O	immunol201038828910	dep	7	SENT_343	56805/56824
16	.1007	CD	NUMBER	.1007	num	15	SENT_343	56824/56829
17	/	:	O	/	punct	15	SENT_343	56829/56830
18	s12016-009-8140-31956536026	NN	O	s12016-009-8140-31956536026	prep_of	5	SENT_343	56830/56857
19	.	.	O	.		-1	SENT_343	56857/56858

1	VasquezEMPollakROKT3	NN	O	vasquezempollakrokt3	nn	2	SENT_344	56858/56878
2	therapy	NN	O	therapy	nsubj	3	SENT_344	56879/56886
3	increases	VBZ	O	increase		-1	SENT_344	56887/56896
4	cyclosporine	NN	O	cyclosporine	nn	7	SENT_344	56897/56909
5	blood	NN	O	blood	nn	7	SENT_344	56910/56915
6	levelsClin	NN	O	levelsclin	nn	7	SENT_344	56916/56926
7	Transplant19971113841906769327	NN	O	transplant19971113841906769327	dobj	3	SENT_344	56927/56957
8	.	.	O	.		-1	SENT_344	56957/56958

1	SifontisNMBenedettiEVasquezEMClinically	NNP	O	SifontisNMBenedettiEVasquezEMClinically		-1	SENT_345	56958/56997
2	significant	JJ	O	significant	amod	4	SENT_345	56998/57009
3	drug	NN	O	drug	nn	4	SENT_345	57010/57014
4	interaction	NN	O	interaction	dep	1	SENT_345	57015/57026
5	between	IN	O	between		-1	SENT_345	57027/57034
6	basiliximab	NN	O	basiliximab	prep_between	4	SENT_345	57035/57046
7	and	CC	O	and		-1	SENT_345	57047/57050
8	tacrolimus	NN	O	tacrolimus	conj_and	6	SENT_345	57051/57061
9	in	IN	O	in		-1	SENT_345	57062/57064
10	renal	JJ	O	renal	amod	13	SENT_345	57065/57070
11	transplant	NN	O	transplant	nn	13	SENT_345	57071/57081
12	recipientsTransplant	NN	O	recipientstransplant	nn	13	SENT_345	57082/57102
13	Proc2002341730173210	NN	O	proc2002341730173210	prep_in	4	SENT_345	57103/57123
14	.1016	CD	NUMBER	.1016	dep	13	SENT_345	57123/57128
15	/	:	O	/	punct	1	SENT_345	57128/57129
16	S0041-1345	CD	NUMBER	s0041-1345	number	17	SENT_345	57129/57139
17	(	CD	NUMBER	(	dep	1	SENT_345	57139/57140
18	02	CD	NUMBER	02	num	19	SENT_345	57140/57142
19	)	NN	O	)	dep	17	SENT_345	57142/57143
20	03000	CD	NUMBER	03000	dep	17	SENT_345	57143/57148
21	-	:	O	-		-1	SENT_345	57148/57149
22	21217655428.StrehlauJPapeLOffnerGNashanBEhrichJHInterleukin-2	NN	O	21217655428.strehlaujpapeloffnergnashanbehrichjhinterleukin-2	nn	25	SENT_345	57150/57211
23	receptor	NN	O	receptor	nn	25	SENT_345	57212/57220
24	antibody-induced	JJ	O	antibody-induced	amod	25	SENT_345	57221/57237
25	alterations	NNS	O	alteration	dep	17	SENT_345	57238/57249
26	of	IN	O	of		-1	SENT_345	57250/57252
27	ciclosporin	NN	O	ciclosporin	nn	29	SENT_345	57253/57264
28	dose	NN	O	dose	nn	29	SENT_345	57265/57269
29	requirements	NNS	O	requirement	prep_of	25	SENT_345	57270/57282
30	in	IN	O	in		-1	SENT_345	57283/57285
31	paediatric	JJ	O	paediatric	amod	33	SENT_345	57286/57296
32	transplant	NN	O	transplant	nn	33	SENT_345	57297/57307
33	recipientsLancet20003561327132810	NN	O	recipientslancet20003561327132810	prep_in	29	SENT_345	57308/57341
34	.1016	CD	NUMBER	.1016	dep	25	SENT_345	57341/57346
35	/	:	O	/	punct	17	SENT_345	57346/57347
36	S0140-6736	CD	NUMBER	s0140-6736	dep	17	SENT_345	57347/57357
37	(	CD	NUMBER	(	number	38	SENT_345	57357/57358
38	00	CD	NUMBER	00	num	39	SENT_345	57358/57360
39	)	NN	O	)	dep	36	SENT_345	57360/57361
40	02822-11107302	CD	NUMBER	02822-11107302	number	41	SENT_345	57361/57375
41	729	CD	NUMBER	729	num	39	SENT_345	57376/57379
42	.	.	O	.		-1	SENT_345	57379/57380

1	Arcalyst	NNP	O	Arcalyst		-1	SENT_346	57380/57388
2	(	CD	NUMBER	(	num	1	SENT_346	57391/57392
3	Rilonacept	NNP	O	Rilonacept	dep	1	SENT_346	57392/57402
4	)	CD	NUMBER	)	num	3	SENT_346	57402/57403
5	[	CD	NUMBER	[	num	8	SENT_346	57404/57405
6	packet	NN	O	packet	nn	8	SENT_346	57405/57411
7	insert	NN	O	insert	nn	8	SENT_346	57412/57418
8	]	NN	O	]	dep	3	SENT_346	57418/57419
9	.	.	O	.		-1	SENT_346	57419/57420

1	Tarrytown	NNP	LOCATION	Tarrytown		-1	SENT_347	57421/57430
2	,	,	O	,		-1	SENT_347	57430/57431
3	NY	NNP	O	NY	appos	1	SENT_347	57432/57434
4	.	.	O	.		-1	SENT_347	57434/57435

1	Regeneron	NNP	ORGANIZATION	Regeneron	nn	4	SENT_348	57436/57445
2	Pharmaceuticals	NNP	ORGANIZATION	Pharmaceuticals	nn	4	SENT_348	57446/57461
3	,	,	O	,		-1	SENT_348	57461/57462
4	Inc.	NNP	ORGANIZATION	Inc.		-1	SENT_348	57463/57467
5	;	:	O	;		-1	SENT_348	57467/57468
6	2010.30	CD	NUMBER	2010.30	dep	4	SENT_348	57469/57476
7	.	.	O	.		-1	SENT_348	57476/57477

1	Ilaris	FW	O	ilaris	nn	7	SENT_349	57477/57483
2	(	FW	O	(	nn	7	SENT_349	57486/57487
3	Canakinumab	FW	O	canakinumab	nn	7	SENT_349	57487/57498
4	)	FW	O	)	nn	7	SENT_349	57498/57499
5	[	FW	O	[	nn	7	SENT_349	57500/57501
6	packet	NN	O	packet	nn	7	SENT_349	57501/57507
7	insert	NN	O	insert		-1	SENT_349	57508/57514
8	]	NN	O	]	dep	7	SENT_349	57514/57515
9	.	.	O	.		-1	SENT_349	57515/57516

1	East	NNP	O	East	nn	2	SENT_350	57517/57521
2	Hanover	NNP	O	Hanover		-1	SENT_350	57522/57529
3	,	,	O	,		-1	SENT_350	57529/57530
4	NJ	NNP	O	NJ	appos	2	SENT_350	57531/57533
5	.	.	O	.		-1	SENT_350	57533/57534

1	Novartis	NNP	ORGANIZATION	Novartis	nn	3	SENT_351	57535/57543
2	Pharmaceuticals	NNP	ORGANIZATION	Pharmaceuticals	nn	3	SENT_351	57544/57559
3	Corporation	NNP	ORGANIZATION	Corporation		-1	SENT_351	57560/57571
4	;	:	O	;		-1	SENT_351	57571/57572
5	2009.31	CD	NUMBER	2009.31	dep	3	SENT_351	57573/57580
6	.	.	O	.		-1	SENT_351	57580/57581

1	Simponi	NNP	LOCATION	Simponi		-1	SENT_352	57581/57588
2	(	CD	NUMBER	(	num	1	SENT_352	57591/57592
3	Golimumab	NNP	O	Golimumab	dep	1	SENT_352	57592/57601
4	)	CD	NUMBER	)	num	3	SENT_352	57601/57602
5	[	CD	NUMBER	[	num	8	SENT_352	57603/57604
6	packet	NN	O	packet	nn	8	SENT_352	57604/57610
7	insert	NN	O	insert	nn	8	SENT_352	57611/57617
8	]	NN	O	]	dep	3	SENT_352	57617/57618
9	.	.	O	.		-1	SENT_352	57618/57619

1	Horsham	NNP	ORGANIZATION	Horsham		-1	SENT_353	57620/57627
2	,	,	O	,		-1	SENT_353	57627/57628
3	PA.	NNP	LOCATION	PA.	appos	1	SENT_353	57629/57631
4	.	.	O	.		-1	SENT_353	57631/57632

1	Centocor	NNP	ORGANIZATION	Centocor	nn	4	SENT_354	57633/57641
2	Ortho	NNP	ORGANIZATION	Ortho	nn	4	SENT_354	57642/57647
3	Biotech	NNP	ORGANIZATION	Biotech	nn	4	SENT_354	57648/57655
4	Inc.	NNP	ORGANIZATION	Inc.		-1	SENT_354	57656/57660
5	;	:	O	;		-1	SENT_354	57660/57661
6	2010.32	CD	NUMBER	2010.32	dep	4	SENT_354	57662/57669
7	.	.	O	.		-1	SENT_354	57669/57670

1	Stelara	FW	PERSON	stelara	nn	7	SENT_355	57670/57677
2	(	FW	O	(	nn	7	SENT_355	57680/57681
3	Ustekinumab	FW	O	ustekinumab	nn	7	SENT_355	57681/57692
4	)	FW	O	)	nn	7	SENT_355	57692/57693
5	[	FW	O	[	nn	7	SENT_355	57694/57695
6	packet	NN	O	packet	nn	7	SENT_355	57695/57701
7	insert	NN	O	insert		-1	SENT_355	57702/57708
8	]	NN	O	]	dep	7	SENT_355	57708/57709
9	.	.	O	.		-1	SENT_355	57709/57710

1	Horsham	NNP	ORGANIZATION	Horsham		-1	SENT_356	57711/57718
2	,	,	O	,		-1	SENT_356	57718/57719
3	PA.	NNP	LOCATION	PA.	appos	1	SENT_356	57720/57722
4	.	.	O	.		-1	SENT_356	57722/57723

1	Centocor	NNP	ORGANIZATION	Centocor	nn	4	SENT_357	57724/57732
2	Ortho	NNP	ORGANIZATION	Ortho	nn	4	SENT_357	57733/57738
3	Biotech	NNP	ORGANIZATION	Biotech	nn	4	SENT_357	57739/57746
4	Inc.	NNP	ORGANIZATION	Inc.		-1	SENT_357	57747/57751
5	;	:	O	;		-1	SENT_357	57751/57752
6	2010.33	CD	NUMBER	2010.33	dep	4	SENT_357	57753/57760
7	.	.	O	.		-1	SENT_357	57760/57761

1	Actemra	NNP	O	Actemra		-1	SENT_358	57761/57768
2	(	CD	NUMBER	(	num	1	SENT_358	57771/57772
3	Tocilizumab	NNP	O	Tocilizumab	dep	1	SENT_358	57772/57783
4	)	CD	NUMBER	)	num	3	SENT_358	57783/57784
5	[	CD	NUMBER	[	num	8	SENT_358	57785/57786
6	packet	NN	O	packet	nn	8	SENT_358	57786/57792
7	insert	NN	O	insert	nn	8	SENT_358	57793/57799
8	]	NN	O	]	dep	3	SENT_358	57799/57800
9	.	.	O	.		-1	SENT_358	57800/57801

1	South	NNP	LOCATION	South	nn	3	SENT_359	57802/57807
2	San	NNP	LOCATION	San	nn	3	SENT_359	57808/57811
3	Francisco	NNP	LOCATION	Francisco		-1	SENT_359	57812/57821
4	,	,	O	,		-1	SENT_359	57821/57822
5	CA	NNP	O	CA	appos	3	SENT_359	57823/57825
6	.	.	O	.		-1	SENT_359	57825/57826

1	Genentech	NNP	ORGANIZATION	Genentech	nn	3	SENT_360	57827/57836
2	,	,	ORGANIZATION	,		-1	SENT_360	57836/57837
3	Inc.	NNP	ORGANIZATION	Inc.		-1	SENT_360	57838/57842
4	;	:	O	;		-1	SENT_360	57842/57843
5	2010.34	CD	NUMBER	2010.34	dep	3	SENT_360	57844/57851
6	.	.	O	.		-1	SENT_360	57851/57852

1	DenlingerCSBlanchardRXuLBernaardsCLitwinSSpittleCPharmacokinetic	JJ	O	denlingercsblanchardrxulbernaardsclitwinsspittlecpharmacokinetic	amod	2	SENT_361	57852/57916
2	analysis	NN	O	analysis		-1	SENT_361	57917/57925
3	of	IN	O	of		-1	SENT_361	57926/57928
4	irinotecan	NN	O	irinotecan	prep_of	2	SENT_361	57929/57939
5	plus	CC	O	plus	prep	2	SENT_361	57940/57944
6	bevacizumab	NN	O	bevacizumab	dep	5	SENT_361	57945/57956
7	in	IN	O	in		-1	SENT_361	57957/57959
8	patients	NNS	O	patient	prep_in	6	SENT_361	57960/57968
9	with	IN	O	with		-1	SENT_361	57969/57973
10	advanced	JJ	O	advanced	amod	13	SENT_361	57974/57982
11	solid	JJ	O	solid	amod	13	SENT_361	57983/57988
12	tumorsCancer	NN	O	tumorscancer	nn	13	SENT_361	57989/58001
13	Chemother	NN	O	chemother	prep_with	2	SENT_361	58002/58011
14	Pharmacol20096519710510	NN	O	pharmacol20096519710510	dep	13	SENT_361	58012/58035
15	.1007	CD	NUMBER	.1007	num	14	SENT_361	58035/58040
16	/	:	O	/	punct	2	SENT_361	58040/58041
17	s00280-009-1008-71941528135	NN	O	s00280-009-1008-71941528135	dep	2	SENT_361	58041/58068
18	.	.	O	.		-1	SENT_361	58068/58069

1	European	JJ	ORGANIZATION	european		-1	SENT_362	58069/58077
2	Medicine	NNP	ORGANIZATION	Medicine	nn	3	SENT_362	58078/58086
3	Agency	NNP	ORGANIZATION	Agency	dep	1	SENT_362	58087/58093
4	.	.	O	.		-1	SENT_362	58093/58094

1	Clinical	JJ	O	clinical	amod	2	SENT_363	58095/58103
2	efficacy	NN	O	efficacy		-1	SENT_363	58104/58112
3	and	CC	O	and		-1	SENT_363	58113/58116
4	safety	NN	O	safety	nn	5	SENT_363	58117/58123
5	guidelines	NNS	O	guideline	conj_and	2	SENT_363	58124/58134
6	introduction	NN	O	introduction	dep	2	SENT_363	58135/58147
7	.	.	O	.		-1	SENT_363	58147/58148

1	London	NNP	LOCATION	London		-1	SENT_364	58149/58155
2	,	,	O	,		-1	SENT_364	58155/58156
3	UK	NNP	LOCATION	UK	appos	1	SENT_364	58157/58159
4	.	.	O	.		-1	SENT_364	58159/58160

1	http://www.emea.europa.eu/htms/human/humanguidelines/efficacy.htm	NN	O	http://www.emea.europa.eu/htms/human/humanguidelines/efficacy.htm		-1	SENT_365	58161/58226
2	.	.	O	.		-1	SENT_365	58226/58227

1	Accessed	VBN	O	access		-1	SENT_366	58228/58236
2	04	CD	DATE	04	num	4	SENT_366	58237/58239
3	Jan	NNP	DATE	Jan	nn	4	SENT_366	58240/58243
4	2011.36.HuangS-MTempleRIs	NNS	O	2011.36.huangs-mtempleri	nsubj	7	SENT_366	58244/58269
5	this	DT	O	this	det	7	SENT_366	58270/58274
6	the	DT	O	the	det	7	SENT_366	58275/58278
7	drug	NN	O	drug	xcomp	1	SENT_366	58279/58283
8	or	CC	O	or		-1	SENT_366	58284/58286
9	dose	NN	O	dose	conj_or	7	SENT_366	58287/58291
10	for	IN	O	for		-1	SENT_366	58292/58295
11	you	PRP	O	you	prep_for	7	SENT_366	58296/58299
12	?	.	O	?		-1	SENT_366	58299/58300

1	--	:	O	--		-1	SENT_367	58300/58302
2	Impact	NN	O	impact	dep	17	SENT_367	58302/58308
3	of	IN	O	of		-1	SENT_367	58309/58311
4	ethnic	JJ	O	ethnic	amod	5	SENT_367	58312/58318
5	factors	NNS	O	factor	prep_of	2	SENT_367	58319/58326
6	in	IN	O	in		-1	SENT_367	58327/58329
7	global	JJ	O	global	amod	9	SENT_367	58330/58336
8	drug	NN	O	drug	nn	9	SENT_367	58337/58341
9	development	NN	O	development	prep_in	5	SENT_367	58342/58353
10	,	,	O	,		-1	SENT_367	58353/58354
11	regulatory	JJ	O	regulatory	amod	12	SENT_367	58355/58365
12	review	NN	O	review	conj_and	9	SENT_367	58366/58372
13	and	CC	O	and		-1	SENT_367	58373/58376
14	clinical	JJ	O	clinical	amod	15	SENT_367	58377/58385
15	practiceClin	NN	O	practiceclin	conj_and	9	SENT_367	58386/58398
16	Pharmacol	NN	O	pharmacol	dep	17	SENT_367	58399/58408
17	Ther200884328729410	NN	O	ther200884328729410	dep	21	SENT_367	58409/58428
18	.1038	CD	NUMBER	.1038	dep	17	SENT_367	58428/58433
19	/	:	O	/	punct	21	SENT_367	58433/58434
20	clpt	JJ	O	clpt	amod	21	SENT_367	58434/58438
21	.2008.1441871431437	NN	O	.2008.1441871431437		-1	SENT_367	58438/58457
22	.	.	O	.		-1	SENT_367	58457/58458

1	US	NNP	ORGANIZATION	US	nn	2	SENT_368	58458/58460
2	Food	NNP	ORGANIZATION	Food		-1	SENT_368	58461/58465
3	and	CC	ORGANIZATION	and		-1	SENT_368	58466/58469
4	Drug	NNP	ORGANIZATION	Drug	nn	5	SENT_368	58470/58474
5	Administration	NNP	ORGANIZATION	Administration	conj_and	2	SENT_368	58475/58489
6	.	.	O	.		-1	SENT_368	58489/58490

1	Clinical	JJ	O	clinical	amod	3	SENT_369	58491/58499
2	Pharmacology	NN	O	pharmacology	nn	3	SENT_369	58500/58512
3	Guidance	NN	O	guidance		-1	SENT_369	58513/58521
4	for	IN	O	for		-1	SENT_369	58522/58525
5	Industry	NN	O	industry	prep_for	3	SENT_369	58526/58534
6	.	.	O	.		-1	SENT_369	58534/58535

1	Rockville	NNP	LOCATION	Rockville		-1	SENT_370	58536/58545
2	,	,	O	,		-1	SENT_370	58545/58546
3	MD.	NNP	O	MD.	nn	5	SENT_370	58547/58550
4	http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformatio	NNP	O	http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformatio	nn	5	SENT_370	58551/58614
5	n/Guidances/ucm064982	NN	O	n/guidances/ucm064982	appos	1	SENT_370	58615/58636
6	.	.	O	.		-1	SENT_370	58636/58637

1	htm	NN	O	htm		-1	SENT_371	58637/58640
2	.	.	O	.		-1	SENT_371	58640/58641

1	Accessed	VBN	O	access		-1	SENT_372	58642/58650
2	July	NNP	DATE	July	tmod	1	SENT_372	58651/58655
3	5	CD	DATE	5	num	2	SENT_372	58656/58657
4	,	,	O	,		-1	SENT_372	58657/58658
5	2010.38.GiacominiKMHuangS-MTweedie	JJ	O	2010.38.giacominikmhuangs-mtweedie	amod	7	SENT_372	58659/58693
6	DJBenetLZBrouwerKLRChuXDahlinAEversRFischerVHillgrenKMHoffmasterKAIshikawaTKep	NN	O	djbenetlzbrouwerklrchuxdahlinaeversrfischervhillgrenkmhoffmasterkaishikawatkep	nn	7	SENT_372	58694/58772
7	plerDKimRBLeeCANiemiMPolliJWSugiyamaYSwaanPWWareJAWrightSHYeeSWZamek	NN	O	plerdkimrbleecaniemimpollijwsugiyamayswaanpwwarejawrightshyeeswzamek	dobj	1	SENT_372	58773/58841
8	-	:	O	-		-1	SENT_372	58841/58842
9	GliszczynskiMJZhangLThe	NNP	O	GliszczynskiMJZhangLThe	nn	12	SENT_372	58843/58866
10	International	NNP	O	International	nn	12	SENT_372	58867/58880
11	Transporter	NNP	O	Transporter	nn	12	SENT_372	58881/58892
12	Consortium	NNP	O	Consortium	dep	7	SENT_372	58893/58903
13	,	,	O	,		-1	SENT_372	58903/58904
14	ITC	NNP	ORGANIZATION	ITC	appos	12	SENT_372	58905/58908
15	.	.	O	.		-1	SENT_372	58908/58909

1	Membrane	NN	O	membrane	nn	2	SENT_373	58910/58918
2	Transporters	NNS	O	transporter	dep	6	SENT_373	58919/58931
3	in	IN	O	in		-1	SENT_373	58932/58934
4	Drug	NN	O	drug	prep_in	2	SENT_373	58935/58939
5	DevelopmentNat	NNP	O	DevelopmentNat	dep	6	SENT_373	58940/58954
6	Rev	NN	O	rev	dep	9	SENT_373	58955/58958
7	Drug	NN	O	drug	nn	8	SENT_373	58959/58963
8	Discov2010921523610	NN	O	discov2010921523610	dep	6	SENT_373	58964/58983
9	.1038	CD	NUMBER	.1038		-1	SENT_373	58983/58988
10	/	:	O	/	punct	9	SENT_373	58988/58989
11	nrd30282019078739	CD	NUMBER	nrd30282019078739	dep	9	SENT_373	58989/59006
12	.	.	O	.		-1	SENT_373	59006/59007

1	US	NNP	ORGANIZATION	US	nn	2	SENT_374	59007/59009
2	Food	NNP	ORGANIZATION	Food		-1	SENT_374	59010/59014
3	and	CC	ORGANIZATION	and		-1	SENT_374	59015/59018
4	Drug	NNP	ORGANIZATION	Drug	nn	5	SENT_374	59019/59023
5	Administration	NNP	ORGANIZATION	Administration	conj_and	2	SENT_374	59024/59038
6	.	.	O	.		-1	SENT_374	59038/59039

1	Briefing	NN	O	briefing	nn	2	SENT_375	59040/59048
2	Information	NN	O	information		-1	SENT_375	59049/59060
3	for	IN	O	for		-1	SENT_375	59061/59064
4	the	DT	O	the	prep_for	2	SENT_375	59065/59068
5	March	NNP	DATE	March	tmod	4	SENT_375	59069/59074
6	17	CD	DATE	17	num	5	SENT_375	59075/59077
7	,	,	DATE	,		-1	SENT_375	59077/59078
8	2010	CD	DATE	2010	num	5	SENT_375	59079/59083
9	Meeting	VBG	O	meet	partmod	2	SENT_375	59084/59091
10	of	IN	O	of		-1	SENT_375	59092/59094
11	the	DT	O	the	det	13	SENT_375	59095/59098
12	Pharmaceutical	NNP	ORGANIZATION	Pharmaceutical	nn	13	SENT_375	59099/59113
13	Science	NNP	ORGANIZATION	Science	prep_of	9	SENT_375	59114/59121
14	and	CC	ORGANIZATION	and		-1	SENT_375	59122/59125
15	Clinical	JJ	ORGANIZATION	clinical	amod	18	SENT_375	59126/59134
16	Pharmacology	NNP	ORGANIZATION	Pharmacology	nn	18	SENT_375	59135/59147
17	Advisory	NNP	ORGANIZATION	Advisory	nn	18	SENT_375	59148/59156
18	Committee	NNP	ORGANIZATION	Committee	conj_and	13	SENT_375	59157/59166
19	.	.	O	.		-1	SENT_375	59166/59167

1	Rockville	NNP	LOCATION	Rockville		-1	SENT_376	59168/59177
2	,	,	O	,		-1	SENT_376	59177/59178
3	MD.	NNP	O	MD.	appos	1	SENT_376	59179/59182
4	2010	CD	DATE	2010	num	3	SENT_376	59183/59187
5	.	.	O	.		-1	SENT_376	59187/59188

1	htt	NN	O	htt	nn	2	SENT_377	59189/59192
2	p	NN	O	p		-1	SENT_377	59193/59194
3	:	:	O	:		-1	SENT_377	59194/59195
4	/	:	O	/	dep	7	SENT_377	59195/59196
5	/	:	O	/	punct	7	SENT_377	59196/59197
6	www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/AdvisoryCo	NN	O	www.fda.gov/advisorycommittees/committeesmeetingmaterials/drugs/advisoryco	nn	7	SENT_377	59197/59271
7	mmitteeforPharmaceuticalScienceandClinicalPharmacology/ucm204260	NN	O	mmitteeforpharmaceuticalscienceandclinicalpharmacology/ucm204260	dep	2	SENT_377	59272/59336
8	.	.	O	.		-1	SENT_377	59336/59337

1	htm	NN	O	htm		-1	SENT_378	59337/59340
2	.	.	O	.		-1	SENT_378	59340/59341

1	Accessed	VBN	O	access		-1	SENT_379	59342/59350
2	5	CD	DATE	5	dobj	1	SENT_379	59351/59352
3	July	NNP	DATE	July	tmod	1	SENT_379	59353/59357
4	2010.40	CD	NUMBER	2010.40	num	3	SENT_379	59358/59365
5	.	.	O	.		-1	SENT_379	59365/59366

1	ZhaoPZhangLGrilloJLiuQBullockJMMoonYJSongPBrarSMadabushiRWuTCBo	NN	O	zhaopzhanglgrillojliuqbullockjmmoonyjsongpbrarsmadabushirwutcbo	nn	3	SENT_380	59366/59429
2	othBPRahmanNAReynoldsKGil	NN	O	othbprahmannareynoldskgil	nn	3	SENT_380	59430/59455
3	BerglundELeskoLJHuangS-MApplication	NN	O	berglundeleskoljhuangs-mapplication	nsubj	6	SENT_380	59456/59491
4	of	IN	O	of	prep	3	SENT_380	59492/59494
5	physiologically	RB	O	physiologically	pcomp	4	SENT_380	59495/59510
6	based	VBN	O	base		-1	SENT_380	59511/59516
7	pharmacokinetic	JJ	O	pharmacokinetic	amod	11	SENT_380	59517/59532
8	(	NN	O	(	nn	11	SENT_380	59533/59534
9	PBPK	NN	O	pbpk	nn	11	SENT_380	59534/59538
10	)	CD	NUMBER	)	num	11	SENT_380	59538/59539
11	modeling	NN	O	modeling	dobj	6	SENT_380	59540/59548
12	and	CC	O	and		-1	SENT_380	59549/59552
13	simulation	NN	O	simulation	conj_and	11	SENT_380	59553/59563
14	in	IN	O	in	prep	6	SENT_380	59564/59566
15	regulatory	JJ	O	regulatory	amod	18	SENT_380	59567/59577
16	reviewClin	NN	O	reviewclin	nn	18	SENT_380	59578/59588
17	Pharmacol	NN	O	pharmacol	nn	18	SENT_380	59589/59598
18	Ther201189225926710	NN	O	ther201189225926710	dep	14	SENT_380	59599/59618
19	.1038	CD	NUMBER	.1038	dep	18	SENT_380	59618/59623
20	/	:	O	/	punct	18	SENT_380	59623/59624
21	clpt.2010.2982119138141.HuangS-MWoodcockJCommentary	JJ	O	clpt.2010.2982119138141.huangs-mwoodcockjcommentary	dep	18	SENT_380	59624/59675
22	on	IN	O	on		-1	SENT_380	59676/59678
23	ITC	NNP	ORGANIZATION	ITC	nn	25	SENT_380	59679/59682
24	Membrane	NN	ORGANIZATION	membrane	nn	25	SENT_380	59683/59691
25	Transporters	NNS	ORGANIZATION	transporter	prep_on	21	SENT_380	59692/59704
26	in	IN	O	in		-1	SENT_380	59705/59707
27	Drug	NNP	O	Drug	nn	28	SENT_380	59708/59712
28	Development	NNP	O	Development	prep_in	21	SENT_380	59713/59724
29	;	:	O	;		-1	SENT_380	59724/59725
30	Report	NNP	O	Report	dep	41	SENT_380	59726/59732
31	from	IN	O	from		-1	SENT_380	59733/59737
32	the	DT	O	the	det	35	SENT_380	59738/59741
33	FDA	NNP	ORGANIZATION	FDA	nn	35	SENT_380	59742/59745
34	Critical	JJ	O	critical	amod	35	SENT_380	59746/59754
35	Path	NN	O	path	prep_from	30	SENT_380	59755/59759
36	Initiative	NNP	O	Initiative	nn	40	SENT_380	59760/59770
37	Sponsored	NNP	O	Sponsored	nn	40	SENT_380	59771/59780
38	WorkshopNat	NNP	O	WorkshopNat	nn	40	SENT_380	59781/59792
39	Rev	NN	O	rev	nn	40	SENT_380	59793/59796
40	Drug	NN	O	drug	dep	41	SENT_380	59797/59801
41	Discov2010917517610	NN	O	discov2010917517610	dep	44	SENT_380	59802/59821
42	.1038	CD	NUMBER	.1038	dep	41	SENT_380	59821/59826
43	/	:	O	/	punct	44	SENT_380	59826/59827
44	nrd31242022218042	NN	O	nrd31242022218042	dep	18	SENT_380	59827/59844
45	.	.	O	.		-1	SENT_380	59844/59845

1	Remicade	NNP	O	Remicade	nn	3	SENT_381	59845/59853
2	(	NNP	O	(	nn	3	SENT_381	59856/59857
3	Infliximab	NNP	O	Infliximab		-1	SENT_381	59857/59867
4	)	NN	O	)	nn	7	SENT_381	59867/59868
5	[	CD	NUMBER	[	num	7	SENT_381	59869/59870
6	packet	NN	O	packet	nn	7	SENT_381	59870/59876
7	insert	NN	O	insert	dep	3	SENT_381	59877/59883
8	]	NN	O	]	dep	7	SENT_381	59883/59884
9	.	.	O	.		-1	SENT_381	59884/59885

1	Horsham	NNP	ORGANIZATION	Horsham		-1	SENT_382	59886/59893
2	,	,	O	,		-1	SENT_382	59893/59894
3	PA.	NNP	LOCATION	PA.	appos	1	SENT_382	59895/59897
4	.	.	O	.		-1	SENT_382	59897/59898

1	Centocor	NNP	ORGANIZATION	Centocor	nn	4	SENT_383	59899/59907
2	Ortho	NNP	ORGANIZATION	Ortho	nn	4	SENT_383	59908/59913
3	Biotech	NNP	ORGANIZATION	Biotech	nn	4	SENT_383	59914/59921
4	Inc.	NNP	ORGANIZATION	Inc.		-1	SENT_383	59922/59926
5	;	:	O	;		-1	SENT_383	59926/59927
6	2010	CD	DATE	2010	dep	4	SENT_383	59928/59932
7	.	.	O	.		-1	SENT_383	59932/59933

